<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<ReleaseSet Dated="2018-10-01" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" Type="full" xsi:noNamespaceSchemaLocation="http://ftp.ncbi.nlm.nih.gov/pub/clinvar/xsd_public/clinvar_public_1.54.xsd">
<ClinVarSet ID="18625541">
  <RecordStatus>current</RecordStatus>
  <Title>CYP17A1, IVS7+5G-A AND Complete combined 17-alpha-hydroxylase/17,20-lyase deficiency</Title>
  <ReferenceClinVarAssertion DateCreated="2012-08-13" DateLastUpdated="2017-04-07" ID="59362">
    <ClinVarAccession Acc="RCV000001859" Version="3" Type="RCV" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="1997-06-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData ID="17804347">
        <Attribute Type="Description">Yamaguchi et al. (1997) sequenced the CYP17 gene from a Japanese patient with combined complete 17-alpha-hydroxylase/17,20-lyase deficiency (202110) previously reported by Yazaki et al. (1982). The patient was homozygous for a G-to-A transition at position +5 of the 5-prime splice site of intron 7. In vitro expression analysis of an allelic minigene containing exons 6-8 of the mutant gene showed skipping of exon 7. This exon skipping alters the translational reading frame of exon 8 and introduces a premature stop codon at amino acid position 410, proximal to the heme iron-binding site essential for the enzymatic activity of CYP17. Restriction enzyme analysis showed that the patient was homozygous and the parents were heterozygous for the mutation.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">6976525</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">9177409</ID>
        </Citation>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant" ID="1786">
      <Measure Type="single nucleotide variant" ID="16825">
        <Name>
          <ElementValue Type="Preferred">CYP17A1, IVS7+5G-A</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="nucleotide change">IVS7+5G-A</Attribute>
          <XRef Type="Allelic variant" ID="609300.0011" DB="OMIM"/>
        </AttributeSet>
        <CytogeneticLocation>10q24.3</CytogeneticLocation>
        <MeasureRelationship Type="asserted, but not computed">
          <Name>
            <ElementValue Type="Preferred">cytochrome P450 family 17 subfamily A member 1</ElementValue>
          </Name>
          <Symbol>
            <ElementValue Type="Preferred">CYP17A1</ElementValue>
          </Symbol>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="10" Accession="NC_000010.11" start="102830531" stop="102837533" display_start="102830531" display_stop="102837533" Strand="-"/>
          <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="10" Accession="NC_000010.10" start="104590287" stop="104597289" display_start="104590287" display_stop="104597289" variantLength="7003" Strand="-"/>
          <XRef ID="1586" DB="Gene"/>
          <XRef Type="MIM" ID="609300" DB="OMIM"/>
          <XRef ID="HGNC:2593" DB="HGNC"/>
        </MeasureRelationship>
        <XRef Type="Allelic variant" ID="609300.0011" DB="OMIM"/>
      </Measure>
      <Name>
        <ElementValue Type="Preferred">CYP17A1, IVS7+5G-A</ElementValue>
      </Name>
    </MeasureSet>
    <TraitSet Type="Disease" ID="457">
      <Trait ID="8871" Type="Disease">
        <Name>
          <ElementValue Type="Preferred">Complete combined 17-alpha-hydroxylase/17,20-lyase deficiency</ElementValue>
        </Name>
        <XRef ID="CN042980" DB="MedGen"/>
      </Trait>
    </TraitSet>
  </ReferenceClinVarAssertion>
  <ClinVarAssertion ID="22015">
    <ClinVarSubmissionID localKey="609300.0011_17-@ALPHA-HYDROXYLASE/17,20-LYASE DEFICIENCY, COMBINED COMPLETE" submitter="OMIM" submitterDate="2016-10-05" title="CYP17A1, IVS7+5G-A_17-@ALPHA-HYDROXYLASE/17,20-LYASE DEFICIENCY, COMBINED COMPLETE"/>
    <ClinVarAccession Acc="SCV000022015" OrgType="primary" OrganizationCategory="resource" Version="2" Type="SCV" OrgID="3" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="1997-06-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ExternalID DB="OMIM" ID="609300.0011" Type="Allelic variant"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species>human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="Description">Yamaguchi et al. (1997) sequenced the CYP17 gene from a Japanese patient with combined complete 17-alpha-hydroxylase/17,20-lyase deficiency (202110) previously reported by Yazaki et al. (1982). The patient was homozygous for a G-to-A transition at position +5 of the 5-prime splice site of intron 7. In vitro expression analysis of an allelic minigene containing exons 6-8 of the mutant gene showed skipping of exon 7. This exon skipping alters the translational reading frame of exon 8 and introduces a premature stop codon at amino acid position 410, proximal to the heme iron-binding site essential for the enzymatic activity of CYP17. Restriction enzyme analysis showed that the patient was homozygous and the parents were heterozygous for the mutation.</Attribute>
        <Citation>
          <ID Source="PubMed">9177409</ID>
        </Citation>
        <Citation>
          <ID Source="PubMed">6976525</ID>
        </Citation>
        <XRef DB="OMIM" ID="202110" Type="MIM"/>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant">
      <Measure Type="Variation">
        <Name>
          <ElementValue Type="Preferred">CYP17A1, IVS7+5G-A</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="NonHGVS">IVS7+5G-A</Attribute>
        </AttributeSet>
        <MeasureRelationship Type="variant in gene">
          <Symbol>
            <ElementValue Type="Preferred">CYP17A1</ElementValue>
          </Symbol>
        </MeasureRelationship>
        <XRef DB="OMIM" ID="609300.0011" Type="Allelic variant"/>
      </Measure>
    </MeasureSet>
    <TraitSet Type="Disease">
      <Trait Type="Disease">
        <Name>
          <ElementValue Type="Preferred">17-@ALPHA-HYDROXYLASE/17,20-LYASE DEFICIENCY, COMBINED COMPLETE</ElementValue>
        </Name>
      </Trait>
    </TraitSet>
  </ClinVarAssertion>
</ClinVarSet>

<ClinVarSet ID="18549939">
  <RecordStatus>current</RecordStatus>
  <Title>NC_000008.11:g.16090726_16168455del77730 AND Normal pregnancy</Title>
  <ReferenceClinVarAssertion DateCreated="2015-02-25" DateLastUpdated="2017-04-05" ID="381398">
    <ClinVarAccession Acc="RCV000161527" Version="1" Type="RCV" DateUpdated="2017-04-05"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance>
      <ReviewStatus>no assertion provided</ReviewStatus>
      <Description>not provided</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>unknown</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>yes</AffectedStatus>
      </Sample>
      <Method>
        <NamePlatform>Illumina HumanOmniExpress Beadchip</NamePlatform>
        <Description>Genomic DNA copy number estimation from GenomeStudio-normalised genotyping microarray data (probe signal intensity). Using Illumina's baseline data for microarray signal intensity normalisation, QuantiSNP default baseline data (OB-HMM parameter values) for CNV calling.</Description>
        <MethodType>case-control</MethodType>
      </Method>
      <ObservedData ID="17757783">
        <Attribute Type="Description">not provided</Attribute>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant" ID="157101">
      <Measure Type="Deletion" ID="166961">
        <Name>
          <ElementValue Type="Preferred">NC_000008.11:g.16090726_16168455del77730</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Change="g.15948235_16025964del" Accession="CM000670" Version="1" Type="HGVS, genomic">CM000670.1:g.15948235_16025964del</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Change="g.16090726_16168455del77730" Accession="NC_000008" Version="11" Type="HGVS, genomic, top level" integerValue="38">NC_000008.11:g.16090726_16168455del77730</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Change="g.15948235_16025964del77730" Accession="NC_000008" Version="10" Type="HGVS, genomic, top level, previous" integerValue="37">NC_000008.10:g.15948235_16025964del77730</Attribute>
        </AttributeSet>
        <CytogeneticLocation>8p22</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="8" Accession="NC_000008.11" start="16090726" stop="16168455" display_start="16090726" display_stop="16168455" variantLength="77730"/>
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="8" Accession="NC_000008.10" start="15948235" stop="16025964" display_start="15948235" display_stop="16025964" variantLength="77730"/>
        <MeasureRelationship Type="genes overlapped by variant">
          <Name>
            <ElementValue Type="Preferred">macrophage scavenger receptor 1</ElementValue>
          </Name>
          <Symbol>
            <ElementValue Type="Preferred">MSR1</ElementValue>
          </Symbol>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="8" Accession="NC_000008.11" start="16107878" stop="16192791" display_start="16107878" display_stop="16192791" Strand="-"/>
          <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="8" Accession="NC_000008.10" start="15965386" stop="16050299" display_start="15965386" display_stop="16050299" variantLength="84914" Strand="-"/>
          <XRef ID="4481" DB="Gene"/>
          <XRef Type="MIM" ID="153622" DB="OMIM"/>
          <XRef ID="HGNC:7376" DB="HGNC"/>
        </MeasureRelationship>
        <Citation Type="general">
          <ID Source="PubMed">25666259</ID>
        </Citation>
      </Measure>
      <Name>
        <ElementValue Type="Preferred">NC_000008.11:g.16090726_16168455del77730</ElementValue>
      </Name>
    </MeasureSet>
    <TraitSet Type="Finding" ID="19843">
      <Trait ID="32125" Type="Finding">
        <Name>
          <ElementValue Type="Preferred">Normal pregnancy</ElementValue>
          <XRef ID="CNV_4" DB="Institute of Molecular and Cell Biology, University of Tartu"/>
        </Name>
        <XRef ID="CN220684" DB="MedGen"/>
      </Trait>
    </TraitSet>
  </ReferenceClinVarAssertion>
  <ClinVarAssertion ID="338752" SubmissionName="Kasak">
    <ClinVarSubmissionID localKey="CNV_441" submitter="Institute of Molecular and Cell Biology, University of Tartu" submitterDate="2014-10-23"/>
    <ClinVarAccession Acc="SCV000191484" OrgType="primary" OrganizationCategory="other" Version="1" Type="SCV" OrgID="505255" DateUpdated="2017-04-05"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance>
      <ReviewStatus>no assertion provided</ReviewStatus>
      <Description>not provided</Description>
      <Citation Type="general">
        <ID Source="PubMed">25666259</ID>
      </Citation>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ExternalID DB="EVA" ID="CNV_441"/>
    <ObservedIn>
      <Sample>
        <Origin>unknown</Origin>
        <Tissue>Blood</Tissue>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>yes</AffectedStatus>
        <Gender>mixed</Gender>
      </Sample>
      <Method>
        <NamePlatform>Illumina HumanOmniExpress Beadchip</NamePlatform>
        <TypePlatform>SNP array</TypePlatform>
        <Description>Genomic DNA copy number estimation from GenomeStudio-normalised genotyping microarray data (probe signal intensity). Using Illumina's baseline data for microarray signal intensity normalisation, QuantiSNP default baseline data (OB-HMM parameter values) for CNV calling.</Description>
        <Software name="QuantiSNP, GADA, CNstream" purpose="Normalized signal intensity data was obtained through Illumina GenomeStudio software. Information on Log2 R ratios, B allele frequencies, markers and chromosomal coordinates from each sample were used for CNV identification with Hidden Markov Model-based algorithm QuantiSNP 2.3 (Colella et al., 2007) and a sparse Bayesian learning approach GADA (Genome Alteration Detection Analysis) (Pique-Regi et al., 2010). QuantiSNP was run with default settings, the adjustment for ‘genomic waves’ in signal intensities was turned on with the ‘--gcdir’ key in addition to the default calling parameters. GADA was run using the options “–T 5 –M 3”. CNstream (Alonso et al., 2010) algorithm was used in parallel to estimate CNVs from X and Y channel intensities loaded from Illumina GenomeStudio. CNVs were calculated under the following parameters: number of probes per segment (=3), minimum number of probes in one segment that must exceed the threshold for identifying an amplification/deletion (=3), CNV frequency threshold (=0). CNVs with QuantiSNP log Bayes Factor value &lt;5 and/or rearrangements shorter than 350 bp were excluded from the resulting list of CNVs. In this project we analysed only autosomal CNVs. HD-CNV (Hotspot Detector for Copy Number Variants) (Butler et al., 2013) was used to merge CNV regions called by alternative computational algorithms, QuantiSNP, GADA and CNstream. A criterion of 40% reciprocal overlap between parallel CNV calls was used to define two calls as identifying the same event. All CNVs called by at least two algorithms for the same individual in the same genomic loci were considered in the subsequent global analysis."/>
        <MethodType>case-control</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="Description">not provided</Attribute>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant">
      <Measure Type="Variation">
        <AttributeSet>
          <Attribute Type="HGVS">CM000670.1:g.15948235_16025964del</Attribute>
        </AttributeSet>
      </Measure>
    </MeasureSet>
    <TraitSet Type="Finding">
      <Trait Type="Finding">
        <Name>
          <ElementValue Type="Preferred">Normal pregnancy</ElementValue>
        </Name>
        <XRef DB="MedGen" ID="C0232989" Type="CUI"/>
      </Trait>
    </TraitSet>
    <Citation Type="general">
      <ID Source="PubMed">25666259</ID>
    </Citation>
    <Citation Type="general">
      <ID Source="PubMed">25666259</ID>
    </Citation>
    <StudyName>Kasak2014</StudyName>
    <StudyDescription>The study aimed to determine the contribution of copy number variants in the genetic etiology of normal and complicated pregnancies. The samples represented (i) maternal blood DNA drawn from healthy pregnant women during 1st or 2nd trimester and (ii) maternal and paternal blood DNA drawn at term pregnancy cases representing normal and complicated gestations (severe preeclampsia, PE; gestational diabetes, GD; small-for-gestational age newborn, SGA; large-for-gestational age newborn, LGA). We performed CNV calling based on genome-wide genotyping dataset (Illumina HumanOmniExpress-24-v1 BeadChip) by applying three algorithms, QuantiSNP, GADA (Genome Alteration Detection Algorithm) and CNstream in parallel. The acquired CNV calls were merged with HD-CNV (Hotspot Detector for Copy Number Variants) program and only the CNVs predicted by at least two programs, were considered in subsequent analysis.</StudyDescription>
    <Comment>The study aimed to determine the contribution of copy number variants in the genetic etiology of normal and complicated pregnancies. The samples represented (i) maternal blood DNA drawn from healthy pregnant women during 1st or 2nd trimester and (ii) maternal and paternal blood DNA drawn at term pregnancy cases representing normal and complicated gestations (severe preeclampsia, PE; gestational diabetes, GD; small-for-gestational age newborn, SGA; large-for-gestational age newborn, LGA). We performed CNV calling based on genome-wide genotyping dataset (Illumina HumanOmniExpress-24-v1 BeadChip) by applying three algorithms, QuantiSNP, GADA (Genome Alteration Detection Algorithm) and CNstream in parallel. The acquired CNV calls were merged with HD-CNV (Hotspot Detector for Copy Number Variants) program and only the CNVs predicted by at least two programs, were considered in subsequent analysis.</Comment>
  </ClinVarAssertion>
</ClinVarSet>

<ClinVarSet ID="18549955">
  <RecordStatus>current</RecordStatus>
  <Title>NC_000008.11:g.82359160_82381637del22478 AND Small for gestational age</Title>
  <ReferenceClinVarAssertion DateCreated="2015-02-25" DateLastUpdated="2017-04-05" ID="381414">
    <ClinVarAccession Acc="RCV000161543" Version="1" Type="RCV" DateUpdated="2017-04-05"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance>
      <ReviewStatus>no assertion provided</ReviewStatus>
      <Description>not provided</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>unknown</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>yes</AffectedStatus>
      </Sample>
      <Method>
        <NamePlatform>Illumina HumanOmniExpress Beadchip</NamePlatform>
        <Description>Genomic DNA copy number estimation from GenomeStudio-normalised genotyping microarray data (probe signal intensity). Using Illumina's baseline data for microarray signal intensity normalisation, QuantiSNP default baseline data (OB-HMM parameter values) for CNV calling.</Description>
        <MethodType>case-control</MethodType>
      </Method>
      <ObservedData ID="17756811">
        <Attribute Type="Description">not provided</Attribute>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant" ID="157117">
      <Measure Type="Deletion" ID="166977">
        <Name>
          <ElementValue Type="Preferred">NC_000008.11:g.82359160_82381637del22478</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Change="g.83271395_83293872del" Accession="CM000670" Version="1" Type="HGVS, genomic">CM000670.1:g.83271395_83293872del</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Change="g.82359160_82381637del22478" Accession="NC_000008" Version="11" Type="HGVS, genomic, top level" integerValue="38">NC_000008.11:g.82359160_82381637del22478</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Change="g.83271395_83293872del22478" Accession="NC_000008" Version="10" Type="HGVS, genomic, top level, previous" integerValue="37">NC_000008.10:g.83271395_83293872del22478</Attribute>
        </AttributeSet>
        <CytogeneticLocation>8q21.13</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="8" Accession="NC_000008.11" start="82359160" stop="82381637" display_start="82359160" display_stop="82381637" variantLength="22478"/>
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="8" Accession="NC_000008.10" start="83271395" stop="83293872" display_start="83271395" display_stop="83293872" variantLength="22478"/>
        <Citation Type="general">
          <ID Source="PubMed">25666259</ID>
        </Citation>
      </Measure>
      <Name>
        <ElementValue Type="Preferred">NC_000008.11:g.82359160_82381637del22478</ElementValue>
      </Name>
    </MeasureSet>
    <TraitSet Type="Finding" ID="17776">
      <Trait ID="22432" Type="Finding">
        <Name>
          <ElementValue Type="Preferred">Small for gestational age</ElementValue>
          <XRef ID="HP:0001518" DB="Human Phenotype Ontology"/>
        </Name>
        <Name>
          <ElementValue Type="Alternate">Birth weight less than 10th percentile</ElementValue>
          <XRef ID="HP:0001518" DB="Human Phenotype Ontology"/>
        </Name>
        <Name>
          <ElementValue Type="Alternate">Low birth weight</ElementValue>
          <XRef ID="HP:0001518" DB="Human Phenotype Ontology"/>
        </Name>
        <XRef ID="C0021288" DB="MedGen"/>
        <XRef Type="primary" ID="HP:0001518" DB="Human Phenotype Ontology"/>
        <XRef Type="secondary" ID="HP:0001422" DB="Human Phenotype Ontology"/>
        <XRef Type="secondary" ID="HP:0008849" DB="Human Phenotype Ontology"/>
        <XRef Type="secondary" ID="HP:0008919" DB="Human Phenotype Ontology"/>
        <XRef Type="secondary" ID="HP:0008927" DB="Human Phenotype Ontology"/>
      </Trait>
    </TraitSet>
  </ReferenceClinVarAssertion>
  <ClinVarAssertion ID="338768" SubmissionName="Kasak">
    <ClinVarSubmissionID localKey="CNV_458" submitter="Institute of Molecular and Cell Biology, University of Tartu" submitterDate="2014-10-23"/>
    <ClinVarAccession Acc="SCV000191500" OrgType="primary" OrganizationCategory="other" Version="1" Type="SCV" OrgID="505255" DateUpdated="2017-04-05"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance>
      <ReviewStatus>no assertion provided</ReviewStatus>
      <Description>not provided</Description>
      <Citation Type="general">
        <ID Source="PubMed">25666259</ID>
      </Citation>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ExternalID DB="EVA" ID="CNV_458"/>
    <ObservedIn>
      <Sample>
        <Origin>unknown</Origin>
        <Tissue>Blood</Tissue>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>yes</AffectedStatus>
        <Gender>mixed</Gender>
      </Sample>
      <Method>
        <NamePlatform>Illumina HumanOmniExpress Beadchip</NamePlatform>
        <TypePlatform>SNP array</TypePlatform>
        <Description>Genomic DNA copy number estimation from GenomeStudio-normalised genotyping microarray data (probe signal intensity). Using Illumina's baseline data for microarray signal intensity normalisation, QuantiSNP default baseline data (OB-HMM parameter values) for CNV calling.</Description>
        <Software name="QuantiSNP, GADA, CNstream" purpose="Normalized signal intensity data was obtained through Illumina GenomeStudio software. Information on Log2 R ratios, B allele frequencies, markers and chromosomal coordinates from each sample were used for CNV identification with Hidden Markov Model-based algorithm QuantiSNP 2.3 (Colella et al., 2007) and a sparse Bayesian learning approach GADA (Genome Alteration Detection Analysis) (Pique-Regi et al., 2010). QuantiSNP was run with default settings, the adjustment for ‘genomic waves’ in signal intensities was turned on with the ‘--gcdir’ key in addition to the default calling parameters. GADA was run using the options “–T 5 –M 3”. CNstream (Alonso et al., 2010) algorithm was used in parallel to estimate CNVs from X and Y channel intensities loaded from Illumina GenomeStudio. CNVs were calculated under the following parameters: number of probes per segment (=3), minimum number of probes in one segment that must exceed the threshold for identifying an amplification/deletion (=3), CNV frequency threshold (=0). CNVs with QuantiSNP log Bayes Factor value &lt;5 and/or rearrangements shorter than 350 bp were excluded from the resulting list of CNVs. In this project we analysed only autosomal CNVs. HD-CNV (Hotspot Detector for Copy Number Variants) (Butler et al., 2013) was used to merge CNV regions called by alternative computational algorithms, QuantiSNP, GADA and CNstream. A criterion of 40% reciprocal overlap between parallel CNV calls was used to define two calls as identifying the same event. All CNVs called by at least two algorithms for the same individual in the same genomic loci were considered in the subsequent global analysis."/>
        <MethodType>case-control</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="Description">not provided</Attribute>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant">
      <Measure Type="Variation">
        <AttributeSet>
          <Attribute Type="HGVS">CM000670.1:g.83271395_83293872del</Attribute>
        </AttributeSet>
      </Measure>
    </MeasureSet>
    <TraitSet Type="Disease">
      <Trait Type="Finding">
        <Name>
          <ElementValue Type="Preferred">Small for gestational age</ElementValue>
        </Name>
        <XRef DB="MedGen" ID="C0024032" Type="CUI"/>
      </Trait>
    </TraitSet>
    <Citation Type="general">
      <ID Source="PubMed">25666259</ID>
    </Citation>
    <Citation Type="general">
      <ID Source="PubMed">25666259</ID>
    </Citation>
    <StudyName>Kasak2014</StudyName>
    <StudyDescription>The study aimed to determine the contribution of copy number variants in the genetic etiology of normal and complicated pregnancies. The samples represented (i) maternal blood DNA drawn from healthy pregnant women during 1st or 2nd trimester and (ii) maternal and paternal blood DNA drawn at term pregnancy cases representing normal and complicated gestations (severe preeclampsia, PE; gestational diabetes, GD; small-for-gestational age newborn, SGA; large-for-gestational age newborn, LGA). We performed CNV calling based on genome-wide genotyping dataset (Illumina HumanOmniExpress-24-v1 BeadChip) by applying three algorithms, QuantiSNP, GADA (Genome Alteration Detection Algorithm) and CNstream in parallel. The acquired CNV calls were merged with HD-CNV (Hotspot Detector for Copy Number Variants) program and only the CNVs predicted by at least two programs, were considered in subsequent analysis.</StudyDescription>
    <Comment>The study aimed to determine the contribution of copy number variants in the genetic etiology of normal and complicated pregnancies. The samples represented (i) maternal blood DNA drawn from healthy pregnant women during 1st or 2nd trimester and (ii) maternal and paternal blood DNA drawn at term pregnancy cases representing normal and complicated gestations (severe preeclampsia, PE; gestational diabetes, GD; small-for-gestational age newborn, SGA; large-for-gestational age newborn, LGA). We performed CNV calling based on genome-wide genotyping dataset (Illumina HumanOmniExpress-24-v1 BeadChip) by applying three algorithms, QuantiSNP, GADA (Genome Alteration Detection Algorithm) and CNstream in parallel. The acquired CNV calls were merged with HD-CNV (Hotspot Detector for Copy Number Variants) program and only the CNVs predicted by at least two programs, were considered in subsequent analysis.</Comment>
  </ClinVarAssertion>
</ClinVarSet>

<ClinVarSet ID="18549971">
  <RecordStatus>current</RecordStatus>
  <Title>NC_000009.12:g.3628376_3747376del119001 AND Large for gestational age</Title>
  <ReferenceClinVarAssertion DateCreated="2015-02-25" DateLastUpdated="2017-04-05" ID="381430">
    <ClinVarAccession Acc="RCV000161559" Version="1" Type="RCV" DateUpdated="2017-04-05"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance>
      <ReviewStatus>no assertion provided</ReviewStatus>
      <Description>not provided</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>unknown</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>yes</AffectedStatus>
      </Sample>
      <Method>
        <NamePlatform>Illumina HumanOmniExpress Beadchip</NamePlatform>
        <Description>Genomic DNA copy number estimation from GenomeStudio-normalised genotyping microarray data (probe signal intensity). Using Illumina's baseline data for microarray signal intensity normalisation, QuantiSNP default baseline data (OB-HMM parameter values) for CNV calling.</Description>
        <MethodType>case-control</MethodType>
      </Method>
      <ObservedData ID="17756815">
        <Attribute Type="Description">not provided</Attribute>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant" ID="157133">
      <Measure Type="Deletion" ID="166993">
        <Name>
          <ElementValue Type="Preferred">NC_000009.12:g.3628376_3747376del119001</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Change="g.3628376_3747376del" Accession="CM000671" Version="1" Type="HGVS, genomic">CM000671.1:g.3628376_3747376del</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Change="g.3628376_3747376del119001" Accession="NC_000009" Version="12" Type="HGVS, genomic, top level" integerValue="38">NC_000009.12:g.3628376_3747376del119001</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Change="g.3628376_3747376del119001" Accession="NC_000009" Version="11" Type="HGVS, genomic, top level, previous" integerValue="37">NC_000009.11:g.3628376_3747376del119001</Attribute>
        </AttributeSet>
        <CytogeneticLocation>9p24.2</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="9" Accession="NC_000009.12" start="3628376" stop="3747376" display_start="3628376" display_stop="3747376" variantLength="119001"/>
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="9" Accession="NC_000009.11" start="3628376" stop="3747376" display_start="3628376" display_stop="3747376" variantLength="119001"/>
        <MeasureRelationship Type="genes overlapped by variant">
          <Name>
            <ElementValue Type="Preferred">RFX3 antisense RNA 1</ElementValue>
          </Name>
          <Symbol>
            <ElementValue Type="Preferred">RFX3-AS1</ElementValue>
          </Symbol>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="9" Accession="NC_000009.12" start="3668086" stop="3691756" display_start="3668086" display_stop="3691756" Strand="+"/>
          <XRef ID="101929302" DB="Gene"/>
          <XRef ID="HGNC:51197" DB="HGNC"/>
        </MeasureRelationship>
        <Citation Type="general">
          <ID Source="PubMed">25666259</ID>
        </Citation>
      </Measure>
      <Name>
        <ElementValue Type="Preferred">NC_000009.12:g.3628376_3747376del119001</ElementValue>
      </Name>
    </MeasureSet>
    <TraitSet Type="Disease" ID="19842">
      <Trait ID="22433" Type="Finding">
        <Name>
          <ElementValue Type="Preferred">Large for gestational age</ElementValue>
          <XRef ID="HP:0001520" DB="Human Phenotype Ontology"/>
        </Name>
        <Name>
          <ElementValue Type="Alternate">Birth weight &gt; 90th percentile</ElementValue>
          <XRef ID="HP:0001520" DB="Human Phenotype Ontology"/>
        </Name>
        <Name>
          <ElementValue Type="Alternate">Birthweight &gt; 90th percentile</ElementValue>
          <XRef ID="HP:0001520" DB="Human Phenotype Ontology"/>
        </Name>
        <Name>
          <ElementValue Type="Alternate">Fetal macrosomia</ElementValue>
          <XRef ID="HP:0001520" DB="Human Phenotype Ontology"/>
        </Name>
        <Name>
          <ElementValue Type="Alternate">Macrosomia</ElementValue>
          <XRef ID="HP:0001520" DB="Human Phenotype Ontology"/>
        </Name>
        <Name>
          <ElementValue Type="Alternate">Macrosomia, neonatal</ElementValue>
          <XRef ID="HP:0001520" DB="Human Phenotype Ontology"/>
        </Name>
        <XRef ID="C1848395" DB="MedGen"/>
        <XRef Type="primary" ID="HP:0001520" DB="Human Phenotype Ontology"/>
        <XRef Type="secondary" ID="HP:0001825" DB="Human Phenotype Ontology"/>
      </Trait>
    </TraitSet>
  </ReferenceClinVarAssertion>
  <ClinVarAssertion ID="338784" SubmissionName="Kasak">
    <ClinVarSubmissionID localKey="CNV_475" submitter="Institute of Molecular and Cell Biology, University of Tartu" submitterDate="2014-10-23"/>
    <ClinVarAccession Acc="SCV000191516" OrgType="primary" OrganizationCategory="other" Version="1" Type="SCV" OrgID="505255" DateUpdated="2017-04-05"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance>
      <ReviewStatus>no assertion provided</ReviewStatus>
      <Description>not provided</Description>
      <Citation Type="general">
        <ID Source="PubMed">25666259</ID>
      </Citation>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ExternalID DB="EVA" ID="CNV_475"/>
    <ObservedIn>
      <Sample>
        <Origin>unknown</Origin>
        <Tissue>Blood</Tissue>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>yes</AffectedStatus>
        <Gender>mixed</Gender>
      </Sample>
      <Method>
        <NamePlatform>Illumina HumanOmniExpress Beadchip</NamePlatform>
        <TypePlatform>SNP array</TypePlatform>
        <Description>Genomic DNA copy number estimation from GenomeStudio-normalised genotyping microarray data (probe signal intensity). Using Illumina's baseline data for microarray signal intensity normalisation, QuantiSNP default baseline data (OB-HMM parameter values) for CNV calling.</Description>
        <Software name="QuantiSNP, GADA, CNstream" purpose="Normalized signal intensity data was obtained through Illumina GenomeStudio software. Information on Log2 R ratios, B allele frequencies, markers and chromosomal coordinates from each sample were used for CNV identification with Hidden Markov Model-based algorithm QuantiSNP 2.3 (Colella et al., 2007) and a sparse Bayesian learning approach GADA (Genome Alteration Detection Analysis) (Pique-Regi et al., 2010). QuantiSNP was run with default settings, the adjustment for ‘genomic waves’ in signal intensities was turned on with the ‘--gcdir’ key in addition to the default calling parameters. GADA was run using the options “–T 5 –M 3”. CNstream (Alonso et al., 2010) algorithm was used in parallel to estimate CNVs from X and Y channel intensities loaded from Illumina GenomeStudio. CNVs were calculated under the following parameters: number of probes per segment (=3), minimum number of probes in one segment that must exceed the threshold for identifying an amplification/deletion (=3), CNV frequency threshold (=0). CNVs with QuantiSNP log Bayes Factor value &lt;5 and/or rearrangements shorter than 350 bp were excluded from the resulting list of CNVs. In this project we analysed only autosomal CNVs. HD-CNV (Hotspot Detector for Copy Number Variants) (Butler et al., 2013) was used to merge CNV regions called by alternative computational algorithms, QuantiSNP, GADA and CNstream. A criterion of 40% reciprocal overlap between parallel CNV calls was used to define two calls as identifying the same event. All CNVs called by at least two algorithms for the same individual in the same genomic loci were considered in the subsequent global analysis."/>
        <MethodType>case-control</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="Description">not provided</Attribute>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant">
      <Measure Type="Variation">
        <AttributeSet>
          <Attribute Type="HGVS">CM000671.1:g.3628376_3747376del</Attribute>
        </AttributeSet>
      </Measure>
    </MeasureSet>
    <TraitSet Type="Disease">
      <Trait Type="Finding">
        <Name>
          <ElementValue Type="Preferred">Large for gestational age</ElementValue>
        </Name>
        <XRef DB="MedGen" ID="C0158915" Type="CUI"/>
      </Trait>
    </TraitSet>
    <Citation Type="general">
      <ID Source="PubMed">25666259</ID>
    </Citation>
    <Citation Type="general">
      <ID Source="PubMed">25666259</ID>
    </Citation>
    <StudyName>Kasak2014</StudyName>
    <StudyDescription>The study aimed to determine the contribution of copy number variants in the genetic etiology of normal and complicated pregnancies. The samples represented (i) maternal blood DNA drawn from healthy pregnant women during 1st or 2nd trimester and (ii) maternal and paternal blood DNA drawn at term pregnancy cases representing normal and complicated gestations (severe preeclampsia, PE; gestational diabetes, GD; small-for-gestational age newborn, SGA; large-for-gestational age newborn, LGA). We performed CNV calling based on genome-wide genotyping dataset (Illumina HumanOmniExpress-24-v1 BeadChip) by applying three algorithms, QuantiSNP, GADA (Genome Alteration Detection Algorithm) and CNstream in parallel. The acquired CNV calls were merged with HD-CNV (Hotspot Detector for Copy Number Variants) program and only the CNVs predicted by at least two programs, were considered in subsequent analysis.</StudyDescription>
    <Comment>The study aimed to determine the contribution of copy number variants in the genetic etiology of normal and complicated pregnancies. The samples represented (i) maternal blood DNA drawn from healthy pregnant women during 1st or 2nd trimester and (ii) maternal and paternal blood DNA drawn at term pregnancy cases representing normal and complicated gestations (severe preeclampsia, PE; gestational diabetes, GD; small-for-gestational age newborn, SGA; large-for-gestational age newborn, LGA). We performed CNV calling based on genome-wide genotyping dataset (Illumina HumanOmniExpress-24-v1 BeadChip) by applying three algorithms, QuantiSNP, GADA (Genome Alteration Detection Algorithm) and CNstream in parallel. The acquired CNV calls were merged with HD-CNV (Hotspot Detector for Copy Number Variants) program and only the CNVs predicted by at least two programs, were considered in subsequent analysis.</Comment>
  </ClinVarAssertion>
</ClinVarSet>

<ClinVarSet ID="18550005">
  <RecordStatus>current</RecordStatus>
  <Title>NG_009191.2:g.786137_830589del44453 AND Small for gestational age</Title>
  <ReferenceClinVarAssertion DateCreated="2015-02-25" DateLastUpdated="2017-04-05" ID="381464">
    <ClinVarAccession Acc="RCV000161593" Version="1" Type="RCV" DateUpdated="2017-04-05"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance>
      <ReviewStatus>no assertion provided</ReviewStatus>
      <Description>not provided</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>unknown</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>yes</AffectedStatus>
      </Sample>
      <Method>
        <NamePlatform>Illumina HumanOmniExpress Beadchip</NamePlatform>
        <Description>Genomic DNA copy number estimation from GenomeStudio-normalised genotyping microarray data (probe signal intensity). Using Illumina's baseline data for microarray signal intensity normalisation, QuantiSNP default baseline data (OB-HMM parameter values) for CNV calling.</Description>
        <MethodType>case-control</MethodType>
      </Method>
      <ObservedData ID="17761668">
        <Attribute Type="Description">not provided</Attribute>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant" ID="157167">
      <Measure Type="Deletion" ID="167027">
        <Name>
          <ElementValue Type="Preferred">NG_009191.2:g.786137_830589del44453</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Change="g.55735463_55779915del" Accession="CM000672" Version="1" Type="HGVS, genomic">CM000672.1:g.55735463_55779915del</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Change="g.786137_830589del44453" Accession="NG_009191" Version="2" Type="HGVS, genomic, RefSeqGene">NG_009191.2:g.786137_830589del44453</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Change="g.53975703_54020155del44453" Accession="NC_000010" Version="11" Type="HGVS, genomic, top level" integerValue="38">NC_000010.11:g.53975703_54020155del44453</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Change="g.55735463_55779915del44453" Accession="NC_000010" Version="10" Type="HGVS, genomic, top level, previous" integerValue="37">NC_000010.10:g.55735463_55779915del44453</Attribute>
        </AttributeSet>
        <CytogeneticLocation>10q21.1</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="10" Accession="NC_000010.11" start="53975703" stop="54020155" display_start="53975703" display_stop="54020155" variantLength="44453"/>
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="10" Accession="NC_000010.10" start="55735463" stop="55779915" display_start="55735463" display_stop="55779915" variantLength="44453"/>
        <MeasureRelationship Type="within single gene">
          <Name>
            <ElementValue Type="Preferred">protocadherin related 15</ElementValue>
          </Name>
          <Symbol>
            <ElementValue Type="Preferred">PCDH15</ElementValue>
          </Symbol>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="10" Accession="NC_000010.11" start="53802771" stop="55629182" display_start="53802771" display_stop="55629182" Strand="-"/>
          <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="10" Accession="NC_000010.10" start="55562530" stop="56561050" display_start="55562530" display_stop="56561050" variantLength="998521" Strand="-"/>
          <XRef ID="65217" DB="Gene"/>
          <XRef Type="MIM" ID="605514" DB="OMIM"/>
          <XRef ID="HGNC:14674" DB="HGNC"/>
        </MeasureRelationship>
        <Citation Type="general">
          <ID Source="PubMed">25666259</ID>
        </Citation>
      </Measure>
      <Name>
        <ElementValue Type="Preferred">NG_009191.2:g.786137_830589del44453</ElementValue>
      </Name>
    </MeasureSet>
    <TraitSet Type="Finding" ID="17776">
      <Trait ID="22432" Type="Finding">
        <Name>
          <ElementValue Type="Preferred">Small for gestational age</ElementValue>
          <XRef ID="HP:0001518" DB="Human Phenotype Ontology"/>
        </Name>
        <Name>
          <ElementValue Type="Alternate">Birth weight less than 10th percentile</ElementValue>
          <XRef ID="HP:0001518" DB="Human Phenotype Ontology"/>
        </Name>
        <Name>
          <ElementValue Type="Alternate">Low birth weight</ElementValue>
          <XRef ID="HP:0001518" DB="Human Phenotype Ontology"/>
        </Name>
        <XRef ID="C0021288" DB="MedGen"/>
        <XRef Type="primary" ID="HP:0001518" DB="Human Phenotype Ontology"/>
        <XRef Type="secondary" ID="HP:0001422" DB="Human Phenotype Ontology"/>
        <XRef Type="secondary" ID="HP:0008849" DB="Human Phenotype Ontology"/>
        <XRef Type="secondary" ID="HP:0008919" DB="Human Phenotype Ontology"/>
        <XRef Type="secondary" ID="HP:0008927" DB="Human Phenotype Ontology"/>
      </Trait>
    </TraitSet>
  </ReferenceClinVarAssertion>
  <ClinVarAssertion ID="338818" SubmissionName="Kasak">
    <ClinVarSubmissionID localKey="CNV_515" submitter="Institute of Molecular and Cell Biology, University of Tartu" submitterDate="2014-10-23"/>
    <ClinVarAccession Acc="SCV000191550" OrgType="primary" OrganizationCategory="other" Version="1" Type="SCV" OrgID="505255" DateUpdated="2017-04-05"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance>
      <ReviewStatus>no assertion provided</ReviewStatus>
      <Description>not provided</Description>
      <Citation Type="general">
        <ID Source="PubMed">25666259</ID>
      </Citation>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ExternalID DB="EVA" ID="CNV_515"/>
    <ObservedIn>
      <Sample>
        <Origin>unknown</Origin>
        <Tissue>Blood</Tissue>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>yes</AffectedStatus>
        <Gender>mixed</Gender>
      </Sample>
      <Method>
        <NamePlatform>Illumina HumanOmniExpress Beadchip</NamePlatform>
        <TypePlatform>SNP array</TypePlatform>
        <Description>Genomic DNA copy number estimation from GenomeStudio-normalised genotyping microarray data (probe signal intensity). Using Illumina's baseline data for microarray signal intensity normalisation, QuantiSNP default baseline data (OB-HMM parameter values) for CNV calling.</Description>
        <Software name="QuantiSNP, GADA, CNstream" purpose="Normalized signal intensity data was obtained through Illumina GenomeStudio software. Information on Log2 R ratios, B allele frequencies, markers and chromosomal coordinates from each sample were used for CNV identification with Hidden Markov Model-based algorithm QuantiSNP 2.3 (Colella et al., 2007) and a sparse Bayesian learning approach GADA (Genome Alteration Detection Analysis) (Pique-Regi et al., 2010). QuantiSNP was run with default settings, the adjustment for ‘genomic waves’ in signal intensities was turned on with the ‘--gcdir’ key in addition to the default calling parameters. GADA was run using the options “–T 5 –M 3”. CNstream (Alonso et al., 2010) algorithm was used in parallel to estimate CNVs from X and Y channel intensities loaded from Illumina GenomeStudio. CNVs were calculated under the following parameters: number of probes per segment (=3), minimum number of probes in one segment that must exceed the threshold for identifying an amplification/deletion (=3), CNV frequency threshold (=0). CNVs with QuantiSNP log Bayes Factor value &lt;5 and/or rearrangements shorter than 350 bp were excluded from the resulting list of CNVs. In this project we analysed only autosomal CNVs. HD-CNV (Hotspot Detector for Copy Number Variants) (Butler et al., 2013) was used to merge CNV regions called by alternative computational algorithms, QuantiSNP, GADA and CNstream. A criterion of 40% reciprocal overlap between parallel CNV calls was used to define two calls as identifying the same event. All CNVs called by at least two algorithms for the same individual in the same genomic loci were considered in the subsequent global analysis."/>
        <MethodType>case-control</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="Description">not provided</Attribute>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant">
      <Measure Type="Variation">
        <AttributeSet>
          <Attribute Type="HGVS">CM000672.1:g.55735463_55779915del</Attribute>
        </AttributeSet>
      </Measure>
    </MeasureSet>
    <TraitSet Type="Disease">
      <Trait Type="Finding">
        <Name>
          <ElementValue Type="Preferred">Small for gestational age</ElementValue>
        </Name>
        <XRef DB="MedGen" ID="C0024032" Type="CUI"/>
      </Trait>
    </TraitSet>
    <Citation Type="general">
      <ID Source="PubMed">25666259</ID>
    </Citation>
    <Citation Type="general">
      <ID Source="PubMed">25666259</ID>
    </Citation>
    <StudyName>Kasak2014</StudyName>
    <StudyDescription>The study aimed to determine the contribution of copy number variants in the genetic etiology of normal and complicated pregnancies. The samples represented (i) maternal blood DNA drawn from healthy pregnant women during 1st or 2nd trimester and (ii) maternal and paternal blood DNA drawn at term pregnancy cases representing normal and complicated gestations (severe preeclampsia, PE; gestational diabetes, GD; small-for-gestational age newborn, SGA; large-for-gestational age newborn, LGA). We performed CNV calling based on genome-wide genotyping dataset (Illumina HumanOmniExpress-24-v1 BeadChip) by applying three algorithms, QuantiSNP, GADA (Genome Alteration Detection Algorithm) and CNstream in parallel. The acquired CNV calls were merged with HD-CNV (Hotspot Detector for Copy Number Variants) program and only the CNVs predicted by at least two programs, were considered in subsequent analysis.</StudyDescription>
    <Comment>The study aimed to determine the contribution of copy number variants in the genetic etiology of normal and complicated pregnancies. The samples represented (i) maternal blood DNA drawn from healthy pregnant women during 1st or 2nd trimester and (ii) maternal and paternal blood DNA drawn at term pregnancy cases representing normal and complicated gestations (severe preeclampsia, PE; gestational diabetes, GD; small-for-gestational age newborn, SGA; large-for-gestational age newborn, LGA). We performed CNV calling based on genome-wide genotyping dataset (Illumina HumanOmniExpress-24-v1 BeadChip) by applying three algorithms, QuantiSNP, GADA (Genome Alteration Detection Algorithm) and CNstream in parallel. The acquired CNV calls were merged with HD-CNV (Hotspot Detector for Copy Number Variants) program and only the CNVs predicted by at least two programs, were considered in subsequent analysis.</Comment>
  </ClinVarAssertion>
</ClinVarSet>

<ClinVarSet ID="18550022">
  <RecordStatus>current</RecordStatus>
  <Title>NC_000010.11:g.105858290_105921689del63400 AND Small for gestational age</Title>
  <ReferenceClinVarAssertion DateCreated="2015-02-25" DateLastUpdated="2017-04-05" ID="381481">
    <ClinVarAccession Acc="RCV000161610" Version="1" Type="RCV" DateUpdated="2017-04-05"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance>
      <ReviewStatus>no assertion provided</ReviewStatus>
      <Description>not provided</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>unknown</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>yes</AffectedStatus>
      </Sample>
      <Method>
        <NamePlatform>Illumina HumanOmniExpress Beadchip</NamePlatform>
        <Description>Genomic DNA copy number estimation from GenomeStudio-normalised genotyping microarray data (probe signal intensity). Using Illumina's baseline data for microarray signal intensity normalisation, QuantiSNP default baseline data (OB-HMM parameter values) for CNV calling.</Description>
        <MethodType>case-control</MethodType>
      </Method>
      <ObservedData ID="17758330">
        <Attribute Type="Description">not provided</Attribute>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant" ID="157184">
      <Measure Type="Deletion" ID="167044">
        <Name>
          <ElementValue Type="Preferred">NC_000010.11:g.105858290_105921689del63400</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Change="g.107618048_107681447del" Accession="CM000672" Version="1" Type="HGVS, genomic">CM000672.1:g.107618048_107681447del</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Change="g.105858290_105921689del63400" Accession="NC_000010" Version="11" Type="HGVS, genomic, top level" integerValue="38">NC_000010.11:g.105858290_105921689del63400</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Change="g.107618048_107681447del63400" Accession="NC_000010" Version="10" Type="HGVS, genomic, top level, previous" integerValue="37">NC_000010.10:g.107618048_107681447del63400</Attribute>
        </AttributeSet>
        <CytogeneticLocation>10q25.1</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="10" Accession="NC_000010.11" start="105858290" stop="105921689" display_start="105858290" display_stop="105921689" variantLength="63400"/>
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="10" Accession="NC_000010.10" start="107618048" stop="107681447" display_start="107618048" display_stop="107681447" variantLength="63400"/>
        <Citation Type="general">
          <ID Source="PubMed">25666259</ID>
        </Citation>
      </Measure>
      <Name>
        <ElementValue Type="Preferred">NC_000010.11:g.105858290_105921689del63400</ElementValue>
      </Name>
    </MeasureSet>
    <TraitSet Type="Finding" ID="17776">
      <Trait ID="22432" Type="Finding">
        <Name>
          <ElementValue Type="Preferred">Small for gestational age</ElementValue>
          <XRef ID="HP:0001518" DB="Human Phenotype Ontology"/>
        </Name>
        <Name>
          <ElementValue Type="Alternate">Birth weight less than 10th percentile</ElementValue>
          <XRef ID="HP:0001518" DB="Human Phenotype Ontology"/>
        </Name>
        <Name>
          <ElementValue Type="Alternate">Low birth weight</ElementValue>
          <XRef ID="HP:0001518" DB="Human Phenotype Ontology"/>
        </Name>
        <XRef ID="C0021288" DB="MedGen"/>
        <XRef Type="primary" ID="HP:0001518" DB="Human Phenotype Ontology"/>
        <XRef Type="secondary" ID="HP:0001422" DB="Human Phenotype Ontology"/>
        <XRef Type="secondary" ID="HP:0008849" DB="Human Phenotype Ontology"/>
        <XRef Type="secondary" ID="HP:0008919" DB="Human Phenotype Ontology"/>
        <XRef Type="secondary" ID="HP:0008927" DB="Human Phenotype Ontology"/>
      </Trait>
    </TraitSet>
  </ReferenceClinVarAssertion>
  <ClinVarAssertion ID="338835" SubmissionName="Kasak">
    <ClinVarSubmissionID localKey="CNV_535" submitter="Institute of Molecular and Cell Biology, University of Tartu" submitterDate="2014-10-23"/>
    <ClinVarAccession Acc="SCV000191567" OrgType="primary" OrganizationCategory="other" Version="1" Type="SCV" OrgID="505255" DateUpdated="2017-04-05"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance>
      <ReviewStatus>no assertion provided</ReviewStatus>
      <Description>not provided</Description>
      <Citation Type="general">
        <ID Source="PubMed">25666259</ID>
      </Citation>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ExternalID DB="EVA" ID="CNV_535"/>
    <ObservedIn>
      <Sample>
        <Origin>unknown</Origin>
        <Tissue>Blood</Tissue>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>yes</AffectedStatus>
        <Gender>mixed</Gender>
      </Sample>
      <Method>
        <NamePlatform>Illumina HumanOmniExpress Beadchip</NamePlatform>
        <TypePlatform>SNP array</TypePlatform>
        <Description>Genomic DNA copy number estimation from GenomeStudio-normalised genotyping microarray data (probe signal intensity). Using Illumina's baseline data for microarray signal intensity normalisation, QuantiSNP default baseline data (OB-HMM parameter values) for CNV calling.</Description>
        <Software name="QuantiSNP, GADA, CNstream" purpose="Normalized signal intensity data was obtained through Illumina GenomeStudio software. Information on Log2 R ratios, B allele frequencies, markers and chromosomal coordinates from each sample were used for CNV identification with Hidden Markov Model-based algorithm QuantiSNP 2.3 (Colella et al., 2007) and a sparse Bayesian learning approach GADA (Genome Alteration Detection Analysis) (Pique-Regi et al., 2010). QuantiSNP was run with default settings, the adjustment for ‘genomic waves’ in signal intensities was turned on with the ‘--gcdir’ key in addition to the default calling parameters. GADA was run using the options “–T 5 –M 3”. CNstream (Alonso et al., 2010) algorithm was used in parallel to estimate CNVs from X and Y channel intensities loaded from Illumina GenomeStudio. CNVs were calculated under the following parameters: number of probes per segment (=3), minimum number of probes in one segment that must exceed the threshold for identifying an amplification/deletion (=3), CNV frequency threshold (=0). CNVs with QuantiSNP log Bayes Factor value &lt;5 and/or rearrangements shorter than 350 bp were excluded from the resulting list of CNVs. In this project we analysed only autosomal CNVs. HD-CNV (Hotspot Detector for Copy Number Variants) (Butler et al., 2013) was used to merge CNV regions called by alternative computational algorithms, QuantiSNP, GADA and CNstream. A criterion of 40% reciprocal overlap between parallel CNV calls was used to define two calls as identifying the same event. All CNVs called by at least two algorithms for the same individual in the same genomic loci were considered in the subsequent global analysis."/>
        <MethodType>case-control</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="Description">not provided</Attribute>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant">
      <Measure Type="Variation">
        <AttributeSet>
          <Attribute Type="HGVS">CM000672.1:g.107618048_107681447del</Attribute>
        </AttributeSet>
      </Measure>
    </MeasureSet>
    <TraitSet Type="Disease">
      <Trait Type="Finding">
        <Name>
          <ElementValue Type="Preferred">Small for gestational age</ElementValue>
        </Name>
        <XRef DB="MedGen" ID="C0024032" Type="CUI"/>
      </Trait>
    </TraitSet>
    <Citation Type="general">
      <ID Source="PubMed">25666259</ID>
    </Citation>
    <Citation Type="general">
      <ID Source="PubMed">25666259</ID>
    </Citation>
    <StudyName>Kasak2014</StudyName>
    <StudyDescription>The study aimed to determine the contribution of copy number variants in the genetic etiology of normal and complicated pregnancies. The samples represented (i) maternal blood DNA drawn from healthy pregnant women during 1st or 2nd trimester and (ii) maternal and paternal blood DNA drawn at term pregnancy cases representing normal and complicated gestations (severe preeclampsia, PE; gestational diabetes, GD; small-for-gestational age newborn, SGA; large-for-gestational age newborn, LGA). We performed CNV calling based on genome-wide genotyping dataset (Illumina HumanOmniExpress-24-v1 BeadChip) by applying three algorithms, QuantiSNP, GADA (Genome Alteration Detection Algorithm) and CNstream in parallel. The acquired CNV calls were merged with HD-CNV (Hotspot Detector for Copy Number Variants) program and only the CNVs predicted by at least two programs, were considered in subsequent analysis.</StudyDescription>
    <Comment>The study aimed to determine the contribution of copy number variants in the genetic etiology of normal and complicated pregnancies. The samples represented (i) maternal blood DNA drawn from healthy pregnant women during 1st or 2nd trimester and (ii) maternal and paternal blood DNA drawn at term pregnancy cases representing normal and complicated gestations (severe preeclampsia, PE; gestational diabetes, GD; small-for-gestational age newborn, SGA; large-for-gestational age newborn, LGA). We performed CNV calling based on genome-wide genotyping dataset (Illumina HumanOmniExpress-24-v1 BeadChip) by applying three algorithms, QuantiSNP, GADA (Genome Alteration Detection Algorithm) and CNstream in parallel. The acquired CNV calls were merged with HD-CNV (Hotspot Detector for Copy Number Variants) program and only the CNVs predicted by at least two programs, were considered in subsequent analysis.</Comment>
  </ClinVarAssertion>
</ClinVarSet>

<ClinVarSet ID="18550048">
  <RecordStatus>current</RecordStatus>
  <Title>NC_000011.10:g.81792950_81815531del22582 AND Small for gestational age</Title>
  <ReferenceClinVarAssertion DateCreated="2015-02-25" DateLastUpdated="2017-04-05" ID="381507">
    <ClinVarAccession Acc="RCV000161636" Version="1" Type="RCV" DateUpdated="2017-04-05"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance>
      <ReviewStatus>no assertion provided</ReviewStatus>
      <Description>not provided</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>unknown</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>yes</AffectedStatus>
      </Sample>
      <Method>
        <NamePlatform>Illumina HumanOmniExpress Beadchip</NamePlatform>
        <Description>Genomic DNA copy number estimation from GenomeStudio-normalised genotyping microarray data (probe signal intensity). Using Illumina's baseline data for microarray signal intensity normalisation, QuantiSNP default baseline data (OB-HMM parameter values) for CNV calling.</Description>
        <MethodType>case-control</MethodType>
      </Method>
      <ObservedData ID="17756835">
        <Attribute Type="Description">not provided</Attribute>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant" ID="157210">
      <Measure Type="Deletion" ID="167070">
        <Name>
          <ElementValue Type="Preferred">NC_000011.10:g.81792950_81815531del22582</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Change="g.81503992_81526573del" Accession="CM000673" Version="1" Type="HGVS, genomic">CM000673.1:g.81503992_81526573del</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Change="g.81792950_81815531del22582" Accession="NC_000011" Version="10" Type="HGVS, genomic, top level" integerValue="38">NC_000011.10:g.81792950_81815531del22582</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Change="g.81503992_81526573del22582" Accession="NC_000011" Version="9" Type="HGVS, genomic, top level, previous" integerValue="37">NC_000011.9:g.81503992_81526573del22582</Attribute>
        </AttributeSet>
        <CytogeneticLocation>11q14.1</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="11" Accession="NC_000011.10" start="81792950" stop="81815531" display_start="81792950" display_stop="81815531" variantLength="22582"/>
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="11" Accession="NC_000011.9" start="81503992" stop="81526573" display_start="81503992" display_stop="81526573" variantLength="22582"/>
        <Citation Type="general">
          <ID Source="PubMed">25666259</ID>
        </Citation>
      </Measure>
      <Name>
        <ElementValue Type="Preferred">NC_000011.10:g.81792950_81815531del22582</ElementValue>
      </Name>
    </MeasureSet>
    <TraitSet Type="Finding" ID="17776">
      <Trait ID="22432" Type="Finding">
        <Name>
          <ElementValue Type="Preferred">Small for gestational age</ElementValue>
          <XRef ID="HP:0001518" DB="Human Phenotype Ontology"/>
        </Name>
        <Name>
          <ElementValue Type="Alternate">Birth weight less than 10th percentile</ElementValue>
          <XRef ID="HP:0001518" DB="Human Phenotype Ontology"/>
        </Name>
        <Name>
          <ElementValue Type="Alternate">Low birth weight</ElementValue>
          <XRef ID="HP:0001518" DB="Human Phenotype Ontology"/>
        </Name>
        <XRef ID="C0021288" DB="MedGen"/>
        <XRef Type="primary" ID="HP:0001518" DB="Human Phenotype Ontology"/>
        <XRef Type="secondary" ID="HP:0001422" DB="Human Phenotype Ontology"/>
        <XRef Type="secondary" ID="HP:0008849" DB="Human Phenotype Ontology"/>
        <XRef Type="secondary" ID="HP:0008919" DB="Human Phenotype Ontology"/>
        <XRef Type="secondary" ID="HP:0008927" DB="Human Phenotype Ontology"/>
      </Trait>
    </TraitSet>
  </ReferenceClinVarAssertion>
  <ClinVarAssertion ID="338861" SubmissionName="Kasak">
    <ClinVarSubmissionID localKey="CNV_562" submitter="Institute of Molecular and Cell Biology, University of Tartu" submitterDate="2014-10-23"/>
    <ClinVarAccession Acc="SCV000191593" OrgType="primary" OrganizationCategory="other" Version="1" Type="SCV" OrgID="505255" DateUpdated="2017-04-05"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance>
      <ReviewStatus>no assertion provided</ReviewStatus>
      <Description>not provided</Description>
      <Citation Type="general">
        <ID Source="PubMed">25666259</ID>
      </Citation>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ExternalID DB="EVA" ID="CNV_562"/>
    <ObservedIn>
      <Sample>
        <Origin>unknown</Origin>
        <Tissue>Blood</Tissue>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>yes</AffectedStatus>
        <Gender>mixed</Gender>
      </Sample>
      <Method>
        <NamePlatform>Illumina HumanOmniExpress Beadchip</NamePlatform>
        <TypePlatform>SNP array</TypePlatform>
        <Description>Genomic DNA copy number estimation from GenomeStudio-normalised genotyping microarray data (probe signal intensity). Using Illumina's baseline data for microarray signal intensity normalisation, QuantiSNP default baseline data (OB-HMM parameter values) for CNV calling.</Description>
        <Software name="QuantiSNP, GADA, CNstream" purpose="Normalized signal intensity data was obtained through Illumina GenomeStudio software. Information on Log2 R ratios, B allele frequencies, markers and chromosomal coordinates from each sample were used for CNV identification with Hidden Markov Model-based algorithm QuantiSNP 2.3 (Colella et al., 2007) and a sparse Bayesian learning approach GADA (Genome Alteration Detection Analysis) (Pique-Regi et al., 2010). QuantiSNP was run with default settings, the adjustment for ‘genomic waves’ in signal intensities was turned on with the ‘--gcdir’ key in addition to the default calling parameters. GADA was run using the options “–T 5 –M 3”. CNstream (Alonso et al., 2010) algorithm was used in parallel to estimate CNVs from X and Y channel intensities loaded from Illumina GenomeStudio. CNVs were calculated under the following parameters: number of probes per segment (=3), minimum number of probes in one segment that must exceed the threshold for identifying an amplification/deletion (=3), CNV frequency threshold (=0). CNVs with QuantiSNP log Bayes Factor value &lt;5 and/or rearrangements shorter than 350 bp were excluded from the resulting list of CNVs. In this project we analysed only autosomal CNVs. HD-CNV (Hotspot Detector for Copy Number Variants) (Butler et al., 2013) was used to merge CNV regions called by alternative computational algorithms, QuantiSNP, GADA and CNstream. A criterion of 40% reciprocal overlap between parallel CNV calls was used to define two calls as identifying the same event. All CNVs called by at least two algorithms for the same individual in the same genomic loci were considered in the subsequent global analysis."/>
        <MethodType>case-control</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="Description">not provided</Attribute>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant">
      <Measure Type="Variation">
        <AttributeSet>
          <Attribute Type="HGVS">CM000673.1:g.81503992_81526573del</Attribute>
        </AttributeSet>
      </Measure>
    </MeasureSet>
    <TraitSet Type="Disease">
      <Trait Type="Finding">
        <Name>
          <ElementValue Type="Preferred">Small for gestational age</ElementValue>
        </Name>
        <XRef DB="MedGen" ID="C0024032" Type="CUI"/>
      </Trait>
    </TraitSet>
    <Citation Type="general">
      <ID Source="PubMed">25666259</ID>
    </Citation>
    <Citation Type="general">
      <ID Source="PubMed">25666259</ID>
    </Citation>
    <StudyName>Kasak2014</StudyName>
    <StudyDescription>The study aimed to determine the contribution of copy number variants in the genetic etiology of normal and complicated pregnancies. The samples represented (i) maternal blood DNA drawn from healthy pregnant women during 1st or 2nd trimester and (ii) maternal and paternal blood DNA drawn at term pregnancy cases representing normal and complicated gestations (severe preeclampsia, PE; gestational diabetes, GD; small-for-gestational age newborn, SGA; large-for-gestational age newborn, LGA). We performed CNV calling based on genome-wide genotyping dataset (Illumina HumanOmniExpress-24-v1 BeadChip) by applying three algorithms, QuantiSNP, GADA (Genome Alteration Detection Algorithm) and CNstream in parallel. The acquired CNV calls were merged with HD-CNV (Hotspot Detector for Copy Number Variants) program and only the CNVs predicted by at least two programs, were considered in subsequent analysis.</StudyDescription>
    <Comment>The study aimed to determine the contribution of copy number variants in the genetic etiology of normal and complicated pregnancies. The samples represented (i) maternal blood DNA drawn from healthy pregnant women during 1st or 2nd trimester and (ii) maternal and paternal blood DNA drawn at term pregnancy cases representing normal and complicated gestations (severe preeclampsia, PE; gestational diabetes, GD; small-for-gestational age newborn, SGA; large-for-gestational age newborn, LGA). We performed CNV calling based on genome-wide genotyping dataset (Illumina HumanOmniExpress-24-v1 BeadChip) by applying three algorithms, QuantiSNP, GADA (Genome Alteration Detection Algorithm) and CNstream in parallel. The acquired CNV calls were merged with HD-CNV (Hotspot Detector for Copy Number Variants) program and only the CNVs predicted by at least two programs, were considered in subsequent analysis.</Comment>
  </ClinVarAssertion>
</ClinVarSet>

<ClinVarSet ID="18626355">
  <RecordStatus>current</RecordStatus>
  <Title>APOC2, 1-BP DEL AND APOLIPOPROTEIN C-II (TORONTO)</Title>
  <ReferenceClinVarAssertion DateCreated="2012-08-13" DateLastUpdated="2017-04-07" ID="60190">
    <ClinVarAccession Acc="RCV000002687" Version="2" Type="RCV" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="1988-10-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData ID="17807300">
        <Attribute Type="Description">In subsequent studies of the family with hyperlipoproteinemia type IB (207750) reported by Cox et al. (1978), Connelly et al. (1987) identified 14 homozygotes and 23 obligate heterozygotes in the extended pedigree. Their plasma contained a unique apoC-II (designated Toronto, according to the system for hemoglobins) that had an apparent pI of 5.54 instead of 4.88 as in normal apoC-II. It was found that the sequence of apoC-II(Toronto) was identical to that of normal apoC-II from residues 1-68. It differs from residue 69, where asp69-gln70-val71-leu72-ser73-val74-leu75-lys76-gly77-glu78-glu79 is replaced by thr69-lys70-phe71-phe72-leu73-cys74. This change is consistent with the deletion of a nucleotide in the codon for either thr68 or asp69 and a resulting translation reading frameshift. Thus, it show similarities to apoC-II(St. Michael). In the apoC-II(Toronto), Cox et al. (1988) demonstrated a deletion of 1 base in the codon for amino acid threonine-68, causing an alteration of 6 amino acids and a premature termination of the protein at amino acid 74.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">213719</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">3225819</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">3467353</ID>
        </Citation>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant" ID="2576">
      <Measure Type="Deletion" ID="17615">
        <Name>
          <ElementValue Type="Preferred">APOC2, 1-BP DEL</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="nucleotide change">1-BP DEL</Attribute>
          <XRef Type="Allelic variant" ID="608083.0004" DB="OMIM"/>
        </AttributeSet>
        <CytogeneticLocation>19q13.2</CytogeneticLocation>
        <MeasureRelationship Type="asserted, but not computed">
          <Name>
            <ElementValue Type="Preferred">apolipoprotein C2</ElementValue>
          </Name>
          <Symbol>
            <ElementValue Type="Preferred">APOC2</ElementValue>
          </Symbol>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="19" Accession="NC_000019.10" start="44945982" stop="44949565" display_start="44945982" display_stop="44949565" Strand="+"/>
          <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="19" Accession="NC_000019.9" start="45449238" stop="45452821" display_start="45449238" display_stop="45452821" variantLength="3584" Strand="+"/>
          <XRef ID="344" DB="Gene"/>
          <XRef Type="MIM" ID="608083" DB="OMIM"/>
          <XRef ID="HGNC:609" DB="HGNC"/>
        </MeasureRelationship>
        <XRef Type="Allelic variant" ID="608083.0004" DB="OMIM"/>
      </Measure>
      <Name>
        <ElementValue Type="Preferred">APOC2, 1-BP DEL</ElementValue>
      </Name>
    </MeasureSet>
    <TraitSet Type="Disease" ID="656">
      <Trait ID="9791" Type="Disease">
        <Name>
          <ElementValue Type="Preferred">APOLIPOPROTEIN C-II (TORONTO)</ElementValue>
          <XRef Type="Allelic variant" ID="608083.0004" DB="OMIM"/>
        </Name>
      </Trait>
    </TraitSet>
  </ReferenceClinVarAssertion>
  <ClinVarAssertion ID="22845">
    <ClinVarSubmissionID localKey="608083.0004_APOLIPOPROTEIN C-II (TORONTO)" submitter="OMIM" submitterDate="2008-07-08" title="APOC2, 1-BP DEL_APOLIPOPROTEIN C-II (TORONTO)"/>
    <ClinVarAccession Acc="SCV000022845" OrgType="primary" OrganizationCategory="resource" Version="1" Type="SCV" OrgID="3" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="1988-10-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ExternalID DB="OMIM" ID="608083.0004" Type="Allelic variant"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species>human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="Description">In subsequent studies of the family with hyperlipoproteinemia type IB (207750) reported by Cox et al. (1978), Connelly et al. (1987) identified 14 homozygotes and 23 obligate heterozygotes in the extended pedigree. Their plasma contained a unique apoC-II (designated Toronto, according to the system for hemoglobins) that had an apparent pI of 5.54 instead of 4.88 as in normal apoC-II. It was found that the sequence of apoC-II(Toronto) was identical to that of normal apoC-II from residues 1-68. It differs from residue 69, where asp69-gln70-val71-leu72-ser73-val74-leu75-lys76-gly77-glu78-glu79 is replaced by thr69-lys70-phe71-phe72-leu73-cys74. This change is consistent with the deletion of a nucleotide in the codon for either thr68 or asp69 and a resulting translation reading frameshift. Thus, it show similarities to apoC-II(St. Michael). In the apoC-II(Toronto), Cox et al. (1988) demonstrated a deletion of 1 base in the codon for amino acid threonine-68, causing an alteration of 6 amino acids and a premature termination of the protein at amino acid 74.</Attribute>
        <Citation>
          <ID Source="PubMed">213719</ID>
        </Citation>
        <Citation>
          <ID Source="PubMed">3467353</ID>
        </Citation>
        <Citation>
          <ID Source="PubMed">3225819</ID>
        </Citation>
        <XRef DB="OMIM" ID="207750" Type="MIM"/>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant">
      <Measure Type="Variation">
        <Name>
          <ElementValue Type="Preferred">APOC2, 1-BP DEL</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="NonHGVS">1-BP DEL</Attribute>
        </AttributeSet>
        <MeasureRelationship Type="variant in gene">
          <Symbol>
            <ElementValue Type="Preferred">APOC2</ElementValue>
          </Symbol>
        </MeasureRelationship>
        <XRef DB="OMIM" ID="608083.0004" Type="Allelic variant"/>
      </Measure>
    </MeasureSet>
    <TraitSet Type="Disease">
      <Trait Type="Disease">
        <Name>
          <ElementValue Type="Preferred">APOLIPOPROTEIN C-II (TORONTO)</ElementValue>
        </Name>
      </Trait>
    </TraitSet>
  </ClinVarAssertion>
</ClinVarSet>

<ClinVarSet ID="18626357">
  <RecordStatus>current</RecordStatus>
  <Title>APOC2, IVS2, G-C, +1 AND APOLIPOPROTEIN C-II (HAMBURG)</Title>
  <ReferenceClinVarAssertion DateCreated="2012-08-13" DateLastUpdated="2017-04-07" ID="60192">
    <ClinVarAccession Acc="RCV000002689" Version="2" Type="RCV" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="1992-02-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData ID="17804823">
        <Attribute Type="Description">Fojo et al. (1988) analyzed the DNA, RNA, and protein of apoC-II in a patient with apoC-II deficiency (207750) of the Hamburg type. By immunoblotting and immunohistochemical analysis, a marked reduction in plasma and intrahepatic C-II apolipoprotein was demonstrated. Northern, slot blot, and in situ hybridization studies showed, furthermore, low levels of a normal-sized apoC-II mRNA. No major rearrangement of apoC-II gene was detected by Southern blotting. Sequence analysis of apoC-II genomic clones showed a G-to-C substitution within the donor splice site of intron 2. This base substitution resulted in the formation of a new DdeI and loss of an HphI restriction enzyme cleavage site. Beil et al. (1992) characterized the clinical and biochemical features of 3 sibs in a kindred with severe hypertriglyceridemia due to apolipoprotein C-II deficiency caused by apoC-II(Hamburg).</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">1349286</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">3263393</ID>
        </Citation>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant" ID="2577">
      <Measure Type="single nucleotide variant" ID="17616">
        <Name>
          <ElementValue Type="Preferred">APOC2, IVS2, G-C, +1</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="nucleotide change">IVS2, G-C, +1</Attribute>
          <XRef Type="Allelic variant" ID="608083.0005" DB="OMIM"/>
        </AttributeSet>
        <CytogeneticLocation>19q13.2</CytogeneticLocation>
        <MeasureRelationship Type="asserted, but not computed">
          <Name>
            <ElementValue Type="Preferred">apolipoprotein C2</ElementValue>
          </Name>
          <Symbol>
            <ElementValue Type="Preferred">APOC2</ElementValue>
          </Symbol>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="19" Accession="NC_000019.10" start="44945982" stop="44949565" display_start="44945982" display_stop="44949565" Strand="+"/>
          <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="19" Accession="NC_000019.9" start="45449238" stop="45452821" display_start="45449238" display_stop="45452821" variantLength="3584" Strand="+"/>
          <XRef ID="344" DB="Gene"/>
          <XRef Type="MIM" ID="608083" DB="OMIM"/>
          <XRef ID="HGNC:609" DB="HGNC"/>
        </MeasureRelationship>
        <XRef Type="Allelic variant" ID="608083.0005" DB="OMIM"/>
      </Measure>
      <Name>
        <ElementValue Type="Preferred">APOC2, IVS2, G-C, +1</ElementValue>
      </Name>
    </MeasureSet>
    <TraitSet Type="Disease" ID="657">
      <Trait ID="9792" Type="Disease">
        <Name>
          <ElementValue Type="Preferred">APOLIPOPROTEIN C-II (HAMBURG)</ElementValue>
          <XRef Type="Allelic variant" ID="608083.0005" DB="OMIM"/>
        </Name>
      </Trait>
    </TraitSet>
  </ReferenceClinVarAssertion>
  <ClinVarAssertion ID="22847">
    <ClinVarSubmissionID localKey="608083.0005_APOLIPOPROTEIN C-II (HAMBURG)" submitter="OMIM" submitterDate="2008-07-08" title="APOC2, IVS2, G-C, +1_APOLIPOPROTEIN C-II (HAMBURG)"/>
    <ClinVarAccession Acc="SCV000022847" OrgType="primary" OrganizationCategory="resource" Version="1" Type="SCV" OrgID="3" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="1992-02-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ExternalID DB="OMIM" ID="608083.0005" Type="Allelic variant"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species>human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="Description">Fojo et al. (1988) analyzed the DNA, RNA, and protein of apoC-II in a patient with apoC-II deficiency (207750) of the Hamburg type. By immunoblotting and immunohistochemical analysis, a marked reduction in plasma and intrahepatic C-II apolipoprotein was demonstrated. Northern, slot blot, and in situ hybridization studies showed, furthermore, low levels of a normal-sized apoC-II mRNA. No major rearrangement of apoC-II gene was detected by Southern blotting. Sequence analysis of apoC-II genomic clones showed a G-to-C substitution within the donor splice site of intron 2. This base substitution resulted in the formation of a new DdeI and loss of an HphI restriction enzyme cleavage site. Beil et al. (1992) characterized the clinical and biochemical features of 3 sibs in a kindred with severe hypertriglyceridemia due to apolipoprotein C-II deficiency caused by apoC-II(Hamburg).</Attribute>
        <Citation>
          <ID Source="PubMed">3263393</ID>
        </Citation>
        <Citation>
          <ID Source="PubMed">1349286</ID>
        </Citation>
        <XRef DB="OMIM" ID="207750" Type="MIM"/>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant">
      <Measure Type="Variation">
        <Name>
          <ElementValue Type="Preferred">APOC2, IVS2, G-C, +1</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="NonHGVS">IVS2, G-C, +1</Attribute>
        </AttributeSet>
        <MeasureRelationship Type="variant in gene">
          <Symbol>
            <ElementValue Type="Preferred">APOC2</ElementValue>
          </Symbol>
        </MeasureRelationship>
        <XRef DB="OMIM" ID="608083.0005" Type="Allelic variant"/>
      </Measure>
    </MeasureSet>
    <TraitSet Type="Disease">
      <Trait Type="Disease">
        <Name>
          <ElementValue Type="Preferred">APOLIPOPROTEIN C-II (HAMBURG)</ElementValue>
        </Name>
      </Trait>
    </TraitSet>
  </ClinVarAssertion>
</ClinVarSet>

<ClinVarSet ID="18626359">
  <RecordStatus>current</RecordStatus>
  <Title>APOC2, 1-BP DEL, 2943G AND APOLIPOPROTEIN C-II (NIJMEGEN)</Title>
  <ReferenceClinVarAssertion DateCreated="2012-08-13" DateLastUpdated="2017-04-07" ID="60194">
    <ClinVarAccession Acc="RCV000002691" Version="2" Type="RCV" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="1988-12-05">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData ID="17806318">
        <Attribute Type="Description">Fojo et al. (1988) cloned and sequenced the APOC2 gene from an affected member of a family in Nijmegen, the Netherlands, with deficiency of apoC-II (207750). They demonstrated deletion of a guanosine at base 2943 in the third exon of the APOC2 gene, resulting in the loss of a normal HphI site, a shift in the reading frame, introduction of a premature termination codon, and the formation of a truncated 17-amino acid C-II apolipoprotein. Since the lipoprotein lipase activating domains of the protein are located to amino acids 55-78, this abnormally truncated protein, if secreted, would be nonfunctional as a cofactor for lipoprotein lipase. The proband was found to be homozygous for the base deletion mutation. Since the postheparin plasma lipoprotein lipase activity was reduced even after exogenous C-II was added, it is possible that the truncated 17-amino acid protein is indeed secreted into plasma and acts as an inhibitor, rather than an activator, of lipoprotein lipase.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">3192518</ID>
        </Citation>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant" ID="2578">
      <Measure Type="Deletion" ID="17617">
        <Name>
          <ElementValue Type="Preferred">APOC2, 1-BP DEL, 2943G</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="nucleotide change">1-BP DEL, 2943G</Attribute>
          <XRef Type="Allelic variant" ID="608083.0006" DB="OMIM"/>
        </AttributeSet>
        <CytogeneticLocation>19q13.2</CytogeneticLocation>
        <MeasureRelationship Type="asserted, but not computed">
          <Name>
            <ElementValue Type="Preferred">apolipoprotein C2</ElementValue>
          </Name>
          <Symbol>
            <ElementValue Type="Preferred">APOC2</ElementValue>
          </Symbol>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="19" Accession="NC_000019.10" start="44945982" stop="44949565" display_start="44945982" display_stop="44949565" Strand="+"/>
          <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="19" Accession="NC_000019.9" start="45449238" stop="45452821" display_start="45449238" display_stop="45452821" variantLength="3584" Strand="+"/>
          <XRef ID="344" DB="Gene"/>
          <XRef Type="MIM" ID="608083" DB="OMIM"/>
          <XRef ID="HGNC:609" DB="HGNC"/>
        </MeasureRelationship>
        <XRef Type="Allelic variant" ID="608083.0006" DB="OMIM"/>
      </Measure>
      <Name>
        <ElementValue Type="Preferred">APOC2, 1-BP DEL, 2943G</ElementValue>
      </Name>
    </MeasureSet>
    <TraitSet Type="Disease" ID="658">
      <Trait ID="9793" Type="Disease">
        <Name>
          <ElementValue Type="Preferred">APOLIPOPROTEIN C-II (NIJMEGEN)</ElementValue>
          <XRef Type="Allelic variant" ID="608083.0006" DB="OMIM"/>
        </Name>
      </Trait>
    </TraitSet>
  </ReferenceClinVarAssertion>
  <ClinVarAssertion ID="22849">
    <ClinVarSubmissionID localKey="608083.0006_APOLIPOPROTEIN C-II (NIJMEGEN)" submitter="OMIM" submitterDate="2008-07-08" title="APOC2, 1-BP DEL, 2943G_APOLIPOPROTEIN C-II (NIJMEGEN)"/>
    <ClinVarAccession Acc="SCV000022849" OrgType="primary" OrganizationCategory="resource" Version="1" Type="SCV" OrgID="3" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="1988-12-05">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ExternalID DB="OMIM" ID="608083.0006" Type="Allelic variant"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species>human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="Description">Fojo et al. (1988) cloned and sequenced the APOC2 gene from an affected member of a family in Nijmegen, the Netherlands, with deficiency of apoC-II (207750). They demonstrated deletion of a guanosine at base 2943 in the third exon of the APOC2 gene, resulting in the loss of a normal HphI site, a shift in the reading frame, introduction of a premature termination codon, and the formation of a truncated 17-amino acid C-II apolipoprotein. Since the lipoprotein lipase activating domains of the protein are located to amino acids 55-78, this abnormally truncated protein, if secreted, would be nonfunctional as a cofactor for lipoprotein lipase. The proband was found to be homozygous for the base deletion mutation. Since the postheparin plasma lipoprotein lipase activity was reduced even after exogenous C-II was added, it is possible that the truncated 17-amino acid protein is indeed secreted into plasma and acts as an inhibitor, rather than an activator, of lipoprotein lipase.</Attribute>
        <Citation>
          <ID Source="PubMed">3192518</ID>
        </Citation>
        <XRef DB="OMIM" ID="207750" Type="MIM"/>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant">
      <Measure Type="Variation">
        <Name>
          <ElementValue Type="Preferred">APOC2, 1-BP DEL, 2943G</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="NonHGVS">1-BP DEL, 2943G</Attribute>
        </AttributeSet>
        <MeasureRelationship Type="variant in gene">
          <Symbol>
            <ElementValue Type="Preferred">APOC2</ElementValue>
          </Symbol>
        </MeasureRelationship>
        <XRef DB="OMIM" ID="608083.0006" Type="Allelic variant"/>
      </Measure>
    </MeasureSet>
    <TraitSet Type="Disease">
      <Trait Type="Disease">
        <Name>
          <ElementValue Type="Preferred">APOLIPOPROTEIN C-II (NIJMEGEN)</ElementValue>
        </Name>
      </Trait>
    </TraitSet>
  </ClinVarAssertion>
</ClinVarSet>

<ClinVarSet ID="18550078">
  <RecordStatus>current</RecordStatus>
  <Title>NC_000012.12:g.7851162_7970710del119549 AND Normal pregnancy</Title>
  <ReferenceClinVarAssertion DateCreated="2015-02-25" DateLastUpdated="2017-04-05" ID="381537">
    <ClinVarAccession Acc="RCV000161666" Version="1" Type="RCV" DateUpdated="2017-04-05"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance>
      <ReviewStatus>no assertion provided</ReviewStatus>
      <Description>not provided</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>unknown</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>yes</AffectedStatus>
      </Sample>
      <Method>
        <NamePlatform>Illumina HumanOmniExpress Beadchip</NamePlatform>
        <Description>Genomic DNA copy number estimation from GenomeStudio-normalised genotyping microarray data (probe signal intensity). Using Illumina's baseline data for microarray signal intensity normalisation, QuantiSNP default baseline data (OB-HMM parameter values) for CNV calling.</Description>
        <MethodType>case-control</MethodType>
      </Method>
      <ObservedData ID="17761763">
        <Attribute Type="Description">not provided</Attribute>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant" ID="157240">
      <Measure Type="Deletion" ID="167100">
        <Name>
          <ElementValue Type="Preferred">NC_000012.12:g.7851162_7970710del119549</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Change="g.8003758_8123306del" Accession="CM000674" Version="1" Type="HGVS, genomic">CM000674.1:g.8003758_8123306del</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Change="g.7851162_7970710del119549" Accession="NC_000012" Version="12" Type="HGVS, genomic, top level" integerValue="38">NC_000012.12:g.7851162_7970710del119549</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Change="g.8003758_8123306del119549" Accession="NC_000012" Version="11" Type="HGVS, genomic, top level, previous" integerValue="37">NC_000012.11:g.8003758_8123306del119549</Attribute>
        </AttributeSet>
        <CytogeneticLocation>12p13.31</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="12" Accession="NC_000012.12" start="7851162" stop="7970710" display_start="7851162" display_stop="7970710" variantLength="119549"/>
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="12" Accession="NC_000012.11" start="8003758" stop="8123306" display_start="8003758" display_stop="8123306" variantLength="119549"/>
        <MeasureRelationship Type="genes overlapped by variant">
          <Name>
            <ElementValue Type="Preferred">solute carrier family 2 member 14</ElementValue>
          </Name>
          <Symbol>
            <ElementValue Type="Preferred">SLC2A14</ElementValue>
          </Symbol>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="12" Accession="NC_000012.12" start="7812512" stop="7891196" display_start="7812512" display_stop="7891196" Strand="-"/>
          <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="12" Accession="NC_000012.11" start="7966396" stop="8025494" display_start="7966396" display_stop="8025494" variantLength="59099" Strand="-"/>
          <XRef ID="144195" DB="Gene"/>
          <XRef Type="MIM" ID="611039" DB="OMIM"/>
          <XRef ID="HGNC:18301" DB="HGNC"/>
        </MeasureRelationship>
        <MeasureRelationship Type="genes overlapped by variant">
          <Name>
            <ElementValue Type="Preferred">solute carrier family 2 member 3</ElementValue>
          </Name>
          <Symbol>
            <ElementValue Type="Preferred">SLC2A3</ElementValue>
          </Symbol>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="12" Accession="NC_000012.12" start="7919228" stop="7936296" display_start="7919228" display_stop="7936296" Strand="-"/>
          <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="12" Accession="NC_000012.11" start="8071823" stop="8088891" display_start="8071823" display_stop="8088891" variantLength="17069" Strand="-"/>
          <XRef ID="6515" DB="Gene"/>
          <XRef Type="MIM" ID="138170" DB="OMIM"/>
          <XRef ID="HGNC:11007" DB="HGNC"/>
        </MeasureRelationship>
        <Citation Type="general">
          <ID Source="PubMed">25666259</ID>
        </Citation>
      </Measure>
      <Name>
        <ElementValue Type="Preferred">NC_000012.12:g.7851162_7970710del119549</ElementValue>
      </Name>
    </MeasureSet>
    <TraitSet Type="Finding" ID="19843">
      <Trait ID="32125" Type="Finding">
        <Name>
          <ElementValue Type="Preferred">Normal pregnancy</ElementValue>
          <XRef ID="CNV_4" DB="Institute of Molecular and Cell Biology, University of Tartu"/>
        </Name>
        <XRef ID="CN220684" DB="MedGen"/>
      </Trait>
    </TraitSet>
  </ReferenceClinVarAssertion>
  <ClinVarAssertion ID="338891" SubmissionName="Kasak">
    <ClinVarSubmissionID localKey="CNV_598" submitter="Institute of Molecular and Cell Biology, University of Tartu" submitterDate="2014-10-23"/>
    <ClinVarAccession Acc="SCV000191623" OrgType="primary" OrganizationCategory="other" Version="1" Type="SCV" OrgID="505255" DateUpdated="2017-04-05"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance>
      <ReviewStatus>no assertion provided</ReviewStatus>
      <Description>not provided</Description>
      <Citation Type="general">
        <ID Source="PubMed">25666259</ID>
      </Citation>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ExternalID DB="EVA" ID="CNV_598"/>
    <ObservedIn>
      <Sample>
        <Origin>unknown</Origin>
        <Tissue>Blood</Tissue>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>yes</AffectedStatus>
        <Gender>female</Gender>
      </Sample>
      <Method>
        <NamePlatform>Illumina HumanOmniExpress Beadchip</NamePlatform>
        <TypePlatform>SNP array</TypePlatform>
        <Description>Genomic DNA copy number estimation from GenomeStudio-normalised genotyping microarray data (probe signal intensity). Using Illumina's baseline data for microarray signal intensity normalisation, QuantiSNP default baseline data (OB-HMM parameter values) for CNV calling.</Description>
        <Software name="QuantiSNP, GADA, CNstream" purpose="Normalized signal intensity data was obtained through Illumina GenomeStudio software. Information on Log2 R ratios, B allele frequencies, markers and chromosomal coordinates from each sample were used for CNV identification with Hidden Markov Model-based algorithm QuantiSNP 2.3 (Colella et al., 2007) and a sparse Bayesian learning approach GADA (Genome Alteration Detection Analysis) (Pique-Regi et al., 2010). QuantiSNP was run with default settings, the adjustment for ‘genomic waves’ in signal intensities was turned on with the ‘--gcdir’ key in addition to the default calling parameters. GADA was run using the options “–T 5 –M 3”. CNstream (Alonso et al., 2010) algorithm was used in parallel to estimate CNVs from X and Y channel intensities loaded from Illumina GenomeStudio. CNVs were calculated under the following parameters: number of probes per segment (=3), minimum number of probes in one segment that must exceed the threshold for identifying an amplification/deletion (=3), CNV frequency threshold (=0). CNVs with QuantiSNP log Bayes Factor value &lt;5 and/or rearrangements shorter than 350 bp were excluded from the resulting list of CNVs. In this project we analysed only autosomal CNVs. HD-CNV (Hotspot Detector for Copy Number Variants) (Butler et al., 2013) was used to merge CNV regions called by alternative computational algorithms, QuantiSNP, GADA and CNstream. A criterion of 40% reciprocal overlap between parallel CNV calls was used to define two calls as identifying the same event. All CNVs called by at least two algorithms for the same individual in the same genomic loci were considered in the subsequent global analysis."/>
        <MethodType>case-control</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="Description">not provided</Attribute>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant">
      <Measure Type="Variation">
        <AttributeSet>
          <Attribute Type="HGVS">CM000674.1:g.8003758_8123306del</Attribute>
        </AttributeSet>
      </Measure>
    </MeasureSet>
    <TraitSet Type="Finding">
      <Trait Type="Finding">
        <Name>
          <ElementValue Type="Preferred">Normal pregnancy</ElementValue>
        </Name>
        <XRef DB="MedGen" ID="C0232989" Type="CUI"/>
      </Trait>
    </TraitSet>
    <Citation Type="general">
      <ID Source="PubMed">25666259</ID>
    </Citation>
    <Citation Type="general">
      <ID Source="PubMed">25666259</ID>
    </Citation>
    <StudyName>Kasak2014</StudyName>
    <StudyDescription>The study aimed to determine the contribution of copy number variants in the genetic etiology of normal and complicated pregnancies. The samples represented (i) maternal blood DNA drawn from healthy pregnant women during 1st or 2nd trimester and (ii) maternal and paternal blood DNA drawn at term pregnancy cases representing normal and complicated gestations (severe preeclampsia, PE; gestational diabetes, GD; small-for-gestational age newborn, SGA; large-for-gestational age newborn, LGA). We performed CNV calling based on genome-wide genotyping dataset (Illumina HumanOmniExpress-24-v1 BeadChip) by applying three algorithms, QuantiSNP, GADA (Genome Alteration Detection Algorithm) and CNstream in parallel. The acquired CNV calls were merged with HD-CNV (Hotspot Detector for Copy Number Variants) program and only the CNVs predicted by at least two programs, were considered in subsequent analysis.</StudyDescription>
    <Comment>The study aimed to determine the contribution of copy number variants in the genetic etiology of normal and complicated pregnancies. The samples represented (i) maternal blood DNA drawn from healthy pregnant women during 1st or 2nd trimester and (ii) maternal and paternal blood DNA drawn at term pregnancy cases representing normal and complicated gestations (severe preeclampsia, PE; gestational diabetes, GD; small-for-gestational age newborn, SGA; large-for-gestational age newborn, LGA). We performed CNV calling based on genome-wide genotyping dataset (Illumina HumanOmniExpress-24-v1 BeadChip) by applying three algorithms, QuantiSNP, GADA (Genome Alteration Detection Algorithm) and CNstream in parallel. The acquired CNV calls were merged with HD-CNV (Hotspot Detector for Copy Number Variants) program and only the CNVs predicted by at least two programs, were considered in subsequent analysis.</Comment>
  </ClinVarAssertion>
</ClinVarSet>

<ClinVarSet ID="18550097">
  <RecordStatus>current</RecordStatus>
  <Title>NM_001320322.1(TMTC2):c.84-78853_84-44447del AND Small for gestational age</Title>
  <ReferenceClinVarAssertion DateCreated="2015-02-25" DateLastUpdated="2017-04-05" ID="381556">
    <ClinVarAccession Acc="RCV000161685" Version="1" Type="RCV" DateUpdated="2017-04-05"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance>
      <ReviewStatus>no assertion provided</ReviewStatus>
      <Description>not provided</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>unknown</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>yes</AffectedStatus>
      </Sample>
      <Method>
        <NamePlatform>Illumina HumanOmniExpress Beadchip</NamePlatform>
        <Description>Genomic DNA copy number estimation from GenomeStudio-normalised genotyping microarray data (probe signal intensity). Using Illumina's baseline data for microarray signal intensity normalisation, QuantiSNP default baseline data (OB-HMM parameter values) for CNV calling.</Description>
        <MethodType>case-control</MethodType>
      </Method>
      <ObservedData ID="17761768">
        <Attribute Type="Description">not provided</Attribute>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant" ID="157259">
      <Measure Type="Deletion" ID="167119">
        <Name>
          <ElementValue Type="Preferred">NM_001320322.1(TMTC2):c.84-78853_84-44447del</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Change="c.84-78853_84-44447del" Accession="NM_001320322" Version="1" Type="HGVS, coding, RefSeq">NM_001320322.1:c.84-78853_84-44447del</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Change="c.84-78853_84-44447del" Accession="NM_152588" Version="2" Type="HGVS, coding, RefSeq">NM_152588.2:c.84-78853_84-44447del</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Change="g.83171936_83206342del" Accession="CM000674" Version="1" Type="HGVS, genomic">CM000674.1:g.83171936_83206342del</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Change="g.82778157_82812563del34407" Accession="NC_000012" Version="12" Type="HGVS, genomic, top level" integerValue="38">NC_000012.12:g.82778157_82812563del34407</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Change="g.83171936_83206342del34407" Accession="NC_000012" Version="11" Type="HGVS, genomic, top level, previous" integerValue="37">NC_000012.11:g.83171936_83206342del34407</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="MolecularConsequence">intron variant</Attribute>
          <XRef ID="SO:0001627" DB="Sequence Ontology"/>
          <XRef ID="NM_001320322.1:c.84-78853_84-44447del" DB="RefSeq"/>
        </AttributeSet>
        <CytogeneticLocation>12q21.31</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="12" Accession="NC_000012.12" start="82778157" stop="82812563" display_start="82778157" display_stop="82812563" variantLength="34407"/>
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="12" Accession="NC_000012.11" start="83171936" stop="83206342" display_start="83171936" display_stop="83206342" variantLength="34407"/>
        <MeasureRelationship Type="within single gene">
          <Name>
            <ElementValue Type="Preferred">transmembrane and tetratricopeptide repeat containing 2</ElementValue>
          </Name>
          <Symbol>
            <ElementValue Type="Preferred">TMTC2</ElementValue>
          </Symbol>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="12" Accession="NC_000012.12" start="82686952" stop="83134868" display_start="82686952" display_stop="83134868" Strand="+"/>
          <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="12" Accession="NC_000012.11" start="83080933" stop="83528064" display_start="83080933" display_stop="83528064" variantLength="447132" Strand="+"/>
          <XRef ID="160335" DB="Gene"/>
          <XRef Type="MIM" ID="615856" DB="OMIM"/>
          <XRef ID="HGNC:25440" DB="HGNC"/>
        </MeasureRelationship>
        <Citation Type="general">
          <ID Source="PubMed">25666259</ID>
        </Citation>
      </Measure>
      <Name>
        <ElementValue Type="Preferred">NM_001320322.1(TMTC2):c.84-78853_84-44447del</ElementValue>
      </Name>
    </MeasureSet>
    <TraitSet Type="Finding" ID="17776">
      <Trait ID="22432" Type="Finding">
        <Name>
          <ElementValue Type="Preferred">Small for gestational age</ElementValue>
          <XRef ID="HP:0001518" DB="Human Phenotype Ontology"/>
        </Name>
        <Name>
          <ElementValue Type="Alternate">Birth weight less than 10th percentile</ElementValue>
          <XRef ID="HP:0001518" DB="Human Phenotype Ontology"/>
        </Name>
        <Name>
          <ElementValue Type="Alternate">Low birth weight</ElementValue>
          <XRef ID="HP:0001518" DB="Human Phenotype Ontology"/>
        </Name>
        <XRef ID="C0021288" DB="MedGen"/>
        <XRef Type="primary" ID="HP:0001518" DB="Human Phenotype Ontology"/>
        <XRef Type="secondary" ID="HP:0001422" DB="Human Phenotype Ontology"/>
        <XRef Type="secondary" ID="HP:0008849" DB="Human Phenotype Ontology"/>
        <XRef Type="secondary" ID="HP:0008919" DB="Human Phenotype Ontology"/>
        <XRef Type="secondary" ID="HP:0008927" DB="Human Phenotype Ontology"/>
      </Trait>
    </TraitSet>
  </ReferenceClinVarAssertion>
  <ClinVarAssertion ID="338910" SubmissionName="Kasak">
    <ClinVarSubmissionID localKey="CNV_618" submitter="Institute of Molecular and Cell Biology, University of Tartu" submitterDate="2014-10-23"/>
    <ClinVarAccession Acc="SCV000191642" OrgType="primary" OrganizationCategory="other" Version="1" Type="SCV" OrgID="505255" DateUpdated="2017-04-05"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance>
      <ReviewStatus>no assertion provided</ReviewStatus>
      <Description>not provided</Description>
      <Citation Type="general">
        <ID Source="PubMed">25666259</ID>
      </Citation>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ExternalID DB="EVA" ID="CNV_618"/>
    <ObservedIn>
      <Sample>
        <Origin>unknown</Origin>
        <Tissue>Blood</Tissue>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>yes</AffectedStatus>
        <Gender>mixed</Gender>
      </Sample>
      <Method>
        <NamePlatform>Illumina HumanOmniExpress Beadchip</NamePlatform>
        <TypePlatform>SNP array</TypePlatform>
        <Description>Genomic DNA copy number estimation from GenomeStudio-normalised genotyping microarray data (probe signal intensity). Using Illumina's baseline data for microarray signal intensity normalisation, QuantiSNP default baseline data (OB-HMM parameter values) for CNV calling.</Description>
        <Software name="QuantiSNP, GADA, CNstream" purpose="Normalized signal intensity data was obtained through Illumina GenomeStudio software. Information on Log2 R ratios, B allele frequencies, markers and chromosomal coordinates from each sample were used for CNV identification with Hidden Markov Model-based algorithm QuantiSNP 2.3 (Colella et al., 2007) and a sparse Bayesian learning approach GADA (Genome Alteration Detection Analysis) (Pique-Regi et al., 2010). QuantiSNP was run with default settings, the adjustment for ‘genomic waves’ in signal intensities was turned on with the ‘--gcdir’ key in addition to the default calling parameters. GADA was run using the options “–T 5 –M 3”. CNstream (Alonso et al., 2010) algorithm was used in parallel to estimate CNVs from X and Y channel intensities loaded from Illumina GenomeStudio. CNVs were calculated under the following parameters: number of probes per segment (=3), minimum number of probes in one segment that must exceed the threshold for identifying an amplification/deletion (=3), CNV frequency threshold (=0). CNVs with QuantiSNP log Bayes Factor value &lt;5 and/or rearrangements shorter than 350 bp were excluded from the resulting list of CNVs. In this project we analysed only autosomal CNVs. HD-CNV (Hotspot Detector for Copy Number Variants) (Butler et al., 2013) was used to merge CNV regions called by alternative computational algorithms, QuantiSNP, GADA and CNstream. A criterion of 40% reciprocal overlap between parallel CNV calls was used to define two calls as identifying the same event. All CNVs called by at least two algorithms for the same individual in the same genomic loci were considered in the subsequent global analysis."/>
        <MethodType>case-control</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="Description">not provided</Attribute>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant">
      <Measure Type="Variation">
        <AttributeSet>
          <Attribute Type="HGVS">CM000674.1:g.83171936_83206342del</Attribute>
        </AttributeSet>
      </Measure>
    </MeasureSet>
    <TraitSet Type="Disease">
      <Trait Type="Finding">
        <Name>
          <ElementValue Type="Preferred">Small for gestational age</ElementValue>
        </Name>
        <XRef DB="MedGen" ID="C0024032" Type="CUI"/>
      </Trait>
    </TraitSet>
    <Citation Type="general">
      <ID Source="PubMed">25666259</ID>
    </Citation>
    <Citation Type="general">
      <ID Source="PubMed">25666259</ID>
    </Citation>
    <StudyName>Kasak2014</StudyName>
    <StudyDescription>The study aimed to determine the contribution of copy number variants in the genetic etiology of normal and complicated pregnancies. The samples represented (i) maternal blood DNA drawn from healthy pregnant women during 1st or 2nd trimester and (ii) maternal and paternal blood DNA drawn at term pregnancy cases representing normal and complicated gestations (severe preeclampsia, PE; gestational diabetes, GD; small-for-gestational age newborn, SGA; large-for-gestational age newborn, LGA). We performed CNV calling based on genome-wide genotyping dataset (Illumina HumanOmniExpress-24-v1 BeadChip) by applying three algorithms, QuantiSNP, GADA (Genome Alteration Detection Algorithm) and CNstream in parallel. The acquired CNV calls were merged with HD-CNV (Hotspot Detector for Copy Number Variants) program and only the CNVs predicted by at least two programs, were considered in subsequent analysis.</StudyDescription>
    <Comment>The study aimed to determine the contribution of copy number variants in the genetic etiology of normal and complicated pregnancies. The samples represented (i) maternal blood DNA drawn from healthy pregnant women during 1st or 2nd trimester and (ii) maternal and paternal blood DNA drawn at term pregnancy cases representing normal and complicated gestations (severe preeclampsia, PE; gestational diabetes, GD; small-for-gestational age newborn, SGA; large-for-gestational age newborn, LGA). We performed CNV calling based on genome-wide genotyping dataset (Illumina HumanOmniExpress-24-v1 BeadChip) by applying three algorithms, QuantiSNP, GADA (Genome Alteration Detection Algorithm) and CNstream in parallel. The acquired CNV calls were merged with HD-CNV (Hotspot Detector for Copy Number Variants) program and only the CNVs predicted by at least two programs, were considered in subsequent analysis.</Comment>
  </ClinVarAssertion>
</ClinVarSet>

<ClinVarSet ID="18550127">
  <RecordStatus>current</RecordStatus>
  <Title>NC_000013.11:g.83529572_83583792del54221 AND Normal pregnancy</Title>
  <ReferenceClinVarAssertion DateCreated="2015-02-25" DateLastUpdated="2017-04-05" ID="381586">
    <ClinVarAccession Acc="RCV000161715" Version="1" Type="RCV" DateUpdated="2017-04-05"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance>
      <ReviewStatus>no assertion provided</ReviewStatus>
      <Description>not provided</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>unknown</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>yes</AffectedStatus>
      </Sample>
      <Method>
        <NamePlatform>Illumina HumanOmniExpress Beadchip</NamePlatform>
        <Description>Genomic DNA copy number estimation from GenomeStudio-normalised genotyping microarray data (probe signal intensity). Using Illumina's baseline data for microarray signal intensity normalisation, QuantiSNP default baseline data (OB-HMM parameter values) for CNV calling.</Description>
        <MethodType>case-control</MethodType>
      </Method>
      <ObservedData ID="17756855">
        <Attribute Type="Description">not provided</Attribute>
      </ObservedData>
      <ObservedData ID="17756855">
        <Attribute Type="Description">not provided</Attribute>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant" ID="157288">
      <Measure Type="Deletion" ID="167148">
        <Name>
          <ElementValue Type="Preferred">NC_000013.11:g.83529572_83583792del54221</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Change="g.84103707_84157927del" Accession="CM000675" Version="1" Type="HGVS, genomic">CM000675.1:g.84103707_84157927del</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Change="g.83529572_83583792del54221" Accession="NC_000013" Version="11" Type="HGVS, genomic, top level" integerValue="38">NC_000013.11:g.83529572_83583792del54221</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Change="g.84103707_84157927del54221" Accession="NC_000013" Version="10" Type="HGVS, genomic, top level, previous" integerValue="37">NC_000013.10:g.84103707_84157927del54221</Attribute>
        </AttributeSet>
        <CytogeneticLocation>13q31.1</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="13" Accession="NC_000013.11" start="83529572" stop="83583792" display_start="83529572" display_stop="83583792" variantLength="54221"/>
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="13" Accession="NC_000013.10" start="84103707" stop="84157927" display_start="84103707" display_stop="84157927" variantLength="54221"/>
        <Citation Type="general">
          <ID Source="PubMed">25666259</ID>
        </Citation>
      </Measure>
      <Name>
        <ElementValue Type="Preferred">NC_000013.11:g.83529572_83583792del54221</ElementValue>
      </Name>
    </MeasureSet>
    <TraitSet Type="Finding" ID="19843">
      <Trait ID="32125" Type="Finding">
        <Name>
          <ElementValue Type="Preferred">Normal pregnancy</ElementValue>
          <XRef ID="CNV_4" DB="Institute of Molecular and Cell Biology, University of Tartu"/>
        </Name>
        <XRef ID="CN220684" DB="MedGen"/>
      </Trait>
    </TraitSet>
  </ReferenceClinVarAssertion>
  <ClinVarAssertion ID="338940" SubmissionName="Kasak">
    <ClinVarSubmissionID localKey="CNV_652" submitter="Institute of Molecular and Cell Biology, University of Tartu" submitterDate="2014-10-23"/>
    <ClinVarAccession Acc="SCV000191672" OrgType="primary" OrganizationCategory="other" Version="1" Type="SCV" OrgID="505255" DateUpdated="2017-04-05"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance>
      <ReviewStatus>no assertion provided</ReviewStatus>
      <Description>not provided</Description>
      <Citation Type="general">
        <ID Source="PubMed">25666259</ID>
      </Citation>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ExternalID DB="EVA" ID="CNV_652"/>
    <ObservedIn>
      <Sample>
        <Origin>unknown</Origin>
        <Tissue>Blood</Tissue>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>yes</AffectedStatus>
        <Gender>female</Gender>
      </Sample>
      <Method>
        <NamePlatform>Illumina HumanOmniExpress Beadchip</NamePlatform>
        <TypePlatform>SNP array</TypePlatform>
        <Description>Genomic DNA copy number estimation from GenomeStudio-normalised genotyping microarray data (probe signal intensity). Using Illumina's baseline data for microarray signal intensity normalisation, QuantiSNP default baseline data (OB-HMM parameter values) for CNV calling.</Description>
        <Software name="QuantiSNP, GADA, CNstream" purpose="Normalized signal intensity data was obtained through Illumina GenomeStudio software. Information on Log2 R ratios, B allele frequencies, markers and chromosomal coordinates from each sample were used for CNV identification with Hidden Markov Model-based algorithm QuantiSNP 2.3 (Colella et al., 2007) and a sparse Bayesian learning approach GADA (Genome Alteration Detection Analysis) (Pique-Regi et al., 2010). QuantiSNP was run with default settings, the adjustment for ‘genomic waves’ in signal intensities was turned on with the ‘--gcdir’ key in addition to the default calling parameters. GADA was run using the options “–T 5 –M 3”. CNstream (Alonso et al., 2010) algorithm was used in parallel to estimate CNVs from X and Y channel intensities loaded from Illumina GenomeStudio. CNVs were calculated under the following parameters: number of probes per segment (=3), minimum number of probes in one segment that must exceed the threshold for identifying an amplification/deletion (=3), CNV frequency threshold (=0). CNVs with QuantiSNP log Bayes Factor value &lt;5 and/or rearrangements shorter than 350 bp were excluded from the resulting list of CNVs. In this project we analysed only autosomal CNVs. HD-CNV (Hotspot Detector for Copy Number Variants) (Butler et al., 2013) was used to merge CNV regions called by alternative computational algorithms, QuantiSNP, GADA and CNstream. A criterion of 40% reciprocal overlap between parallel CNV calls was used to define two calls as identifying the same event. All CNVs called by at least two algorithms for the same individual in the same genomic loci were considered in the subsequent global analysis."/>
        <MethodType>case-control</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="Description">not provided</Attribute>
      </ObservedData>
    </ObservedIn>
    <ObservedIn>
      <Sample>
        <Origin>unknown</Origin>
        <Tissue>Blood</Tissue>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>yes</AffectedStatus>
        <Gender>female</Gender>
      </Sample>
      <Method>
        <NamePlatform>Illumina HumanOmniExpress Beadchip</NamePlatform>
        <TypePlatform>SNP array</TypePlatform>
        <Description>Genomic DNA copy number estimation from GenomeStudio-normalised genotyping microarray data (probe signal intensity). Using Illumina's baseline data for microarray signal intensity normalisation, QuantiSNP default baseline data (OB-HMM parameter values) for CNV calling.</Description>
        <Software name="QuantiSNP, GADA, CNstream" purpose="Normalized signal intensity data was obtained through Illumina GenomeStudio software. Information on Log2 R ratios, B allele frequencies, markers and chromosomal coordinates from each sample were used for CNV identification with Hidden Markov Model-based algorithm QuantiSNP 2.3 (Colella et al., 2007) and a sparse Bayesian learning approach GADA (Genome Alteration Detection Analysis) (Pique-Regi et al., 2010). QuantiSNP was run with default settings, the adjustment for ‘genomic waves’ in signal intensities was turned on with the ‘--gcdir’ key in addition to the default calling parameters. GADA was run using the options “–T 5 –M 3”. CNstream (Alonso et al., 2010) algorithm was used in parallel to estimate CNVs from X and Y channel intensities loaded from Illumina GenomeStudio. CNVs were calculated under the following parameters: number of probes per segment (=3), minimum number of probes in one segment that must exceed the threshold for identifying an amplification/deletion (=3), CNV frequency threshold (=0). CNVs with QuantiSNP log Bayes Factor value &lt;5 and/or rearrangements shorter than 350 bp were excluded from the resulting list of CNVs. In this project we analysed only autosomal CNVs. HD-CNV (Hotspot Detector for Copy Number Variants) (Butler et al., 2013) was used to merge CNV regions called by alternative computational algorithms, QuantiSNP, GADA and CNstream. A criterion of 40% reciprocal overlap between parallel CNV calls was used to define two calls as identifying the same event. All CNVs called by at least two algorithms for the same individual in the same genomic loci were considered in the subsequent global analysis."/>
        <MethodType>case-control</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="Description">not provided</Attribute>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant">
      <Measure Type="Variation">
        <AttributeSet>
          <Attribute Type="HGVS">CM000675.1:g.84103707_84157927del</Attribute>
        </AttributeSet>
      </Measure>
    </MeasureSet>
    <TraitSet Type="Finding">
      <Trait Type="Finding">
        <Name>
          <ElementValue Type="Preferred">Normal pregnancy</ElementValue>
        </Name>
        <XRef DB="MedGen" ID="C0232989" Type="CUI"/>
      </Trait>
    </TraitSet>
    <Citation Type="general">
      <ID Source="PubMed">25666259</ID>
    </Citation>
    <Citation Type="general">
      <ID Source="PubMed">25666259</ID>
    </Citation>
    <StudyName>Kasak2014</StudyName>
    <StudyDescription>The study aimed to determine the contribution of copy number variants in the genetic etiology of normal and complicated pregnancies. The samples represented (i) maternal blood DNA drawn from healthy pregnant women during 1st or 2nd trimester and (ii) maternal and paternal blood DNA drawn at term pregnancy cases representing normal and complicated gestations (severe preeclampsia, PE; gestational diabetes, GD; small-for-gestational age newborn, SGA; large-for-gestational age newborn, LGA). We performed CNV calling based on genome-wide genotyping dataset (Illumina HumanOmniExpress-24-v1 BeadChip) by applying three algorithms, QuantiSNP, GADA (Genome Alteration Detection Algorithm) and CNstream in parallel. The acquired CNV calls were merged with HD-CNV (Hotspot Detector for Copy Number Variants) program and only the CNVs predicted by at least two programs, were considered in subsequent analysis.</StudyDescription>
    <Comment>The study aimed to determine the contribution of copy number variants in the genetic etiology of normal and complicated pregnancies. The samples represented (i) maternal blood DNA drawn from healthy pregnant women during 1st or 2nd trimester and (ii) maternal and paternal blood DNA drawn at term pregnancy cases representing normal and complicated gestations (severe preeclampsia, PE; gestational diabetes, GD; small-for-gestational age newborn, SGA; large-for-gestational age newborn, LGA). We performed CNV calling based on genome-wide genotyping dataset (Illumina HumanOmniExpress-24-v1 BeadChip) by applying three algorithms, QuantiSNP, GADA (Genome Alteration Detection Algorithm) and CNstream in parallel. The acquired CNV calls were merged with HD-CNV (Hotspot Detector for Copy Number Variants) program and only the CNVs predicted by at least two programs, were considered in subsequent analysis.</Comment>
  </ClinVarAssertion>
</ClinVarSet>

<ClinVarSet ID="18626997">
  <RecordStatus>current</RecordStatus>
  <Title>FKTN, L1 INS AND Congenital muscular dystrophy-dystroglycanopathy with brain and eye anomalies, type A4</Title>
  <ReferenceClinVarAssertion DateCreated="2012-08-13" DateLastUpdated="2017-04-07" ID="60858">
    <ClinVarAccession Acc="RCV000003355" Version="3" Type="RCV" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="1999-11-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData ID="17808065">
        <Attribute Type="Description">In 2 unrelated patients with unusually severe FCMD (MDDGA4; 253800), Kondo-Iida et al. (1999) detected a 1.2-kb L1 insertion in the FKTN gene. Each patient carried the founder 3-kb retrotransposal insertion (607440.0001) on one allele and a distinctive haplotype on the other. Sequence analysis revealed that the 3-prime region of an L1 repetitive element had been inserted 24 basepairs before the intron 7-exon 8 boundary. The patients' RNA was tested for the effects of the insertion by means of reverse transcriptase-PCR analysis, using primers that amplified exons 5-10. Products of various sizes were obtained, suggesting exon skipping.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">10545611</ID>
        </Citation>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant" ID="3202">
      <Measure Type="Insertion" ID="18241">
        <Name>
          <ElementValue Type="Preferred">FKTN, L1 INS</ElementValue>
        </Name>
        <Name>
          <ElementValue Type="Alternate">FKTN, L1 INS</ElementValue>
          <XRef Type="Allelic variant" ID="607440.0004" DB="OMIM"/>
        </Name>
        <CytogeneticLocation>9q31</CytogeneticLocation>
        <MeasureRelationship Type="asserted, but not computed">
          <Name>
            <ElementValue Type="Preferred">fukutin</ElementValue>
          </Name>
          <Symbol>
            <ElementValue Type="Preferred">FKTN</ElementValue>
          </Symbol>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="9" Accession="NC_000009.12" start="105558117" stop="105655950" display_start="105558117" display_stop="105655950" Strand="+"/>
          <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="9" Accession="NC_000009.11" start="108320410" stop="108403398" display_start="108320410" display_stop="108403398" variantLength="82989" Strand="+"/>
          <XRef ID="2218" DB="Gene"/>
          <XRef Type="MIM" ID="607440" DB="OMIM"/>
          <XRef ID="HGNC:3622" DB="HGNC"/>
        </MeasureRelationship>
        <XRef Type="Allelic variant" ID="607440.0004" DB="OMIM"/>
      </Measure>
      <Name>
        <ElementValue Type="Preferred">FKTN, L1 INS</ElementValue>
      </Name>
    </MeasureSet>
    <TraitSet Type="Disease" ID="820">
      <Trait ID="9860" Type="Disease">
        <Name>
          <ElementValue Type="Preferred">Congenital muscular dystrophy-dystroglycanopathy with brain and eye anomalies, type A4</ElementValue>
        </Name>
        <Name>
          <ElementValue Type="Alternate">MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 4</ElementValue>
          <XRef Type="Allelic variant" ID="607440.0001" DB="OMIM"/>
          <XRef Type="Allelic variant" ID="607440.0002" DB="OMIM"/>
          <XRef Type="Allelic variant" ID="607440.0003" DB="OMIM"/>
          <XRef Type="Allelic variant" ID="607440.0004" DB="OMIM"/>
          <XRef Type="Allelic variant" ID="607440.0005" DB="OMIM"/>
          <XRef Type="Allelic variant" ID="607440.0006" DB="OMIM"/>
          <XRef Type="Allelic variant" ID="607440.0007" DB="OMIM"/>
          <XRef Type="Allelic variant" ID="607440.0013" DB="OMIM"/>
          <XRef Type="Allelic variant" ID="607440.0016" DB="OMIM"/>
          <XRef Type="Allelic variant" ID="607440.0017" DB="OMIM"/>
          <XRef Type="Allelic variant" ID="607440.0018" DB="OMIM"/>
        </Name>
      </Trait>
    </TraitSet>
  </ReferenceClinVarAssertion>
  <ClinVarAssertion ID="23513">
    <ClinVarSubmissionID localKey="607440.0004_MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 4" submitter="OMIM" submitterDate="2014-10-20" title="FKTN, L1 INS_MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 4"/>
    <ClinVarAccession Acc="SCV000023513" OrgType="primary" OrganizationCategory="resource" Version="2" Type="SCV" OrgID="3" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="1999-11-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ExternalID DB="OMIM" ID="607440.0004" Type="Allelic variant"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species>human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="Description">In 2 unrelated patients with unusually severe FCMD (MDDGA4; 253800), Kondo-Iida et al. (1999) detected a 1.2-kb L1 insertion in the FKTN gene. Each patient carried the founder 3-kb retrotransposal insertion (607440.0001) on one allele and a distinctive haplotype on the other. Sequence analysis revealed that the 3-prime region of an L1 repetitive element had been inserted 24 basepairs before the intron 7-exon 8 boundary. The patients' RNA was tested for the effects of the insertion by means of reverse transcriptase-PCR analysis, using primers that amplified exons 5-10. Products of various sizes were obtained, suggesting exon skipping.</Attribute>
        <Citation>
          <ID Source="PubMed">10545611</ID>
        </Citation>
        <XRef DB="OMIM" ID="253800" Type="MIM"/>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant">
      <Measure Type="Variation">
        <Name>
          <ElementValue Type="Preferred">FKTN, L1 INS</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="NonHGVS">L1 INS</Attribute>
        </AttributeSet>
        <MeasureRelationship Type="variant in gene">
          <Symbol>
            <ElementValue Type="Preferred">FKTN</ElementValue>
          </Symbol>
        </MeasureRelationship>
        <XRef DB="OMIM" ID="607440.0004" Type="Allelic variant"/>
      </Measure>
    </MeasureSet>
    <TraitSet Type="Disease">
      <Trait Type="Disease">
        <Name>
          <ElementValue Type="Preferred">MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 4</ElementValue>
        </Name>
      </Trait>
    </TraitSet>
  </ClinVarAssertion>
</ClinVarSet>

<ClinVarSet ID="18550148">
  <RecordStatus>current</RecordStatus>
  <Title>NC_000014.9:g.62187980_62268148del80169 AND Small for gestational age</Title>
  <ReferenceClinVarAssertion DateCreated="2015-02-25" DateLastUpdated="2017-04-05" ID="381607">
    <ClinVarAccession Acc="RCV000161736" Version="1" Type="RCV" DateUpdated="2017-04-05"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance>
      <ReviewStatus>no assertion provided</ReviewStatus>
      <Description>not provided</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>unknown</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>yes</AffectedStatus>
      </Sample>
      <Method>
        <NamePlatform>Illumina HumanOmniExpress Beadchip</NamePlatform>
        <Description>Genomic DNA copy number estimation from GenomeStudio-normalised genotyping microarray data (probe signal intensity). Using Illumina's baseline data for microarray signal intensity normalisation, QuantiSNP default baseline data (OB-HMM parameter values) for CNV calling.</Description>
        <MethodType>case-control</MethodType>
      </Method>
      <ObservedData ID="17761781">
        <Attribute Type="Description">not provided</Attribute>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant" ID="157310">
      <Measure Type="Deletion" ID="167170">
        <Name>
          <ElementValue Type="Preferred">NC_000014.9:g.62187980_62268148del80169</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Change="g.62654698_62734866del" Accession="CM000676" Version="1" Type="HGVS, genomic">CM000676.1:g.62654698_62734866del</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Change="g.62187980_62268148del80169" Accession="NC_000014" Version="9" Type="HGVS, genomic, top level" integerValue="38">NC_000014.9:g.62187980_62268148del80169</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Change="g.62654698_62734866del80169" Accession="NC_000014" Version="8" Type="HGVS, genomic, top level, previous" integerValue="37">NC_000014.8:g.62654698_62734866del80169</Attribute>
        </AttributeSet>
        <CytogeneticLocation>14q23.2</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="14" Accession="NC_000014.9" start="62187980" stop="62268148" display_start="62187980" display_stop="62268148" variantLength="80169"/>
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="14" Accession="NC_000014.8" start="62654698" stop="62734866" display_start="62654698" display_stop="62734866" variantLength="80169"/>
        <Citation Type="general">
          <ID Source="PubMed">25666259</ID>
        </Citation>
      </Measure>
      <Name>
        <ElementValue Type="Preferred">NC_000014.9:g.62187980_62268148del80169</ElementValue>
      </Name>
    </MeasureSet>
    <TraitSet Type="Finding" ID="17776">
      <Trait ID="22432" Type="Finding">
        <Name>
          <ElementValue Type="Preferred">Small for gestational age</ElementValue>
          <XRef ID="HP:0001518" DB="Human Phenotype Ontology"/>
        </Name>
        <Name>
          <ElementValue Type="Alternate">Birth weight less than 10th percentile</ElementValue>
          <XRef ID="HP:0001518" DB="Human Phenotype Ontology"/>
        </Name>
        <Name>
          <ElementValue Type="Alternate">Low birth weight</ElementValue>
          <XRef ID="HP:0001518" DB="Human Phenotype Ontology"/>
        </Name>
        <XRef ID="C0021288" DB="MedGen"/>
        <XRef Type="primary" ID="HP:0001518" DB="Human Phenotype Ontology"/>
        <XRef Type="secondary" ID="HP:0001422" DB="Human Phenotype Ontology"/>
        <XRef Type="secondary" ID="HP:0008849" DB="Human Phenotype Ontology"/>
        <XRef Type="secondary" ID="HP:0008919" DB="Human Phenotype Ontology"/>
        <XRef Type="secondary" ID="HP:0008927" DB="Human Phenotype Ontology"/>
      </Trait>
    </TraitSet>
  </ReferenceClinVarAssertion>
  <ClinVarAssertion ID="338961" SubmissionName="Kasak">
    <ClinVarSubmissionID localKey="CNV_676" submitter="Institute of Molecular and Cell Biology, University of Tartu" submitterDate="2014-10-23"/>
    <ClinVarAccession Acc="SCV000191693" OrgType="primary" OrganizationCategory="other" Version="1" Type="SCV" OrgID="505255" DateUpdated="2017-04-05"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance>
      <ReviewStatus>no assertion provided</ReviewStatus>
      <Description>not provided</Description>
      <Citation Type="general">
        <ID Source="PubMed">25666259</ID>
      </Citation>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ExternalID DB="EVA" ID="CNV_676"/>
    <ObservedIn>
      <Sample>
        <Origin>unknown</Origin>
        <Tissue>Blood</Tissue>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>yes</AffectedStatus>
        <Gender>mixed</Gender>
      </Sample>
      <Method>
        <NamePlatform>Illumina HumanOmniExpress Beadchip</NamePlatform>
        <TypePlatform>SNP array</TypePlatform>
        <Description>Genomic DNA copy number estimation from GenomeStudio-normalised genotyping microarray data (probe signal intensity). Using Illumina's baseline data for microarray signal intensity normalisation, QuantiSNP default baseline data (OB-HMM parameter values) for CNV calling.</Description>
        <Software name="QuantiSNP, GADA, CNstream" purpose="Normalized signal intensity data was obtained through Illumina GenomeStudio software. Information on Log2 R ratios, B allele frequencies, markers and chromosomal coordinates from each sample were used for CNV identification with Hidden Markov Model-based algorithm QuantiSNP 2.3 (Colella et al., 2007) and a sparse Bayesian learning approach GADA (Genome Alteration Detection Analysis) (Pique-Regi et al., 2010). QuantiSNP was run with default settings, the adjustment for ‘genomic waves’ in signal intensities was turned on with the ‘--gcdir’ key in addition to the default calling parameters. GADA was run using the options “–T 5 –M 3”. CNstream (Alonso et al., 2010) algorithm was used in parallel to estimate CNVs from X and Y channel intensities loaded from Illumina GenomeStudio. CNVs were calculated under the following parameters: number of probes per segment (=3), minimum number of probes in one segment that must exceed the threshold for identifying an amplification/deletion (=3), CNV frequency threshold (=0). CNVs with QuantiSNP log Bayes Factor value &lt;5 and/or rearrangements shorter than 350 bp were excluded from the resulting list of CNVs. In this project we analysed only autosomal CNVs. HD-CNV (Hotspot Detector for Copy Number Variants) (Butler et al., 2013) was used to merge CNV regions called by alternative computational algorithms, QuantiSNP, GADA and CNstream. A criterion of 40% reciprocal overlap between parallel CNV calls was used to define two calls as identifying the same event. All CNVs called by at least two algorithms for the same individual in the same genomic loci were considered in the subsequent global analysis."/>
        <MethodType>case-control</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="Description">not provided</Attribute>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant">
      <Measure Type="Variation">
        <AttributeSet>
          <Attribute Type="HGVS">CM000676.1:g.62654698_62734866del</Attribute>
        </AttributeSet>
      </Measure>
    </MeasureSet>
    <TraitSet Type="Disease">
      <Trait Type="Finding">
        <Name>
          <ElementValue Type="Preferred">Small for gestational age</ElementValue>
        </Name>
        <XRef DB="MedGen" ID="C0024032" Type="CUI"/>
      </Trait>
    </TraitSet>
    <Citation Type="general">
      <ID Source="PubMed">25666259</ID>
    </Citation>
    <Citation Type="general">
      <ID Source="PubMed">25666259</ID>
    </Citation>
    <StudyName>Kasak2014</StudyName>
    <StudyDescription>The study aimed to determine the contribution of copy number variants in the genetic etiology of normal and complicated pregnancies. The samples represented (i) maternal blood DNA drawn from healthy pregnant women during 1st or 2nd trimester and (ii) maternal and paternal blood DNA drawn at term pregnancy cases representing normal and complicated gestations (severe preeclampsia, PE; gestational diabetes, GD; small-for-gestational age newborn, SGA; large-for-gestational age newborn, LGA). We performed CNV calling based on genome-wide genotyping dataset (Illumina HumanOmniExpress-24-v1 BeadChip) by applying three algorithms, QuantiSNP, GADA (Genome Alteration Detection Algorithm) and CNstream in parallel. The acquired CNV calls were merged with HD-CNV (Hotspot Detector for Copy Number Variants) program and only the CNVs predicted by at least two programs, were considered in subsequent analysis.</StudyDescription>
    <Comment>The study aimed to determine the contribution of copy number variants in the genetic etiology of normal and complicated pregnancies. The samples represented (i) maternal blood DNA drawn from healthy pregnant women during 1st or 2nd trimester and (ii) maternal and paternal blood DNA drawn at term pregnancy cases representing normal and complicated gestations (severe preeclampsia, PE; gestational diabetes, GD; small-for-gestational age newborn, SGA; large-for-gestational age newborn, LGA). We performed CNV calling based on genome-wide genotyping dataset (Illumina HumanOmniExpress-24-v1 BeadChip) by applying three algorithms, QuantiSNP, GADA (Genome Alteration Detection Algorithm) and CNstream in parallel. The acquired CNV calls were merged with HD-CNV (Hotspot Detector for Copy Number Variants) program and only the CNVs predicted by at least two programs, were considered in subsequent analysis.</Comment>
  </ClinVarAssertion>
</ClinVarSet>

<ClinVarSet ID="18550182">
  <RecordStatus>current</RecordStatus>
  <Title>NC_000015.10:g.37145047_37209649del64603 AND Small for gestational age</Title>
  <ReferenceClinVarAssertion DateCreated="2015-02-26" DateLastUpdated="2017-04-05" ID="381641">
    <ClinVarAccession Acc="RCV000161770" Version="1" Type="RCV" DateUpdated="2017-04-05"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance>
      <ReviewStatus>no assertion provided</ReviewStatus>
      <Description>not provided</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>unknown</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>yes</AffectedStatus>
      </Sample>
      <Method>
        <NamePlatform>Illumina HumanOmniExpress Beadchip</NamePlatform>
        <Description>Genomic DNA copy number estimation from GenomeStudio-normalised genotyping microarray data (probe signal intensity). Using Illumina's baseline data for microarray signal intensity normalisation, QuantiSNP default baseline data (OB-HMM parameter values) for CNV calling.</Description>
        <MethodType>case-control</MethodType>
      </Method>
      <ObservedData ID="17758073">
        <Attribute Type="Description">not provided</Attribute>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant" ID="157344">
      <Measure Type="Deletion" ID="167204">
        <Name>
          <ElementValue Type="Preferred">NC_000015.10:g.37145047_37209649del64603</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Change="g.37437248_37501850del" Accession="CM000677" Version="1" Type="HGVS, genomic">CM000677.1:g.37437248_37501850del</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Change="g.37145047_37209649del64603" Accession="NC_000015" Version="10" Type="HGVS, genomic, top level" integerValue="38">NC_000015.10:g.37145047_37209649del64603</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Change="g.37437248_37501850del64603" Accession="NC_000015" Version="9" Type="HGVS, genomic, top level, previous" integerValue="37">NC_000015.9:g.37437248_37501850del64603</Attribute>
        </AttributeSet>
        <CytogeneticLocation>15q14</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="15" Accession="NC_000015.10" start="37145047" stop="37209649" display_start="37145047" display_stop="37209649" variantLength="64603"/>
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="15" Accession="NC_000015.9" start="37437248" stop="37501850" display_start="37437248" display_stop="37501850" variantLength="64603"/>
        <Citation Type="general">
          <ID Source="PubMed">25666259</ID>
        </Citation>
      </Measure>
      <Name>
        <ElementValue Type="Preferred">NC_000015.10:g.37145047_37209649del64603</ElementValue>
      </Name>
    </MeasureSet>
    <TraitSet Type="Finding" ID="17776">
      <Trait ID="22432" Type="Finding">
        <Name>
          <ElementValue Type="Preferred">Small for gestational age</ElementValue>
          <XRef ID="HP:0001518" DB="Human Phenotype Ontology"/>
        </Name>
        <Name>
          <ElementValue Type="Alternate">Birth weight less than 10th percentile</ElementValue>
          <XRef ID="HP:0001518" DB="Human Phenotype Ontology"/>
        </Name>
        <Name>
          <ElementValue Type="Alternate">Low birth weight</ElementValue>
          <XRef ID="HP:0001518" DB="Human Phenotype Ontology"/>
        </Name>
        <XRef ID="C0021288" DB="MedGen"/>
        <XRef Type="primary" ID="HP:0001518" DB="Human Phenotype Ontology"/>
        <XRef Type="secondary" ID="HP:0001422" DB="Human Phenotype Ontology"/>
        <XRef Type="secondary" ID="HP:0008849" DB="Human Phenotype Ontology"/>
        <XRef Type="secondary" ID="HP:0008919" DB="Human Phenotype Ontology"/>
        <XRef Type="secondary" ID="HP:0008927" DB="Human Phenotype Ontology"/>
      </Trait>
    </TraitSet>
  </ReferenceClinVarAssertion>
  <ClinVarAssertion ID="338995" SubmissionName="Kasak">
    <ClinVarSubmissionID localKey="CNV_714" submitter="Institute of Molecular and Cell Biology, University of Tartu" submitterDate="2014-10-23"/>
    <ClinVarAccession Acc="SCV000191727" OrgType="primary" OrganizationCategory="other" Version="1" Type="SCV" OrgID="505255" DateUpdated="2017-04-05"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance>
      <ReviewStatus>no assertion provided</ReviewStatus>
      <Description>not provided</Description>
      <Citation Type="general">
        <ID Source="PubMed">25666259</ID>
      </Citation>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ExternalID DB="EVA" ID="CNV_714"/>
    <ObservedIn>
      <Sample>
        <Origin>unknown</Origin>
        <Tissue>Blood</Tissue>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>yes</AffectedStatus>
        <Gender>mixed</Gender>
      </Sample>
      <Method>
        <NamePlatform>Illumina HumanOmniExpress Beadchip</NamePlatform>
        <TypePlatform>SNP array</TypePlatform>
        <Description>Genomic DNA copy number estimation from GenomeStudio-normalised genotyping microarray data (probe signal intensity). Using Illumina's baseline data for microarray signal intensity normalisation, QuantiSNP default baseline data (OB-HMM parameter values) for CNV calling.</Description>
        <Software name="QuantiSNP, GADA, CNstream" purpose="Normalized signal intensity data was obtained through Illumina GenomeStudio software. Information on Log2 R ratios, B allele frequencies, markers and chromosomal coordinates from each sample were used for CNV identification with Hidden Markov Model-based algorithm QuantiSNP 2.3 (Colella et al., 2007) and a sparse Bayesian learning approach GADA (Genome Alteration Detection Analysis) (Pique-Regi et al., 2010). QuantiSNP was run with default settings, the adjustment for ‘genomic waves’ in signal intensities was turned on with the ‘--gcdir’ key in addition to the default calling parameters. GADA was run using the options “–T 5 –M 3”. CNstream (Alonso et al., 2010) algorithm was used in parallel to estimate CNVs from X and Y channel intensities loaded from Illumina GenomeStudio. CNVs were calculated under the following parameters: number of probes per segment (=3), minimum number of probes in one segment that must exceed the threshold for identifying an amplification/deletion (=3), CNV frequency threshold (=0). CNVs with QuantiSNP log Bayes Factor value &lt;5 and/or rearrangements shorter than 350 bp were excluded from the resulting list of CNVs. In this project we analysed only autosomal CNVs. HD-CNV (Hotspot Detector for Copy Number Variants) (Butler et al., 2013) was used to merge CNV regions called by alternative computational algorithms, QuantiSNP, GADA and CNstream. A criterion of 40% reciprocal overlap between parallel CNV calls was used to define two calls as identifying the same event. All CNVs called by at least two algorithms for the same individual in the same genomic loci were considered in the subsequent global analysis."/>
        <MethodType>case-control</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="Description">not provided</Attribute>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant">
      <Measure Type="Variation">
        <AttributeSet>
          <Attribute Type="HGVS">CM000677.1:g.37437248_37501850del</Attribute>
        </AttributeSet>
      </Measure>
    </MeasureSet>
    <TraitSet Type="Disease">
      <Trait Type="Finding">
        <Name>
          <ElementValue Type="Preferred">Small for gestational age</ElementValue>
        </Name>
        <XRef DB="MedGen" ID="C0024032" Type="CUI"/>
      </Trait>
    </TraitSet>
    <Citation Type="general">
      <ID Source="PubMed">25666259</ID>
    </Citation>
    <Citation Type="general">
      <ID Source="PubMed">25666259</ID>
    </Citation>
    <StudyName>Kasak2014</StudyName>
    <StudyDescription>The study aimed to determine the contribution of copy number variants in the genetic etiology of normal and complicated pregnancies. The samples represented (i) maternal blood DNA drawn from healthy pregnant women during 1st or 2nd trimester and (ii) maternal and paternal blood DNA drawn at term pregnancy cases representing normal and complicated gestations (severe preeclampsia, PE; gestational diabetes, GD; small-for-gestational age newborn, SGA; large-for-gestational age newborn, LGA). We performed CNV calling based on genome-wide genotyping dataset (Illumina HumanOmniExpress-24-v1 BeadChip) by applying three algorithms, QuantiSNP, GADA (Genome Alteration Detection Algorithm) and CNstream in parallel. The acquired CNV calls were merged with HD-CNV (Hotspot Detector for Copy Number Variants) program and only the CNVs predicted by at least two programs, were considered in subsequent analysis.</StudyDescription>
    <Comment>The study aimed to determine the contribution of copy number variants in the genetic etiology of normal and complicated pregnancies. The samples represented (i) maternal blood DNA drawn from healthy pregnant women during 1st or 2nd trimester and (ii) maternal and paternal blood DNA drawn at term pregnancy cases representing normal and complicated gestations (severe preeclampsia, PE; gestational diabetes, GD; small-for-gestational age newborn, SGA; large-for-gestational age newborn, LGA). We performed CNV calling based on genome-wide genotyping dataset (Illumina HumanOmniExpress-24-v1 BeadChip) by applying three algorithms, QuantiSNP, GADA (Genome Alteration Detection Algorithm) and CNstream in parallel. The acquired CNV calls were merged with HD-CNV (Hotspot Detector for Copy Number Variants) program and only the CNVs predicted by at least two programs, were considered in subsequent analysis.</Comment>
  </ClinVarAssertion>
</ClinVarSet>

<ClinVarSet ID="18550204">
  <RecordStatus>current</RecordStatus>
  <Title>NC_000016.9:g.32608438_33557021del948584 AND Large for gestational age</Title>
  <ReferenceClinVarAssertion DateCreated="2015-02-26" DateLastUpdated="2017-04-05" ID="381663">
    <ClinVarAccession Acc="RCV000161792" Version="1" Type="RCV" DateUpdated="2017-04-05"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance>
      <ReviewStatus>no assertion provided</ReviewStatus>
      <Description>not provided</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>unknown</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>yes</AffectedStatus>
      </Sample>
      <Method>
        <NamePlatform>Illumina HumanOmniExpress Beadchip</NamePlatform>
        <Description>Genomic DNA copy number estimation from GenomeStudio-normalised genotyping microarray data (probe signal intensity). Using Illumina's baseline data for microarray signal intensity normalisation, QuantiSNP default baseline data (OB-HMM parameter values) for CNV calling.</Description>
        <MethodType>case-control</MethodType>
      </Method>
      <ObservedData ID="17757259">
        <Attribute Type="Description">not provided</Attribute>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant" ID="157366">
      <Measure Type="Deletion" ID="167226">
        <Name>
          <ElementValue Type="Preferred">NC_000016.9:g.32608438_33557021del948584</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Change="g.32608438_33557021del" Accession="CM000678" Version="1" Type="HGVS, genomic">CM000678.1:g.32608438_33557021del</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Change="g.32608438_33557021del948584" Accession="NC_000016" Version="9" Type="HGVS, genomic, top level, previous" integerValue="37">NC_000016.9:g.32608438_33557021del948584</Attribute>
        </AttributeSet>
        <CytogeneticLocation>16p11.2</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="16" Accession="NC_000016.9" start="32608438" stop="33557021" display_start="32608438" display_stop="33557021" variantLength="948584"/>
        <MeasureRelationship Type="genes overlapped by variant">
          <Name>
            <ElementValue Type="Preferred">TP53 target 3</ElementValue>
          </Name>
          <Symbol>
            <ElementValue Type="Preferred">TP53TG3</ElementValue>
          </Symbol>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="16" Accession="NC_000016.10" start="32673528" stop="32678621" display_start="32673528" display_stop="32678621" Strand="-"/>
          <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="16" Accession="NC_000016.9" start="32684848" stop="32687447" display_start="32684848" display_stop="32687447" variantLength="2600" Strand="-"/>
          <XRef ID="24150" DB="Gene"/>
          <XRef ID="HGNC:30759" DB="HGNC"/>
        </MeasureRelationship>
        <MeasureRelationship Type="genes overlapped by variant">
          <Name>
            <ElementValue Type="Preferred">TP53 target 3B</ElementValue>
          </Name>
          <Symbol>
            <ElementValue Type="Preferred">TP53TG3B</ElementValue>
          </Symbol>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="16" Accession="NC_000016.10" start="33358385" stop="33363478" display_start="33358385" display_stop="33363478" Strand="+"/>
          <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="16" Accession="NC_000016.9" start="33262119" stop="33264718" display_start="33262119" display_stop="33264718" variantLength="2600" Strand="+"/>
          <XRef ID="729355" DB="Gene"/>
          <XRef ID="HGNC:37202" DB="HGNC"/>
        </MeasureRelationship>
        <MeasureRelationship Type="genes overlapped by variant">
          <Name>
            <ElementValue Type="Preferred">TP53 target 3C</ElementValue>
          </Name>
          <Symbol>
            <ElementValue Type="Preferred">TP53TG3C</ElementValue>
          </Symbol>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="16" Accession="NC_000016.10" start="33191770" stop="33196858" display_start="33191770" display_stop="33196858" Strand="+"/>
          <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="16" Accession="NC_000016.9" start="33205584" stop="33207558" display_start="33205584" display_stop="33207558" variantLength="1975" Strand="+"/>
          <XRef ID="653550" DB="Gene"/>
          <XRef ID="HGNC:42962" DB="HGNC"/>
        </MeasureRelationship>
        <Citation Type="general">
          <ID Source="PubMed">25666259</ID>
        </Citation>
      </Measure>
      <Name>
        <ElementValue Type="Preferred">NC_000016.9:g.32608438_33557021del948584</ElementValue>
      </Name>
    </MeasureSet>
    <TraitSet Type="Disease" ID="19842">
      <Trait ID="22433" Type="Finding">
        <Name>
          <ElementValue Type="Preferred">Large for gestational age</ElementValue>
          <XRef ID="HP:0001520" DB="Human Phenotype Ontology"/>
        </Name>
        <Name>
          <ElementValue Type="Alternate">Birth weight &gt; 90th percentile</ElementValue>
          <XRef ID="HP:0001520" DB="Human Phenotype Ontology"/>
        </Name>
        <Name>
          <ElementValue Type="Alternate">Birthweight &gt; 90th percentile</ElementValue>
          <XRef ID="HP:0001520" DB="Human Phenotype Ontology"/>
        </Name>
        <Name>
          <ElementValue Type="Alternate">Fetal macrosomia</ElementValue>
          <XRef ID="HP:0001520" DB="Human Phenotype Ontology"/>
        </Name>
        <Name>
          <ElementValue Type="Alternate">Macrosomia</ElementValue>
          <XRef ID="HP:0001520" DB="Human Phenotype Ontology"/>
        </Name>
        <Name>
          <ElementValue Type="Alternate">Macrosomia, neonatal</ElementValue>
          <XRef ID="HP:0001520" DB="Human Phenotype Ontology"/>
        </Name>
        <XRef ID="C1848395" DB="MedGen"/>
        <XRef Type="primary" ID="HP:0001520" DB="Human Phenotype Ontology"/>
        <XRef Type="secondary" ID="HP:0001825" DB="Human Phenotype Ontology"/>
      </Trait>
    </TraitSet>
  </ReferenceClinVarAssertion>
  <ClinVarAssertion ID="339017" SubmissionName="Kasak">
    <ClinVarSubmissionID localKey="CNV_737" submitter="Institute of Molecular and Cell Biology, University of Tartu" submitterDate="2014-10-23"/>
    <ClinVarAccession Acc="SCV000191749" OrgType="primary" OrganizationCategory="other" Version="1" Type="SCV" OrgID="505255" DateUpdated="2017-04-05"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance>
      <ReviewStatus>no assertion provided</ReviewStatus>
      <Description>not provided</Description>
      <Citation Type="general">
        <ID Source="PubMed">25666259</ID>
      </Citation>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ExternalID DB="EVA" ID="CNV_737"/>
    <ObservedIn>
      <Sample>
        <Origin>unknown</Origin>
        <Tissue>Blood</Tissue>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>yes</AffectedStatus>
        <Gender>mixed</Gender>
      </Sample>
      <Method>
        <NamePlatform>Illumina HumanOmniExpress Beadchip</NamePlatform>
        <TypePlatform>SNP array</TypePlatform>
        <Description>Genomic DNA copy number estimation from GenomeStudio-normalised genotyping microarray data (probe signal intensity). Using Illumina's baseline data for microarray signal intensity normalisation, QuantiSNP default baseline data (OB-HMM parameter values) for CNV calling.</Description>
        <Software name="QuantiSNP, GADA, CNstream" purpose="Normalized signal intensity data was obtained through Illumina GenomeStudio software. Information on Log2 R ratios, B allele frequencies, markers and chromosomal coordinates from each sample were used for CNV identification with Hidden Markov Model-based algorithm QuantiSNP 2.3 (Colella et al., 2007) and a sparse Bayesian learning approach GADA (Genome Alteration Detection Analysis) (Pique-Regi et al., 2010). QuantiSNP was run with default settings, the adjustment for ‘genomic waves’ in signal intensities was turned on with the ‘--gcdir’ key in addition to the default calling parameters. GADA was run using the options “–T 5 –M 3”. CNstream (Alonso et al., 2010) algorithm was used in parallel to estimate CNVs from X and Y channel intensities loaded from Illumina GenomeStudio. CNVs were calculated under the following parameters: number of probes per segment (=3), minimum number of probes in one segment that must exceed the threshold for identifying an amplification/deletion (=3), CNV frequency threshold (=0). CNVs with QuantiSNP log Bayes Factor value &lt;5 and/or rearrangements shorter than 350 bp were excluded from the resulting list of CNVs. In this project we analysed only autosomal CNVs. HD-CNV (Hotspot Detector for Copy Number Variants) (Butler et al., 2013) was used to merge CNV regions called by alternative computational algorithms, QuantiSNP, GADA and CNstream. A criterion of 40% reciprocal overlap between parallel CNV calls was used to define two calls as identifying the same event. All CNVs called by at least two algorithms for the same individual in the same genomic loci were considered in the subsequent global analysis."/>
        <MethodType>case-control</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="Description">not provided</Attribute>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant">
      <Measure Type="Variation">
        <AttributeSet>
          <Attribute Type="HGVS">CM000678.1:g.32608438_33557021del</Attribute>
        </AttributeSet>
      </Measure>
    </MeasureSet>
    <TraitSet Type="Disease">
      <Trait Type="Finding">
        <Name>
          <ElementValue Type="Preferred">Large for gestational age</ElementValue>
        </Name>
        <XRef DB="MedGen" ID="C0158915" Type="CUI"/>
      </Trait>
    </TraitSet>
    <Citation Type="general">
      <ID Source="PubMed">25666259</ID>
    </Citation>
    <Citation Type="general">
      <ID Source="PubMed">25666259</ID>
    </Citation>
    <StudyName>Kasak2014</StudyName>
    <StudyDescription>The study aimed to determine the contribution of copy number variants in the genetic etiology of normal and complicated pregnancies. The samples represented (i) maternal blood DNA drawn from healthy pregnant women during 1st or 2nd trimester and (ii) maternal and paternal blood DNA drawn at term pregnancy cases representing normal and complicated gestations (severe preeclampsia, PE; gestational diabetes, GD; small-for-gestational age newborn, SGA; large-for-gestational age newborn, LGA). We performed CNV calling based on genome-wide genotyping dataset (Illumina HumanOmniExpress-24-v1 BeadChip) by applying three algorithms, QuantiSNP, GADA (Genome Alteration Detection Algorithm) and CNstream in parallel. The acquired CNV calls were merged with HD-CNV (Hotspot Detector for Copy Number Variants) program and only the CNVs predicted by at least two programs, were considered in subsequent analysis.</StudyDescription>
    <Comment>The study aimed to determine the contribution of copy number variants in the genetic etiology of normal and complicated pregnancies. The samples represented (i) maternal blood DNA drawn from healthy pregnant women during 1st or 2nd trimester and (ii) maternal and paternal blood DNA drawn at term pregnancy cases representing normal and complicated gestations (severe preeclampsia, PE; gestational diabetes, GD; small-for-gestational age newborn, SGA; large-for-gestational age newborn, LGA). We performed CNV calling based on genome-wide genotyping dataset (Illumina HumanOmniExpress-24-v1 BeadChip) by applying three algorithms, QuantiSNP, GADA (Genome Alteration Detection Algorithm) and CNstream in parallel. The acquired CNV calls were merged with HD-CNV (Hotspot Detector for Copy Number Variants) program and only the CNVs predicted by at least two programs, were considered in subsequent analysis.</Comment>
  </ClinVarAssertion>
</ClinVarSet>

<ClinVarSet ID="18550237">
  <RecordStatus>current</RecordStatus>
  <Title>NG_046948.1:g.10588_38632del28045 AND Normal pregnancy</Title>
  <ReferenceClinVarAssertion DateCreated="2015-02-26" DateLastUpdated="2017-04-05" ID="381696">
    <ClinVarAccession Acc="RCV000161825" Version="1" Type="RCV" DateUpdated="2017-04-05"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance>
      <ReviewStatus>no assertion provided</ReviewStatus>
      <Description>not provided</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>unknown</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>yes</AffectedStatus>
      </Sample>
      <Method>
        <NamePlatform>Illumina HumanOmniExpress Beadchip</NamePlatform>
        <Description>Genomic DNA copy number estimation from GenomeStudio-normalised genotyping microarray data (probe signal intensity). Using Illumina's baseline data for microarray signal intensity normalisation, QuantiSNP default baseline data (OB-HMM parameter values) for CNV calling.</Description>
        <MethodType>case-control</MethodType>
      </Method>
      <ObservedData ID="17761803">
        <Attribute Type="Description">not provided</Attribute>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant" ID="157399">
      <Measure Type="Deletion" ID="167259">
        <Name>
          <ElementValue Type="Preferred">NG_046948.1:g.10588_38632del28045</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Change="g.60109041_60137085del" Accession="CM000679" Version="1" Type="HGVS, genomic">CM000679.1:g.60109041_60137085del</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Change="g.10588_38632del28045" Accession="NG_046948" Version="1" Type="HGVS, genomic, RefSeqGene">NG_046948.1:g.10588_38632del28045</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Change="g.62031680_62059724del28045" Accession="NC_000017" Version="11" Type="HGVS, genomic, top level" integerValue="38">NC_000017.11:g.62031680_62059724del28045</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Change="g.60109041_60137085del28045" Accession="NC_000017" Version="10" Type="HGVS, genomic, top level, previous" integerValue="37">NC_000017.10:g.60109041_60137085del28045</Attribute>
        </AttributeSet>
        <CytogeneticLocation>17q23.2</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="17" Accession="NC_000017.11" start="62031680" stop="62059724" display_start="62031680" display_stop="62059724" variantLength="28045"/>
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="17" Accession="NC_000017.10" start="60109041" stop="60137085" display_start="60109041" display_stop="60137085" variantLength="28045"/>
        <MeasureRelationship Type="within single gene">
          <Name>
            <ElementValue Type="Preferred">mediator complex subunit 13</ElementValue>
          </Name>
          <Symbol>
            <ElementValue Type="Preferred">MED13</ElementValue>
          </Symbol>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="17" Accession="NC_000017.11" start="61942605" stop="62065983" display_start="61942605" display_stop="62065983" Strand="-"/>
          <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="17" Accession="NC_000017.10" start="60019965" stop="60142642" display_start="60019965" display_stop="60142642" variantLength="122678" Strand="-"/>
          <XRef ID="9969" DB="Gene"/>
          <XRef Type="MIM" ID="603808" DB="OMIM"/>
          <XRef ID="HGNC:22474" DB="HGNC"/>
        </MeasureRelationship>
        <Citation Type="general">
          <ID Source="PubMed">25666259</ID>
        </Citation>
      </Measure>
      <Name>
        <ElementValue Type="Preferred">NG_046948.1:g.10588_38632del28045</ElementValue>
      </Name>
    </MeasureSet>
    <TraitSet Type="Finding" ID="19843">
      <Trait ID="32125" Type="Finding">
        <Name>
          <ElementValue Type="Preferred">Normal pregnancy</ElementValue>
          <XRef ID="CNV_4" DB="Institute of Molecular and Cell Biology, University of Tartu"/>
        </Name>
        <XRef ID="CN220684" DB="MedGen"/>
      </Trait>
    </TraitSet>
  </ReferenceClinVarAssertion>
  <ClinVarAssertion ID="339050" SubmissionName="Kasak">
    <ClinVarSubmissionID localKey="CNV_773" submitter="Institute of Molecular and Cell Biology, University of Tartu" submitterDate="2014-10-23"/>
    <ClinVarAccession Acc="SCV000191782" OrgType="primary" OrganizationCategory="other" Version="1" Type="SCV" OrgID="505255" DateUpdated="2017-04-05"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance>
      <ReviewStatus>no assertion provided</ReviewStatus>
      <Description>not provided</Description>
      <Citation Type="general">
        <ID Source="PubMed">25666259</ID>
      </Citation>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ExternalID DB="EVA" ID="CNV_773"/>
    <ObservedIn>
      <Sample>
        <Origin>unknown</Origin>
        <Tissue>Blood</Tissue>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>yes</AffectedStatus>
        <Gender>mixed</Gender>
      </Sample>
      <Method>
        <NamePlatform>Illumina HumanOmniExpress Beadchip</NamePlatform>
        <TypePlatform>SNP array</TypePlatform>
        <Description>Genomic DNA copy number estimation from GenomeStudio-normalised genotyping microarray data (probe signal intensity). Using Illumina's baseline data for microarray signal intensity normalisation, QuantiSNP default baseline data (OB-HMM parameter values) for CNV calling.</Description>
        <Software name="QuantiSNP, GADA, CNstream" purpose="Normalized signal intensity data was obtained through Illumina GenomeStudio software. Information on Log2 R ratios, B allele frequencies, markers and chromosomal coordinates from each sample were used for CNV identification with Hidden Markov Model-based algorithm QuantiSNP 2.3 (Colella et al., 2007) and a sparse Bayesian learning approach GADA (Genome Alteration Detection Analysis) (Pique-Regi et al., 2010). QuantiSNP was run with default settings, the adjustment for ‘genomic waves’ in signal intensities was turned on with the ‘--gcdir’ key in addition to the default calling parameters. GADA was run using the options “–T 5 –M 3”. CNstream (Alonso et al., 2010) algorithm was used in parallel to estimate CNVs from X and Y channel intensities loaded from Illumina GenomeStudio. CNVs were calculated under the following parameters: number of probes per segment (=3), minimum number of probes in one segment that must exceed the threshold for identifying an amplification/deletion (=3), CNV frequency threshold (=0). CNVs with QuantiSNP log Bayes Factor value &lt;5 and/or rearrangements shorter than 350 bp were excluded from the resulting list of CNVs. In this project we analysed only autosomal CNVs. HD-CNV (Hotspot Detector for Copy Number Variants) (Butler et al., 2013) was used to merge CNV regions called by alternative computational algorithms, QuantiSNP, GADA and CNstream. A criterion of 40% reciprocal overlap between parallel CNV calls was used to define two calls as identifying the same event. All CNVs called by at least two algorithms for the same individual in the same genomic loci were considered in the subsequent global analysis."/>
        <MethodType>case-control</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="Description">not provided</Attribute>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant">
      <Measure Type="Variation">
        <AttributeSet>
          <Attribute Type="HGVS">CM000679.1:g.60109041_60137085del</Attribute>
        </AttributeSet>
      </Measure>
    </MeasureSet>
    <TraitSet Type="Finding">
      <Trait Type="Finding">
        <Name>
          <ElementValue Type="Preferred">Normal pregnancy</ElementValue>
        </Name>
        <XRef DB="MedGen" ID="C0232989" Type="CUI"/>
      </Trait>
    </TraitSet>
    <Citation Type="general">
      <ID Source="PubMed">25666259</ID>
    </Citation>
    <Citation Type="general">
      <ID Source="PubMed">25666259</ID>
    </Citation>
    <StudyName>Kasak2014</StudyName>
    <StudyDescription>The study aimed to determine the contribution of copy number variants in the genetic etiology of normal and complicated pregnancies. The samples represented (i) maternal blood DNA drawn from healthy pregnant women during 1st or 2nd trimester and (ii) maternal and paternal blood DNA drawn at term pregnancy cases representing normal and complicated gestations (severe preeclampsia, PE; gestational diabetes, GD; small-for-gestational age newborn, SGA; large-for-gestational age newborn, LGA). We performed CNV calling based on genome-wide genotyping dataset (Illumina HumanOmniExpress-24-v1 BeadChip) by applying three algorithms, QuantiSNP, GADA (Genome Alteration Detection Algorithm) and CNstream in parallel. The acquired CNV calls were merged with HD-CNV (Hotspot Detector for Copy Number Variants) program and only the CNVs predicted by at least two programs, were considered in subsequent analysis.</StudyDescription>
    <Comment>The study aimed to determine the contribution of copy number variants in the genetic etiology of normal and complicated pregnancies. The samples represented (i) maternal blood DNA drawn from healthy pregnant women during 1st or 2nd trimester and (ii) maternal and paternal blood DNA drawn at term pregnancy cases representing normal and complicated gestations (severe preeclampsia, PE; gestational diabetes, GD; small-for-gestational age newborn, SGA; large-for-gestational age newborn, LGA). We performed CNV calling based on genome-wide genotyping dataset (Illumina HumanOmniExpress-24-v1 BeadChip) by applying three algorithms, QuantiSNP, GADA (Genome Alteration Detection Algorithm) and CNstream in parallel. The acquired CNV calls were merged with HD-CNV (Hotspot Detector for Copy Number Variants) program and only the CNVs predicted by at least two programs, were considered in subsequent analysis.</Comment>
  </ClinVarAssertion>
</ClinVarSet>

<ClinVarSet ID="18550268">
  <RecordStatus>current</RecordStatus>
  <Title>NC_000019.9:g.20626179_20707568del81390 AND Normal pregnancy</Title>
  <ReferenceClinVarAssertion DateCreated="2015-02-26" DateLastUpdated="2017-04-05" ID="381727">
    <ClinVarAccession Acc="RCV000161856" Version="1" Type="RCV" DateUpdated="2017-04-05"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance>
      <ReviewStatus>no assertion provided</ReviewStatus>
      <Description>not provided</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>unknown</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>yes</AffectedStatus>
      </Sample>
      <Method>
        <NamePlatform>Illumina HumanOmniExpress Beadchip</NamePlatform>
        <Description>Genomic DNA copy number estimation from GenomeStudio-normalised genotyping microarray data (probe signal intensity). Using Illumina's baseline data for microarray signal intensity normalisation, QuantiSNP default baseline data (OB-HMM parameter values) for CNV calling.</Description>
        <MethodType>case-control</MethodType>
      </Method>
      <ObservedData ID="17758094">
        <Attribute Type="Description">not provided</Attribute>
      </ObservedData>
      <ObservedData ID="17758094">
        <Attribute Type="Description">not provided</Attribute>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant" ID="157430">
      <Measure Type="Deletion" ID="167290">
        <Name>
          <ElementValue Type="Preferred">NC_000019.9:g.20626179_20707568del81390</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Change="g.20626179_20707568del" Accession="CM000681" Version="1" Type="HGVS, genomic">CM000681.1:g.20626179_20707568del</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Change="g.20626179_20707568del81390" Accession="NC_000019" Version="9" Type="HGVS, genomic, top level, previous" integerValue="37">NC_000019.9:g.20626179_20707568del81390</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Change="g.360626_442015del81390" Accession="NW_003571053" Version="2" Type="HGVS, genomic, top level, previous" integerValue="37">NW_003571053.2:g.360626_442015del81390</Attribute>
        </AttributeSet>
        <CytogeneticLocation>19p12</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="19" Accession="NW_003571053.2" start="360626" stop="442015" display_start="360626" display_stop="442015" variantLength="81390"/>
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="19" Accession="NC_000019.9" start="20626179" stop="20707568" display_start="20626179" display_stop="20707568" variantLength="81390"/>
        <Citation Type="general">
          <ID Source="PubMed">25666259</ID>
        </Citation>
      </Measure>
      <Name>
        <ElementValue Type="Preferred">NC_000019.9:g.20626179_20707568del81390</ElementValue>
      </Name>
    </MeasureSet>
    <TraitSet Type="Finding" ID="19843">
      <Trait ID="32125" Type="Finding">
        <Name>
          <ElementValue Type="Preferred">Normal pregnancy</ElementValue>
          <XRef ID="CNV_4" DB="Institute of Molecular and Cell Biology, University of Tartu"/>
        </Name>
        <XRef ID="CN220684" DB="MedGen"/>
      </Trait>
    </TraitSet>
  </ReferenceClinVarAssertion>
  <ClinVarAssertion ID="339081" SubmissionName="Kasak">
    <ClinVarSubmissionID localKey="CNV_809" submitter="Institute of Molecular and Cell Biology, University of Tartu" submitterDate="2014-10-23"/>
    <ClinVarAccession Acc="SCV000191813" OrgType="primary" OrganizationCategory="other" Version="1" Type="SCV" OrgID="505255" DateUpdated="2017-04-05"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance>
      <ReviewStatus>no assertion provided</ReviewStatus>
      <Description>not provided</Description>
      <Citation Type="general">
        <ID Source="PubMed">25666259</ID>
      </Citation>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ExternalID DB="EVA" ID="CNV_809"/>
    <ObservedIn>
      <Sample>
        <Origin>unknown</Origin>
        <Tissue>Blood</Tissue>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>yes</AffectedStatus>
        <Gender>mixed</Gender>
      </Sample>
      <Method>
        <NamePlatform>Illumina HumanOmniExpress Beadchip</NamePlatform>
        <TypePlatform>SNP array</TypePlatform>
        <Description>Genomic DNA copy number estimation from GenomeStudio-normalised genotyping microarray data (probe signal intensity). Using Illumina's baseline data for microarray signal intensity normalisation, QuantiSNP default baseline data (OB-HMM parameter values) for CNV calling.</Description>
        <Software name="QuantiSNP, GADA, CNstream" purpose="Normalized signal intensity data was obtained through Illumina GenomeStudio software. Information on Log2 R ratios, B allele frequencies, markers and chromosomal coordinates from each sample were used for CNV identification with Hidden Markov Model-based algorithm QuantiSNP 2.3 (Colella et al., 2007) and a sparse Bayesian learning approach GADA (Genome Alteration Detection Analysis) (Pique-Regi et al., 2010). QuantiSNP was run with default settings, the adjustment for ‘genomic waves’ in signal intensities was turned on with the ‘--gcdir’ key in addition to the default calling parameters. GADA was run using the options “–T 5 –M 3”. CNstream (Alonso et al., 2010) algorithm was used in parallel to estimate CNVs from X and Y channel intensities loaded from Illumina GenomeStudio. CNVs were calculated under the following parameters: number of probes per segment (=3), minimum number of probes in one segment that must exceed the threshold for identifying an amplification/deletion (=3), CNV frequency threshold (=0). CNVs with QuantiSNP log Bayes Factor value &lt;5 and/or rearrangements shorter than 350 bp were excluded from the resulting list of CNVs. In this project we analysed only autosomal CNVs. HD-CNV (Hotspot Detector for Copy Number Variants) (Butler et al., 2013) was used to merge CNV regions called by alternative computational algorithms, QuantiSNP, GADA and CNstream. A criterion of 40% reciprocal overlap between parallel CNV calls was used to define two calls as identifying the same event. All CNVs called by at least two algorithms for the same individual in the same genomic loci were considered in the subsequent global analysis."/>
        <MethodType>case-control</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="Description">not provided</Attribute>
      </ObservedData>
    </ObservedIn>
    <ObservedIn>
      <Sample>
        <Origin>unknown</Origin>
        <Tissue>Blood</Tissue>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>yes</AffectedStatus>
        <Gender>mixed</Gender>
      </Sample>
      <Method>
        <NamePlatform>Illumina HumanOmniExpress Beadchip</NamePlatform>
        <TypePlatform>SNP array</TypePlatform>
        <Description>Genomic DNA copy number estimation from GenomeStudio-normalised genotyping microarray data (probe signal intensity). Using Illumina's baseline data for microarray signal intensity normalisation, QuantiSNP default baseline data (OB-HMM parameter values) for CNV calling.</Description>
        <Software name="QuantiSNP, GADA, CNstream" purpose="Normalized signal intensity data was obtained through Illumina GenomeStudio software. Information on Log2 R ratios, B allele frequencies, markers and chromosomal coordinates from each sample were used for CNV identification with Hidden Markov Model-based algorithm QuantiSNP 2.3 (Colella et al., 2007) and a sparse Bayesian learning approach GADA (Genome Alteration Detection Analysis) (Pique-Regi et al., 2010). QuantiSNP was run with default settings, the adjustment for ‘genomic waves’ in signal intensities was turned on with the ‘--gcdir’ key in addition to the default calling parameters. GADA was run using the options “–T 5 –M 3”. CNstream (Alonso et al., 2010) algorithm was used in parallel to estimate CNVs from X and Y channel intensities loaded from Illumina GenomeStudio. CNVs were calculated under the following parameters: number of probes per segment (=3), minimum number of probes in one segment that must exceed the threshold for identifying an amplification/deletion (=3), CNV frequency threshold (=0). CNVs with QuantiSNP log Bayes Factor value &lt;5 and/or rearrangements shorter than 350 bp were excluded from the resulting list of CNVs. In this project we analysed only autosomal CNVs. HD-CNV (Hotspot Detector for Copy Number Variants) (Butler et al., 2013) was used to merge CNV regions called by alternative computational algorithms, QuantiSNP, GADA and CNstream. A criterion of 40% reciprocal overlap between parallel CNV calls was used to define two calls as identifying the same event. All CNVs called by at least two algorithms for the same individual in the same genomic loci were considered in the subsequent global analysis."/>
        <MethodType>case-control</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="Description">not provided</Attribute>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant">
      <Measure Type="Variation">
        <AttributeSet>
          <Attribute Type="HGVS">CM000681.1:g.20626179_20707568del</Attribute>
        </AttributeSet>
      </Measure>
    </MeasureSet>
    <TraitSet Type="Finding">
      <Trait Type="Finding">
        <Name>
          <ElementValue Type="Preferred">Normal pregnancy</ElementValue>
        </Name>
        <XRef DB="MedGen" ID="C0232989" Type="CUI"/>
      </Trait>
    </TraitSet>
    <Citation Type="general">
      <ID Source="PubMed">25666259</ID>
    </Citation>
    <Citation Type="general">
      <ID Source="PubMed">25666259</ID>
    </Citation>
    <StudyName>Kasak2014</StudyName>
    <StudyDescription>The study aimed to determine the contribution of copy number variants in the genetic etiology of normal and complicated pregnancies. The samples represented (i) maternal blood DNA drawn from healthy pregnant women during 1st or 2nd trimester and (ii) maternal and paternal blood DNA drawn at term pregnancy cases representing normal and complicated gestations (severe preeclampsia, PE; gestational diabetes, GD; small-for-gestational age newborn, SGA; large-for-gestational age newborn, LGA). We performed CNV calling based on genome-wide genotyping dataset (Illumina HumanOmniExpress-24-v1 BeadChip) by applying three algorithms, QuantiSNP, GADA (Genome Alteration Detection Algorithm) and CNstream in parallel. The acquired CNV calls were merged with HD-CNV (Hotspot Detector for Copy Number Variants) program and only the CNVs predicted by at least two programs, were considered in subsequent analysis.</StudyDescription>
    <Comment>The study aimed to determine the contribution of copy number variants in the genetic etiology of normal and complicated pregnancies. The samples represented (i) maternal blood DNA drawn from healthy pregnant women during 1st or 2nd trimester and (ii) maternal and paternal blood DNA drawn at term pregnancy cases representing normal and complicated gestations (severe preeclampsia, PE; gestational diabetes, GD; small-for-gestational age newborn, SGA; large-for-gestational age newborn, LGA). We performed CNV calling based on genome-wide genotyping dataset (Illumina HumanOmniExpress-24-v1 BeadChip) by applying three algorithms, QuantiSNP, GADA (Genome Alteration Detection Algorithm) and CNstream in parallel. The acquired CNV calls were merged with HD-CNV (Hotspot Detector for Copy Number Variants) program and only the CNVs predicted by at least two programs, were considered in subsequent analysis.</Comment>
  </ClinVarAssertion>
</ClinVarSet>

<ClinVarSet ID="18550293">
  <RecordStatus>current</RecordStatus>
  <Title>NC_000019.10:g.43162545_43331618del169074 AND Normal pregnancy</Title>
  <ReferenceClinVarAssertion DateCreated="2015-02-26" DateLastUpdated="2017-04-05" ID="381752">
    <ClinVarAccession Acc="RCV000161881" Version="1" Type="RCV" DateUpdated="2017-04-05"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance>
      <ReviewStatus>no assertion provided</ReviewStatus>
      <Description>not provided</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>unknown</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>yes</AffectedStatus>
      </Sample>
      <Method>
        <NamePlatform>Illumina HumanOmniExpress Beadchip</NamePlatform>
        <Description>Genomic DNA copy number estimation from GenomeStudio-normalised genotyping microarray data (probe signal intensity). Using Illumina's baseline data for microarray signal intensity normalisation, QuantiSNP default baseline data (OB-HMM parameter values) for CNV calling.</Description>
        <MethodType>case-control</MethodType>
      </Method>
      <ObservedData ID="17758785">
        <Attribute Type="Description">not provided</Attribute>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant" ID="157455">
      <Measure Type="Deletion" ID="167315">
        <Name>
          <ElementValue Type="Preferred">NC_000019.10:g.43162545_43331618del169074</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Change="g.43666697_43835770del" Accession="CM000681" Version="1" Type="HGVS, genomic">CM000681.1:g.43666697_43835770del</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Change="g.43162545_43331618del169074" Accession="NC_000019" Version="10" Type="HGVS, genomic, top level" integerValue="38">NC_000019.10:g.43162545_43331618del169074</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Change="g.43666697_43835770del169074" Accession="NC_000019" Version="9" Type="HGVS, genomic, top level, previous" integerValue="37">NC_000019.9:g.43666697_43835770del169074</Attribute>
        </AttributeSet>
        <CytogeneticLocation>19q13.31</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="19" Accession="NC_000019.10" start="43162545" stop="43331618" display_start="43162545" display_stop="43331618" variantLength="169074"/>
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="19" Accession="NC_000019.9" start="43666697" stop="43835770" display_start="43666697" display_stop="43835770" variantLength="169074"/>
        <MeasureRelationship Type="genes overlapped by variant">
          <Name>
            <ElementValue Type="Preferred">pregnancy specific beta-1-glycoprotein 4</ElementValue>
          </Name>
          <Symbol>
            <ElementValue Type="Preferred">PSG4</ElementValue>
          </Symbol>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="19" Accession="NC_000019.10" start="43192702" stop="43205774" display_start="43192702" display_stop="43205774" Strand="-"/>
          <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="19" Accession="NC_000019.9" start="43696853" stop="43709789" display_start="43696853" display_stop="43709789" variantLength="12937" Strand="-"/>
          <XRef ID="5672" DB="Gene"/>
          <XRef Type="MIM" ID="176393" DB="OMIM"/>
          <XRef ID="HGNC:9521" DB="HGNC"/>
        </MeasureRelationship>
        <MeasureRelationship Type="genes overlapped by variant">
          <Name>
            <ElementValue Type="Preferred">pregnancy specific beta-1-glycoprotein 5</ElementValue>
          </Name>
          <Symbol>
            <ElementValue Type="Preferred">PSG5</ElementValue>
          </Symbol>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="19" Accession="NC_000019.10" start="43167743" stop="43186536" display_start="43167743" display_stop="43186536" Strand="-"/>
          <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="19" Accession="NC_000019.9" start="43671894" stop="43690687" display_start="43671894" display_stop="43690687" variantLength="18794" Strand="-"/>
          <XRef ID="5673" DB="Gene"/>
          <XRef Type="MIM" ID="176394" DB="OMIM"/>
          <XRef ID="HGNC:9522" DB="HGNC"/>
        </MeasureRelationship>
        <MeasureRelationship Type="genes overlapped by variant">
          <Name>
            <ElementValue Type="Preferred">pregnancy specific beta-1-glycoprotein 9</ElementValue>
          </Name>
          <Symbol>
            <ElementValue Type="Preferred">PSG9</ElementValue>
          </Symbol>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="19" Accession="NC_000019.10" start="43253282" stop="43269563" display_start="43253282" display_stop="43269563" Strand="-"/>
          <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="19" Accession="NC_000019.9" start="43757434" stop="43773681" display_start="43757434" display_stop="43773681" variantLength="16248" Strand="-"/>
          <XRef ID="5678" DB="Gene"/>
          <XRef Type="MIM" ID="176398" DB="OMIM"/>
          <XRef ID="HGNC:9526" DB="HGNC"/>
        </MeasureRelationship>
        <MeasureRelationship Type="genes overlapped by variant">
          <Name>
            <ElementValue Type="Preferred">uncharacterized LOC284344</ElementValue>
          </Name>
          <Symbol>
            <ElementValue Type="Preferred">LOC284344</ElementValue>
          </Symbol>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="19" Accession="NC_000019.10" start="43211791" stop="43248646" display_start="43211791" display_stop="43248646" Strand="-"/>
          <XRef ID="284344" DB="Gene"/>
        </MeasureRelationship>
        <Citation Type="general">
          <ID Source="PubMed">25666259</ID>
        </Citation>
      </Measure>
      <Name>
        <ElementValue Type="Preferred">NC_000019.10:g.43162545_43331618del169074</ElementValue>
      </Name>
    </MeasureSet>
    <TraitSet Type="Finding" ID="19843">
      <Trait ID="32125" Type="Finding">
        <Name>
          <ElementValue Type="Preferred">Normal pregnancy</ElementValue>
          <XRef ID="CNV_4" DB="Institute of Molecular and Cell Biology, University of Tartu"/>
        </Name>
        <XRef ID="CN220684" DB="MedGen"/>
      </Trait>
    </TraitSet>
  </ReferenceClinVarAssertion>
  <ClinVarAssertion ID="339106" SubmissionName="Kasak">
    <ClinVarSubmissionID localKey="CNV_848" submitter="Institute of Molecular and Cell Biology, University of Tartu" submitterDate="2014-10-23"/>
    <ClinVarAccession Acc="SCV000191838" OrgType="primary" OrganizationCategory="other" Version="1" Type="SCV" OrgID="505255" DateUpdated="2017-04-05"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance>
      <ReviewStatus>no assertion provided</ReviewStatus>
      <Description>not provided</Description>
      <Citation Type="general">
        <ID Source="PubMed">25666259</ID>
      </Citation>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ExternalID DB="EVA" ID="CNV_848"/>
    <ObservedIn>
      <Sample>
        <Origin>unknown</Origin>
        <Tissue>Blood</Tissue>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>yes</AffectedStatus>
        <Gender>female</Gender>
      </Sample>
      <Method>
        <NamePlatform>Illumina HumanOmniExpress Beadchip</NamePlatform>
        <TypePlatform>SNP array</TypePlatform>
        <Description>Genomic DNA copy number estimation from GenomeStudio-normalised genotyping microarray data (probe signal intensity). Using Illumina's baseline data for microarray signal intensity normalisation, QuantiSNP default baseline data (OB-HMM parameter values) for CNV calling.</Description>
        <Software name="QuantiSNP, GADA, CNstream" purpose="Normalized signal intensity data was obtained through Illumina GenomeStudio software. Information on Log2 R ratios, B allele frequencies, markers and chromosomal coordinates from each sample were used for CNV identification with Hidden Markov Model-based algorithm QuantiSNP 2.3 (Colella et al., 2007) and a sparse Bayesian learning approach GADA (Genome Alteration Detection Analysis) (Pique-Regi et al., 2010). QuantiSNP was run with default settings, the adjustment for ‘genomic waves’ in signal intensities was turned on with the ‘--gcdir’ key in addition to the default calling parameters. GADA was run using the options “–T 5 –M 3”. CNstream (Alonso et al., 2010) algorithm was used in parallel to estimate CNVs from X and Y channel intensities loaded from Illumina GenomeStudio. CNVs were calculated under the following parameters: number of probes per segment (=3), minimum number of probes in one segment that must exceed the threshold for identifying an amplification/deletion (=3), CNV frequency threshold (=0). CNVs with QuantiSNP log Bayes Factor value &lt;5 and/or rearrangements shorter than 350 bp were excluded from the resulting list of CNVs. In this project we analysed only autosomal CNVs. HD-CNV (Hotspot Detector for Copy Number Variants) (Butler et al., 2013) was used to merge CNV regions called by alternative computational algorithms, QuantiSNP, GADA and CNstream. A criterion of 40% reciprocal overlap between parallel CNV calls was used to define two calls as identifying the same event. All CNVs called by at least two algorithms for the same individual in the same genomic loci were considered in the subsequent global analysis."/>
        <MethodType>case-control</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="Description">not provided</Attribute>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant">
      <Measure Type="Variation">
        <AttributeSet>
          <Attribute Type="HGVS">CM000681.1:g.43666697_43835770del</Attribute>
        </AttributeSet>
      </Measure>
    </MeasureSet>
    <TraitSet Type="Finding">
      <Trait Type="Finding">
        <Name>
          <ElementValue Type="Preferred">Normal pregnancy</ElementValue>
        </Name>
        <XRef DB="MedGen" ID="C0232989" Type="CUI"/>
      </Trait>
    </TraitSet>
    <Citation Type="general">
      <ID Source="PubMed">25666259</ID>
    </Citation>
    <Citation Type="general">
      <ID Source="PubMed">25666259</ID>
    </Citation>
    <StudyName>Kasak2014</StudyName>
    <StudyDescription>The study aimed to determine the contribution of copy number variants in the genetic etiology of normal and complicated pregnancies. The samples represented (i) maternal blood DNA drawn from healthy pregnant women during 1st or 2nd trimester and (ii) maternal and paternal blood DNA drawn at term pregnancy cases representing normal and complicated gestations (severe preeclampsia, PE; gestational diabetes, GD; small-for-gestational age newborn, SGA; large-for-gestational age newborn, LGA). We performed CNV calling based on genome-wide genotyping dataset (Illumina HumanOmniExpress-24-v1 BeadChip) by applying three algorithms, QuantiSNP, GADA (Genome Alteration Detection Algorithm) and CNstream in parallel. The acquired CNV calls were merged with HD-CNV (Hotspot Detector for Copy Number Variants) program and only the CNVs predicted by at least two programs, were considered in subsequent analysis.</StudyDescription>
    <Comment>The study aimed to determine the contribution of copy number variants in the genetic etiology of normal and complicated pregnancies. The samples represented (i) maternal blood DNA drawn from healthy pregnant women during 1st or 2nd trimester and (ii) maternal and paternal blood DNA drawn at term pregnancy cases representing normal and complicated gestations (severe preeclampsia, PE; gestational diabetes, GD; small-for-gestational age newborn, SGA; large-for-gestational age newborn, LGA). We performed CNV calling based on genome-wide genotyping dataset (Illumina HumanOmniExpress-24-v1 BeadChip) by applying three algorithms, QuantiSNP, GADA (Genome Alteration Detection Algorithm) and CNstream in parallel. The acquired CNV calls were merged with HD-CNV (Hotspot Detector for Copy Number Variants) program and only the CNVs predicted by at least two programs, were considered in subsequent analysis.</Comment>
  </ClinVarAssertion>
</ClinVarSet>

<ClinVarSet ID="18607144">
  <RecordStatus>current</RecordStatus>
  <Title>NC_000024.8:g.(?_23368221)_(23953342_57772954)dup AND See cases</Title>
  <ReferenceClinVarAssertion DateCreated="2017-03-31" DateLastUpdated="2017-04-05" ID="1047851">
    <ClinVarAccession Acc="RCV000453367" Version="1" Type="RCV" DateUpdated="2017-04-05"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance>
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Benign</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>not provided</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>yes</AffectedStatus>
      </Sample>
      <Method>
        <Purpose>Discovery</Purpose>
        <Description>Microarray</Description>
        <MethodType>clinical testing</MethodType>
      </Method>
      <ObservedData ID="17790009">
        <Attribute integerValue="1" Type="VariantAlleles"/>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant" ID="393623">
      <Measure Type="copy number gain" ID="380515">
        <Name>
          <ElementValue Type="Preferred">NC_000024.8:g.(?_23368221)_(23953342_57772954)dup</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="AbsoluteCopyNumber" integerValue="3"/>
        </AttributeSet>
        <AttributeSet>
          <Attribute Accession="NC_000024" Version="8" Type="HGVS, genomic, top level, previous" integerValue="36">NC_000024.8:g.(?_23368221)_(23953342_57772954)dup</Attribute>
        </AttributeSet>
        <SequenceLocation Assembly="NCBI36" AssemblyAccessionVersion="GCF_000001405.12" AssemblyStatus="previous" Chr="Y" Accession="NC_000024.8" innerStart="23368221" innerStop="23953342" outerStop="57772954" display_start="23368221" display_stop="57772954"/>
        <XRef ID="nssv13642680" DB="dbVar"/>
        <XRef ID="nsv2768319" DB="dbVar"/>
      </Measure>
      <Name>
        <ElementValue Type="Preferred">NC_000024.8:g.(?_23368221)_(23953342_57772954)dup</ElementValue>
      </Name>
    </MeasureSet>
    <TraitSet Type="PhenotypeInstruction" ID="16994">
      <Trait ID="18728" Type="PhenotypeInstruction">
        <Name>
          <ElementValue Type="Preferred">See cases</ElementValue>
        </Name>
      </Trait>
    </TraitSet>
  </ReferenceClinVarAssertion>
  <ClinVarAssertion ID="1031179" SubmissionName="nstd37">
    <ClinVarSubmissionID localKey="nsv2768319:copy number gain:See cases:3:SCV000494770" submitter="ISCA site 19" submitterDate="2017-02-28"/>
    <ClinVarAccession Acc="SCV000494770" OrgType="primary" OrganizationCategory="laboratory" Version="1" Type="SCV" OrgID="505431" DateUpdated="2017-04-05"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance>
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Benign</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>not provided</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>yes</AffectedStatus>
      </Sample>
      <Method>
        <TypePlatform>Oligo aCGH</TypePlatform>
        <Purpose>Discovery</Purpose>
        <Description>Microarray</Description>
        <SourceType>submitter-generated</SourceType>
        <MethodType>clinical testing</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="VariantAlleles" integerValue="1"/>
      </ObservedData>
      <TraitSet Type="Finding">
        <Trait Type="Finding">
          <Name>
            <ElementValue Type="Preferred">Global developmental delay</ElementValue>
          </Name>
          <XRef DB="HP" ID="HP:0001263"/>
        </Trait>
      </TraitSet>
      <XRef DB="dbVar" ID="nssv13642680" Type="dbVarVariantCallId"/>
    </ObservedIn>
    <MeasureSet Type="Variant">
      <Measure Type="copy number gain">
        <AttributeSet>
          <Attribute Type="AbsoluteCopyNumber">3</Attribute>
        </AttributeSet>
        <SequenceLocation Accession="NC_000024.8" Assembly="NCBI36" Chr="Y" innerStart="23368221" innerStop="23953342" outerStop="57772954"/>
        <XRef DB="dbVar" ID="nssv13642680" Type="dbVarVariantCallId"/>
        <XRef DB="dbVar" ID="nsv2768319" Type="dbVarVariantRegionId"/>
      </Measure>
    </MeasureSet>
    <TraitSet Type="PhenotypeInstruction">
      <Trait Type="PhenotypeInstruction">
        <Name>
          <ElementValue Type="Preferred">See cases</ElementValue>
        </Name>
      </Trait>
    </TraitSet>
    <Citation Abbrev="ISCA, 2010" Type="Position Statement">
      <ID Source="PubMed">20466091</ID>
    </Citation>
    <Comment>Copy number variation identified through the course of routine clinical cytogenomic testing in postnatal populations, with clinical assertions as classified by the original submitter. For data from the original published study, [Kaminsky, et al. 2011|/pubmed/21844811], please see [nstd101|/dbvar/studies/nstd101/].</Comment>
  </ClinVarAssertion>
</ClinVarSet>

<ClinVarSet ID="18624712">
  <RecordStatus>current</RecordStatus>
  <Title>OCA2, IVS1, HAPLOTYPE 1 AND Skin/hair/eye pigmentation, variation in, 1</Title>
  <ReferenceClinVarAssertion DateCreated="2012-08-13" DateLastUpdated="2017-04-07" ID="58518">
    <ClinVarAccession Acc="RCV000001015" Version="7" Type="RCV" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2007-12-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Affects</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData ID="17804894">
        <Attribute Type="Description">To clarify the role of OCA2 locus in the inheritance of eye color and other pigmentary traits associated with skin-cancer risk in white populations, Duffy et al. (2007) genotyped 3,839 adolescent twins, sibs, and parents for 58 synonymous and nonsynonymous exonic SNPs and tagging SNPs at the OCA2 locus. The authors found that the highest association for blue/nonblue eye color (227220) was found with 3 OCA2 SNPs in intron 1: rs7495174, T/C; rs4778241 (formerly rs6497268), G/T; and rs4778138 (formerly 11855019), T/C. These 3 SNPs are in 1 major haplotype block, with TGT representing 78.4% of alleles. The TGT/TGT diplotype found in 62.2% of samples was the major genotype seen to modify eye color, with a frequency of 0.905 in blue or green compared with only 0.095 in brown eye color. This genotype was also at highest frequency in subjects with light brown hair and was more frequent in fair and medium skin types, consistent with the TGT haplotype acting as a recessive modifier of lighter pigmentary phenotypes. Homozygotes for rs4778138 C/C were predominantly without freckles and had lower mole counts.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">17236130</ID>
        </Citation>
      </ObservedData>
      <ObservedData ID="17804894">
        <Attribute Type="Description">In an association study of pigmentation variants using Icelandic and Dutch population samples, Sulem et al. (2007) found association of the rs7495174, rs4778241, and rs4778138 identified by Duffy et al. (2007) with blue eye color and blond hair. The A allele of rs7495174 was strongly associated with blue versus brown eyes (OR = 6.90, p = 3.0 x 10(-24)).</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">17236130</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">17952075</ID>
        </Citation>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant" ID="964">
      <Measure Type="Variation" ID="16003">
        <Name>
          <ElementValue Type="Preferred">OCA2, IVS1, HAPLOTYPE 1</ElementValue>
        </Name>
        <CytogeneticLocation>15q11.2-q12</CytogeneticLocation>
        <MeasureRelationship Type="asserted, but not computed">
          <Name>
            <ElementValue Type="Preferred">OCA2 melanosomal transmembrane protein</ElementValue>
          </Name>
          <Symbol>
            <ElementValue Type="Preferred">OCA2</ElementValue>
          </Symbol>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="15" Accession="NC_000015.10" start="27719008" stop="28099342" display_start="27719008" display_stop="28099342" Strand="-"/>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="15" Accession="NT_187660.1" start="5441" stop="233611" display_start="5441" display_stop="233611" Strand="-"/>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="15" Accession="NW_011332701.1" start="5441" stop="233611" display_start="5441" display_stop="233611" Strand="-"/>
          <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="15" Accession="NC_000015.9" start="28000020" stop="28344457" display_start="28000020" display_stop="28344457" variantLength="344438" Strand="-"/>
          <XRef ID="4948" DB="Gene"/>
          <XRef Type="MIM" ID="611409" DB="OMIM"/>
          <XRef ID="HGNC:8101" DB="HGNC"/>
        </MeasureRelationship>
        <XRef Type="Allelic variant" ID="611409.0013" DB="OMIM"/>
      </Measure>
      <Name>
        <ElementValue Type="Preferred">OCA2, IVS1, HAPLOTYPE 1</ElementValue>
      </Name>
    </MeasureSet>
    <TraitSet Type="Disease" ID="252">
      <Trait ID="4148" Type="Disease">
        <Name>
          <ElementValue Type="Preferred">Skin/hair/eye pigmentation, variation in, 1</ElementValue>
          <XRef ID="Skin-hair-eye+pigmentation%2C+variation+in%2C+1/9304" DB="Genetic Alliance"/>
        </Name>
        <Name>
          <ElementValue Type="Alternate">BROWN EYE COLOR 2</ElementValue>
          <XRef Type="MIM" ID="227220" DB="OMIM"/>
        </Name>
        <Name>
          <ElementValue Type="Alternate">EYE COLOR 3</ElementValue>
          <XRef Type="MIM" ID="227220" DB="OMIM"/>
        </Name>
        <Name>
          <ElementValue Type="Alternate">EYE COLOR, BLUE/NONBLUE</ElementValue>
          <XRef Type="MIM" ID="227220" DB="OMIM"/>
        </Name>
        <Name>
          <ElementValue Type="Alternate">EYE COLOR, BROWN/BLUE</ElementValue>
          <XRef Type="MIM" ID="227220" DB="OMIM"/>
        </Name>
        <Name>
          <ElementValue Type="Alternate">HAIR COLOR 3</ElementValue>
          <XRef Type="MIM" ID="227220" DB="OMIM"/>
        </Name>
        <Name>
          <ElementValue Type="Alternate">SKIN/HAIR/EYE PIGMENTATION 1, BLOND/BROWN HAIR</ElementValue>
          <XRef Type="MIM" ID="227220" DB="OMIM"/>
          <XRef Type="Allelic variant" ID="605837.0001" DB="OMIM"/>
          <XRef Type="Allelic variant" ID="611409.0013" DB="OMIM"/>
        </Name>
        <Name>
          <ElementValue Type="Alternate">SKIN/HAIR/EYE PIGMENTATION 1, BLUE/BROWN EYES</ElementValue>
          <XRef Type="MIM" ID="227220" DB="OMIM"/>
          <XRef Type="Allelic variant" ID="611409.0011" DB="OMIM"/>
          <XRef Type="Allelic variant" ID="611409.0013" DB="OMIM"/>
        </Name>
        <Name>
          <ElementValue Type="Alternate">SKIN/HAIR/EYE PIGMENTATION 1, BLUE/NONBLUE EYES</ElementValue>
          <XRef Type="MIM" ID="227220" DB="OMIM"/>
          <XRef Type="Allelic variant" ID="605837.0001" DB="OMIM"/>
          <XRef Type="Allelic variant" ID="605837.0002" DB="OMIM"/>
          <XRef Type="Allelic variant" ID="605837.0003" DB="OMIM"/>
          <XRef Type="Allelic variant" ID="611409.0011" DB="OMIM"/>
          <XRef Type="Allelic variant" ID="611409.0012" DB="OMIM"/>
          <XRef Type="Allelic variant" ID="611409.0013" DB="OMIM"/>
        </Name>
        <Symbol>
          <ElementValue Type="Preferred">SHEP1</ElementValue>
          <XRef Type="MIM" ID="227220" DB="OMIM"/>
        </Symbol>
        <Symbol>
          <ElementValue Type="Alternate">BEY2</ElementValue>
          <XRef Type="MIM" ID="227220" DB="OMIM"/>
        </Symbol>
        <Symbol>
          <ElementValue Type="Alternate">EYCL3</ElementValue>
          <XRef Type="MIM" ID="227220" DB="OMIM"/>
        </Symbol>
        <Symbol>
          <ElementValue Type="Alternate">HCL3</ElementValue>
          <XRef Type="MIM" ID="227220" DB="OMIM"/>
        </Symbol>
        <XRef ID="C1856895" DB="MedGen"/>
        <XRef Type="MIM" ID="227220" DB="OMIM"/>
      </Trait>
    </TraitSet>
  </ReferenceClinVarAssertion>
  <ClinVarAssertion ID="21165">
    <ClinVarSubmissionID localKey="611409.0013_SKIN/HAIR/EYE PIGMENTATION 1, BLUE/NONBLUE EYES" submitter="OMIM" submitterDate="2016-10-11" title="OCA2, IVS1, HAPLOTYPE 1_SKIN/HAIR/EYE PIGMENTATION 1, BLUE/NONBLUE EYES"/>
    <ClinVarAccession Acc="SCV000021165" OrgType="primary" OrganizationCategory="resource" Version="3" Type="SCV" OrgID="3" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2007-12-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Affects</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ExternalID DB="OMIM" ID="611409.0013" Type="Allelic variant"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species>human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="Description">To clarify the role of OCA2 locus in the inheritance of eye color and other pigmentary traits associated with skin-cancer risk in white populations, Duffy et al. (2007) genotyped 3,839 adolescent twins, sibs, and parents for 58 synonymous and nonsynonymous exonic SNPs and tagging SNPs at the OCA2 locus. The authors found that the highest association for blue/nonblue eye color (227220) was found with 3 OCA2 SNPs in intron 1: rs7495174, T/C; rs4778241 (formerly rs6497268), G/T; and rs4778138 (formerly 11855019), T/C. These 3 SNPs are in 1 major haplotype block, with TGT representing 78.4% of alleles. The TGT/TGT diplotype found in 62.2% of samples was the major genotype seen to modify eye color, with a frequency of 0.905 in blue or green compared with only 0.095 in brown eye color. This genotype was also at highest frequency in subjects with light brown hair and was more frequent in fair and medium skin types, consistent with the TGT haplotype acting as a recessive modifier of lighter pigmentary phenotypes. Homozygotes for rs4778138 C/C were predominantly without freckles and had lower mole counts.</Attribute>
        <Citation>
          <ID Source="PubMed">17236130</ID>
        </Citation>
        <XRef DB="OMIM" ID="227220" Type="MIM"/>
      </ObservedData>
      <ObservedData>
        <Attribute Type="Description">In an association study of pigmentation variants using Icelandic and Dutch population samples, Sulem et al. (2007) found association of the rs7495174, rs4778241, and rs4778138 identified by Duffy et al. (2007) with blue eye color and blond hair. The A allele of rs7495174 was strongly associated with blue versus brown eyes (OR = 6.90, p = 3.0 x 10(-24)).</Attribute>
        <Citation>
          <ID Source="PubMed">17952075</ID>
        </Citation>
        <Citation>
          <ID Source="PubMed">17236130</ID>
        </Citation>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant">
      <Measure Type="Variation">
        <Name>
          <ElementValue Type="Preferred">OCA2, IVS1, HAPLOTYPE 1</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="NonHGVS">IVS1, HAPLOTYPE 1</Attribute>
        </AttributeSet>
        <MeasureRelationship Type="variant in gene">
          <Symbol>
            <ElementValue Type="Preferred">OCA2</ElementValue>
          </Symbol>
        </MeasureRelationship>
        <XRef DB="OMIM" ID="611409.0013" Type="Allelic variant"/>
      </Measure>
    </MeasureSet>
    <TraitSet Type="Disease">
      <Trait Type="Disease">
        <Name>
          <ElementValue Type="Preferred">SKIN/HAIR/EYE PIGMENTATION 1, BLUE/NONBLUE EYES</ElementValue>
        </Name>
      </Trait>
    </TraitSet>
  </ClinVarAssertion>
</ClinVarSet>

<ClinVarSet ID="18624718">
  <RecordStatus>current</RecordStatus>
  <Title>fragile site, folic acid type, rare, fra(12)(q13.1) AND Mental retardation, fra12a type</Title>
  <ReferenceClinVarAssertion DateCreated="2012-08-13" DateLastUpdated="2017-04-07" ID="58524">
    <ClinVarAccession Acc="RCV000001021" Version="2" Type="RCV" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2007-02-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData ID="17804099">
        <Attribute Type="Description">In 2 patients with mental retardation associated with FRA12A (136630), Winnepenninckx et al. (2007) identified a polymorphic CGG repeat expansion in the 5-prime untranslated region of the DIP2B gene. The length of the expanded allele in the affected individuals was greater than 1,050 to 1,150 basepairs, whereas unaffected FRA12A family carriers had 650 to 860 basepairs. In 7 individuals with significant neurocognitive problems reported in the literature, the average level of FRA12A expression in lymphocytes was 43.7%, whereas that in unaffected carrier individuals was 16.6%. The percentage of cytogenetic expression of FRA12A was thus associated with the clinical phenotype. DIP2B mRNA levels were halved in 2 subjects with FRA12A with mental retardation in whom the repeat expansion was methylated. In 2 individuals without mental retardation but with an expanded and methylated repeat, DIP2B expression was reduced to approximately two-thirds of the values observed in controls. A carrier of an unmethylated CGG repeat expansion showed increased levels of DIP2B mRNA, which suggested that the repeat elongation increases gene expression.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">17236128</ID>
        </Citation>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant" ID="970">
      <Measure Type="Microsatellite" ID="16009">
        <Name>
          <ElementValue Type="Preferred">fragile site, folic acid type, rare, fra(12)(q13.1)</ElementValue>
          <XRef ID="2448" DB="Gene"/>
        </Name>
        <Name>
          <ElementValue Type="Alternate">DIP2B, CGG(n) EXPANSION</ElementValue>
          <XRef Type="Allelic variant" ID="611379.0001" DB="OMIM"/>
        </Name>
        <Symbol>
          <ElementValue Type="Preferred">FRA12A</ElementValue>
          <XRef ID="2448" DB="Gene"/>
        </Symbol>
        <AttributeSet>
          <Attribute Change="g.5020_5022(1050-1150)" Accession="NG_021196" Version="1" Type="HGVS, genomic">NG_021196.1:g.5020_5022(1050-1150)</Attribute>
          <Citation Type="general">
            <ID Source="PubMed">17236128</ID>
          </Citation>
        </AttributeSet>
        <AttributeSet>
          <Attribute Change="g.(5020_5022)(350-383)" Accession="NG_021196" Version="1" Type="HGVS, genomic, RefSeqGene">NG_021196.1:g.(5020_5022)(350-383)</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Change="g.(50505004_50505006)(350-383)" Accession="NC_000012" Version="12" Type="HGVS, genomic, top level" integerValue="38">NC_000012.12:g.(50505004_50505006)(350-383)</Attribute>
        </AttributeSet>
        <CytogeneticLocation>12q13.1</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="12" Accession="NC_000012.11" start="50898787" stop="50898807" display_start="50898787" display_stop="50898807" Strand="+"/>
        <MeasureRelationship Type="within single gene">
          <Name>
            <ElementValue Type="Preferred">disco interacting protein 2 homolog B</ElementValue>
          </Name>
          <Symbol>
            <ElementValue Type="Preferred">DIP2B</ElementValue>
          </Symbol>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="12" Accession="NC_000012.12" start="50504985" stop="50748667" display_start="50504985" display_stop="50748667" Strand="+"/>
          <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="12" Accession="NC_000012.11" start="50898767" stop="51142449" display_start="50898767" display_stop="51142449" variantLength="243683" Strand="+"/>
          <XRef ID="57609" DB="Gene"/>
          <XRef Type="MIM" ID="611379" DB="OMIM"/>
          <XRef ID="HGNC:29284" DB="HGNC"/>
        </MeasureRelationship>
        <XRef Type="Allelic variant" ID="611379.0001" DB="OMIM"/>
        <Source DataSource="MedGen" ID="CN192494"/>
      </Measure>
      <Name>
        <ElementValue Type="Preferred">fragile site, folic acid type, rare, fra(12)(q13.1)</ElementValue>
      </Name>
    </MeasureSet>
    <TraitSet Type="Disease" ID="254">
      <Trait ID="2890" Type="Disease">
        <Name>
          <ElementValue Type="Preferred">Mental retardation, fra12a type</ElementValue>
          <XRef ID="Mental+retardation%2C+fra12a+type/8844" DB="Genetic Alliance"/>
        </Name>
        <XRef ID="C1969893" DB="MedGen"/>
        <XRef Type="MIM" ID="136630" DB="OMIM"/>
      </Trait>
    </TraitSet>
  </ReferenceClinVarAssertion>
  <ClinVarAssertion ID="21171">
    <ClinVarSubmissionID localKey="611379.0001_MENTAL RETARDATION, FRA12A TYPE" submitter="OMIM" submitterDate="2007-09-06" title="DIP2B, CGG(n) EXPANSION  _MENTAL RETARDATION, FRA12A TYPE"/>
    <ClinVarAccession Acc="SCV000021171" OrgType="primary" OrganizationCategory="resource" Version="1" Type="SCV" OrgID="3" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2007-02-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ExternalID DB="OMIM" ID="611379.0001" Type="Allelic variant"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species>human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="Description">In 2 patients with mental retardation associated with FRA12A (136630), Winnepenninckx et al. (2007) identified a polymorphic CGG repeat expansion in the 5-prime untranslated region of the DIP2B gene. The length of the expanded allele in the affected individuals was greater than 1,050 to 1,150 basepairs, whereas unaffected FRA12A family carriers had 650 to 860 basepairs. In 7 individuals with significant neurocognitive problems reported in the literature, the average level of FRA12A expression in lymphocytes was 43.7%, whereas that in unaffected carrier individuals was 16.6%. The percentage of cytogenetic expression of FRA12A was thus associated with the clinical phenotype. DIP2B mRNA levels were halved in 2 subjects with FRA12A with mental retardation in whom the repeat expansion was methylated. In 2 individuals without mental retardation but with an expanded and methylated repeat, DIP2B expression was reduced to approximately two-thirds of the values observed in controls. A carrier of an unmethylated CGG repeat expansion showed increased levels of DIP2B mRNA, which suggested that the repeat elongation increases gene expression.</Attribute>
        <Citation>
          <ID Source="PubMed">17236128</ID>
        </Citation>
        <XRef DB="OMIM" ID="136630" Type="MIM"/>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant">
      <Measure Type="Variation">
        <Name>
          <ElementValue Type="Preferred">DIP2B, CGG(n) EXPANSION</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="NonHGVS">CGG(n) EXPANSION</Attribute>
        </AttributeSet>
        <MeasureRelationship Type="variant in gene">
          <Symbol>
            <ElementValue Type="Preferred">DIP2B</ElementValue>
          </Symbol>
        </MeasureRelationship>
        <XRef DB="OMIM" ID="611379.0001" Type="Allelic variant"/>
      </Measure>
    </MeasureSet>
    <TraitSet Type="Disease">
      <Trait Type="Disease">
        <Name>
          <ElementValue Type="Preferred">MENTAL RETARDATION, FRA12A TYPE</ElementValue>
        </Name>
      </Trait>
    </TraitSet>
  </ClinVarAssertion>
</ClinVarSet>

<ClinVarSet ID="18624919">
  <RecordStatus>current</RecordStatus>
  <Title>F12, CYS571SER AND FACTOR XII (WASHINGTON D.C.)</Title>
  <ReferenceClinVarAssertion DateCreated="2012-08-13" DateLastUpdated="2017-04-07" ID="58726">
    <ClinVarAccession Acc="RCV000001223" Version="3" Type="RCV" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="1989-11-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData ID="17805273">
        <Attribute Type="Description">Miyata et al. (1989) demonstrated that the functional impairment of factor XII (Washington D.C.) (234000) is due to replacement of cys571 with serine in the catalytic domain.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">2510163</ID>
        </Citation>
      </ObservedData>
      <ObservedData ID="17805273">
        <Attribute Type="Description">This mutation has also been referred to as CYS590SER (C90S).</Attribute>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant" ID="1164">
      <Measure Type="Variation" ID="16203">
        <Name>
          <ElementValue Type="Preferred">F12, CYS571SER</ElementValue>
        </Name>
        <Name>
          <ElementValue Type="Alternate">F12, CYS571SER</ElementValue>
          <XRef Type="Allelic variant" ID="610619.0001" DB="OMIM"/>
        </Name>
        <AttributeSet>
          <Attribute Type="ProteinChange1LetterCode">C571S</Attribute>
          <XRef Type="Allelic variant" ID="610619.0001" DB="OMIM"/>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="ProteinChange3LetterCode">CYS571SER</Attribute>
          <XRef Type="Allelic variant" ID="610619.0001" DB="OMIM"/>
        </AttributeSet>
        <CytogeneticLocation>5q33-qter</CytogeneticLocation>
        <MeasureRelationship Type="asserted, but not computed">
          <Name>
            <ElementValue Type="Preferred">coagulation factor XII</ElementValue>
          </Name>
          <Symbol>
            <ElementValue Type="Preferred">F12</ElementValue>
          </Symbol>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="5" Accession="NC_000005.10" start="177402138" stop="177409576" display_start="177402138" display_stop="177409576" Strand="-"/>
          <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="5" Accession="NC_000005.9" start="176829138" stop="176836576" display_start="176829138" display_stop="176836576" variantLength="7439" Strand="-"/>
          <XRef ID="2161" DB="Gene"/>
          <XRef Type="MIM" ID="610619" DB="OMIM"/>
          <XRef ID="HGNC:3530" DB="HGNC"/>
        </MeasureRelationship>
        <XRef Type="Allelic variant" ID="610619.0001" DB="OMIM"/>
      </Measure>
      <Name>
        <ElementValue Type="Preferred">F12, CYS571SER</ElementValue>
      </Name>
    </MeasureSet>
    <TraitSet Type="Disease" ID="306">
      <Trait ID="9698" Type="Disease">
        <Name>
          <ElementValue Type="Preferred">FACTOR XII (WASHINGTON D.C.)</ElementValue>
          <XRef Type="Allelic variant" ID="610619.0001" DB="OMIM"/>
        </Name>
      </Trait>
    </TraitSet>
  </ReferenceClinVarAssertion>
  <ClinVarAssertion ID="21373">
    <ClinVarSubmissionID localKey="610619.0001_FACTOR XII (WASHINGTON D.C.)" submitter="OMIM" submitterDate="2013-11-21" title="F12, CYS571SER_FACTOR XII (WASHINGTON D.C.)"/>
    <ClinVarAccession Acc="SCV000021373" OrgType="primary" OrganizationCategory="resource" Version="2" Type="SCV" OrgID="3" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="1989-11-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ExternalID DB="OMIM" ID="610619.0001" Type="Allelic variant"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species>human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="Description">Miyata et al. (1989) demonstrated that the functional impairment of factor XII (Washington D.C.) (234000) is due to replacement of cys571 with serine in the catalytic domain.</Attribute>
        <Citation>
          <ID Source="PubMed">2510163</ID>
        </Citation>
        <XRef DB="OMIM" ID="234000" Type="MIM"/>
      </ObservedData>
      <ObservedData>
        <Attribute Type="Description">This mutation has also been referred to as CYS590SER (C90S).</Attribute>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant">
      <Measure Type="Variation">
        <Name>
          <ElementValue Type="Preferred">F12, CYS571SER</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="NonHGVS">CYS571SER</Attribute>
        </AttributeSet>
        <MeasureRelationship Type="variant in gene">
          <Symbol>
            <ElementValue Type="Preferred">F12</ElementValue>
          </Symbol>
        </MeasureRelationship>
        <XRef DB="OMIM" ID="610619.0001" Type="Allelic variant"/>
      </Measure>
    </MeasureSet>
    <TraitSet Type="Disease">
      <Trait Type="Disease">
        <Name>
          <ElementValue Type="Preferred">FACTOR XII (WASHINGTON D.C.)</ElementValue>
        </Name>
      </Trait>
    </TraitSet>
  </ClinVarAssertion>
</ClinVarSet>

<ClinVarSet ID="18625533">
  <RecordStatus>current</RecordStatus>
  <Title>CYP17A1, 7-BP DUP, EX2 AND Complete combined 17-alpha-hydroxylase/17,20-lyase deficiency</Title>
  <ReferenceClinVarAssertion DateCreated="2012-08-13" DateLastUpdated="2017-04-07" ID="59354">
    <ClinVarAccession Acc="RCV000001851" Version="2" Type="RCV" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="1990-05-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData ID="17804345">
        <Attribute Type="Description">In a Japanese child, born of consanguineous parents, with combined 17-alpha-hydroxylase/17,20-lyase deficiency (202110), Yanase et al. (1990) identified a 7-bp duplication (GCGCACA) in exon 2 of the CYP17A1 gene, resulting in a frameshift and premature stop codon N-terminal to the heme-binding sequence. The patient was genotypically male (46,XY), but phenotypically female. The mutation led to the absence of a functional protein in the adrenal cortex and testis. This lack of protein led to an absence of sex steroids, resulting in female external genitalia, and excessive secretion of steroids with mineralocorticoid activity, resulting in hypertension.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">2335573</ID>
        </Citation>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant" ID="1779">
      <Measure Type="Duplication" ID="16818">
        <Name>
          <ElementValue Type="Preferred">CYP17A1, 7-BP DUP, EX2</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="nucleotide change">7-BP DUP, EX2</Attribute>
          <XRef Type="Allelic variant" ID="609300.0003" DB="OMIM"/>
        </AttributeSet>
        <CytogeneticLocation>10q24.3</CytogeneticLocation>
        <MeasureRelationship Type="asserted, but not computed">
          <Name>
            <ElementValue Type="Preferred">cytochrome P450 family 17 subfamily A member 1</ElementValue>
          </Name>
          <Symbol>
            <ElementValue Type="Preferred">CYP17A1</ElementValue>
          </Symbol>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="10" Accession="NC_000010.11" start="102830531" stop="102837533" display_start="102830531" display_stop="102837533" Strand="-"/>
          <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="10" Accession="NC_000010.10" start="104590287" stop="104597289" display_start="104590287" display_stop="104597289" variantLength="7003" Strand="-"/>
          <XRef ID="1586" DB="Gene"/>
          <XRef Type="MIM" ID="609300" DB="OMIM"/>
          <XRef ID="HGNC:2593" DB="HGNC"/>
        </MeasureRelationship>
        <XRef Type="Allelic variant" ID="609300.0003" DB="OMIM"/>
      </Measure>
      <Name>
        <ElementValue Type="Preferred">CYP17A1, 7-BP DUP, EX2</ElementValue>
      </Name>
    </MeasureSet>
    <TraitSet Type="Disease" ID="457">
      <Trait ID="8871" Type="Disease">
        <Name>
          <ElementValue Type="Preferred">Complete combined 17-alpha-hydroxylase/17,20-lyase deficiency</ElementValue>
        </Name>
        <XRef ID="CN042980" DB="MedGen"/>
      </Trait>
    </TraitSet>
  </ReferenceClinVarAssertion>
  <ClinVarAssertion ID="22007">
    <ClinVarSubmissionID localKey="609300.0003_17-@ALPHA-HYDROXYLASE/17,20-LYASE DEFICIENCY, COMBINED COMPLETE" submitter="OMIM" submitterDate="2013-04-19" title="CYP17A1, 7-BP DUP, EX2_17-@ALPHA-HYDROXYLASE/17,20-LYASE DEFICIENCY, COMBINED COMPLETE"/>
    <ClinVarAccession Acc="SCV000022007" OrgType="primary" OrganizationCategory="resource" Version="1" Type="SCV" OrgID="3" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="1990-05-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ExternalID DB="OMIM" ID="609300.0003" Type="Allelic variant"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species>human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="Description">In a Japanese child, born of consanguineous parents, with combined 17-alpha-hydroxylase/17,20-lyase deficiency (202110), Yanase et al. (1990) identified a 7-bp duplication (GCGCACA) in exon 2 of the CYP17A1 gene, resulting in a frameshift and premature stop codon N-terminal to the heme-binding sequence. The patient was genotypically male (46,XY), but phenotypically female. The mutation led to the absence of a functional protein in the adrenal cortex and testis. This lack of protein led to an absence of sex steroids, resulting in female external genitalia, and excessive secretion of steroids with mineralocorticoid activity, resulting in hypertension.</Attribute>
        <Citation>
          <ID Source="PubMed">2335573</ID>
        </Citation>
        <XRef DB="OMIM" ID="202110" Type="MIM"/>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant">
      <Measure Type="Variation">
        <Name>
          <ElementValue Type="Preferred">CYP17A1, 7-BP DUP, EX2</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="NonHGVS">7-BP DUP, EX2</Attribute>
        </AttributeSet>
        <MeasureRelationship Type="variant in gene">
          <Symbol>
            <ElementValue Type="Preferred">CYP17A1</ElementValue>
          </Symbol>
        </MeasureRelationship>
        <XRef DB="OMIM" ID="609300.0003" Type="Allelic variant"/>
      </Measure>
    </MeasureSet>
    <TraitSet Type="Disease">
      <Trait Type="Disease">
        <Name>
          <ElementValue Type="Preferred">17-@ALPHA-HYDROXYLASE/17,20-LYASE DEFICIENCY, COMBINED COMPLETE</ElementValue>
        </Name>
      </Trait>
    </TraitSet>
  </ClinVarAssertion>
</ClinVarSet>

<ClinVarSet ID="18633962">
  <RecordStatus>current</RecordStatus>
  <Title>CYP3A5, 6986A-G AND Hypertension, salt-sensitive essential, susceptibility to</Title>
  <ReferenceClinVarAssertion DateCreated="2012-08-13" DateLastUpdated="2017-04-07" ID="62873">
    <ClinVarAccession Acc="RCV000005370" Version="2" Type="RCV" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2004-12-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>risk factor</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData ID="17810357">
        <Attribute Type="Description">In many populations, total adult CYP3A protein content of tissues remains constant and consists largely of CYP3A4, whereas CYP3A5 expression has extreme interpopulation variability. This variation is largely due to a 6986A-G substitution in intron 3 of CYP3A5 (the CYP3A5*3 allele; SV1-CYP3A5) that results in improperly spliced mRNA and a nonfunctional protein truncated at amino acid 102 (Kuehl et al., 2001; Lin et al., 2002). The CYP3A5*3 allele is reported to have a frequency of approximately 27 to 50% among African Americans, 85 to 95% among whites (Hustert et al., 2001; Kuehl et al., 2001), and 60 to 73% among Asians (Hustert et al., 2001).</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">11279519</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">11740341</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">12065767</ID>
        </Citation>
      </ObservedData>
      <ObservedData ID="17810357">
        <Attribute Type="Description">Givens et al. (2003) found that, among renal microsomes from 21 organ donors, those from *1/*3 individuals had at least 8-fold higher mean kidney microsomal CYP3A5 content and 18-fold higher mean CYP3A catalytic activity than did those from *3/*3 individuals (p = 0.0001 and p = 0.0137, respectively). They also found significant associations between the 6986A-G polymorphism and systolic blood pressure (p = 0.0007), mean arterial pressure (p = 0.0075), and creatinine clearance (p = 0.0035) among 25 healthy African American adults. The associations remained significant when sex, age, and body mass index were considered. The mean systolic blood pressure of homozygous CYP3A5 expressors (*1/*1) exceeded that of homozygous nonexpressors (*3/*3) by 19.3 mm Hg. Givens et al. (2003) speculated that a high CYPA5 expressor allele frequency among African Americans may contribute to a high prevalence of salt-sensitive hypertension (145500) in this population.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">12754175</ID>
        </Citation>
      </ObservedData>
      <ObservedData ID="17810357">
        <Attribute Type="Description">Thompson et al. (2004) found that the CYP3A5*3 allele is significantly correlated with distance from the equator. They noted that a met235-to-thr SNP in the AGT gene (M235T; 106150.0001), previously implicated in hypertension and preeclampsia, exhibited a similar geographic distribution and had a significantly correlated frequency with CYP3A5*1/*3. Thompson et al. (2004) concluded that variants that influence salt homeostasis are the targets of a shared selective pressure that results from an environmental variable correlated with latitude.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">15492926</ID>
        </Citation>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant" ID="5066">
      <Measure Type="single nucleotide variant" ID="20105">
        <Name>
          <ElementValue Type="Preferred">CYP3A5, 6986A-G</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="nucleotide change">6986A-G</Attribute>
          <XRef Type="Allelic variant" ID="605325.0001" DB="OMIM"/>
        </AttributeSet>
        <CytogeneticLocation>7q22.1</CytogeneticLocation>
        <MeasureRelationship Type="asserted, but not computed">
          <Name>
            <ElementValue Type="Preferred">cytochrome P450 family 3 subfamily A member 5</ElementValue>
          </Name>
          <Symbol>
            <ElementValue Type="Preferred">CYP3A5</ElementValue>
          </Symbol>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="7" Accession="NC_000007.14" start="99648189" stop="99680026" display_start="99648189" display_stop="99680026" Strand="-"/>
          <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="7" Accession="NC_000007.13" start="99245812" stop="99277620" display_start="99245812" display_stop="99277620" variantLength="31809" Strand="-"/>
          <XRef ID="1577" DB="Gene"/>
          <XRef Type="MIM" ID="605325" DB="OMIM"/>
          <XRef ID="HGNC:2638" DB="HGNC"/>
        </MeasureRelationship>
        <XRef Type="Allelic variant" ID="605325.0001" DB="OMIM"/>
      </Measure>
      <Name>
        <ElementValue Type="Preferred">CYP3A5, 6986A-G</ElementValue>
      </Name>
    </MeasureSet>
    <TraitSet Type="Disease" ID="1401">
      <Trait ID="10131" Type="Disease">
        <Name>
          <ElementValue Type="Preferred">Hypertension, salt-sensitive essential, susceptibility to</ElementValue>
        </Name>
      </Trait>
    </TraitSet>
  </ReferenceClinVarAssertion>
  <ClinVarAssertion ID="25550">
    <ClinVarSubmissionID localKey="605325.0001_HYPERTENSION, SALT-SENSITIVE ESSENTIAL, SUSCEPTIBILITY TO" submitter="OMIM" submitterDate="2009-03-04" title="CYP3A5, 6986A-G_HYPERTENSION, SALT-SENSITIVE ESSENTIAL, SUSCEPTIBILITY TO"/>
    <ClinVarAccession Acc="SCV000025550" OrgType="primary" OrganizationCategory="resource" Version="1" Type="SCV" OrgID="3" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2004-12-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>risk factor</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ExternalID DB="OMIM" ID="605325.0001" Type="Allelic variant"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species>human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="Description">In many populations, total adult CYP3A protein content of tissues remains constant and consists largely of CYP3A4, whereas CYP3A5 expression has extreme interpopulation variability. This variation is largely due to a 6986A-G substitution in intron 3 of CYP3A5 (the CYP3A5*3 allele; SV1-CYP3A5) that results in improperly spliced mRNA and a nonfunctional protein truncated at amino acid 102 (Kuehl et al., 2001; Lin et al., 2002). The CYP3A5*3 allele is reported to have a frequency of approximately 27 to 50% among African Americans, 85 to 95% among whites (Hustert et al., 2001; Kuehl et al., 2001), and 60 to 73% among Asians (Hustert et al., 2001).</Attribute>
        <Citation>
          <ID Source="PubMed">11279519</ID>
        </Citation>
        <Citation>
          <ID Source="PubMed">12065767</ID>
        </Citation>
        <Citation>
          <ID Source="PubMed">11740341</ID>
        </Citation>
      </ObservedData>
      <ObservedData>
        <Attribute Type="Description">Givens et al. (2003) found that, among renal microsomes from 21 organ donors, those from *1/*3 individuals had at least 8-fold higher mean kidney microsomal CYP3A5 content and 18-fold higher mean CYP3A catalytic activity than did those from *3/*3 individuals (p = 0.0001 and p = 0.0137, respectively). They also found significant associations between the 6986A-G polymorphism and systolic blood pressure (p = 0.0007), mean arterial pressure (p = 0.0075), and creatinine clearance (p = 0.0035) among 25 healthy African American adults. The associations remained significant when sex, age, and body mass index were considered. The mean systolic blood pressure of homozygous CYP3A5 expressors (*1/*1) exceeded that of homozygous nonexpressors (*3/*3) by 19.3 mm Hg. Givens et al. (2003) speculated that a high CYPA5 expressor allele frequency among African Americans may contribute to a high prevalence of salt-sensitive hypertension (145500) in this population.</Attribute>
        <Citation>
          <ID Source="PubMed">12754175</ID>
        </Citation>
        <XRef DB="OMIM" ID="145500" Type="MIM"/>
      </ObservedData>
      <ObservedData>
        <Attribute Type="Description">Thompson et al. (2004) found that the CYP3A5*3 allele is significantly correlated with distance from the equator. They noted that a met235-to-thr SNP in the AGT gene (M235T; 106150.0001), previously implicated in hypertension and preeclampsia, exhibited a similar geographic distribution and had a significantly correlated frequency with CYP3A5*1/*3. Thompson et al. (2004) concluded that variants that influence salt homeostasis are the targets of a shared selective pressure that results from an environmental variable correlated with latitude.</Attribute>
        <Citation>
          <ID Source="PubMed">15492926</ID>
        </Citation>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant">
      <Measure Type="Variation">
        <Name>
          <ElementValue Type="Preferred">CYP3A5, 6986A-G</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="NonHGVS">6986A-G</Attribute>
        </AttributeSet>
        <MeasureRelationship Type="variant in gene">
          <Symbol>
            <ElementValue Type="Preferred">CYP3A5</ElementValue>
          </Symbol>
        </MeasureRelationship>
        <XRef DB="OMIM" ID="605325.0001" Type="Allelic variant"/>
      </Measure>
    </MeasureSet>
    <TraitSet Type="Disease">
      <Trait Type="Disease">
        <Name>
          <ElementValue Type="Preferred">HYPERTENSION, SALT-SENSITIVE ESSENTIAL, SUSCEPTIBILITY TO</ElementValue>
        </Name>
      </Trait>
    </TraitSet>
  </ClinVarAssertion>
</ClinVarSet>

<ClinVarSet ID="18625560">
  <RecordStatus>current</RecordStatus>
  <Title>CYP17A1, 9-BP DEL AND Complete combined 17-alpha-hydroxylase/17,20-lyase deficiency</Title>
  <ReferenceClinVarAssertion DateCreated="2012-08-13" DateLastUpdated="2017-04-07" ID="59381">
    <ClinVarAccession Acc="RCV000001878" Version="2" Type="RCV" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2006-09-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData ID="17804352">
        <Attribute Type="Description">In 4 of 8 Chinese patients with combined complete 17-alpha-hydroxylase/17,20-lyase deficiency (202110), Yang et al. (2006) identified a 9-bp deletion (1517_1525del; D487_F489del) in the CYP17A1 gene; 2 patients were homozygous and the other 2 compound heterozygous for the mutation. The authors concluded that this may be a founder mutation.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">16772352</ID>
        </Citation>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant" ID="1805">
      <Measure Type="Deletion" ID="16844">
        <Name>
          <ElementValue Type="Preferred">CYP17A1, 9-BP DEL</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="nucleotide change">9-BP DEL</Attribute>
          <XRef Type="Allelic variant" ID="609300.0032" DB="OMIM"/>
        </AttributeSet>
        <CytogeneticLocation>10q24.3</CytogeneticLocation>
        <MeasureRelationship Type="asserted, but not computed">
          <Name>
            <ElementValue Type="Preferred">cytochrome P450 family 17 subfamily A member 1</ElementValue>
          </Name>
          <Symbol>
            <ElementValue Type="Preferred">CYP17A1</ElementValue>
          </Symbol>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="10" Accession="NC_000010.11" start="102830531" stop="102837533" display_start="102830531" display_stop="102837533" Strand="-"/>
          <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="10" Accession="NC_000010.10" start="104590287" stop="104597289" display_start="104590287" display_stop="104597289" variantLength="7003" Strand="-"/>
          <XRef ID="1586" DB="Gene"/>
          <XRef Type="MIM" ID="609300" DB="OMIM"/>
          <XRef ID="HGNC:2593" DB="HGNC"/>
        </MeasureRelationship>
        <XRef Type="Allelic variant" ID="609300.0032" DB="OMIM"/>
      </Measure>
      <Name>
        <ElementValue Type="Preferred">CYP17A1, 9-BP DEL</ElementValue>
      </Name>
    </MeasureSet>
    <TraitSet Type="Disease" ID="457">
      <Trait ID="8871" Type="Disease">
        <Name>
          <ElementValue Type="Preferred">Complete combined 17-alpha-hydroxylase/17,20-lyase deficiency</ElementValue>
        </Name>
        <XRef ID="CN042980" DB="MedGen"/>
      </Trait>
    </TraitSet>
  </ReferenceClinVarAssertion>
  <ClinVarAssertion ID="22034">
    <ClinVarSubmissionID localKey="609300.0032_17-@ALPHA-HYDROXYLASE/17,20-LYASE DEFICIENCY, COMBINED COMPLETE" submitter="OMIM" submitterDate="2013-04-19" title="CYP17A1, 9-BP DEL_17-@ALPHA-HYDROXYLASE/17,20-LYASE DEFICIENCY, COMBINED COMPLETE"/>
    <ClinVarAccession Acc="SCV000022034" OrgType="primary" OrganizationCategory="resource" Version="1" Type="SCV" OrgID="3" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2006-09-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ExternalID DB="OMIM" ID="609300.0032" Type="Allelic variant"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species>human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="Description">In 4 of 8 Chinese patients with combined complete 17-alpha-hydroxylase/17,20-lyase deficiency (202110), Yang et al. (2006) identified a 9-bp deletion (1517_1525del; D487_F489del) in the CYP17A1 gene; 2 patients were homozygous and the other 2 compound heterozygous for the mutation. The authors concluded that this may be a founder mutation.</Attribute>
        <Citation>
          <ID Source="PubMed">16772352</ID>
        </Citation>
        <XRef DB="OMIM" ID="202110" Type="MIM"/>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant">
      <Measure Type="Variation">
        <Name>
          <ElementValue Type="Preferred">CYP17A1, 9-BP DEL</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="NonHGVS">9-BP DEL</Attribute>
        </AttributeSet>
        <MeasureRelationship Type="variant in gene">
          <Symbol>
            <ElementValue Type="Preferred">CYP17A1</ElementValue>
          </Symbol>
        </MeasureRelationship>
        <XRef DB="OMIM" ID="609300.0032" Type="Allelic variant"/>
      </Measure>
    </MeasureSet>
    <TraitSet Type="Disease">
      <Trait Type="Disease">
        <Name>
          <ElementValue Type="Preferred">17-@ALPHA-HYDROXYLASE/17,20-LYASE DEFICIENCY, COMBINED COMPLETE</ElementValue>
        </Name>
      </Trait>
    </TraitSet>
  </ClinVarAssertion>
</ClinVarSet>

<ClinVarSet ID="18634320">
  <RecordStatus>current</RecordStatus>
  <Title>CD209, -336A-G AND Dengue fever, protection against</Title>
  <ReferenceClinVarAssertion DateCreated="2012-08-13" DateLastUpdated="2017-04-07" ID="63243">
    <ClinVarAccession Acc="RCV000005740" Version="2" Type="RCV" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2006-02-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>protective</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData ID="17811025">
        <Attribute Type="Description">Martin et al. (2004) found that European Americans at risk for parenteral HIV infection (see 609423) were more likely to carry the -336C SNP than the -336T SNP in the promoter of DCSIGN. This association was not observed in those at risk for mucosally acquired infection. Although the -336C SNP was common in African Americans, no significant association with risk of infection was observed in this group.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">15564514</ID>
        </Citation>
      </ObservedData>
      <ObservedData ID="17811025">
        <Attribute Type="Description">Sakuntabhai et al. (2005) reported strong association between the -336A-G polymorphism in the promoter of CD209, which they called DCSIGN1-336, and risk of dengue fever (614371). The G allele of the variant was associated with strong protection against dengue fever in 3 independent cohorts from Thailand, with a carrier frequency of 4.7% in individuals with dengue fever compared with 22.4% in individuals with dengue hemorrhagic fever (odds ratio for risk of dengue hemorrhagic fever vs dengue fever = 5.84) and 19.5% in controls (odds ratio for protection = 4.90). This variant affects an Sp1-like binding site and transcriptional activity in vitro. Carrington (2006) confirmed that the -336T-C SNP reported by Martin et al. (2004) and the -336A-G SNP reported by Sakuntabhai et al. (2005) are the same variant.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">15564514</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">15838506</ID>
        </Citation>
        <Citation Type="general">
          <CitationText>Carrington, M. Personal Communication. 2006. Baltimore, Md.</CitationText>
        </Citation>
      </ObservedData>
      <ObservedData ID="17811025">
        <Attribute Type="Description">Barreiro et al. (2006) found an association between susceptibility to tuberculosis (607948) and -336G in a South African Coloured population.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">16379498</ID>
        </Citation>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant" ID="5408">
      <Measure Type="single nucleotide variant" ID="20447">
        <Name>
          <ElementValue Type="Preferred">CD209, -336A-G</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="nucleotide change">-336A-G</Attribute>
          <XRef Type="Allelic variant" ID="604672.0001" DB="OMIM"/>
        </AttributeSet>
        <CytogeneticLocation>19p13.3</CytogeneticLocation>
        <MeasureRelationship Type="asserted, but not computed">
          <Name>
            <ElementValue Type="Preferred">CD209 molecule</ElementValue>
          </Name>
          <Symbol>
            <ElementValue Type="Preferred">CD209</ElementValue>
          </Symbol>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="19" Accession="NC_000019.10" start="7739993" stop="7747609" display_start="7739993" display_stop="7747609" Strand="-"/>
          <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="19" Accession="NC_000019.9" start="7804878" stop="7812463" display_start="7804878" display_stop="7812463" variantLength="7586" Strand="-"/>
          <XRef ID="30835" DB="Gene"/>
          <XRef Type="MIM" ID="604672" DB="OMIM"/>
          <XRef ID="HGNC:1641" DB="HGNC"/>
        </MeasureRelationship>
        <XRef Type="Allelic variant" ID="604672.0001" DB="OMIM"/>
      </Measure>
      <Name>
        <ElementValue Type="Preferred">CD209, -336A-G</ElementValue>
      </Name>
    </MeasureSet>
    <TraitSet Type="Disease" ID="1514">
      <Trait ID="10171" Type="Disease">
        <Name>
          <ElementValue Type="Preferred">Dengue fever, protection against</ElementValue>
        </Name>
        <XRef ID="C1858186" DB="MedGen"/>
      </Trait>
    </TraitSet>
  </ReferenceClinVarAssertion>
  <ClinVarAssertion ID="25922">
    <ClinVarSubmissionID localKey="604672.0001_DENGUE FEVER, PROTECTION AGAINST" submitter="OMIM" submitterDate="2012-03-09" title="CD209, -336A-G_DENGUE FEVER, PROTECTION AGAINST"/>
    <ClinVarAccession Acc="SCV000025922" OrgType="primary" OrganizationCategory="resource" Version="1" Type="SCV" OrgID="3" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2006-02-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>protective</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to included disease"/>
    <ExternalID DB="OMIM" ID="604672.0001" Type="Allelic variant"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species>human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="Description">Martin et al. (2004) found that European Americans at risk for parenteral HIV infection (see 609423) were more likely to carry the -336C SNP than the -336T SNP in the promoter of DCSIGN. This association was not observed in those at risk for mucosally acquired infection. Although the -336C SNP was common in African Americans, no significant association with risk of infection was observed in this group.</Attribute>
        <Citation>
          <ID Source="PubMed">15564514</ID>
        </Citation>
        <XRef DB="OMIM" ID="609423" Type="MIM"/>
      </ObservedData>
      <ObservedData>
        <Attribute Type="Description">Sakuntabhai et al. (2005) reported strong association between the -336A-G polymorphism in the promoter of CD209, which they called DCSIGN1-336, and risk of dengue fever (614371). The G allele of the variant was associated with strong protection against dengue fever in 3 independent cohorts from Thailand, with a carrier frequency of 4.7% in individuals with dengue fever compared with 22.4% in individuals with dengue hemorrhagic fever (odds ratio for risk of dengue hemorrhagic fever vs dengue fever = 5.84) and 19.5% in controls (odds ratio for protection = 4.90). This variant affects an Sp1-like binding site and transcriptional activity in vitro. Carrington (2006) confirmed that the -336T-C SNP reported by Martin et al. (2004) and the -336A-G SNP reported by Sakuntabhai et al. (2005) are the same variant.</Attribute>
        <Citation>
          <ID Source="PubMed">15838506</ID>
        </Citation>
        <Citation>
          <CitationText>Carrington, M. Personal Communication. 2006. Baltimore, Md.</CitationText>
        </Citation>
        <Citation>
          <ID Source="PubMed">15564514</ID>
        </Citation>
        <XRef DB="OMIM" ID="614371" Type="MIM"/>
      </ObservedData>
      <ObservedData>
        <Attribute Type="Description">Barreiro et al. (2006) found an association between susceptibility to tuberculosis (607948) and -336G in a South African Coloured population.</Attribute>
        <Citation>
          <ID Source="PubMed">16379498</ID>
        </Citation>
        <XRef DB="OMIM" ID="607948" Type="MIM"/>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant">
      <Measure Type="Variation">
        <Name>
          <ElementValue Type="Preferred">CD209, -336A-G</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="NonHGVS">-336A-G</Attribute>
        </AttributeSet>
        <MeasureRelationship Type="variant in gene">
          <Symbol>
            <ElementValue Type="Preferred">CD209</ElementValue>
          </Symbol>
        </MeasureRelationship>
        <XRef DB="OMIM" ID="604672.0001" Type="Allelic variant"/>
      </Measure>
    </MeasureSet>
    <TraitSet Type="Disease">
      <Trait Type="Disease">
        <Name>
          <ElementValue Type="included">DENGUE FEVER, PROTECTION AGAINST</ElementValue>
        </Name>
      </Trait>
    </TraitSet>
  </ClinVarAssertion>
</ClinVarSet>

<ClinVarSet ID="18625563">
  <RecordStatus>current</RecordStatus>
  <Title>CYP17A1, IVS3AS, 4-BP DEL AND Complete combined 17-alpha-hydroxylase/17,20-lyase deficiency</Title>
  <ReferenceClinVarAssertion DateCreated="2012-08-13" DateLastUpdated="2017-04-07" ID="59384">
    <ClinVarAccession Acc="RCV000001881" Version="3" Type="RCV" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2004-01-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData ID="17804353">
        <Attribute Type="Description">In a 46,XY American subject with complete 17-alpha-hydroxylase/17,20-lyase deficiency (202110), Costa-Santos et al. (2004) identified homozygosity for a 4-bp deletion, TTTT, near the 3-prime end of intron 3 of the CYP17A1 gene. RNA derived from the TTTT deletion skipped exon 4 entirely, deleting 29 amino acids in-frame; cells expressing the mutant gene had no 17-hydroxylase activity. The diagnosis in the patient had been based on extremely elevated 11-deoxycorticosterone and corticosterone values, and failure of pubertal progression.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">14715826</ID>
        </Citation>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant" ID="1808">
      <Measure Type="Deletion" ID="16847">
        <Name>
          <ElementValue Type="Preferred">CYP17A1, IVS3AS, 4-BP DEL</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="nucleotide change">IVS3AS, 4-BP DEL</Attribute>
          <XRef Type="Allelic variant" ID="609300.0035" DB="OMIM"/>
        </AttributeSet>
        <CytogeneticLocation>10q24.3</CytogeneticLocation>
        <MeasureRelationship Type="asserted, but not computed">
          <Name>
            <ElementValue Type="Preferred">cytochrome P450 family 17 subfamily A member 1</ElementValue>
          </Name>
          <Symbol>
            <ElementValue Type="Preferred">CYP17A1</ElementValue>
          </Symbol>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="10" Accession="NC_000010.11" start="102830531" stop="102837533" display_start="102830531" display_stop="102837533" Strand="-"/>
          <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="10" Accession="NC_000010.10" start="104590287" stop="104597289" display_start="104590287" display_stop="104597289" variantLength="7003" Strand="-"/>
          <XRef ID="1586" DB="Gene"/>
          <XRef Type="MIM" ID="609300" DB="OMIM"/>
          <XRef ID="HGNC:2593" DB="HGNC"/>
        </MeasureRelationship>
        <XRef Type="Allelic variant" ID="609300.0035" DB="OMIM"/>
      </Measure>
      <Name>
        <ElementValue Type="Preferred">CYP17A1, IVS3AS, 4-BP DEL</ElementValue>
      </Name>
    </MeasureSet>
    <TraitSet Type="Disease" ID="457">
      <Trait ID="8871" Type="Disease">
        <Name>
          <ElementValue Type="Preferred">Complete combined 17-alpha-hydroxylase/17,20-lyase deficiency</ElementValue>
        </Name>
        <XRef ID="CN042980" DB="MedGen"/>
      </Trait>
    </TraitSet>
  </ReferenceClinVarAssertion>
  <ClinVarAssertion ID="22037">
    <ClinVarSubmissionID localKey="609300.0035_17-@ALPHA-HYDROXYLASE/17,20-LYASE DEFICIENCY, COMBINED COMPLETE" submitter="OMIM" submitterDate="2016-10-05" title="CYP17A1, IVS3AS, 4-BP DEL_17-@ALPHA-HYDROXYLASE/17,20-LYASE DEFICIENCY, COMBINED COMPLETE"/>
    <ClinVarAccession Acc="SCV000022037" OrgType="primary" OrganizationCategory="resource" Version="2" Type="SCV" OrgID="3" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2004-01-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ExternalID DB="OMIM" ID="609300.0035" Type="Allelic variant"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species>human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="Description">In a 46,XY American subject with complete 17-alpha-hydroxylase/17,20-lyase deficiency (202110), Costa-Santos et al. (2004) identified homozygosity for a 4-bp deletion, TTTT, near the 3-prime end of intron 3 of the CYP17A1 gene. RNA derived from the TTTT deletion skipped exon 4 entirely, deleting 29 amino acids in-frame; cells expressing the mutant gene had no 17-hydroxylase activity. The diagnosis in the patient had been based on extremely elevated 11-deoxycorticosterone and corticosterone values, and failure of pubertal progression.</Attribute>
        <Citation>
          <ID Source="PubMed">14715826</ID>
        </Citation>
        <XRef DB="OMIM" ID="202110" Type="MIM"/>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant">
      <Measure Type="Variation">
        <Name>
          <ElementValue Type="Preferred">CYP17A1, IVS3AS, 4-BP DEL</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="NonHGVS">IVS3AS, 4-BP DEL</Attribute>
        </AttributeSet>
        <MeasureRelationship Type="variant in gene">
          <Symbol>
            <ElementValue Type="Preferred">CYP17A1</ElementValue>
          </Symbol>
        </MeasureRelationship>
        <XRef DB="OMIM" ID="609300.0035" Type="Allelic variant"/>
      </Measure>
    </MeasureSet>
    <TraitSet Type="Disease">
      <Trait Type="Disease">
        <Name>
          <ElementValue Type="Preferred">17-@ALPHA-HYDROXYLASE/17,20-LYASE DEFICIENCY, COMBINED COMPLETE</ElementValue>
        </Name>
      </Trait>
    </TraitSet>
  </ClinVarAssertion>
</ClinVarSet>

<ClinVarSet ID="18625778">
  <RecordStatus>current</RecordStatus>
  <Title>SLC6A19, IVS7, G-A, -4 AND Iminoglycinuria, digenic</Title>
  <ReferenceClinVarAssertion DateCreated="2012-08-13" DateLastUpdated="2017-04-07" ID="59601">
    <ClinVarAccession Acc="RCV000002098" Version="2" Type="RCV" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2008-12-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData ID="17806156">
        <Attribute Type="Description">In 5 families with iminoglycinuria (IG; 242600) or hyperglycinuria (HG; 138500) and 2 with HG only, Broer et al. (2008) screened 5 known imino acid and glycine transporter candidates and identified homozygosity or heterozygosity for a known polymorphism in the SLC6A19 gene in 5 of the families: a G-to-A transition within the splice acceptor site (-4G-A) in intron 7 of the SLC6A19 gene that was predicted to affect splicing and branch site selection. One affected individual with IG who was homozygous for a partially inactivating mutation in the SLC36A2 gene (G87V; 608331.0001) but did not carry mutations in the SLC6A20 (605616) or SLC6A18 (610300) genes was found to be homozygous for this SLC6A19 polymorphism. In addition, 2 unaffected individuals were homozygous for the SLC6A19 polymorphism; 1 was also heterozygous for G87V in SLC36A12, whereas the other had no other variants detected in the genes that were screened. Noting that most of these affected individuals also carried mono- or biallelic variants of the putative glycine transporter gene SLC6A18 (610300), Broer et al. (2008) suggested that these variants might also contribute to the phenotype.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">19033659</ID>
        </Citation>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant" ID="2021">
      <Measure Type="single nucleotide variant" ID="17060">
        <Name>
          <ElementValue Type="Preferred">SLC6A19, IVS7, G-A, -4</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="nucleotide change">IVS7, G-A, -4</Attribute>
          <XRef Type="Allelic variant" ID="608893.0005" DB="OMIM"/>
        </AttributeSet>
        <CytogeneticLocation>5p15.33</CytogeneticLocation>
        <MeasureRelationship Type="asserted, but not computed">
          <Name>
            <ElementValue Type="Preferred">solute carrier family 6 member 19</ElementValue>
          </Name>
          <Symbol>
            <ElementValue Type="Preferred">SLC6A19</ElementValue>
          </Symbol>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="5" Accession="NC_000005.10" start="1201595" stop="1225117" display_start="1201595" display_stop="1225117" Strand="+"/>
          <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="5" Accession="NC_000005.9" start="1201709" stop="1225231" display_start="1201709" display_stop="1225231" variantLength="23523" Strand="+"/>
          <XRef ID="340024" DB="Gene"/>
          <XRef Type="MIM" ID="608893" DB="OMIM"/>
          <XRef ID="HGNC:27960" DB="HGNC"/>
        </MeasureRelationship>
        <XRef Type="Allelic variant" ID="608893.0005" DB="OMIM"/>
      </Measure>
      <Name>
        <ElementValue Type="Preferred">SLC6A19, IVS7, G-A, -4</ElementValue>
      </Name>
    </MeasureSet>
    <TraitSet Type="Disease" ID="511">
      <Trait ID="9755" Type="Disease">
        <Name>
          <ElementValue Type="Preferred">Iminoglycinuria, digenic</ElementValue>
        </Name>
        <XRef ID="C3148959" DB="MedGen"/>
      </Trait>
    </TraitSet>
  </ReferenceClinVarAssertion>
  <ClinVarAssertion ID="22256">
    <ClinVarSubmissionID localKey="608893.0005_IMINOGLYCINURIA, DIGENIC" submitter="OMIM" submitterDate="2012-05-15" title="SLC6A19, IVS7, G-A, -4 _IMINOGLYCINURIA, DIGENIC"/>
    <ClinVarAccession Acc="SCV000022256" OrgType="primary" OrganizationCategory="resource" Version="1" Type="SCV" OrgID="3" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2008-12-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ExternalID DB="OMIM" ID="608893.0005" Type="Allelic variant"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species>human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="Description">In 5 families with iminoglycinuria (IG; 242600) or hyperglycinuria (HG; 138500) and 2 with HG only, Broer et al. (2008) screened 5 known imino acid and glycine transporter candidates and identified homozygosity or heterozygosity for a known polymorphism in the SLC6A19 gene in 5 of the families: a G-to-A transition within the splice acceptor site (-4G-A) in intron 7 of the SLC6A19 gene that was predicted to affect splicing and branch site selection. One affected individual with IG who was homozygous for a partially inactivating mutation in the SLC36A2 gene (G87V; 608331.0001) but did not carry mutations in the SLC6A20 (605616) or SLC6A18 (610300) genes was found to be homozygous for this SLC6A19 polymorphism. In addition, 2 unaffected individuals were homozygous for the SLC6A19 polymorphism; 1 was also heterozygous for G87V in SLC36A12, whereas the other had no other variants detected in the genes that were screened. Noting that most of these affected individuals also carried mono- or biallelic variants of the putative glycine transporter gene SLC6A18 (610300), Broer et al. (2008) suggested that these variants might also contribute to the phenotype.</Attribute>
        <Citation>
          <ID Source="PubMed">19033659</ID>
        </Citation>
        <XRef DB="OMIM" ID="242600" Type="MIM"/>
        <XRef DB="OMIM" ID="138500" Type="MIM"/>
        <XRef DB="OMIM" ID="605616" Type="MIM"/>
        <XRef DB="OMIM" ID="610300" Type="MIM"/>
        <XRef DB="OMIM" ID="610300" Type="MIM"/>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant">
      <Measure Type="Variation">
        <Name>
          <ElementValue Type="Preferred">SLC6A19, IVS7, G-A, -4</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="NonHGVS">IVS7, G-A, -4</Attribute>
        </AttributeSet>
        <MeasureRelationship Type="variant in gene">
          <Symbol>
            <ElementValue Type="Preferred">SLC6A19</ElementValue>
          </Symbol>
        </MeasureRelationship>
        <XRef DB="OMIM" ID="608893.0005" Type="Allelic variant"/>
      </Measure>
    </MeasureSet>
    <TraitSet Type="Disease">
      <Trait Type="Disease">
        <Name>
          <ElementValue Type="Preferred">IMINOGLYCINURIA, DIGENIC</ElementValue>
        </Name>
      </Trait>
    </TraitSet>
  </ClinVarAssertion>
</ClinVarSet>

<ClinVarSet ID="18625946">
  <RecordStatus>current</RecordStatus>
  <Title>STRADA, 7-KB DEL AND Polyhydramnios, megalencephaly, and symptomatic epilepsy</Title>
  <ReferenceClinVarAssertion DateCreated="2012-08-13" DateLastUpdated="2017-04-07" ID="59773">
    <ClinVarAccession Acc="RCV000002270" Version="3" Type="RCV" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2010-05-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData ID="17806531">
        <Attribute Type="Description">In all patients studied with PMSE syndrome (611087), Puffenberger et al. (2007) found homozygosity for a 7,304-bp deletion in the LYK5 gene that encompassed the terminal 5 exons (9 through 13). The patients were distantly related Old Order Mennonite children.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">17522105</ID>
        </Citation>
      </ObservedData>
      <ObservedData ID="17806531">
        <Attribute Type="Description">In a PMSE postmortem brain specimen, Orlova et al. (2010) found no STRAD-alpha immunoreactivity. Unlike LKB1 in control brain, LKB1 was exclusively nuclear in PMSE cortical neurons and there was evidence of mTORC1 hyperactivation as exhibited by enlarged cells with hyperphosphorylation of S6 in basal ganglia, thalamus, and pons. Lymphoblastoid cell lines derived from PMSE patient peripheral blood also showed mTORC1 hyperactivation. Orlova et al. (2010) concluded that aberrant nuclear accumulation of LKB1 caused by STRAD-alpha deficiency contributes to hyperactivation of mTORC1 signaling and neurological features associated with PMSE.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">20424326</ID>
        </Citation>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant" ID="2186">
      <Measure Type="Deletion" ID="17225">
        <Name>
          <ElementValue Type="Preferred">STRADA, 7-KB DEL</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="nucleotide change">7-KB DEL</Attribute>
          <XRef Type="Allelic variant" ID="608626.0001" DB="OMIM"/>
        </AttributeSet>
        <CytogeneticLocation>17q23.3</CytogeneticLocation>
        <MeasureRelationship Type="asserted, but not computed">
          <Name>
            <ElementValue Type="Preferred">STE20-related kinase adaptor alpha</ElementValue>
          </Name>
          <Symbol>
            <ElementValue Type="Preferred">STRADA</ElementValue>
          </Symbol>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="17" Accession="NC_000017.11" start="63702832" stop="63741970" display_start="63702832" display_stop="63741970" Strand="-"/>
          <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="17" Accession="NC_000017.10" start="61780191" stop="61819329" display_start="61780191" display_stop="61819329" variantLength="39139" Strand="-"/>
          <XRef ID="92335" DB="Gene"/>
          <XRef Type="MIM" ID="608626" DB="OMIM"/>
          <XRef ID="HGNC:30172" DB="HGNC"/>
        </MeasureRelationship>
        <XRef Type="Allelic variant" ID="608626.0001" DB="OMIM"/>
      </Measure>
      <Name>
        <ElementValue Type="Preferred">STRADA, 7-KB DEL</ElementValue>
      </Name>
    </MeasureSet>
    <TraitSet Type="Disease" ID="558">
      <Trait ID="3512" Type="Disease">
        <Name>
          <ElementValue Type="Preferred">Polyhydramnios, megalencephaly, and symptomatic epilepsy</ElementValue>
          <XRef ID="Polyhydramnios%2C+megalencephaly%2C+and+symptomatic+epilepsy/9127" DB="Genetic Alliance"/>
        </Name>
        <Name>
          <ElementValue Type="Alternate">PMSE SYNDROME</ElementValue>
          <XRef Type="MIM" ID="611087" DB="OMIM"/>
        </Name>
        <Symbol>
          <ElementValue Type="Preferred">PMSE</ElementValue>
          <XRef Type="MIM" ID="611087" DB="OMIM"/>
        </Symbol>
        <XRef ID="C1970203" DB="MedGen"/>
        <XRef Type="MIM" ID="611087" DB="OMIM"/>
      </Trait>
    </TraitSet>
  </ReferenceClinVarAssertion>
  <ClinVarAssertion ID="22428">
    <ClinVarSubmissionID localKey="608626.0001_POLYHYDRAMNIOS, MEGALENCEPHALY, AND SYMPTOMATIC EPILEPSY" submitter="OMIM" submitterDate="2016-09-15" title="STRADA, 7-KB DEL_POLYHYDRAMNIOS, MEGALENCEPHALY, AND SYMPTOMATIC EPILEPSY"/>
    <ClinVarAccession Acc="SCV000022428" OrgType="primary" OrganizationCategory="resource" Version="2" Type="SCV" OrgID="3" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2010-05-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ExternalID DB="OMIM" ID="608626.0001" Type="Allelic variant"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species>human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="Description">In all patients studied with PMSE syndrome (611087), Puffenberger et al. (2007) found homozygosity for a 7,304-bp deletion in the LYK5 gene that encompassed the terminal 5 exons (9 through 13). The patients were distantly related Old Order Mennonite children.</Attribute>
        <Citation>
          <ID Source="PubMed">17522105</ID>
        </Citation>
        <XRef DB="OMIM" ID="611087" Type="MIM"/>
      </ObservedData>
      <ObservedData>
        <Attribute Type="Description">In a PMSE postmortem brain specimen, Orlova et al. (2010) found no STRAD-alpha immunoreactivity. Unlike LKB1 in control brain, LKB1 was exclusively nuclear in PMSE cortical neurons and there was evidence of mTORC1 hyperactivation as exhibited by enlarged cells with hyperphosphorylation of S6 in basal ganglia, thalamus, and pons. Lymphoblastoid cell lines derived from PMSE patient peripheral blood also showed mTORC1 hyperactivation. Orlova et al. (2010) concluded that aberrant nuclear accumulation of LKB1 caused by STRAD-alpha deficiency contributes to hyperactivation of mTORC1 signaling and neurological features associated with PMSE.</Attribute>
        <Citation>
          <ID Source="PubMed">20424326</ID>
        </Citation>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant">
      <Measure Type="Variation">
        <Name>
          <ElementValue Type="Preferred">STRADA, 7-KB DEL</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="NonHGVS">7-KB DEL</Attribute>
        </AttributeSet>
        <MeasureRelationship Type="variant in gene">
          <Symbol>
            <ElementValue Type="Preferred">STRADA</ElementValue>
          </Symbol>
        </MeasureRelationship>
        <XRef DB="OMIM" ID="608626.0001" Type="Allelic variant"/>
      </Measure>
    </MeasureSet>
    <TraitSet Type="Disease">
      <Trait Type="Disease">
        <Name>
          <ElementValue Type="Preferred">POLYHYDRAMNIOS, MEGALENCEPHALY, AND SYMPTOMATIC EPILEPSY</ElementValue>
        </Name>
      </Trait>
    </TraitSet>
  </ClinVarAssertion>
</ClinVarSet>

<ClinVarSet ID="18626079">
  <RecordStatus>current</RecordStatus>
  <Title>PYGM, IVS5AS, G-A, -601 AND McArdle disease, mild</Title>
  <ReferenceClinVarAssertion DateCreated="2012-08-13" DateLastUpdated="2017-04-07" ID="59908">
    <ClinVarAccession Acc="RCV000002405" Version="4" Type="RCV" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2009-06-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData ID="17805993">
        <Attribute Type="Description">In a 30-year-old Swedish woman with a mild form of McArdle disease (GSD5; 232600), Vissing et al. (2009) identified compound heterozygosity for 2 mutations in the PYGM gene: R50X (608455.0001) and a G-to-A transition in intron 5, resulting in a splice site mutation and production of an abnormally spliced fragment in which 175 bp from intron 5 were spliced between exons 5 and 6. There were trace amounts of the aberrantly spliced product, and biochemical studies showed residual PYGM activity (1.0 to 2.5% of normal), suggesting that the splice site mutation was 'leaky' and allowed some normally spliced product to be generated. Although the patient had muscle cramps, pain, and episodes of rhabdomyolysis and myoglobinuria after exercise, she had a high capacity for sustained exercise. Exercise testing showed a phenotype that was intermediate between controls and individuals with typical McArdle disease. The patient could complete 60 minutes of ischemic exercise before muscle cramping occurred, and peak oxidative capacity was about 2-fold higher compared to patients with typical McArdle disease. The findings indicated that very low levels of PYGM are sufficient to sustain glycogenolysis and muscle oxidative metabolism.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">19433441</ID>
        </Citation>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant" ID="2315">
      <Measure Type="single nucleotide variant" ID="17354">
        <Name>
          <ElementValue Type="Preferred">PYGM, IVS5AS, G-A, -601</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="nucleotide change">IVS5AS, G-A, -601</Attribute>
          <XRef Type="Allelic variant" ID="608455.0018" DB="OMIM"/>
        </AttributeSet>
        <CytogeneticLocation>11q13</CytogeneticLocation>
        <MeasureRelationship Type="asserted, but not computed">
          <Name>
            <ElementValue Type="Preferred">glycogen phosphorylase, muscle associated</ElementValue>
          </Name>
          <Symbol>
            <ElementValue Type="Preferred">PYGM</ElementValue>
          </Symbol>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="11" Accession="NC_000011.10" start="64746389" stop="64760715" display_start="64746389" display_stop="64760715" Strand="-"/>
          <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="11" Accession="NC_000011.9" start="64513860" stop="64528186" display_start="64513860" display_stop="64528186" variantLength="14327" Strand="-"/>
          <XRef ID="5837" DB="Gene"/>
          <XRef Type="MIM" ID="608455" DB="OMIM"/>
          <XRef ID="HGNC:9726" DB="HGNC"/>
        </MeasureRelationship>
        <XRef Type="Allelic variant" ID="608455.0018" DB="OMIM"/>
      </Measure>
      <Name>
        <ElementValue Type="Preferred">PYGM, IVS5AS, G-A, -601</ElementValue>
      </Name>
    </MeasureSet>
    <TraitSet Type="Disease" ID="586">
      <Trait ID="9774" Type="Disease">
        <Name>
          <ElementValue Type="Preferred">McArdle disease, mild</ElementValue>
        </Name>
        <XRef ID="C4017156" DB="MedGen"/>
      </Trait>
    </TraitSet>
  </ReferenceClinVarAssertion>
  <ClinVarAssertion ID="22563">
    <ClinVarSubmissionID localKey="608455.0018_MCARDLE DISEASE, MILD" submitter="OMIM" submitterDate="2016-12-13" title="PYGM, IVS5AS, G-A, -601_MCARDLE DISEASE, MILD"/>
    <ClinVarAccession Acc="SCV000022563" OrgType="primary" OrganizationCategory="resource" Version="3" Type="SCV" OrgID="3" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2009-06-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ExternalID DB="OMIM" ID="608455.0018" Type="Allelic variant"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species>human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="Description">In a 30-year-old Swedish woman with a mild form of McArdle disease (GSD5; 232600), Vissing et al. (2009) identified compound heterozygosity for 2 mutations in the PYGM gene: R50X (608455.0001) and a G-to-A transition in intron 5, resulting in a splice site mutation and production of an abnormally spliced fragment in which 175 bp from intron 5 were spliced between exons 5 and 6. There were trace amounts of the aberrantly spliced product, and biochemical studies showed residual PYGM activity (1.0 to 2.5% of normal), suggesting that the splice site mutation was 'leaky' and allowed some normally spliced product to be generated. Although the patient had muscle cramps, pain, and episodes of rhabdomyolysis and myoglobinuria after exercise, she had a high capacity for sustained exercise. Exercise testing showed a phenotype that was intermediate between controls and individuals with typical McArdle disease. The patient could complete 60 minutes of ischemic exercise before muscle cramping occurred, and peak oxidative capacity was about 2-fold higher compared to patients with typical McArdle disease. The findings indicated that very low levels of PYGM are sufficient to sustain glycogenolysis and muscle oxidative metabolism.</Attribute>
        <Citation>
          <ID Source="PubMed">19433441</ID>
        </Citation>
        <XRef DB="OMIM" ID="232600" Type="MIM"/>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant">
      <Measure Type="Variation">
        <Name>
          <ElementValue Type="Preferred">PYGM, IVS5AS, G-A, -601</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="NonHGVS">IVS5AS, G-A, -601</Attribute>
        </AttributeSet>
        <MeasureRelationship Type="variant in gene">
          <Symbol>
            <ElementValue Type="Preferred">PYGM</ElementValue>
          </Symbol>
        </MeasureRelationship>
        <XRef DB="OMIM" ID="608455.0018" Type="Allelic variant"/>
      </Measure>
    </MeasureSet>
    <TraitSet Type="Disease">
      <Trait Type="Disease">
        <Name>
          <ElementValue Type="Preferred">MCARDLE DISEASE, MILD</ElementValue>
        </Name>
      </Trait>
    </TraitSet>
  </ClinVarAssertion>
</ClinVarSet>

<ClinVarSet ID="18626353">
  <RecordStatus>current</RecordStatus>
  <Title>APOC2, 1-BP INS AND APOLIPOPROTEIN C-II (ST. MICHAEL)</Title>
  <ReferenceClinVarAssertion DateCreated="2012-08-13" DateLastUpdated="2017-04-07" ID="60188">
    <ClinVarAccession Acc="RCV000002685" Version="2" Type="RCV" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="1987-12-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData ID="17806976">
        <Attribute Type="Description">Connelly et al. (1987) described a new variant of apoC-II, apoC-II(St. Michael), in a brother and sister with hyperlipoproteinemia type IB (207750) born of white, Anglo-Saxon parents who were first cousins once removed. The sister, aged 60, had a 10-year history of lipemia. While on oral contraceptives, she had 2 attacks of epigastric pain with markedly elevated serum amylase activity that was diagnosed as pancreatitis. A brother, aged 61, had lipemia, recurrent acute pancreatitis, and diabetes mellitus. ApoC-II in these sibs differed from the normal at residue 70, where glutamine was replaced by proline and the sequence terminated with proline as amino acid residue 96. These findings were consistent with a base insertion in the apoC-II gene and a subsequent translation reading frameshift. Both patients had significant ischemic vascular disease, a finding different from that in other homozygotes for apoC-II deficiency. Both were homozygous for apoE*4.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">3680515</ID>
        </Citation>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant" ID="2575">
      <Measure Type="Insertion" ID="17614">
        <Name>
          <ElementValue Type="Preferred">APOC2, 1-BP INS</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="nucleotide change">1-BP INS</Attribute>
          <XRef Type="Allelic variant" ID="608083.0003" DB="OMIM"/>
        </AttributeSet>
        <CytogeneticLocation>19q13.2</CytogeneticLocation>
        <MeasureRelationship Type="asserted, but not computed">
          <Name>
            <ElementValue Type="Preferred">apolipoprotein C2</ElementValue>
          </Name>
          <Symbol>
            <ElementValue Type="Preferred">APOC2</ElementValue>
          </Symbol>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="19" Accession="NC_000019.10" start="44945982" stop="44949565" display_start="44945982" display_stop="44949565" Strand="+"/>
          <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="19" Accession="NC_000019.9" start="45449238" stop="45452821" display_start="45449238" display_stop="45452821" variantLength="3584" Strand="+"/>
          <XRef ID="344" DB="Gene"/>
          <XRef Type="MIM" ID="608083" DB="OMIM"/>
          <XRef ID="HGNC:609" DB="HGNC"/>
        </MeasureRelationship>
        <XRef Type="Allelic variant" ID="608083.0003" DB="OMIM"/>
      </Measure>
      <Name>
        <ElementValue Type="Preferred">APOC2, 1-BP INS</ElementValue>
      </Name>
    </MeasureSet>
    <TraitSet Type="Disease" ID="655">
      <Trait ID="9790" Type="Disease">
        <Name>
          <ElementValue Type="Preferred">APOLIPOPROTEIN C-II (ST. MICHAEL)</ElementValue>
          <XRef Type="Allelic variant" ID="608083.0003" DB="OMIM"/>
        </Name>
      </Trait>
    </TraitSet>
  </ReferenceClinVarAssertion>
  <ClinVarAssertion ID="22843">
    <ClinVarSubmissionID localKey="608083.0003_APOLIPOPROTEIN C-II (ST. MICHAEL)" submitter="OMIM" submitterDate="2008-07-08" title="APOC2, 1-BP INS_APOLIPOPROTEIN C-II (ST. MICHAEL)"/>
    <ClinVarAccession Acc="SCV000022843" OrgType="primary" OrganizationCategory="resource" Version="1" Type="SCV" OrgID="3" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="1987-12-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ExternalID DB="OMIM" ID="608083.0003" Type="Allelic variant"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species>human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="Description">Connelly et al. (1987) described a new variant of apoC-II, apoC-II(St. Michael), in a brother and sister with hyperlipoproteinemia type IB (207750) born of white, Anglo-Saxon parents who were first cousins once removed. The sister, aged 60, had a 10-year history of lipemia. While on oral contraceptives, she had 2 attacks of epigastric pain with markedly elevated serum amylase activity that was diagnosed as pancreatitis. A brother, aged 61, had lipemia, recurrent acute pancreatitis, and diabetes mellitus. ApoC-II in these sibs differed from the normal at residue 70, where glutamine was replaced by proline and the sequence terminated with proline as amino acid residue 96. These findings were consistent with a base insertion in the apoC-II gene and a subsequent translation reading frameshift. Both patients had significant ischemic vascular disease, a finding different from that in other homozygotes for apoC-II deficiency. Both were homozygous for apoE*4.</Attribute>
        <Citation>
          <ID Source="PubMed">3680515</ID>
        </Citation>
        <XRef DB="OMIM" ID="207750" Type="MIM"/>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant">
      <Measure Type="Variation">
        <Name>
          <ElementValue Type="Preferred">APOC2, 1-BP INS</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="NonHGVS">1-BP INS</Attribute>
        </AttributeSet>
        <MeasureRelationship Type="variant in gene">
          <Symbol>
            <ElementValue Type="Preferred">APOC2</ElementValue>
          </Symbol>
        </MeasureRelationship>
        <XRef DB="OMIM" ID="608083.0003" Type="Allelic variant"/>
      </Measure>
    </MeasureSet>
    <TraitSet Type="Disease">
      <Trait Type="Disease">
        <Name>
          <ElementValue Type="Preferred">APOLIPOPROTEIN C-II (ST. MICHAEL)</ElementValue>
        </Name>
      </Trait>
    </TraitSet>
  </ClinVarAssertion>
</ClinVarSet>

<ClinVarSet ID="18626548">
  <RecordStatus>current</RecordStatus>
  <Title>LEMD3, IVS1DS, G-A, +1 AND Dermatofibrosis lenticularis disseminata, isolated</Title>
  <ReferenceClinVarAssertion DateCreated="2012-08-13" DateLastUpdated="2017-04-07" ID="60390">
    <ClinVarAccession Acc="RCV000002887" Version="2" Type="RCV" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2007-02-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData ID="17807032">
        <Attribute Type="Description">In 2 first cousins of Jewish origin, ages 6 and 7 years, respectively, with asymptomatic flesh-colored cutaneous collagenous nodules localized mainly over the extremities and lower trunk (see 166700), Hershkovitz et al. (2007) identified a heterozygous G-to-A transition in intron 1 (1522+1G-A) of the LEMD3 gene, predicted to result in premature termination and haploinsufficiency due to nonsense-mediated mRNA decay. Neither child had any other manifestations, including bone lesions. The authors referred to this disorder as 'familial cutaneous collagenoma' (115250), but noted the phenotypic overlap with Buschke-Ollendorff syndrome (166700). The mutation was also found in the unaffected father of 1 of the children, but not in 100 controls. Hershkovitz et al. (2007) suggested that the findings indicated that abnormal function of LEMD3 may be causally associated with familial collagenomas, and that this family had a variant of BOS without bony abnormalities.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">17223882</ID>
        </Citation>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant" ID="2760">
      <Measure Type="single nucleotide variant" ID="17799">
        <Name>
          <ElementValue Type="Preferred">LEMD3, IVS1DS, G-A, +1</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="nucleotide change">IVS1DS, G-A, +1</Attribute>
          <XRef Type="Allelic variant" ID="607844.0009" DB="OMIM"/>
        </AttributeSet>
        <CytogeneticLocation>12q14</CytogeneticLocation>
        <MeasureRelationship Type="asserted, but not computed">
          <Name>
            <ElementValue Type="Preferred">LEM domain containing 3</ElementValue>
          </Name>
          <Symbol>
            <ElementValue Type="Preferred">LEMD3</ElementValue>
          </Symbol>
          <AttributeSet>
            <Attribute dateValue="2012-03-22" Type="Haploinsufficiency">Sufficient evidence for dosage pathogenicity</Attribute>
            <Citation>
              <URL>https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=LEMD3</URL>
            </Citation>
          </AttributeSet>
          <AttributeSet>
            <Attribute dateValue="2012-03-22" Type="Triplosensitivity">No evidence available</Attribute>
            <Citation>
              <URL>https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=LEMD3</URL>
            </Citation>
          </AttributeSet>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="12" Accession="NC_000012.12" start="65169571" stop="65248361" display_start="65169571" display_stop="65248361" Strand="+"/>
          <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="12" Accession="NC_000012.11" start="65563350" stop="65642140" display_start="65563350" display_stop="65642140" variantLength="78791" Strand="+"/>
          <XRef ID="23592" DB="Gene"/>
          <XRef Type="MIM" ID="607844" DB="OMIM"/>
          <XRef ID="HGNC:28887" DB="HGNC"/>
        </MeasureRelationship>
        <XRef Type="Allelic variant" ID="607844.0009" DB="OMIM"/>
      </Measure>
      <Name>
        <ElementValue Type="Preferred">LEMD3, IVS1DS, G-A, +1</ElementValue>
      </Name>
    </MeasureSet>
    <TraitSet Type="Disease" ID="708">
      <Trait ID="8753" Type="Disease">
        <Name>
          <ElementValue Type="Preferred">Dermatofibrosis lenticularis disseminata, isolated</ElementValue>
        </Name>
        <XRef ID="C3149399" DB="MedGen"/>
      </Trait>
    </TraitSet>
  </ReferenceClinVarAssertion>
  <ClinVarAssertion ID="23045">
    <ClinVarSubmissionID localKey="607844.0009_DERMATOFIBROSIS LENTICULARIS DISSEMINATA, ISOLATED" submitter="OMIM" submitterDate="2013-02-05" title="LEMD3, IVS1DS, G-A, +1 _DERMATOFIBROSIS LENTICULARIS DISSEMINATA, ISOLATED"/>
    <ClinVarAccession Acc="SCV000023045" OrgType="primary" OrganizationCategory="resource" Version="1" Type="SCV" OrgID="3" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2007-02-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ExternalID DB="OMIM" ID="607844.0009" Type="Allelic variant"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species>human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="Description">In 2 first cousins of Jewish origin, ages 6 and 7 years, respectively, with asymptomatic flesh-colored cutaneous collagenous nodules localized mainly over the extremities and lower trunk (see 166700), Hershkovitz et al. (2007) identified a heterozygous G-to-A transition in intron 1 (1522+1G-A) of the LEMD3 gene, predicted to result in premature termination and haploinsufficiency due to nonsense-mediated mRNA decay. Neither child had any other manifestations, including bone lesions. The authors referred to this disorder as 'familial cutaneous collagenoma' (115250), but noted the phenotypic overlap with Buschke-Ollendorff syndrome (166700). The mutation was also found in the unaffected father of 1 of the children, but not in 100 controls. Hershkovitz et al. (2007) suggested that the findings indicated that abnormal function of LEMD3 may be causally associated with familial collagenomas, and that this family had a variant of BOS without bony abnormalities.</Attribute>
        <Citation>
          <ID Source="PubMed">17223882</ID>
        </Citation>
        <XRef DB="OMIM" ID="166700" Type="MIM"/>
        <XRef DB="OMIM" ID="115250" Type="MIM"/>
        <XRef DB="OMIM" ID="166700" Type="MIM"/>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant">
      <Measure Type="Variation">
        <Name>
          <ElementValue Type="Preferred">LEMD3, IVS1DS, G-A, +1</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="NonHGVS">IVS1DS, G-A, +1</Attribute>
        </AttributeSet>
        <MeasureRelationship Type="variant in gene">
          <Symbol>
            <ElementValue Type="Preferred">LEMD3</ElementValue>
          </Symbol>
        </MeasureRelationship>
        <XRef DB="OMIM" ID="607844.0009" Type="Allelic variant"/>
      </Measure>
    </MeasureSet>
    <TraitSet Type="Disease">
      <Trait Type="Disease">
        <Name>
          <ElementValue Type="Preferred">DERMATOFIBROSIS LENTICULARIS DISSEMINATA, ISOLATED</ElementValue>
        </Name>
      </Trait>
    </TraitSet>
  </ClinVarAssertion>
</ClinVarSet>

<ClinVarSet ID="18626871">
  <RecordStatus>current</RecordStatus>
  <Title>ARSA, IVS4DS, G-A, +1 AND Metachromatic leukodystrophy, severe</Title>
  <ReferenceClinVarAssertion DateCreated="2012-08-13" DateLastUpdated="2017-04-07" ID="60725">
    <ClinVarAccession Acc="RCV000003222" Version="3" Type="RCV" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="1994-01-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData ID="17808017">
        <Attribute Type="Description">In Caucasian patients with severe metachromatic leukodystrophy (250100), Pastor-Soler et al. (1994) identified a G-to-A transition of the ARSA gene at nucleotide 848+1 (which is the first nucleotide of the donor splice site) of intron 4, resulting in abnormal splicing. This mutation causes instability of the arylsulfatase A mRNA and was found in all alleles of Navajo Indians patients with late infantile metachromatic leucodystrophy.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">7833949</ID>
        </Citation>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant" ID="3076">
      <Measure Type="single nucleotide variant" ID="18115">
        <Name>
          <ElementValue Type="Preferred">ARSA, IVS4DS, G-A, +1</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="nucleotide change">IVS4DS, G-A, +1</Attribute>
          <XRef Type="Allelic variant" ID="607574.0028" DB="OMIM"/>
        </AttributeSet>
        <CytogeneticLocation>22q13.31-qter</CytogeneticLocation>
        <MeasureRelationship Type="asserted, but not computed">
          <Name>
            <ElementValue Type="Preferred">arylsulfatase A</ElementValue>
          </Name>
          <Symbol>
            <ElementValue Type="Preferred">ARSA</ElementValue>
          </Symbol>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="22" Accession="NC_000022.11" start="50622754" stop="50628173" display_start="50622754" display_stop="50628173" Strand="-"/>
          <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="22" Accession="NC_000022.10" start="51061181" stop="51066600" display_start="51061181" display_stop="51066600" variantLength="5420" Strand="-"/>
          <XRef ID="410" DB="Gene"/>
          <XRef Type="MIM" ID="607574" DB="OMIM"/>
          <XRef ID="HGNC:713" DB="HGNC"/>
        </MeasureRelationship>
        <XRef Type="Allelic variant" ID="607574.0028" DB="OMIM"/>
      </Measure>
      <Name>
        <ElementValue Type="Preferred">ARSA, IVS4DS, G-A, +1</ElementValue>
      </Name>
    </MeasureSet>
    <TraitSet Type="Disease" ID="786">
      <Trait ID="9846" Type="Disease">
        <Name>
          <ElementValue Type="Preferred">Metachromatic leukodystrophy, severe</ElementValue>
        </Name>
        <XRef ID="C4017094" DB="MedGen"/>
      </Trait>
    </TraitSet>
  </ReferenceClinVarAssertion>
  <ClinVarAssertion ID="23380">
    <ClinVarSubmissionID localKey="607574.0028_METACHROMATIC LEUKODYSTROPHY, SEVERE" submitter="OMIM" submitterDate="2016-10-11" title="ARSA, IVS4DS, G-A, +1_METACHROMATIC LEUKODYSTROPHY, SEVERE"/>
    <ClinVarAccession Acc="SCV000023380" OrgType="primary" OrganizationCategory="resource" Version="2" Type="SCV" OrgID="3" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="1994-01-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ExternalID DB="OMIM" ID="607574.0028" Type="Allelic variant"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species>human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="Description">In Caucasian patients with severe metachromatic leukodystrophy (250100), Pastor-Soler et al. (1994) identified a G-to-A transition of the ARSA gene at nucleotide 848+1 (which is the first nucleotide of the donor splice site) of intron 4, resulting in abnormal splicing. This mutation causes instability of the arylsulfatase A mRNA and was found in all alleles of Navajo Indians patients with late infantile metachromatic leucodystrophy.</Attribute>
        <Citation>
          <ID Source="PubMed">7833949</ID>
        </Citation>
        <XRef DB="OMIM" ID="250100" Type="MIM"/>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant">
      <Measure Type="Variation">
        <Name>
          <ElementValue Type="Preferred">ARSA, IVS4DS, G-A, +1</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="NonHGVS">IVS4DS, G-A, +1</Attribute>
        </AttributeSet>
        <MeasureRelationship Type="variant in gene">
          <Symbol>
            <ElementValue Type="Preferred">ARSA</ElementValue>
          </Symbol>
        </MeasureRelationship>
        <XRef DB="OMIM" ID="607574.0028" Type="Allelic variant"/>
      </Measure>
    </MeasureSet>
    <TraitSet Type="Disease">
      <Trait Type="Disease">
        <Name>
          <ElementValue Type="Preferred">METACHROMATIC LEUKODYSTROPHY, SEVERE</ElementValue>
        </Name>
      </Trait>
    </TraitSet>
  </ClinVarAssertion>
</ClinVarSet>

<ClinVarSet ID="18626993">
  <RecordStatus>current</RecordStatus>
  <Title>NM_006731.2(FKTN):c.*4392_*4393insAB185332.1 AND Congenital muscular dystrophy-dystroglycanopathy with brain and eye anomalies, type A4</Title>
  <ReferenceClinVarAssertion DateCreated="2012-08-13" DateLastUpdated="2017-04-07" ID="60854">
    <ClinVarAccession Acc="RCV000003351" Version="3" Type="RCV" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2009-11-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData ID="17807607">
        <Attribute Type="Description">Most Japanese patients with the retrotransposal insertion in the FKTN gene share a common founder haplotype. By applying 2 methods for the study of linkage disequilibrium between flanking polymorphic markers and the disease locus, and of its decay over time, Colombo et al. (2000) calculated the age of the insertion mutation to be approximately 102 generations (95% CI: 86-117 g), or slightly less. The estimated age dates the most recent common ancestor of the mutation-bearing chromosomes back to the time (or a few centuries before) the Yayoi people began migrating to Japan from the Korean peninsula. FCMD was the first human disease known to be caused primarily by an ancient retrotransposal integration.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">11153909</ID>
        </Citation>
      </ObservedData>
      <ObservedData ID="17807607">
        <Attribute Type="Description">Kato et al. (2004) stated that 9 nonfounder mutations had been identified in Japanese FCMD patients. Severe phenotype was significantly more frequent in patients who were compound heterozygotes for a point mutation and the 3-kb founder insertion in the FKTN gene than in homozygotes for the founder mutation. The authors described a PCR-based diagnostic method for rapid detection of the insertion mutation. Using this method, they screened 18 FCMD patients and found 16 homozygotes and 2 heterozygotes for the insertion. In the general Japanese population, they found that 6 of 676 persons were heterozygous carriers. Furthermore, they found 3 homozygotes for the FCMD founder mutation among 97 patients who had been said to have probable Duchenne muscular dystrophy (310200) or Becker muscular dystrophy (300376) (DMD/BMD) without any mutation in the DMD gene (300377). On the other hand, there were no FCMD homozygotes but 4 heterozygous carriers among 335 patients with DMD mutations.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">15103718</ID>
        </Citation>
      </ObservedData>
      <ObservedData ID="17807607">
        <Attribute Type="Description">By sequence analysis, Watanabe et al. (2005) characterized the insertion mutation and found that it was enclosed by target-site duplications at both ends. They noted that the sequence motif was characteristic of a class of retroposon referred to as SINE-VNTR-Alu (SVA).</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">16222679</ID>
        </Citation>
      </ObservedData>
      <ObservedData ID="17807607">
        <Attribute Type="Description">Watanabe et al. (2005) established a rapid PCR-based diagnostic method using 3 primers simultaneously in order to detect the 3,062-bp retrotransposal insertion. Fifteen founder chromosomes were detected among 2,814 Japanese individuals. Heterozygous carriers were identified in various regions throughout Japan, with a carrier frequency of approximately 1 in 188. The insertion mutation was found in 1 in 935 Korean individuals but not among 203 Mongolians and 766 mainland Chinese, suggesting that FCMD carriers are rare outside of Japan.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">16222679</ID>
        </Citation>
      </ObservedData>
      <ObservedData ID="17807607">
        <Attribute Type="Description">In 6 Japanese patients from 4 families with dilated cardiomyopathy and mild or no limb-girdle involvement (CMD1X; 611615), Murakami et al. (2006) identified compound heterozygosity in all for the 3-kb retroposon insertion and another missense mutation: Q358P (607440.0010) or R179T (607440.0011), respectively.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">17036286</ID>
        </Citation>
      </ObservedData>
      <ObservedData ID="17807607">
        <Attribute Type="Description">Xiong et al. (2009) reported a Chinese boy with FCMD who was compound heterozygous for 2 mutations in the fukutin gene: the common 3-kb retroposon insertion and R47X (607440.0002). Although the boy's parents were born in Henan and Shanxi Provinces and had no known Japanese ancestry, haplotype analysis showed that both mutant alleles were on Japanese-derived haplotypes.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">19842201</ID>
        </Citation>
      </ObservedData>
      <ObservedData ID="17807607">
        <Attribute Type="Description">Kobayashi et al. (1998) found that 87% of mutant alleles causing the autosomal recessive disorder Fukuyama congenital muscular dystrophy (MDDGA4; 253800) carried an insertion of a 3,062-bp transposon, situated in the 3-prime UTR of the FKTN gene.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">9690476</ID>
        </Citation>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant" ID="3199">
      <Measure Type="Insertion" ID="18238">
        <Name>
          <ElementValue Type="Preferred">NM_006731.2(FKTN):c.*4392_*4393insAB185332.1</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Change="c.*4392_*4393insAB185332.1" Accession="LRG_434t2" Type="HGVS, coding, LRG">LRG_434t2:c.*4392_*4393insAB185332.1</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Change="c.*4392_*4393insAB185332.1" Accession="NM_006731" Version="2" Type="HGVS, coding, RefSeq">NM_006731.2:c.*4392_*4393insAB185332.1</Attribute>
          <XRef ID="GTR000325670" DB="Genetic Testing Registry (GTR)"/>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="nucleotide change">3-KB INS, SVA RETROTRANSPOSON INS</Attribute>
          <XRef Type="Allelic variant" ID="607440.0001" DB="OMIM"/>
        </AttributeSet>
        <CytogeneticLocation>9q31</CytogeneticLocation>
        <MeasureRelationship Type="asserted, but not computed">
          <Name>
            <ElementValue Type="Preferred">fukutin</ElementValue>
          </Name>
          <Symbol>
            <ElementValue Type="Preferred">FKTN</ElementValue>
          </Symbol>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="9" Accession="NC_000009.12" start="105558117" stop="105655950" display_start="105558117" display_stop="105655950" Strand="+"/>
          <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="9" Accession="NC_000009.11" start="108320410" stop="108403398" display_start="108320410" display_stop="108403398" variantLength="82989" Strand="+"/>
          <XRef ID="2218" DB="Gene"/>
          <XRef Type="MIM" ID="607440" DB="OMIM"/>
          <XRef ID="HGNC:3622" DB="HGNC"/>
        </MeasureRelationship>
        <XRef Type="Allelic variant" ID="607440.0001" DB="OMIM"/>
        <Comment DataSource="NCBI curation" Type="public">Insertion of retrotransposal insertion sequence into 3'-UTR of FKTN.</Comment>
      </Measure>
      <Name>
        <ElementValue Type="Preferred">NM_006731.2(FKTN):c.*4392_*4393insAB185332.1</ElementValue>
      </Name>
    </MeasureSet>
    <TraitSet Type="Disease" ID="820">
      <Trait ID="9860" Type="Disease">
        <Name>
          <ElementValue Type="Preferred">Congenital muscular dystrophy-dystroglycanopathy with brain and eye anomalies, type A4</ElementValue>
        </Name>
        <Name>
          <ElementValue Type="Alternate">MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 4</ElementValue>
          <XRef Type="Allelic variant" ID="607440.0001" DB="OMIM"/>
          <XRef Type="Allelic variant" ID="607440.0002" DB="OMIM"/>
          <XRef Type="Allelic variant" ID="607440.0003" DB="OMIM"/>
          <XRef Type="Allelic variant" ID="607440.0004" DB="OMIM"/>
          <XRef Type="Allelic variant" ID="607440.0005" DB="OMIM"/>
          <XRef Type="Allelic variant" ID="607440.0006" DB="OMIM"/>
          <XRef Type="Allelic variant" ID="607440.0007" DB="OMIM"/>
          <XRef Type="Allelic variant" ID="607440.0013" DB="OMIM"/>
          <XRef Type="Allelic variant" ID="607440.0016" DB="OMIM"/>
          <XRef Type="Allelic variant" ID="607440.0017" DB="OMIM"/>
          <XRef Type="Allelic variant" ID="607440.0018" DB="OMIM"/>
        </Name>
      </Trait>
    </TraitSet>
  </ReferenceClinVarAssertion>
  <ClinVarAssertion ID="23509">
    <ClinVarSubmissionID localKey="607440.0001_MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 4" submitter="OMIM" submitterDate="2014-10-20" title="FKTN, 3-KB INS, SVA RETROTRANSPOSON INS_MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 4"/>
    <ClinVarAccession Acc="SCV000023509" OrgType="primary" OrganizationCategory="resource" Version="2" Type="SCV" OrgID="3" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2009-11-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ExternalID DB="OMIM" ID="607440.0001" Type="Allelic variant"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species>human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="Description">Kobayashi et al. (1998) found that 87% of mutant alleles causing the autosomal recessive disorder Fukuyama congenital muscular dystrophy (MDDGA4; 253800) carried an insertion of a 3,062-bp transposon, situated in the 3-prime UTR of the FKTN gene.</Attribute>
        <Citation>
          <ID Source="PubMed">9690476</ID>
        </Citation>
        <XRef DB="OMIM" ID="253800" Type="MIM"/>
      </ObservedData>
      <ObservedData>
        <Attribute Type="Description">Most Japanese patients with the retrotransposal insertion in the FKTN gene share a common founder haplotype. By applying 2 methods for the study of linkage disequilibrium between flanking polymorphic markers and the disease locus, and of its decay over time, Colombo et al. (2000) calculated the age of the insertion mutation to be approximately 102 generations (95% CI: 86-117 g), or slightly less. The estimated age dates the most recent common ancestor of the mutation-bearing chromosomes back to the time (or a few centuries before) the Yayoi people began migrating to Japan from the Korean peninsula. FCMD was the first human disease known to be caused primarily by an ancient retrotransposal integration.</Attribute>
        <Citation>
          <ID Source="PubMed">11153909</ID>
        </Citation>
      </ObservedData>
      <ObservedData>
        <Attribute Type="Description">Kato et al. (2004) stated that 9 nonfounder mutations had been identified in Japanese FCMD patients. Severe phenotype was significantly more frequent in patients who were compound heterozygotes for a point mutation and the 3-kb founder insertion in the FKTN gene than in homozygotes for the founder mutation. The authors described a PCR-based diagnostic method for rapid detection of the insertion mutation. Using this method, they screened 18 FCMD patients and found 16 homozygotes and 2 heterozygotes for the insertion. In the general Japanese population, they found that 6 of 676 persons were heterozygous carriers. Furthermore, they found 3 homozygotes for the FCMD founder mutation among 97 patients who had been said to have probable Duchenne muscular dystrophy (310200) or Becker muscular dystrophy (300376) (DMD/BMD) without any mutation in the DMD gene (300377). On the other hand, there were no FCMD homozygotes but 4 heterozygous carriers among 335 patients with DMD mutations.</Attribute>
        <Citation>
          <ID Source="PubMed">15103718</ID>
        </Citation>
        <XRef DB="OMIM" ID="310200" Type="MIM"/>
        <XRef DB="OMIM" ID="300376" Type="MIM"/>
        <XRef DB="OMIM" ID="300377" Type="MIM"/>
      </ObservedData>
      <ObservedData>
        <Attribute Type="Description">By sequence analysis, Watanabe et al. (2005) characterized the insertion mutation and found that it was enclosed by target-site duplications at both ends. They noted that the sequence motif was characteristic of a class of retroposon referred to as SINE-VNTR-Alu (SVA).</Attribute>
        <Citation>
          <ID Source="PubMed">16222679</ID>
        </Citation>
      </ObservedData>
      <ObservedData>
        <Attribute Type="Description">Watanabe et al. (2005) established a rapid PCR-based diagnostic method using 3 primers simultaneously in order to detect the 3,062-bp retrotransposal insertion. Fifteen founder chromosomes were detected among 2,814 Japanese individuals. Heterozygous carriers were identified in various regions throughout Japan, with a carrier frequency of approximately 1 in 188. The insertion mutation was found in 1 in 935 Korean individuals but not among 203 Mongolians and 766 mainland Chinese, suggesting that FCMD carriers are rare outside of Japan.</Attribute>
        <Citation>
          <ID Source="PubMed">16222679</ID>
        </Citation>
      </ObservedData>
      <ObservedData>
        <Attribute Type="Description">In 6 Japanese patients from 4 families with dilated cardiomyopathy and mild or no limb-girdle involvement (CMD1X; 611615), Murakami et al. (2006) identified compound heterozygosity in all for the 3-kb retroposon insertion and another missense mutation: Q358P (607440.0010) or R179T (607440.0011), respectively.</Attribute>
        <Citation>
          <ID Source="PubMed">17036286</ID>
        </Citation>
        <XRef DB="OMIM" ID="611615" Type="MIM"/>
      </ObservedData>
      <ObservedData>
        <Attribute Type="Description">Xiong et al. (2009) reported a Chinese boy with FCMD who was compound heterozygous for 2 mutations in the fukutin gene: the common 3-kb retroposon insertion and R47X (607440.0002). Although the boy's parents were born in Henan and Shanxi Provinces and had no known Japanese ancestry, haplotype analysis showed that both mutant alleles were on Japanese-derived haplotypes.</Attribute>
        <Citation>
          <ID Source="PubMed">19842201</ID>
        </Citation>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant">
      <Measure Type="Variation">
        <Name>
          <ElementValue Type="Preferred">FKTN, 3-KB INS, SVA RETROTRANSPOSON INS</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="NonHGVS">3-KB INS, SVA RETROTRANSPOSON INS</Attribute>
        </AttributeSet>
        <MeasureRelationship Type="variant in gene">
          <Symbol>
            <ElementValue Type="Preferred">FKTN</ElementValue>
          </Symbol>
        </MeasureRelationship>
        <XRef DB="OMIM" ID="607440.0001" Type="Allelic variant"/>
      </Measure>
    </MeasureSet>
    <TraitSet Type="Disease">
      <Trait Type="Disease">
        <Name>
          <ElementValue Type="Preferred">MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 4</ElementValue>
        </Name>
      </Trait>
    </TraitSet>
  </ClinVarAssertion>
</ClinVarSet>

<ClinVarSet ID="18636533">
  <RecordStatus>current</RecordStatus>
  <Title>UCP3, IVS6, G-A, +1 AND Morbid obesity</Title>
  <ReferenceClinVarAssertion DateCreated="2012-08-13" DateLastUpdated="2017-04-07" ID="65519">
    <ClinVarAccession Acc="RCV000008016" Version="2" Type="RCV" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="1998-10-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData ID="17813779">
        <Attribute Type="Description">In a 16-year-old female with morbid obesity (601665), Argyropoulos et al. (1998) found compound heterozygosity for a polymorphism at the exon 6 splice donor junction (Ggt-Gat) and the R143X mutation (602004.0002). The rare R143X mutation was inherited in the maternal line; the splice site polymorphism was presumably transmitted from the father. The g-to-a transition at the splice donor site of exon 6 resulted in loss of the splice junction and truncation of the protein product at the first tga stop codon of the adjacent intron.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">9769326</ID>
        </Citation>
      </ObservedData>
      <ObservedData ID="17813779">
        <Attribute Type="Description">Among unrelated individuals, Argyropoulos et al. (1998) found that heterozygotes for the exon 6 splice donor polymorphism had a 50% reduction in fat oxidation adjusted for lean body mass and a marked elevation in the nonprotein respiratory quotient, compared with wildtype subjects. No significant differences were found between heterozygotes and wildtype individuals for BMI, percentage of body fat, and resting energy expenditure adjusted for lean body mass. The same analyses performed for the V102I polymorphism (602044.0001) showed no significant differences between heterozygotes and wildtype individuals for any of the aforementioned quantitative traits. Nonetheless, the African American population studied had a high prevalence of obesity; therefore, the possibility that this could mask a potential effect of UCP3 mutations on BMI was also examined. Indeed, Argyropoulos et al. (1998) found that the frequency of the g/a heterozygous genotype was nearly twice as high (P = 0.04) in obese (30%) compared with lean (16%) individuals.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">9769326</ID>
        </Citation>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant" ID="7578">
      <Measure Type="single nucleotide variant" ID="22617">
        <Name>
          <ElementValue Type="Preferred">UCP3, IVS6, G-A, +1</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="nucleotide change">IVS6, G-A, +1</Attribute>
          <XRef Type="Allelic variant" ID="602044.0003" DB="OMIM"/>
        </AttributeSet>
        <CytogeneticLocation>11q13</CytogeneticLocation>
        <MeasureRelationship Type="asserted, but not computed">
          <Name>
            <ElementValue Type="Preferred">uncoupling protein 3</ElementValue>
          </Name>
          <Symbol>
            <ElementValue Type="Preferred">UCP3</ElementValue>
          </Symbol>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="11" Accession="NC_000011.10" start="74000281" stop="74009237" display_start="74000281" display_stop="74009237" Strand="-"/>
          <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="11" Accession="NC_000011.9" start="73711325" stop="73720281" display_start="73711325" display_stop="73720281" variantLength="8957" Strand="-"/>
          <XRef ID="7352" DB="Gene"/>
          <XRef Type="MIM" ID="602044" DB="OMIM"/>
          <XRef ID="HGNC:12519" DB="HGNC"/>
        </MeasureRelationship>
        <XRef Type="Allelic variant" ID="602044.0003" DB="OMIM"/>
      </Measure>
      <Name>
        <ElementValue Type="Preferred">UCP3, IVS6, G-A, +1</ElementValue>
      </Name>
    </MeasureSet>
    <TraitSet Type="Disease" ID="2065">
      <Trait ID="10339" Type="Disease">
        <Name>
          <ElementValue Type="Preferred">Morbid obesity</ElementValue>
          <XRef ID="238136002" DB="SNOMED CT"/>
        </Name>
        <Name>
          <ElementValue Type="Alternate">OBESITY, SEVERE</ElementValue>
          <XRef Type="Allelic variant" ID="601487.0001" DB="OMIM"/>
          <XRef Type="Allelic variant" ID="602044.0003" DB="OMIM"/>
        </Name>
        <XRef ID="C0028756" DB="MedGen"/>
      </Trait>
    </TraitSet>
  </ReferenceClinVarAssertion>
  <ClinVarAssertion ID="28221">
    <ClinVarSubmissionID localKey="602044.0003_OBESITY, SEVERE" submitter="OMIM" submitterDate="2008-09-02" title="UCP3, IVS6, G-A, +1_OBESITY, SEVERE"/>
    <ClinVarAccession Acc="SCV000028221" OrgType="primary" OrganizationCategory="resource" Version="1" Type="SCV" OrgID="3" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="1998-10-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to included disease"/>
    <ExternalID DB="OMIM" ID="602044.0003" Type="Allelic variant"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species>human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="Description">In a 16-year-old female with morbid obesity (601665), Argyropoulos et al. (1998) found compound heterozygosity for a polymorphism at the exon 6 splice donor junction (Ggt-Gat) and the R143X mutation (602004.0002). The rare R143X mutation was inherited in the maternal line; the splice site polymorphism was presumably transmitted from the father. The g-to-a transition at the splice donor site of exon 6 resulted in loss of the splice junction and truncation of the protein product at the first tga stop codon of the adjacent intron.</Attribute>
        <Citation>
          <ID Source="PubMed">9769326</ID>
        </Citation>
        <XRef DB="OMIM" ID="601665" Type="MIM"/>
      </ObservedData>
      <ObservedData>
        <Attribute Type="Description">Among unrelated individuals, Argyropoulos et al. (1998) found that heterozygotes for the exon 6 splice donor polymorphism had a 50% reduction in fat oxidation adjusted for lean body mass and a marked elevation in the nonprotein respiratory quotient, compared with wildtype subjects. No significant differences were found between heterozygotes and wildtype individuals for BMI, percentage of body fat, and resting energy expenditure adjusted for lean body mass. The same analyses performed for the V102I polymorphism (602044.0001) showed no significant differences between heterozygotes and wildtype individuals for any of the aforementioned quantitative traits. Nonetheless, the African American population studied had a high prevalence of obesity; therefore, the possibility that this could mask a potential effect of UCP3 mutations on BMI was also examined. Indeed, Argyropoulos et al. (1998) found that the frequency of the g/a heterozygous genotype was nearly twice as high (P = 0.04) in obese (30%) compared with lean (16%) individuals.</Attribute>
        <Citation>
          <ID Source="PubMed">9769326</ID>
        </Citation>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant">
      <Measure Type="Variation">
        <Name>
          <ElementValue Type="Preferred">UCP3, IVS6, G-A, +1</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="NonHGVS">IVS6, G-A, +1</Attribute>
        </AttributeSet>
        <MeasureRelationship Type="variant in gene">
          <Symbol>
            <ElementValue Type="Preferred">UCP3</ElementValue>
          </Symbol>
        </MeasureRelationship>
        <XRef DB="OMIM" ID="602044.0003" Type="Allelic variant"/>
      </Measure>
    </MeasureSet>
    <TraitSet Type="Disease">
      <Trait Type="Disease">
        <Name>
          <ElementValue Type="included">OBESITY, SEVERE</ElementValue>
        </Name>
      </Trait>
    </TraitSet>
  </ClinVarAssertion>
</ClinVarSet>

<ClinVarSet ID="18627009">
  <RecordStatus>current</RecordStatus>
  <Title>FKTN, 473-BP DEL, NT5370 AND Congenital muscular dystrophy-dystroglycanopathy with brain and eye anomalies, type A4</Title>
  <ReferenceClinVarAssertion DateCreated="2012-08-13" DateLastUpdated="2017-04-07" ID="60870">
    <ClinVarAccession Acc="RCV000003367" Version="2" Type="RCV" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2008-02-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData ID="17807884">
        <Attribute Type="Description">See 607440.0012 and Cotarelo et al. (2008).</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">18177472</ID>
        </Citation>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant" ID="3212">
      <Measure Type="Deletion" ID="18251">
        <Name>
          <ElementValue Type="Preferred">FKTN, 473-BP DEL, NT5370</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="nucleotide change">473-BP DEL, NT5370</Attribute>
          <XRef Type="Allelic variant" ID="607440.0013" DB="OMIM"/>
        </AttributeSet>
        <CytogeneticLocation>9q31</CytogeneticLocation>
        <MeasureRelationship Type="asserted, but not computed">
          <Name>
            <ElementValue Type="Preferred">fukutin</ElementValue>
          </Name>
          <Symbol>
            <ElementValue Type="Preferred">FKTN</ElementValue>
          </Symbol>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="9" Accession="NC_000009.12" start="105558117" stop="105655950" display_start="105558117" display_stop="105655950" Strand="+"/>
          <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="9" Accession="NC_000009.11" start="108320410" stop="108403398" display_start="108320410" display_stop="108403398" variantLength="82989" Strand="+"/>
          <XRef ID="2218" DB="Gene"/>
          <XRef Type="MIM" ID="607440" DB="OMIM"/>
          <XRef ID="HGNC:3622" DB="HGNC"/>
        </MeasureRelationship>
        <XRef Type="Allelic variant" ID="607440.0013" DB="OMIM"/>
      </Measure>
      <Name>
        <ElementValue Type="Preferred">FKTN, 473-BP DEL, NT5370</ElementValue>
      </Name>
    </MeasureSet>
    <TraitSet Type="Disease" ID="820">
      <Trait ID="9860" Type="Disease">
        <Name>
          <ElementValue Type="Preferred">Congenital muscular dystrophy-dystroglycanopathy with brain and eye anomalies, type A4</ElementValue>
        </Name>
        <Name>
          <ElementValue Type="Alternate">MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 4</ElementValue>
          <XRef Type="Allelic variant" ID="607440.0001" DB="OMIM"/>
          <XRef Type="Allelic variant" ID="607440.0002" DB="OMIM"/>
          <XRef Type="Allelic variant" ID="607440.0003" DB="OMIM"/>
          <XRef Type="Allelic variant" ID="607440.0004" DB="OMIM"/>
          <XRef Type="Allelic variant" ID="607440.0005" DB="OMIM"/>
          <XRef Type="Allelic variant" ID="607440.0006" DB="OMIM"/>
          <XRef Type="Allelic variant" ID="607440.0007" DB="OMIM"/>
          <XRef Type="Allelic variant" ID="607440.0013" DB="OMIM"/>
          <XRef Type="Allelic variant" ID="607440.0016" DB="OMIM"/>
          <XRef Type="Allelic variant" ID="607440.0017" DB="OMIM"/>
          <XRef Type="Allelic variant" ID="607440.0018" DB="OMIM"/>
        </Name>
      </Trait>
    </TraitSet>
  </ReferenceClinVarAssertion>
  <ClinVarAssertion ID="23525">
    <ClinVarSubmissionID localKey="607440.0013_MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 4" submitter="OMIM" submitterDate="2012-06-19" title="FKTN, 473-BP DEL, NT5370_MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 4"/>
    <ClinVarAccession Acc="SCV000023525" OrgType="primary" OrganizationCategory="resource" Version="1" Type="SCV" OrgID="3" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2008-02-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ExternalID DB="OMIM" ID="607440.0013" Type="Allelic variant"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species>human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="Description">See 607440.0012 and Cotarelo et al. (2008).</Attribute>
        <Citation>
          <ID Source="PubMed">18177472</ID>
        </Citation>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant">
      <Measure Type="Variation">
        <Name>
          <ElementValue Type="Preferred">FKTN, 473-BP DEL, NT5370</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="NonHGVS">473-BP DEL, NT5370</Attribute>
        </AttributeSet>
        <MeasureRelationship Type="variant in gene">
          <Symbol>
            <ElementValue Type="Preferred">FKTN</ElementValue>
          </Symbol>
        </MeasureRelationship>
        <XRef DB="OMIM" ID="607440.0013" Type="Allelic variant"/>
      </Measure>
    </MeasureSet>
    <TraitSet Type="Disease">
      <Trait Type="Disease">
        <Name>
          <ElementValue Type="Preferred">MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 4</ElementValue>
        </Name>
      </Trait>
    </TraitSet>
  </ClinVarAssertion>
</ClinVarSet>

<ClinVarSet ID="18627443">
  <RecordStatus>current</RecordStatus>
  <Title>MPO, -463G-A AND Lung cancer, protection against, in smokers</Title>
  <ReferenceClinVarAssertion DateCreated="2012-08-13" DateLastUpdated="2017-04-07" ID="61321">
    <ClinVarAccession Acc="RCV000003818" Version="2" Type="RCV" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2007-02-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>protective</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData ID="17808487">
        <Attribute Type="Description">Reynolds et al. (2000) identified a -463G-A promoter polymorphism within an Alu-encoded hormone response element in the MPO gene. The G allele is associated with stronger promoter activity and gene expression, whereas the A allele creates a binding site for a nuclear factor or receptor. The G/G genotype is the most common. Reynolds et al. (2000) found that the presence of the MPO -463A allele in conjunction with APOE4 (see 107741) significantly increased the risk of Alzheimer disease (104300) in men, but not in women (odds ratio for men with both alleles = 11.4 vs APOE4 alone = 3.0). Reynolds et al. (2000) also found that estrogen receptor-alpha (133430) binds to the MPO A promoter, which may explain the gender differences.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">11087769</ID>
        </Citation>
      </ObservedData>
      <ObservedData ID="17808487">
        <Attribute Type="Description">In a study of 148 patients from southern Italy with sporadic Alzheimer disease, Zappia et al. (2004) found that having the G/G genotype conferred an odds ratio of 1.65 for development of the disease. When combined with an alpha-2-macroglobulin polymorphism genotype, 1000val/val (103950.0001), the odds ratio increased to 23.19. The authors suggested that the synergistic effect of the 2 genotypes may represent a facilitation of beta-amyloid deposition or a decrease in amyloid clearance, and noted that MPO produces oxidizing conditions. The findings were independent of APOE4 status.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">15023809</ID>
        </Citation>
      </ObservedData>
      <ObservedData ID="17808487">
        <Attribute Type="Description">Taioli et al. (2007) conducted a pooled analysis of individual data from 10 studies (3,688 cases and 3,874 controls) from the Genetic Susceptibility to Environmental Carcinogens database. The odds ratio for lung cancer (211980) was 0.88 (95% CI 0.80-0.97) for the A/G genotype of myeloperoxidase -463G-A polymorphism and 0.71 (95% CI 0.57-0.88) for the A/A genotype after adjusting for smoking, age, gender, and ethnicity. The inverse association between lung cancer and myeloperoxidase -463G/A polymorphism was equally found in males and females, without differences in the association according to age in the 2 genders. The myeloperoxidase -463G/A polymorphism was significantly protective in ever smokers but not in never smokers.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">17304047</ID>
        </Citation>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant" ID="3633">
      <Measure Type="single nucleotide variant" ID="18672">
        <Name>
          <ElementValue Type="Preferred">MPO, -463G-A</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="nucleotide change">-463G-A</Attribute>
          <XRef Type="Allelic variant" ID="606989.0008" DB="OMIM"/>
        </AttributeSet>
        <CytogeneticLocation>17q23.1</CytogeneticLocation>
        <MeasureRelationship Type="asserted, but not computed">
          <Name>
            <ElementValue Type="Preferred">myeloperoxidase</ElementValue>
          </Name>
          <Symbol>
            <ElementValue Type="Preferred">MPO</ElementValue>
          </Symbol>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="17" Accession="NC_000017.11" start="58269856" stop="58280935" display_start="58269856" display_stop="58280935" Strand="-"/>
          <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="17" Accession="NC_000017.10" start="56347216" stop="56358295" display_start="56347216" display_stop="56358295" variantLength="11080" Strand="-"/>
          <XRef ID="4353" DB="Gene"/>
          <XRef Type="MIM" ID="606989" DB="OMIM"/>
          <XRef ID="HGNC:7218" DB="HGNC"/>
        </MeasureRelationship>
        <XRef Type="Allelic variant" ID="606989.0008" DB="OMIM"/>
      </Measure>
      <Name>
        <ElementValue Type="Preferred">MPO, -463G-A</ElementValue>
      </Name>
    </MeasureSet>
    <TraitSet Type="Disease" ID="955">
      <Trait ID="9927" Type="Disease">
        <Name>
          <ElementValue Type="Preferred">Lung cancer, protection against, in smokers</ElementValue>
        </Name>
        <XRef ID="C1969821" DB="MedGen"/>
      </Trait>
    </TraitSet>
  </ReferenceClinVarAssertion>
  <ClinVarAssertion ID="23983">
    <ClinVarSubmissionID localKey="606989.0008_LUNG CANCER, PROTECTION AGAINST, IN SMOKERS" submitter="OMIM" submitterDate="2010-06-15" title="MPO, -463G-A _LUNG CANCER, PROTECTION AGAINST, IN SMOKERS"/>
    <ClinVarAccession Acc="SCV000023983" OrgType="primary" OrganizationCategory="resource" Version="1" Type="SCV" OrgID="3" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2007-02-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>protective</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to included disease"/>
    <ExternalID DB="OMIM" ID="606989.0008" Type="Allelic variant"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species>human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="Description">Reynolds et al. (2000) identified a -463G-A promoter polymorphism within an Alu-encoded hormone response element in the MPO gene. The G allele is associated with stronger promoter activity and gene expression, whereas the A allele creates a binding site for a nuclear factor or receptor. The G/G genotype is the most common. Reynolds et al. (2000) found that the presence of the MPO -463A allele in conjunction with APOE4 (see 107741) significantly increased the risk of Alzheimer disease (104300) in men, but not in women (odds ratio for men with both alleles = 11.4 vs APOE4 alone = 3.0). Reynolds et al. (2000) also found that estrogen receptor-alpha (133430) binds to the MPO A promoter, which may explain the gender differences.</Attribute>
        <Citation>
          <ID Source="PubMed">11087769</ID>
        </Citation>
        <XRef DB="OMIM" ID="107741" Type="MIM"/>
        <XRef DB="OMIM" ID="104300" Type="MIM"/>
        <XRef DB="OMIM" ID="133430" Type="MIM"/>
      </ObservedData>
      <ObservedData>
        <Attribute Type="Description">In a study of 148 patients from southern Italy with sporadic Alzheimer disease, Zappia et al. (2004) found that having the G/G genotype conferred an odds ratio of 1.65 for development of the disease. When combined with an alpha-2-macroglobulin polymorphism genotype, 1000val/val (103950.0001), the odds ratio increased to 23.19. The authors suggested that the synergistic effect of the 2 genotypes may represent a facilitation of beta-amyloid deposition or a decrease in amyloid clearance, and noted that MPO produces oxidizing conditions. The findings were independent of APOE4 status.</Attribute>
        <Citation>
          <ID Source="PubMed">15023809</ID>
        </Citation>
      </ObservedData>
      <ObservedData>
        <Attribute Type="Description">Taioli et al. (2007) conducted a pooled analysis of individual data from 10 studies (3,688 cases and 3,874 controls) from the Genetic Susceptibility to Environmental Carcinogens database. The odds ratio for lung cancer (211980) was 0.88 (95% CI 0.80-0.97) for the A/G genotype of myeloperoxidase -463G-A polymorphism and 0.71 (95% CI 0.57-0.88) for the A/A genotype after adjusting for smoking, age, gender, and ethnicity. The inverse association between lung cancer and myeloperoxidase -463G/A polymorphism was equally found in males and females, without differences in the association according to age in the 2 genders. The myeloperoxidase -463G/A polymorphism was significantly protective in ever smokers but not in never smokers.</Attribute>
        <Citation>
          <ID Source="PubMed">17304047</ID>
        </Citation>
        <XRef DB="OMIM" ID="211980" Type="MIM"/>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant">
      <Measure Type="Variation">
        <Name>
          <ElementValue Type="Preferred">MPO, -463G-A</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="NonHGVS">-463G-A</Attribute>
        </AttributeSet>
        <MeasureRelationship Type="variant in gene">
          <Symbol>
            <ElementValue Type="Preferred">MPO</ElementValue>
          </Symbol>
        </MeasureRelationship>
        <XRef DB="OMIM" ID="606989.0008" Type="Allelic variant"/>
      </Measure>
    </MeasureSet>
    <TraitSet Type="Disease">
      <Trait Type="Disease">
        <Name>
          <ElementValue Type="included">LUNG CANCER, PROTECTION AGAINST, IN SMOKERS</ElementValue>
        </Name>
      </Trait>
    </TraitSet>
  </ClinVarAssertion>
</ClinVarSet>

<ClinVarSet ID="18627684">
  <RecordStatus>current</RecordStatus>
  <Title>HEXB, 18-BP INS AND Hexosaminidase B (paris)</Title>
  <ReferenceClinVarAssertion DateCreated="2012-08-13" DateLastUpdated="2017-04-07" ID="61583">
    <ClinVarAccession Acc="RCV000004080" Version="2" Type="RCV" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="1990-10-15">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData ID="17808913">
        <Attribute Type="Description">Dreyfus et al. (1977) characterized a hexosaminidase variant that may represent unstable beta subunits. Dlott et al. (1990) demonstrated that this so-called 'hexosaminidase Paris' had an abnormally elongated beta subunit due to duplication of a region straddling the junction of intron 13 and exon 14, which generated an alternate splice site and caused an in-frame insertion of 18 nucleotides into the mRNA. The normal splice site seemed to be used to some extent, accounting for the residual Hex-A isoenzyme activity.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">2170400</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">868875</ID>
        </Citation>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant" ID="3876">
      <Measure Type="Insertion" ID="18915">
        <Name>
          <ElementValue Type="Preferred">HEXB, 18-BP INS</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="nucleotide change">18-BP INS</Attribute>
          <XRef Type="Allelic variant" ID="606873.0003" DB="OMIM"/>
        </AttributeSet>
        <CytogeneticLocation>5q13</CytogeneticLocation>
        <MeasureRelationship Type="asserted, but not computed">
          <Name>
            <ElementValue Type="Preferred">hexosaminidase subunit beta</ElementValue>
          </Name>
          <Symbol>
            <ElementValue Type="Preferred">HEXB</ElementValue>
          </Symbol>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="5" Accession="NC_000005.10" start="74640023" stop="74721288" display_start="74640023" display_stop="74721288" Strand="+"/>
          <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="5" Accession="NC_000005.9" start="73980968" stop="74017112" display_start="73980968" display_stop="74017112" variantLength="36145" Strand="+"/>
          <XRef ID="3074" DB="Gene"/>
          <XRef Type="MIM" ID="606873" DB="OMIM"/>
          <XRef ID="HGNC:4879" DB="HGNC"/>
        </MeasureRelationship>
        <XRef Type="Allelic variant" ID="606873.0003" DB="OMIM"/>
      </Measure>
      <Name>
        <ElementValue Type="Preferred">HEXB, 18-BP INS</ElementValue>
      </Name>
    </MeasureSet>
    <TraitSet Type="Disease" ID="1061">
      <Trait ID="10010" Type="Disease">
        <Name>
          <ElementValue Type="Preferred">Hexosaminidase B (paris)</ElementValue>
        </Name>
        <XRef ID="C4016989" DB="MedGen"/>
      </Trait>
    </TraitSet>
  </ReferenceClinVarAssertion>
  <ClinVarAssertion ID="24246">
    <ClinVarSubmissionID localKey="606873.0003_HEXOSAMINIDASE B (PARIS)" submitter="OMIM" submitterDate="2009-11-04" title="HEXB, 18-BP INS_HEXOSAMINIDASE B (PARIS)"/>
    <ClinVarAccession Acc="SCV000024246" OrgType="primary" OrganizationCategory="resource" Version="1" Type="SCV" OrgID="3" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="1990-10-15">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ExternalID DB="OMIM" ID="606873.0003" Type="Allelic variant"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species>human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="Description">Dreyfus et al. (1977) characterized a hexosaminidase variant that may represent unstable beta subunits. Dlott et al. (1990) demonstrated that this so-called 'hexosaminidase Paris' had an abnormally elongated beta subunit due to duplication of a region straddling the junction of intron 13 and exon 14, which generated an alternate splice site and caused an in-frame insertion of 18 nucleotides into the mRNA. The normal splice site seemed to be used to some extent, accounting for the residual Hex-A isoenzyme activity.</Attribute>
        <Citation>
          <ID Source="PubMed">868875</ID>
        </Citation>
        <Citation>
          <ID Source="PubMed">2170400</ID>
        </Citation>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant">
      <Measure Type="Variation">
        <Name>
          <ElementValue Type="Preferred">HEXB, 18-BP INS</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="NonHGVS">18-BP INS</Attribute>
        </AttributeSet>
        <MeasureRelationship Type="variant in gene">
          <Symbol>
            <ElementValue Type="Preferred">HEXB</ElementValue>
          </Symbol>
        </MeasureRelationship>
        <XRef DB="OMIM" ID="606873.0003" Type="Allelic variant"/>
      </Measure>
    </MeasureSet>
    <TraitSet Type="Disease">
      <Trait Type="Disease">
        <Name>
          <ElementValue Type="Preferred">HEXOSAMINIDASE B (PARIS)</ElementValue>
        </Name>
      </Trait>
    </TraitSet>
  </ClinVarAssertion>
</ClinVarSet>

<ClinVarSet ID="18627693">
  <RecordStatus>current</RecordStatus>
  <Title>HEXB, IVS8, G-C, +5 AND Sandhoff disease, infantile</Title>
  <ReferenceClinVarAssertion DateCreated="2012-08-13" DateLastUpdated="2017-04-07" ID="61592">
    <ClinVarAccession Acc="RCV000004089" Version="2" Type="RCV" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="1999-01-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData ID="17806335">
        <Attribute Type="Description">Furihata et al. (1999) determined the molecular basis of infantile Sandhoff disease (268800) in a Greek Cypriot patient. The proband had died at the age of 3 years and his parents were not available for study; the molecular analysis was performed on the mother's first cousin who was a carrier. A G-to-C transversion was identified in 1 allele of her HEXB gene at position 5 of the 5-prime splice site of intron 8. A cDNA clone derived from lymphocyte HEXB mRNA lacked the last 4 nucleotides, GTTG, of exon 8, which created a premature termination 11 codons downstream. In vivo transcription of the mutant HEXB gene in CHO cells showed deletion of the GTTG.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">9888387</ID>
        </Citation>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant" ID="3885">
      <Measure Type="single nucleotide variant" ID="18924">
        <Name>
          <ElementValue Type="Preferred">HEXB, IVS8, G-C, +5</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="nucleotide change">IVS8, G-C, +5</Attribute>
          <XRef Type="Allelic variant" ID="606873.0015" DB="OMIM"/>
        </AttributeSet>
        <CytogeneticLocation>5q13</CytogeneticLocation>
        <MeasureRelationship Type="asserted, but not computed">
          <Name>
            <ElementValue Type="Preferred">hexosaminidase subunit beta</ElementValue>
          </Name>
          <Symbol>
            <ElementValue Type="Preferred">HEXB</ElementValue>
          </Symbol>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="5" Accession="NC_000005.10" start="74640023" stop="74721288" display_start="74640023" display_stop="74721288" Strand="+"/>
          <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="5" Accession="NC_000005.9" start="73980968" stop="74017112" display_start="73980968" display_stop="74017112" variantLength="36145" Strand="+"/>
          <XRef ID="3074" DB="Gene"/>
          <XRef Type="MIM" ID="606873" DB="OMIM"/>
          <XRef ID="HGNC:4879" DB="HGNC"/>
        </MeasureRelationship>
        <XRef Type="Allelic variant" ID="606873.0015" DB="OMIM"/>
      </Measure>
      <Name>
        <ElementValue Type="Preferred">HEXB, IVS8, G-C, +5</ElementValue>
      </Name>
    </MeasureSet>
    <TraitSet Type="Disease" ID="1066">
      <Trait ID="10013" Type="Disease">
        <Name>
          <ElementValue Type="Preferred">Sandhoff disease, infantile</ElementValue>
        </Name>
        <XRef ID="C0751490" DB="MedGen"/>
      </Trait>
    </TraitSet>
  </ReferenceClinVarAssertion>
  <ClinVarAssertion ID="24255">
    <ClinVarSubmissionID localKey="606873.0015_SANDHOFF DISEASE, INFANTILE" submitter="OMIM" submitterDate="2009-11-04" title="HEXB, IVS8, G-C, +5 _SANDHOFF DISEASE, INFANTILE"/>
    <ClinVarAccession Acc="SCV000024255" OrgType="primary" OrganizationCategory="resource" Version="1" Type="SCV" OrgID="3" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="1999-01-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ExternalID DB="OMIM" ID="606873.0015" Type="Allelic variant"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species>human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="Description">Furihata et al. (1999) determined the molecular basis of infantile Sandhoff disease (268800) in a Greek Cypriot patient. The proband had died at the age of 3 years and his parents were not available for study; the molecular analysis was performed on the mother's first cousin who was a carrier. A G-to-C transversion was identified in 1 allele of her HEXB gene at position 5 of the 5-prime splice site of intron 8. A cDNA clone derived from lymphocyte HEXB mRNA lacked the last 4 nucleotides, GTTG, of exon 8, which created a premature termination 11 codons downstream. In vivo transcription of the mutant HEXB gene in CHO cells showed deletion of the GTTG.</Attribute>
        <Citation>
          <ID Source="PubMed">9888387</ID>
        </Citation>
        <XRef DB="OMIM" ID="268800" Type="MIM"/>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant">
      <Measure Type="Variation">
        <Name>
          <ElementValue Type="Preferred">HEXB, IVS8, G-C, +5</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="NonHGVS">IVS8, G-C, +5</Attribute>
        </AttributeSet>
        <MeasureRelationship Type="variant in gene">
          <Symbol>
            <ElementValue Type="Preferred">HEXB</ElementValue>
          </Symbol>
        </MeasureRelationship>
        <XRef DB="OMIM" ID="606873.0015" Type="Allelic variant"/>
      </Measure>
    </MeasureSet>
    <TraitSet Type="Disease">
      <Trait Type="Disease">
        <Name>
          <ElementValue Type="Preferred">SANDHOFF DISEASE, INFANTILE</ElementValue>
        </Name>
      </Trait>
    </TraitSet>
  </ClinVarAssertion>
</ClinVarSet>

<ClinVarSet ID="18627694">
  <RecordStatus>current</RecordStatus>
  <Title>HEXB, 1-BP DEL, 76A AND Sandhoff disease, infantile</Title>
  <ReferenceClinVarAssertion DateCreated="2012-08-13" DateLastUpdated="2017-04-07" ID="61593">
    <ClinVarAccession Acc="RCV000004090" Version="2" Type="RCV" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2000-07-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData ID="17808549">
        <Attribute Type="Description">Hara et al. (1994) found a 1-bp deletion, 76delA, in the HEXB gene in a patient from the Maronite community in Cyprus. Drousiotou et al. (2000) measured beta-hexosaminidases A and B in both leukocytes and serum in individuals from Cyprus and identified 35 carriers of Sandhoff disease (268800) among 244 random Maronite samples and 15 among 28 Maronites with a family history of Sandhoff disease, but only 1 carrier out of 115 random samples from the Greek community. Of the 50 Maronite carriers examined, 42 were found to have deletion of 76A.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">10982028</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">8045559</ID>
        </Citation>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant" ID="3886">
      <Measure Type="Deletion" ID="18925">
        <Name>
          <ElementValue Type="Preferred">HEXB, 1-BP DEL, 76A</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="nucleotide change">1-BP DEL, 76A</Attribute>
          <XRef Type="Allelic variant" ID="606873.0016" DB="OMIM"/>
        </AttributeSet>
        <CytogeneticLocation>5q13</CytogeneticLocation>
        <MeasureRelationship Type="asserted, but not computed">
          <Name>
            <ElementValue Type="Preferred">hexosaminidase subunit beta</ElementValue>
          </Name>
          <Symbol>
            <ElementValue Type="Preferred">HEXB</ElementValue>
          </Symbol>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="5" Accession="NC_000005.10" start="74640023" stop="74721288" display_start="74640023" display_stop="74721288" Strand="+"/>
          <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="5" Accession="NC_000005.9" start="73980968" stop="74017112" display_start="73980968" display_stop="74017112" variantLength="36145" Strand="+"/>
          <XRef ID="3074" DB="Gene"/>
          <XRef Type="MIM" ID="606873" DB="OMIM"/>
          <XRef ID="HGNC:4879" DB="HGNC"/>
        </MeasureRelationship>
        <XRef Type="Allelic variant" ID="606873.0016" DB="OMIM"/>
      </Measure>
      <Name>
        <ElementValue Type="Preferred">HEXB, 1-BP DEL, 76A</ElementValue>
      </Name>
    </MeasureSet>
    <TraitSet Type="Disease" ID="1066">
      <Trait ID="10013" Type="Disease">
        <Name>
          <ElementValue Type="Preferred">Sandhoff disease, infantile</ElementValue>
        </Name>
        <XRef ID="C0751490" DB="MedGen"/>
      </Trait>
    </TraitSet>
  </ReferenceClinVarAssertion>
  <ClinVarAssertion ID="24256">
    <ClinVarSubmissionID localKey="606873.0016_SANDHOFF DISEASE, INFANTILE" submitter="OMIM" submitterDate="2009-11-04" title="HEXB, 1-BP DEL, 76A_SANDHOFF DISEASE, INFANTILE"/>
    <ClinVarAccession Acc="SCV000024256" OrgType="primary" OrganizationCategory="resource" Version="1" Type="SCV" OrgID="3" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2000-07-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ExternalID DB="OMIM" ID="606873.0016" Type="Allelic variant"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species>human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="Description">Hara et al. (1994) found a 1-bp deletion, 76delA, in the HEXB gene in a patient from the Maronite community in Cyprus. Drousiotou et al. (2000) measured beta-hexosaminidases A and B in both leukocytes and serum in individuals from Cyprus and identified 35 carriers of Sandhoff disease (268800) among 244 random Maronite samples and 15 among 28 Maronites with a family history of Sandhoff disease, but only 1 carrier out of 115 random samples from the Greek community. Of the 50 Maronite carriers examined, 42 were found to have deletion of 76A.</Attribute>
        <Citation>
          <ID Source="PubMed">8045559</ID>
        </Citation>
        <Citation>
          <ID Source="PubMed">10982028</ID>
        </Citation>
        <XRef DB="OMIM" ID="268800" Type="MIM"/>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant">
      <Measure Type="Variation">
        <Name>
          <ElementValue Type="Preferred">HEXB, 1-BP DEL, 76A</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="NonHGVS">1-BP DEL, 76A</Attribute>
        </AttributeSet>
        <MeasureRelationship Type="variant in gene">
          <Symbol>
            <ElementValue Type="Preferred">HEXB</ElementValue>
          </Symbol>
        </MeasureRelationship>
        <XRef DB="OMIM" ID="606873.0016" Type="Allelic variant"/>
      </Measure>
    </MeasureSet>
    <TraitSet Type="Disease">
      <Trait Type="Disease">
        <Name>
          <ElementValue Type="Preferred">SANDHOFF DISEASE, INFANTILE</ElementValue>
        </Name>
      </Trait>
    </TraitSet>
  </ClinVarAssertion>
</ClinVarSet>

<ClinVarSet ID="18627696">
  <RecordStatus>current</RecordStatus>
  <Title>HEXB, 1-BP DEL, 965T AND Sandhoff disease, infantile</Title>
  <ReferenceClinVarAssertion DateCreated="2012-08-13" DateLastUpdated="2017-04-07" ID="61595">
    <ClinVarAccession Acc="RCV000004092" Version="3" Type="RCV" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2009-02-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData ID="17806336">
        <Attribute Type="Description">In 2 Italian sibs with infantile Sandhoff disease (268800), Zampieri et al. (2009) identified a homozygous 1-bp deletion (965delT) in the HEXB gene, predicted to result in a frameshift and premature termination. In vitro functional expression studies showed that the deletion resulted in nonsense-mediated mRNA decay.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">18758829</ID>
        </Citation>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant" ID="3888">
      <Measure Type="Deletion" ID="18927">
        <Name>
          <ElementValue Type="Preferred">HEXB, 1-BP DEL, 965T</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="nucleotide change">1-BP DEL, 965T</Attribute>
          <XRef Type="Allelic variant" ID="606873.0018" DB="OMIM"/>
        </AttributeSet>
        <CytogeneticLocation>5q13</CytogeneticLocation>
        <MeasureRelationship Type="asserted, but not computed">
          <Name>
            <ElementValue Type="Preferred">hexosaminidase subunit beta</ElementValue>
          </Name>
          <Symbol>
            <ElementValue Type="Preferred">HEXB</ElementValue>
          </Symbol>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="5" Accession="NC_000005.10" start="74640023" stop="74721288" display_start="74640023" display_stop="74721288" Strand="+"/>
          <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="5" Accession="NC_000005.9" start="73980968" stop="74017112" display_start="73980968" display_stop="74017112" variantLength="36145" Strand="+"/>
          <XRef ID="3074" DB="Gene"/>
          <XRef Type="MIM" ID="606873" DB="OMIM"/>
          <XRef ID="HGNC:4879" DB="HGNC"/>
        </MeasureRelationship>
        <XRef Type="Allelic variant" ID="606873.0018" DB="OMIM"/>
      </Measure>
      <Name>
        <ElementValue Type="Preferred">HEXB, 1-BP DEL, 965T</ElementValue>
      </Name>
    </MeasureSet>
    <TraitSet Type="Disease" ID="1066">
      <Trait ID="10013" Type="Disease">
        <Name>
          <ElementValue Type="Preferred">Sandhoff disease, infantile</ElementValue>
        </Name>
        <XRef ID="C0751490" DB="MedGen"/>
      </Trait>
    </TraitSet>
  </ReferenceClinVarAssertion>
  <ClinVarAssertion ID="24258">
    <ClinVarSubmissionID localKey="606873.0018_SANDHOFF DISEASE, INFANTILE" submitter="OMIM" submitterDate="2013-09-19" title="HEXB, 1-BP DEL, 965T _SANDHOFF DISEASE, INFANTILE"/>
    <ClinVarAccession Acc="SCV000024258" OrgType="primary" OrganizationCategory="resource" Version="2" Type="SCV" OrgID="3" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2009-02-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ExternalID DB="OMIM" ID="606873.0018" Type="Allelic variant"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species>human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="Description">In 2 Italian sibs with infantile Sandhoff disease (268800), Zampieri et al. (2009) identified a homozygous 1-bp deletion (965delT) in the HEXB gene, predicted to result in a frameshift and premature termination. In vitro functional expression studies showed that the deletion resulted in nonsense-mediated mRNA decay.</Attribute>
        <Citation>
          <ID Source="PubMed">18758829</ID>
        </Citation>
        <XRef DB="OMIM" ID="268800" Type="MIM"/>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant">
      <Measure Type="Variation">
        <Name>
          <ElementValue Type="Preferred">HEXB, 1-BP DEL, 965T</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="NonHGVS">1-BP DEL, 965T</Attribute>
        </AttributeSet>
        <MeasureRelationship Type="variant in gene">
          <Symbol>
            <ElementValue Type="Preferred">HEXB</ElementValue>
          </Symbol>
        </MeasureRelationship>
        <XRef DB="OMIM" ID="606873.0018" Type="Allelic variant"/>
      </Measure>
    </MeasureSet>
    <TraitSet Type="Disease">
      <Trait Type="Disease">
        <Name>
          <ElementValue Type="Preferred">SANDHOFF DISEASE, INFANTILE</ElementValue>
        </Name>
      </Trait>
    </TraitSet>
  </ClinVarAssertion>
</ClinVarSet>

<ClinVarSet ID="18550305">
  <RecordStatus>current</RecordStatus>
  <Title>NC_000021.9:g.10599016_10684924del85909 AND Large for gestational age</Title>
  <ReferenceClinVarAssertion DateCreated="2015-02-26" DateLastUpdated="2017-04-05" ID="381764">
    <ClinVarAccession Acc="RCV000161893" Version="1" Type="RCV" DateUpdated="2017-04-05"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance>
      <ReviewStatus>no assertion provided</ReviewStatus>
      <Description>not provided</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>unknown</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>yes</AffectedStatus>
      </Sample>
      <Method>
        <NamePlatform>Illumina HumanOmniExpress Beadchip</NamePlatform>
        <Description>Genomic DNA copy number estimation from GenomeStudio-normalised genotyping microarray data (probe signal intensity). Using Illumina's baseline data for microarray signal intensity normalisation, QuantiSNP default baseline data (OB-HMM parameter values) for CNV calling.</Description>
        <MethodType>case-control</MethodType>
      </Method>
      <ObservedData ID="17757285">
        <Attribute Type="Description">not provided</Attribute>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant" ID="157467">
      <Measure Type="Deletion" ID="167327">
        <Name>
          <ElementValue Type="Preferred">NC_000021.9:g.10599016_10684924del85909</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Change="g.10827533_10913441del" Accession="CM000683" Version="1" Type="HGVS, genomic">CM000683.1:g.10827533_10913441del</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Change="g.10599016_10684924del85909" Accession="NC_000021" Version="9" Type="HGVS, genomic, top level" integerValue="38">NC_000021.9:g.10599016_10684924del85909</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Change="g.10827533_10913441del85909" Accession="NC_000021" Version="8" Type="HGVS, genomic, top level, previous" integerValue="37">NC_000021.8:g.10827533_10913441del85909</Attribute>
        </AttributeSet>
        <CytogeneticLocation>21p11.2</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="21" Accession="NC_000021.9" start="10599016" stop="10684924" display_start="10599016" display_stop="10684924" variantLength="85909"/>
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="21" Accession="NC_000021.8" start="10827533" stop="10913441" display_start="10827533" display_stop="10913441" variantLength="85909"/>
        <MeasureRelationship Type="genes overlapped by variant">
          <Name>
            <ElementValue Type="Preferred">transmembrane phosphatase with tensin homology</ElementValue>
          </Name>
          <Symbol>
            <ElementValue Type="Preferred">TPTE</ElementValue>
          </Symbol>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="21" Accession="NC_000021.9" start="10521514" stop="10606270" display_start="10521514" display_stop="10606270" Strand="+"/>
          <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="21" Accession="NC_000021.8" start="10906740" stop="10990919" display_start="10906740" display_stop="10990919" variantLength="84180" Strand="-"/>
          <XRef ID="7179" DB="Gene"/>
          <XRef Type="MIM" ID="604336" DB="OMIM"/>
          <XRef ID="HGNC:12023" DB="HGNC"/>
        </MeasureRelationship>
        <Citation Type="general">
          <ID Source="PubMed">25666259</ID>
        </Citation>
      </Measure>
      <Name>
        <ElementValue Type="Preferred">NC_000021.9:g.10599016_10684924del85909</ElementValue>
      </Name>
    </MeasureSet>
    <TraitSet Type="Disease" ID="19842">
      <Trait ID="22433" Type="Finding">
        <Name>
          <ElementValue Type="Preferred">Large for gestational age</ElementValue>
          <XRef ID="HP:0001520" DB="Human Phenotype Ontology"/>
        </Name>
        <Name>
          <ElementValue Type="Alternate">Birth weight &gt; 90th percentile</ElementValue>
          <XRef ID="HP:0001520" DB="Human Phenotype Ontology"/>
        </Name>
        <Name>
          <ElementValue Type="Alternate">Birthweight &gt; 90th percentile</ElementValue>
          <XRef ID="HP:0001520" DB="Human Phenotype Ontology"/>
        </Name>
        <Name>
          <ElementValue Type="Alternate">Fetal macrosomia</ElementValue>
          <XRef ID="HP:0001520" DB="Human Phenotype Ontology"/>
        </Name>
        <Name>
          <ElementValue Type="Alternate">Macrosomia</ElementValue>
          <XRef ID="HP:0001520" DB="Human Phenotype Ontology"/>
        </Name>
        <Name>
          <ElementValue Type="Alternate">Macrosomia, neonatal</ElementValue>
          <XRef ID="HP:0001520" DB="Human Phenotype Ontology"/>
        </Name>
        <XRef ID="C1848395" DB="MedGen"/>
        <XRef Type="primary" ID="HP:0001520" DB="Human Phenotype Ontology"/>
        <XRef Type="secondary" ID="HP:0001825" DB="Human Phenotype Ontology"/>
      </Trait>
    </TraitSet>
  </ReferenceClinVarAssertion>
  <ClinVarAssertion ID="339118" SubmissionName="Kasak">
    <ClinVarSubmissionID localKey="CNV_860" submitter="Institute of Molecular and Cell Biology, University of Tartu" submitterDate="2014-10-23"/>
    <ClinVarAccession Acc="SCV000191850" OrgType="primary" OrganizationCategory="other" Version="1" Type="SCV" OrgID="505255" DateUpdated="2017-04-05"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance>
      <ReviewStatus>no assertion provided</ReviewStatus>
      <Description>not provided</Description>
      <Citation Type="general">
        <ID Source="PubMed">25666259</ID>
      </Citation>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ExternalID DB="EVA" ID="CNV_860"/>
    <ObservedIn>
      <Sample>
        <Origin>unknown</Origin>
        <Tissue>Blood</Tissue>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>yes</AffectedStatus>
        <Gender>mixed</Gender>
      </Sample>
      <Method>
        <NamePlatform>Illumina HumanOmniExpress Beadchip</NamePlatform>
        <TypePlatform>SNP array</TypePlatform>
        <Description>Genomic DNA copy number estimation from GenomeStudio-normalised genotyping microarray data (probe signal intensity). Using Illumina's baseline data for microarray signal intensity normalisation, QuantiSNP default baseline data (OB-HMM parameter values) for CNV calling.</Description>
        <Software name="QuantiSNP, GADA, CNstream" purpose="Normalized signal intensity data was obtained through Illumina GenomeStudio software. Information on Log2 R ratios, B allele frequencies, markers and chromosomal coordinates from each sample were used for CNV identification with Hidden Markov Model-based algorithm QuantiSNP 2.3 (Colella et al., 2007) and a sparse Bayesian learning approach GADA (Genome Alteration Detection Analysis) (Pique-Regi et al., 2010). QuantiSNP was run with default settings, the adjustment for ‘genomic waves’ in signal intensities was turned on with the ‘--gcdir’ key in addition to the default calling parameters. GADA was run using the options “–T 5 –M 3”. CNstream (Alonso et al., 2010) algorithm was used in parallel to estimate CNVs from X and Y channel intensities loaded from Illumina GenomeStudio. CNVs were calculated under the following parameters: number of probes per segment (=3), minimum number of probes in one segment that must exceed the threshold for identifying an amplification/deletion (=3), CNV frequency threshold (=0). CNVs with QuantiSNP log Bayes Factor value &lt;5 and/or rearrangements shorter than 350 bp were excluded from the resulting list of CNVs. In this project we analysed only autosomal CNVs. HD-CNV (Hotspot Detector for Copy Number Variants) (Butler et al., 2013) was used to merge CNV regions called by alternative computational algorithms, QuantiSNP, GADA and CNstream. A criterion of 40% reciprocal overlap between parallel CNV calls was used to define two calls as identifying the same event. All CNVs called by at least two algorithms for the same individual in the same genomic loci were considered in the subsequent global analysis."/>
        <MethodType>case-control</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="Description">not provided</Attribute>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant">
      <Measure Type="Variation">
        <AttributeSet>
          <Attribute Type="HGVS">CM000683.1:g.10827533_10913441del</Attribute>
        </AttributeSet>
      </Measure>
    </MeasureSet>
    <TraitSet Type="Disease">
      <Trait Type="Finding">
        <Name>
          <ElementValue Type="Preferred">Large for gestational age</ElementValue>
        </Name>
        <XRef DB="MedGen" ID="C0158915" Type="CUI"/>
      </Trait>
    </TraitSet>
    <Citation Type="general">
      <ID Source="PubMed">25666259</ID>
    </Citation>
    <Citation Type="general">
      <ID Source="PubMed">25666259</ID>
    </Citation>
    <StudyName>Kasak2014</StudyName>
    <StudyDescription>The study aimed to determine the contribution of copy number variants in the genetic etiology of normal and complicated pregnancies. The samples represented (i) maternal blood DNA drawn from healthy pregnant women during 1st or 2nd trimester and (ii) maternal and paternal blood DNA drawn at term pregnancy cases representing normal and complicated gestations (severe preeclampsia, PE; gestational diabetes, GD; small-for-gestational age newborn, SGA; large-for-gestational age newborn, LGA). We performed CNV calling based on genome-wide genotyping dataset (Illumina HumanOmniExpress-24-v1 BeadChip) by applying three algorithms, QuantiSNP, GADA (Genome Alteration Detection Algorithm) and CNstream in parallel. The acquired CNV calls were merged with HD-CNV (Hotspot Detector for Copy Number Variants) program and only the CNVs predicted by at least two programs, were considered in subsequent analysis.</StudyDescription>
    <Comment>The study aimed to determine the contribution of copy number variants in the genetic etiology of normal and complicated pregnancies. The samples represented (i) maternal blood DNA drawn from healthy pregnant women during 1st or 2nd trimester and (ii) maternal and paternal blood DNA drawn at term pregnancy cases representing normal and complicated gestations (severe preeclampsia, PE; gestational diabetes, GD; small-for-gestational age newborn, SGA; large-for-gestational age newborn, LGA). We performed CNV calling based on genome-wide genotyping dataset (Illumina HumanOmniExpress-24-v1 BeadChip) by applying three algorithms, QuantiSNP, GADA (Genome Alteration Detection Algorithm) and CNstream in parallel. The acquired CNV calls were merged with HD-CNV (Hotspot Detector for Copy Number Variants) program and only the CNVs predicted by at least two programs, were considered in subsequent analysis.</Comment>
  </ClinVarAssertion>
</ClinVarSet>

<ClinVarSet ID="18588609">
  <RecordStatus>current</RecordStatus>
  <Title>NM_000317.2(PTS):c.(?_-1)_(*1_?)del AND Metabolic disease</Title>
  <ReferenceClinVarAssertion DateCreated="2017-01-26" DateLastUpdated="2017-04-05" ID="966262">
    <ClinVarAccession Acc="RCV000416303" Version="1" Type="RCV" DateUpdated="2017-04-05"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance>
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Likely pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>yes</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>clinical testing</MethodType>
      </Method>
      <ObservedData ID="17779455">
        <Attribute Type="Description">not provided</Attribute>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant" ID="375224">
      <Measure Type="Deletion" ID="361929">
        <Name>
          <ElementValue Type="Preferred">NM_000317.2(PTS):c.(?_-1)_(*1_?)del</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Accession="NM_000317" Version="2" Type="HGVS, coding, RefSeq">NM_000317.2:c.(?_-1)_(*1_?)del</Attribute>
        </AttributeSet>
        <CytogeneticLocation>11q23.1</CytogeneticLocation>
        <MeasureRelationship Type="asserted, but not computed">
          <Name>
            <ElementValue Type="Preferred">6-pyruvoyltetrahydropterin synthase</ElementValue>
          </Name>
          <Symbol>
            <ElementValue Type="Preferred">PTS</ElementValue>
          </Symbol>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="11" Accession="NC_000011.10" start="112226365" stop="112233973" display_start="112226365" display_stop="112233973" Strand="+"/>
          <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="11" Accession="NC_000011.9" start="112097087" stop="112104695" display_start="112097087" display_stop="112104695" variantLength="7609" Strand="+"/>
          <XRef ID="5805" DB="Gene"/>
          <XRef Type="MIM" ID="612719" DB="OMIM"/>
          <XRef ID="HGNC:9689" DB="HGNC"/>
        </MeasureRelationship>
      </Measure>
      <Name>
        <ElementValue Type="Preferred">NM_000317.2(PTS):c.(?_-1)_(*1_?)del</ElementValue>
      </Name>
    </MeasureSet>
    <TraitSet Type="Disease" ID="20214">
      <Trait ID="32361" Type="Disease">
        <Name>
          <ElementValue Type="Preferred">Metabolic disease</ElementValue>
          <XRef ID="UWMG_9636043" DB="CSER_CC_NCGL; University of Washington Medical Center"/>
          <XRef ID="75934005" DB="SNOMED CT"/>
        </Name>
        <Citation Type="practice guideline" Abbrev="Langer et al., 2012">
          <ID Source="PubMed">22947299</ID>
        </Citation>
        <XRef ID="C0025517" DB="MedGen"/>
      </Trait>
    </TraitSet>
  </ReferenceClinVarAssertion>
  <ClinVarAssertion ID="966220" SubmissionName="mcgm_CNV_1">
    <ClinVarSubmissionID localKey="NM_000317.2:c.(?_-1)_(*1_?)del|MedGen:C0025517" submittedAssembly="GRCh37" submitter="Centre for Genomic Medicine, Manchester,Central Manchester University Hospitals" submitterDate="2016-12-12"/>
    <ClinVarAccession Acc="SCV000493117" OrgType="primary" OrganizationCategory="clinic" Version="1" Type="SCV" OrgID="505642" DateUpdated="2017-04-05"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance>
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Likely pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>yes</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>clinical testing</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="Description">not provided</Attribute>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant">
      <Measure Type="Variation">
        <AttributeSet>
          <Attribute Type="HGVS">NM_000317.2:c.(?_-1)_(*1_?)del</Attribute>
        </AttributeSet>
        <MeasureRelationship Type="variant in gene">
          <Symbol>
            <ElementValue Type="Preferred">PTS</ElementValue>
          </Symbol>
        </MeasureRelationship>
      </Measure>
    </MeasureSet>
    <TraitSet Type="Disease">
      <Trait Type="Disease">
        <Name>
          <ElementValue Type="Preferred">Metabolic disease</ElementValue>
        </Name>
        <XRef DB="MedGen" ID="C0025517" Type="CUI"/>
      </Trait>
    </TraitSet>
    <StudyDescription>CNV calls within European Journal Human Genetics manuscript (605-16-EJHG)</StudyDescription>
  </ClinVarAssertion>
</ClinVarSet>

<ClinVarSet ID="18607094">
  <RecordStatus>current</RecordStatus>
  <Title>NC_000018.8:g.(76067297_76082986)_(76113881_76117153)dup AND See cases</Title>
  <ReferenceClinVarAssertion DateCreated="2017-03-31" DateLastUpdated="2017-04-05" ID="1047801">
    <ClinVarAccession Acc="RCV000453317" Version="1" Type="RCV" DateUpdated="2017-04-05"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance>
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Uncertain significance</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>not provided</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>yes</AffectedStatus>
      </Sample>
      <Method>
        <Purpose>Discovery</Purpose>
        <Description>Microarray</Description>
        <MethodType>clinical testing</MethodType>
      </Method>
      <ObservedData ID="17789128">
        <Attribute integerValue="1" Type="VariantAlleles"/>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant" ID="393683">
      <Measure Type="copy number gain" ID="380575">
        <Name>
          <ElementValue Type="Preferred">NC_000018.8:g.(76067297_76082986)_(76113881_76117153)dup</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="AbsoluteCopyNumber" integerValue="3"/>
        </AttributeSet>
        <AttributeSet>
          <Attribute Change="g.(76067297_76082986)_(76113881_76117153)dup" Accession="NC_000018" Version="8" Type="HGVS, genomic, top level, previous" integerValue="36">NC_000018.8:g.(76067297_76082986)_(76113881_76117153)dup</Attribute>
        </AttributeSet>
        <SequenceLocation Assembly="NCBI36" AssemblyAccessionVersion="GCF_000001405.12" AssemblyStatus="previous" Chr="18" Accession="NC_000018.8" outerStart="76067297" innerStart="76082986" innerStop="76113881" outerStop="76117153" display_start="76067297" display_stop="76117153"/>
        <XRef ID="nssv13640240" DB="dbVar"/>
        <XRef ID="nsv2768469" DB="dbVar"/>
      </Measure>
      <Name>
        <ElementValue Type="Preferred">NC_000018.8:g.(76067297_76082986)_(76113881_76117153)dup</ElementValue>
      </Name>
    </MeasureSet>
    <TraitSet Type="PhenotypeInstruction" ID="16994">
      <Trait ID="18728" Type="PhenotypeInstruction">
        <Name>
          <ElementValue Type="Preferred">See cases</ElementValue>
        </Name>
      </Trait>
    </TraitSet>
  </ReferenceClinVarAssertion>
  <ClinVarAssertion ID="1031239" SubmissionName="nstd37">
    <ClinVarSubmissionID localKey="nsv2768469:copy number gain:See cases:3:SCV000494830" submitter="ISCA site 19" submitterDate="2017-02-28"/>
    <ClinVarAccession Acc="SCV000494830" OrgType="primary" OrganizationCategory="laboratory" Version="1" Type="SCV" OrgID="505431" DateUpdated="2017-04-05"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance>
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Uncertain significance</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>not provided</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>yes</AffectedStatus>
      </Sample>
      <Method>
        <TypePlatform>Oligo aCGH</TypePlatform>
        <Purpose>Discovery</Purpose>
        <Description>Microarray</Description>
        <SourceType>submitter-generated</SourceType>
        <MethodType>clinical testing</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="VariantAlleles" integerValue="1"/>
      </ObservedData>
      <TraitSet Type="Finding">
        <Trait Type="Finding">
          <Name>
            <ElementValue Type="Preferred">Global developmental delay</ElementValue>
          </Name>
          <XRef DB="HP" ID="HP:0001263"/>
        </Trait>
      </TraitSet>
      <XRef DB="dbVar" ID="nssv13640240" Type="dbVarVariantCallId"/>
    </ObservedIn>
    <MeasureSet Type="Variant">
      <Measure Type="copy number gain">
        <AttributeSet>
          <Attribute Type="AbsoluteCopyNumber">3</Attribute>
        </AttributeSet>
        <SequenceLocation Accession="NC_000018.8" Assembly="NCBI36" Chr="18" innerStart="76082986" innerStop="76113881" outerStart="76067297" outerStop="76117153"/>
        <XRef DB="dbVar" ID="nssv13640240" Type="dbVarVariantCallId"/>
        <XRef DB="dbVar" ID="nsv2768469" Type="dbVarVariantRegionId"/>
      </Measure>
    </MeasureSet>
    <TraitSet Type="PhenotypeInstruction">
      <Trait Type="PhenotypeInstruction">
        <Name>
          <ElementValue Type="Preferred">See cases</ElementValue>
        </Name>
      </Trait>
    </TraitSet>
    <Citation Abbrev="ISCA, 2010" Type="Position Statement">
      <ID Source="PubMed">20466091</ID>
    </Citation>
    <Comment>Copy number variation identified through the course of routine clinical cytogenomic testing in postnatal populations, with clinical assertions as classified by the original submitter. For data from the original published study, [Kaminsky, et al. 2011|/pubmed/21844811], please see [nstd101|/dbvar/studies/nstd101/].</Comment>
  </ClinVarAssertion>
</ClinVarSet>

<ClinVarSet ID="18628272">
  <RecordStatus>current</RecordStatus>
  <Title>ESPN, 3-BP DEL, 2541AAG AND Deafness, without vestibular involvement, autosomal dominant</Title>
  <ReferenceClinVarAssertion DateCreated="2012-08-13" DateLastUpdated="2017-04-07" ID="62176">
    <ClinVarAccession Acc="RCV000004673" Version="2" Type="RCV" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2006-02-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData ID="17809735">
        <Attribute Type="Description">In a 4-year-old Spanish patient with severe bilateral sensorineural hearing impairment without vestibular involvement (see 609006), Donaudy et al. (2006) detected a sporadic 3-nucleotide deletion in the ESPN gene (2541-2543delAAG) leading to loss of lys848 in the C-terminal peptide (delK848). The lys848 residue of the ESPN protein is highly conserved across species.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">15930085</ID>
        </Citation>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant" ID="4423">
      <Measure Type="Deletion" ID="19462">
        <Name>
          <ElementValue Type="Preferred">ESPN, 3-BP DEL, 2541AAG</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="nucleotide change">3-BP DEL, 2541AAG</Attribute>
          <XRef Type="Allelic variant" ID="606351.0006" DB="OMIM"/>
        </AttributeSet>
        <CytogeneticLocation>1p36.3-p36.1</CytogeneticLocation>
        <MeasureRelationship Type="asserted, but not computed">
          <Name>
            <ElementValue Type="Preferred">espin</ElementValue>
          </Name>
          <Symbol>
            <ElementValue Type="Preferred">ESPN</ElementValue>
          </Symbol>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="1" Accession="NC_000001.11" start="6424776" stop="6461367" display_start="6424776" display_stop="6461367" Strand="+"/>
          <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="1" Accession="NC_000001.10" start="6484847" stop="6521003" display_start="6484847" display_stop="6521003" variantLength="36157" Strand="+"/>
          <XRef ID="83715" DB="Gene"/>
          <XRef Type="MIM" ID="606351" DB="OMIM"/>
          <XRef ID="HGNC:13281" DB="HGNC"/>
        </MeasureRelationship>
        <XRef Type="Allelic variant" ID="606351.0006" DB="OMIM"/>
      </Measure>
      <Name>
        <ElementValue Type="Preferred">ESPN, 3-BP DEL, 2541AAG</ElementValue>
      </Name>
    </MeasureSet>
    <TraitSet Type="Disease" ID="1216">
      <Trait ID="10074" Type="Disease">
        <Name>
          <ElementValue Type="Preferred">Deafness, without vestibular involvement, autosomal dominant</ElementValue>
        </Name>
        <XRef ID="CN068820" DB="MedGen"/>
      </Trait>
    </TraitSet>
  </ReferenceClinVarAssertion>
  <ClinVarAssertion ID="24847">
    <ClinVarSubmissionID localKey="606351.0006_DEAFNESS, AUTOSOMAL DOMINANT, WITHOUT VESTIBULAR INVOLVEMENT" submitter="OMIM" submitterDate="2012-04-24" title="ESPN, 3-BP DEL, 2541AAG _DEAFNESS, AUTOSOMAL DOMINANT, WITHOUT VESTIBULAR INVOLVEMENT"/>
    <ClinVarAccession Acc="SCV000024847" OrgType="primary" OrganizationCategory="resource" Version="1" Type="SCV" OrgID="3" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2006-02-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ExternalID DB="OMIM" ID="606351.0006" Type="Allelic variant"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species>human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="Description">In a 4-year-old Spanish patient with severe bilateral sensorineural hearing impairment without vestibular involvement (see 609006), Donaudy et al. (2006) detected a sporadic 3-nucleotide deletion in the ESPN gene (2541-2543delAAG) leading to loss of lys848 in the C-terminal peptide (delK848). The lys848 residue of the ESPN protein is highly conserved across species.</Attribute>
        <Citation>
          <ID Source="PubMed">15930085</ID>
        </Citation>
        <XRef DB="OMIM" ID="609006" Type="MIM"/>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant">
      <Measure Type="Variation">
        <Name>
          <ElementValue Type="Preferred">ESPN, 3-BP DEL, 2541AAG</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="NonHGVS">3-BP DEL, 2541AAG</Attribute>
        </AttributeSet>
        <MeasureRelationship Type="variant in gene">
          <Symbol>
            <ElementValue Type="Preferred">ESPN</ElementValue>
          </Symbol>
        </MeasureRelationship>
        <XRef DB="OMIM" ID="606351.0006" Type="Allelic variant"/>
      </Measure>
    </MeasureSet>
    <TraitSet Type="Disease">
      <Trait Type="Disease">
        <Name>
          <ElementValue Type="Preferred">DEAFNESS, AUTOSOMAL DOMINANT, WITHOUT VESTIBULAR INVOLVEMENT</ElementValue>
        </Name>
      </Trait>
    </TraitSet>
  </ClinVarAssertion>
</ClinVarSet>

<ClinVarSet ID="18624176">
  <RecordStatus>current</RecordStatus>
  <Title>BCAM, EX3-4DEL AND BLOOD GROUP--LUTHERAN NULL</Title>
  <ReferenceClinVarAssertion DateCreated="2012-08-13" DateLastUpdated="2017-04-07" ID="57973">
    <ClinVarAccession Acc="RCV000000470" Version="4" Type="RCV" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2007-03-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData ID="17803553">
        <Attribute Type="Description">For discussion of the deletion of exons 3 and 4 in the BCAM gene that was found in compound heterozygous state in a patient with the Lutheran null blood group phenotype (247420) by Karamatic Crew et al. (2007), see 612773.0003.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">17319831</ID>
        </Citation>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant" ID="441">
      <Measure Type="Deletion" ID="15480">
        <Name>
          <ElementValue Type="Preferred">BCAM, EX3-4DEL</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="nucleotide change">EX3-4DEL</Attribute>
          <XRef Type="Allelic variant" ID="612773.0004" DB="OMIM"/>
        </AttributeSet>
        <CytogeneticLocation>19q13.2</CytogeneticLocation>
        <MeasureRelationship Type="asserted, but not computed">
          <Name>
            <ElementValue Type="Preferred">basal cell adhesion molecule (Lutheran blood group)</ElementValue>
          </Name>
          <Symbol>
            <ElementValue Type="Preferred">BCAM</ElementValue>
          </Symbol>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="19" Accession="NC_000019.10" start="44809059" stop="44821421" display_start="44809059" display_stop="44821421" Strand="+"/>
          <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="19" Accession="NC_000019.9" start="45312315" stop="45324677" display_start="45312315" display_stop="45324677" variantLength="12363" Strand="+"/>
          <XRef ID="4059" DB="Gene"/>
          <XRef Type="MIM" ID="612773" DB="OMIM"/>
          <XRef ID="HGNC:6722" DB="HGNC"/>
        </MeasureRelationship>
        <XRef Type="Allelic variant" ID="612773.0004" DB="OMIM"/>
      </Measure>
      <Name>
        <ElementValue Type="Preferred">BCAM, EX3-4DEL</ElementValue>
      </Name>
    </MeasureSet>
    <TraitSet Type="Disease" ID="125">
      <Trait ID="9638" Type="BloodGroup">
        <Name>
          <ElementValue Type="Preferred">BLOOD GROUP--LUTHERAN NULL</ElementValue>
          <XRef Type="Allelic variant" ID="612773.0003" DB="OMIM"/>
          <XRef Type="Allelic variant" ID="612773.0004" DB="OMIM"/>
          <XRef Type="Allelic variant" ID="612773.0005" DB="OMIM"/>
          <XRef Type="Allelic variant" ID="612773.0006" DB="OMIM"/>
        </Name>
      </Trait>
    </TraitSet>
  </ReferenceClinVarAssertion>
  <ClinVarAssertion ID="20619">
    <ClinVarSubmissionID localKey="612773.0004_BLOOD GROUP--LUTHERAN NULL" submitter="OMIM" submitterDate="2015-08-20" title="BCAM, EX3-4DEL_BLOOD GROUP--LUTHERAN NULL"/>
    <ClinVarAccession Acc="SCV000020619" OrgType="primary" OrganizationCategory="resource" Version="3" Type="SCV" OrgID="3" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2007-03-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ExternalID DB="OMIM" ID="612773.0004" Type="Allelic variant"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species>human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="Description">For discussion of the deletion of exons 3 and 4 in the BCAM gene that was found in compound heterozygous state in a patient with the Lutheran null blood group phenotype (247420) by Karamatic Crew et al. (2007), see 612773.0003.</Attribute>
        <Citation>
          <ID Source="PubMed">17319831</ID>
        </Citation>
        <XRef DB="OMIM" ID="247420" Type="MIM"/>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant">
      <Measure Type="Variation">
        <Name>
          <ElementValue Type="Preferred">BCAM, EX3-4DEL</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="NonHGVS">EX3-4DEL</Attribute>
        </AttributeSet>
        <MeasureRelationship Type="variant in gene">
          <Symbol>
            <ElementValue Type="Preferred">BCAM</ElementValue>
          </Symbol>
        </MeasureRelationship>
        <XRef DB="OMIM" ID="612773.0004" Type="Allelic variant"/>
      </Measure>
    </MeasureSet>
    <TraitSet Type="Disease">
      <Trait Type="Disease">
        <Name>
          <ElementValue Type="Preferred">BLOOD GROUP--LUTHERAN NULL</ElementValue>
        </Name>
      </Trait>
    </TraitSet>
  </ClinVarAssertion>
</ClinVarSet>

<ClinVarSet ID="18637731">
  <RecordStatus>current</RecordStatus>
  <Title>PPP1R3, 5-BP INS/DEL, 3-PRIME UTR AND Glycemia variation</Title>
  <ReferenceClinVarAssertion DateCreated="2012-08-13" DateLastUpdated="2017-04-07" ID="66749">
    <ClinVarAccession Acc="RCV000009246" Version="3" Type="RCV" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2009-10-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>association</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData ID="17815123">
        <Attribute Type="Description">Hegele et al. (1998) studied a common 5-bp insertion/deletion polymorphism in an mRNA-stabilizing AU(AT)-rich element within the 3-prime UTR of the PPP1R3 gene. The deletion (D) allele had a frequency of 0.30 in the Canadian Oji-Cree. The authors found that this 3-prime UTR variation was significantly associated with variation in 2-hour postprandial glucose in adult Oji-Cree with type II diabetes (125853) or impaired glucose tolerance (IGT). Specifically, Oji-Cree with diabetes or IGT who were D/D homozygotes had significantly lower 2-hour postprandial plasma glucose than subjects with the other genotypes. The authors concluded that this common PPP1R3 3-prime UTR variation that may affect mRNA stability is associated with variation in glycemia in Oji-Cree subjects with type II diabetes.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">9814479</ID>
        </Citation>
      </ObservedData>
      <ObservedData ID="17815123">
        <Attribute Type="Description">To examine the relationship of the 5-bp insertion-deletion polymorphism in the (AU)AT-rich element (ARE) to hormonal and clinical characteristics of women with polycystic ovary syndrome (PCOS; 184700), Alcoser et al. (2004) studied polymorphism genotype in 186 women with PCOS who had undergone a standard 75-g oral glucose tolerance test and measurement of serum androgen and sex hormone-binding globulin (SHBG; 182205) levels. Among the largest cohort of nondiabetic subjects (112 Caucasian women) the presence of the deletion allele (ARE-2) was associated with insulin resistance and hyperandrogenemia. There was no apparent effect of the ARE-2 allele on BMI or blood glucose concentration during the oral glucose tolerance test. Subjects who were homozygous for the insertion allele (ARE-1/1) had a mean insulin area under the curve that was significantly lower than that in either the heterozygous or homozygous deletion groups. In addition, ARE-1/1 subjects had significantly lower serum concentrations of dehydroepiandrosterone sulfate compared with ARE-2/2 subjects and a trend toward lower levels of free testosterone.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">15181086</ID>
        </Citation>
      </ObservedData>
      <ObservedData ID="17815123">
        <Attribute Type="Description">Doney et aL. (2003) analyzed the frequency of the rarer deletion allele (ARE-2) in 1,950 individuals with type II diabetes and found that men homozygous for ARE-2 were younger at diagnosis than men homozygous for ARE-1 (p = 0.008). Carriers of the ARE-2 variant displayed a marked preponderance of early male diagnosis (p = 0.003), whereas there was no difference in age of diagnosis by gender in those carrying only the common ARE-1 variant. Doney et al. (2003) concluded that the ARE-2 allele of PPP1R3A is associated with a male preponderance to early-diagnosed type II diabetes.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">12831406</ID>
        </Citation>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant" ID="8708">
      <Measure Type="Indel" ID="23747">
        <Name>
          <ElementValue Type="Preferred">PPP1R3, 5-BP INS/DEL, 3-PRIME UTR</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="nucleotide change">5-BP INS/DEL, 3-PRIME UTR</Attribute>
          <XRef Type="Allelic variant" ID="600917.0002" DB="OMIM"/>
        </AttributeSet>
        <CytogeneticLocation>7q11.23-q21.11</CytogeneticLocation>
        <MeasureRelationship Type="asserted, but not computed">
          <Name>
            <ElementValue Type="Preferred">protein phosphatase 1 regulatory subunit 3A</ElementValue>
          </Name>
          <Symbol>
            <ElementValue Type="Preferred">PPP1R3A</ElementValue>
          </Symbol>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="7" Accession="NC_000007.14" start="113876827" stop="113919094" display_start="113876827" display_stop="113919094" Strand="-"/>
          <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="7" Accession="NC_000007.13" start="113516881" stop="113559081" display_start="113516881" display_stop="113559081" variantLength="42201" Strand="-"/>
          <XRef ID="5506" DB="Gene"/>
          <XRef Type="MIM" ID="600917" DB="OMIM"/>
          <XRef ID="HGNC:9291" DB="HGNC"/>
        </MeasureRelationship>
        <XRef Type="Allelic variant" ID="600917.0002" DB="OMIM"/>
      </Measure>
      <Name>
        <ElementValue Type="Preferred">PPP1R3, 5-BP INS/DEL, 3-PRIME UTR</ElementValue>
      </Name>
    </MeasureSet>
    <TraitSet Type="Disease" ID="2392">
      <Trait ID="10470" Type="Disease">
        <Name>
          <ElementValue Type="Preferred">Glycemia variation</ElementValue>
        </Name>
        <XRef ID="C4016700" DB="MedGen"/>
      </Trait>
    </TraitSet>
  </ReferenceClinVarAssertion>
  <ClinVarAssertion ID="29464">
    <ClinVarSubmissionID localKey="600917.0002_GLYCEMIA VARIATION" submitter="OMIM" submitterDate="2009-10-01" title="PPP1R3, 5-BP INS/DEL, 3-PRIME UTR_GLYCEMIA VARIATION"/>
    <ClinVarAccession Acc="SCV000029464" OrgType="primary" OrganizationCategory="resource" Version="1" Type="SCV" OrgID="3" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2009-10-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>association</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ExternalID DB="OMIM" ID="600917.0002" Type="Allelic variant"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species>human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="Description">Hegele et al. (1998) studied a common 5-bp insertion/deletion polymorphism in an mRNA-stabilizing AU(AT)-rich element within the 3-prime UTR of the PPP1R3 gene. The deletion (D) allele had a frequency of 0.30 in the Canadian Oji-Cree. The authors found that this 3-prime UTR variation was significantly associated with variation in 2-hour postprandial glucose in adult Oji-Cree with type II diabetes (125853) or impaired glucose tolerance (IGT). Specifically, Oji-Cree with diabetes or IGT who were D/D homozygotes had significantly lower 2-hour postprandial plasma glucose than subjects with the other genotypes. The authors concluded that this common PPP1R3 3-prime UTR variation that may affect mRNA stability is associated with variation in glycemia in Oji-Cree subjects with type II diabetes.</Attribute>
        <Citation>
          <ID Source="PubMed">9814479</ID>
        </Citation>
        <XRef DB="OMIM" ID="125853" Type="MIM"/>
      </ObservedData>
      <ObservedData>
        <Attribute Type="Description">To examine the relationship of the 5-bp insertion-deletion polymorphism in the (AU)AT-rich element (ARE) to hormonal and clinical characteristics of women with polycystic ovary syndrome (PCOS; 184700), Alcoser et al. (2004) studied polymorphism genotype in 186 women with PCOS who had undergone a standard 75-g oral glucose tolerance test and measurement of serum androgen and sex hormone-binding globulin (SHBG; 182205) levels. Among the largest cohort of nondiabetic subjects (112 Caucasian women) the presence of the deletion allele (ARE-2) was associated with insulin resistance and hyperandrogenemia. There was no apparent effect of the ARE-2 allele on BMI or blood glucose concentration during the oral glucose tolerance test. Subjects who were homozygous for the insertion allele (ARE-1/1) had a mean insulin area under the curve that was significantly lower than that in either the heterozygous or homozygous deletion groups. In addition, ARE-1/1 subjects had significantly lower serum concentrations of dehydroepiandrosterone sulfate compared with ARE-2/2 subjects and a trend toward lower levels of free testosterone.</Attribute>
        <Citation>
          <ID Source="PubMed">15181086</ID>
        </Citation>
        <XRef DB="OMIM" ID="184700" Type="MIM"/>
        <XRef DB="OMIM" ID="182205" Type="MIM"/>
      </ObservedData>
      <ObservedData>
        <Attribute Type="Description">Doney et aL. (2003) analyzed the frequency of the rarer deletion allele (ARE-2) in 1,950 individuals with type II diabetes and found that men homozygous for ARE-2 were younger at diagnosis than men homozygous for ARE-1 (p = 0.008). Carriers of the ARE-2 variant displayed a marked preponderance of early male diagnosis (p = 0.003), whereas there was no difference in age of diagnosis by gender in those carrying only the common ARE-1 variant. Doney et al. (2003) concluded that the ARE-2 allele of PPP1R3A is associated with a male preponderance to early-diagnosed type II diabetes.</Attribute>
        <Citation>
          <ID Source="PubMed">12831406</ID>
        </Citation>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant">
      <Measure Type="Variation">
        <Name>
          <ElementValue Type="Preferred">PPP1R3, 5-BP INS/DEL, 3-PRIME UTR</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="NonHGVS">5-BP INS/DEL, 3-PRIME UTR</Attribute>
        </AttributeSet>
        <MeasureRelationship Type="variant in gene">
          <Symbol>
            <ElementValue Type="Preferred">PPP1R3</ElementValue>
          </Symbol>
        </MeasureRelationship>
        <XRef DB="OMIM" ID="600917.0002" Type="Allelic variant"/>
      </Measure>
    </MeasureSet>
    <TraitSet Type="Disease">
      <Trait Type="Disease">
        <Name>
          <ElementValue Type="Preferred">GLYCEMIA VARIATION</ElementValue>
        </Name>
      </Trait>
    </TraitSet>
  </ClinVarAssertion>
</ClinVarSet>

<ClinVarSet ID="18633818">
  <RecordStatus>current</RecordStatus>
  <Title>PCDH15, 1-BP DEL, 16T AND USHER SYNDROME, TYPE ID/F, DIGENIC</Title>
  <ReferenceClinVarAssertion DateCreated="2012-08-13" DateLastUpdated="2017-04-07" ID="62726">
    <ClinVarAccession Acc="RCV000005223" Version="2" Type="RCV" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2005-01-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData ID="17810247">
        <Attribute Type="Description">In a proband with a diagnosis of Usher syndrome type I (see 601067), Zheng et al. (2005) detected a 1-bp deletion in exon 2 of the PCDH15 gene (16delT) in compound heterozygosity with a mutation in the CDH23 gene (R3189W; 605516.0012). The proband's brother, who had normal hearing, carried the 16delT mutation in heterozygosity. The PCDH15 16delT mutation causes a frameshift leading to an altered amino acid sequence from codon 6, followed by a premature termination at codon 11 in the predicted signal peptide of the protein.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">15537665</ID>
        </Citation>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant" ID="4937">
      <Measure Type="Deletion" ID="19976">
        <Name>
          <ElementValue Type="Preferred">PCDH15, 1-BP DEL, 16T</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="nucleotide change">1-BP DEL, 16T</Attribute>
          <XRef Type="Allelic variant" ID="605514.0008" DB="OMIM"/>
        </AttributeSet>
        <CytogeneticLocation>10q21-q22</CytogeneticLocation>
        <MeasureRelationship Type="asserted, but not computed">
          <Name>
            <ElementValue Type="Preferred">protocadherin related 15</ElementValue>
          </Name>
          <Symbol>
            <ElementValue Type="Preferred">PCDH15</ElementValue>
          </Symbol>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="10" Accession="NC_000010.11" start="53802771" stop="55629182" display_start="53802771" display_stop="55629182" Strand="-"/>
          <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="10" Accession="NC_000010.10" start="55562530" stop="56561050" display_start="55562530" display_stop="56561050" variantLength="998521" Strand="-"/>
          <XRef ID="65217" DB="Gene"/>
          <XRef Type="MIM" ID="605514" DB="OMIM"/>
          <XRef ID="HGNC:14674" DB="HGNC"/>
        </MeasureRelationship>
        <XRef Type="Allelic variant" ID="605514.0008" DB="OMIM"/>
      </Measure>
      <Name>
        <ElementValue Type="Preferred">PCDH15, 1-BP DEL, 16T</ElementValue>
      </Name>
    </MeasureSet>
    <TraitSet Type="Disease" ID="1355">
      <Trait ID="10114" Type="Disease">
        <Name>
          <ElementValue Type="Preferred">USHER SYNDROME, TYPE ID/F, DIGENIC</ElementValue>
          <XRef Type="Allelic variant" ID="605514.0005" DB="OMIM"/>
          <XRef Type="Allelic variant" ID="605514.0008" DB="OMIM"/>
          <XRef Type="Allelic variant" ID="605516.0011" DB="OMIM"/>
          <XRef Type="Allelic variant" ID="605516.0012" DB="OMIM"/>
        </Name>
        <XRef ID="C3276419" DB="MedGen"/>
      </Trait>
    </TraitSet>
  </ReferenceClinVarAssertion>
  <ClinVarAssertion ID="25401">
    <ClinVarSubmissionID localKey="605514.0008_USHER SYNDROME, TYPE ID/F, DIGENIC" submitter="OMIM" submitterDate="2013-02-13" title="PCDH15, 1-BP DEL, 16T _USHER SYNDROME, TYPE ID/F, DIGENIC"/>
    <ClinVarAccession Acc="SCV000025401" OrgType="primary" OrganizationCategory="resource" Version="1" Type="SCV" OrgID="3" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2005-01-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ExternalID DB="OMIM" ID="605514.0008" Type="Allelic variant"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species>human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="Description">In a proband with a diagnosis of Usher syndrome type I (see 601067), Zheng et al. (2005) detected a 1-bp deletion in exon 2 of the PCDH15 gene (16delT) in compound heterozygosity with a mutation in the CDH23 gene (R3189W; 605516.0012). The proband's brother, who had normal hearing, carried the 16delT mutation in heterozygosity. The PCDH15 16delT mutation causes a frameshift leading to an altered amino acid sequence from codon 6, followed by a premature termination at codon 11 in the predicted signal peptide of the protein.</Attribute>
        <Citation>
          <ID Source="PubMed">15537665</ID>
        </Citation>
        <XRef DB="OMIM" ID="601067" Type="MIM"/>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant">
      <Measure Type="Variation">
        <Name>
          <ElementValue Type="Preferred">PCDH15, 1-BP DEL, 16T</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="NonHGVS">1-BP DEL, 16T</Attribute>
        </AttributeSet>
        <MeasureRelationship Type="variant in gene">
          <Symbol>
            <ElementValue Type="Preferred">PCDH15</ElementValue>
          </Symbol>
        </MeasureRelationship>
        <XRef DB="OMIM" ID="605514.0008" Type="Allelic variant"/>
      </Measure>
    </MeasureSet>
    <TraitSet Type="Disease">
      <Trait Type="Disease">
        <Name>
          <ElementValue Type="Preferred">USHER SYNDROME, TYPE ID/F, DIGENIC</ElementValue>
        </Name>
      </Trait>
    </TraitSet>
  </ClinVarAssertion>
</ClinVarSet>

<ClinVarSet ID="18633960">
  <RecordStatus>current</RecordStatus>
  <Title>GHRL, 2-BP DEL, CODON 34 AND GHRELIN POLYMORPHISM</Title>
  <ReferenceClinVarAssertion DateCreated="2012-08-13" DateLastUpdated="2017-04-07" ID="62870">
    <ClinVarAccession Acc="RCV000005367" Version="2" Type="RCV" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2002-06-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Benign</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData ID="17807262">
        <Attribute Type="Description">In a healthy normal-weight individual, Hinney et al. (2002) identified a 2-bp deletion at codon 34 of ghrelin leading to the insertion of 36 aberrant amino acids and a stop codon at position 71. This variant affects the coding region of mature ghrelin; presumably, this individual is haploinsufficient for ghrelin.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">12050239</ID>
        </Citation>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant" ID="5064">
      <Measure Type="Deletion" ID="20103">
        <Name>
          <ElementValue Type="Preferred">GHRL, 2-BP DEL, CODON 34</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="nucleotide change">2-BP DEL, CODON 34</Attribute>
          <XRef Type="Allelic variant" ID="605353.0004" DB="OMIM"/>
        </AttributeSet>
        <CytogeneticLocation>3p26-p25</CytogeneticLocation>
        <MeasureRelationship Type="asserted, but not computed">
          <Name>
            <ElementValue Type="Preferred">ghrelin and obestatin prepropeptide</ElementValue>
          </Name>
          <Symbol>
            <ElementValue Type="Preferred">GHRL</ElementValue>
          </Symbol>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="3" Accession="NC_000003.12" start="10285750" stop="10292947" display_start="10285750" display_stop="10292947" Strand="-"/>
          <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="3" Accession="NC_000003.11" start="10327433" stop="10334630" display_start="10327433" display_stop="10334630" variantLength="7198" Strand="-"/>
          <XRef ID="51738" DB="Gene"/>
          <XRef Type="MIM" ID="605353" DB="OMIM"/>
          <XRef ID="HGNC:18129" DB="HGNC"/>
        </MeasureRelationship>
        <XRef Type="Allelic variant" ID="605353.0004" DB="OMIM"/>
      </Measure>
      <Name>
        <ElementValue Type="Preferred">GHRL, 2-BP DEL, CODON 34</ElementValue>
      </Name>
    </MeasureSet>
    <TraitSet Type="Disease" ID="1398">
      <Trait ID="10128" Type="Disease">
        <Name>
          <ElementValue Type="Preferred">GHRELIN POLYMORPHISM</ElementValue>
          <XRef Type="Allelic variant" ID="605353.0004" DB="OMIM"/>
        </Name>
      </Trait>
    </TraitSet>
  </ReferenceClinVarAssertion>
  <ClinVarAssertion ID="25547">
    <ClinVarSubmissionID localKey="605353.0004_GHRELIN POLYMORPHISM" submitter="OMIM" submitterDate="2013-04-19" title="GHRL, 2-BP DEL, CODON 34 _GHRELIN POLYMORPHISM"/>
    <ClinVarAccession Acc="SCV000025547" OrgType="primary" OrganizationCategory="resource" Version="1" Type="SCV" OrgID="3" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2002-06-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Benign</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ExternalID DB="OMIM" ID="605353.0004" Type="Allelic variant"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species>human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="Description">In a healthy normal-weight individual, Hinney et al. (2002) identified a 2-bp deletion at codon 34 of ghrelin leading to the insertion of 36 aberrant amino acids and a stop codon at position 71. This variant affects the coding region of mature ghrelin; presumably, this individual is haploinsufficient for ghrelin.</Attribute>
        <Citation>
          <ID Source="PubMed">12050239</ID>
        </Citation>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant">
      <Measure Type="Variation">
        <Name>
          <ElementValue Type="Preferred">GHRL, 2-BP DEL, CODON 34</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="NonHGVS">2-BP DEL, CODON 34</Attribute>
        </AttributeSet>
        <MeasureRelationship Type="variant in gene">
          <Symbol>
            <ElementValue Type="Preferred">GHRL</ElementValue>
          </Symbol>
        </MeasureRelationship>
        <XRef DB="OMIM" ID="605353.0004" Type="Allelic variant"/>
      </Measure>
    </MeasureSet>
    <TraitSet Type="Disease">
      <Trait Type="Disease">
        <Name>
          <ElementValue Type="Preferred">GHRELIN POLYMORPHISM</ElementValue>
        </Name>
      </Trait>
    </TraitSet>
  </ClinVarAssertion>
</ClinVarSet>

<ClinVarSet ID="18634319">
  <RecordStatus>current</RecordStatus>
  <Title>CD209, -336A-G AND Human immunodeficiency virus type 1, susceptibility to</Title>
  <ReferenceClinVarAssertion DateCreated="2012-08-13" DateLastUpdated="2017-04-07" ID="63242">
    <ClinVarAccession Acc="RCV000005739" Version="2" Type="RCV" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2006-02-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>risk factor</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData ID="17810899">
        <Attribute Type="Description">Martin et al. (2004) found that European Americans at risk for parenteral HIV infection (see 609423) were more likely to carry the -336C SNP than the -336T SNP in the promoter of DCSIGN. This association was not observed in those at risk for mucosally acquired infection. Although the -336C SNP was common in African Americans, no significant association with risk of infection was observed in this group.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">15564514</ID>
        </Citation>
      </ObservedData>
      <ObservedData ID="17810899">
        <Attribute Type="Description">Sakuntabhai et al. (2005) reported strong association between the -336A-G polymorphism in the promoter of CD209, which they called DCSIGN1-336, and risk of dengue fever (614371). The G allele of the variant was associated with strong protection against dengue fever in 3 independent cohorts from Thailand, with a carrier frequency of 4.7% in individuals with dengue fever compared with 22.4% in individuals with dengue hemorrhagic fever (odds ratio for risk of dengue hemorrhagic fever vs dengue fever = 5.84) and 19.5% in controls (odds ratio for protection = 4.90). This variant affects an Sp1-like binding site and transcriptional activity in vitro. Carrington (2006) confirmed that the -336T-C SNP reported by Martin et al. (2004) and the -336A-G SNP reported by Sakuntabhai et al. (2005) are the same variant.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">15564514</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">15838506</ID>
        </Citation>
        <Citation Type="general">
          <CitationText>Carrington, M. Personal Communication. 2006. Baltimore, Md.</CitationText>
        </Citation>
      </ObservedData>
      <ObservedData ID="17810899">
        <Attribute Type="Description">Barreiro et al. (2006) found an association between susceptibility to tuberculosis (607948) and -336G in a South African Coloured population.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">16379498</ID>
        </Citation>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant" ID="5408">
      <Measure Type="single nucleotide variant" ID="20447">
        <Name>
          <ElementValue Type="Preferred">CD209, -336A-G</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="nucleotide change">-336A-G</Attribute>
          <XRef Type="Allelic variant" ID="604672.0001" DB="OMIM"/>
        </AttributeSet>
        <CytogeneticLocation>19p13.3</CytogeneticLocation>
        <MeasureRelationship Type="asserted, but not computed">
          <Name>
            <ElementValue Type="Preferred">CD209 molecule</ElementValue>
          </Name>
          <Symbol>
            <ElementValue Type="Preferred">CD209</ElementValue>
          </Symbol>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="19" Accession="NC_000019.10" start="7739993" stop="7747609" display_start="7739993" display_stop="7747609" Strand="-"/>
          <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="19" Accession="NC_000019.9" start="7804878" stop="7812463" display_start="7804878" display_stop="7812463" variantLength="7586" Strand="-"/>
          <XRef ID="30835" DB="Gene"/>
          <XRef Type="MIM" ID="604672" DB="OMIM"/>
          <XRef ID="HGNC:1641" DB="HGNC"/>
        </MeasureRelationship>
        <XRef Type="Allelic variant" ID="604672.0001" DB="OMIM"/>
      </Measure>
      <Name>
        <ElementValue Type="Preferred">CD209, -336A-G</ElementValue>
      </Name>
    </MeasureSet>
    <TraitSet Type="Disease" ID="1513">
      <Trait ID="5267" Type="Disease">
        <Name>
          <ElementValue Type="Preferred">Human immunodeficiency virus type 1, susceptibility to</ElementValue>
        </Name>
        <Name>
          <ElementValue Type="Alternate">HIV-1, SUSCEPTIBILITY TO</ElementValue>
          <XRef Type="MIM" ID="609423" DB="OMIM"/>
        </Name>
        <Name>
          <ElementValue Type="Alternate">HUMAN IMMUNODEFICIENCY VIRUS TYPE 1, RESISTANCE TO</ElementValue>
          <XRef Type="Allelic variant" ID="158105.0001" DB="OMIM"/>
          <XRef Type="Allelic variant" ID="158105.0002" DB="OMIM"/>
          <XRef Type="Allelic variant" ID="600835.0001" DB="OMIM"/>
          <XRef Type="Allelic variant" ID="601156.0001" DB="OMIM"/>
          <XRef Type="Allelic variant" ID="601267.0001" DB="OMIM"/>
          <XRef Type="Allelic variant" ID="601373.0001" DB="OMIM"/>
          <XRef Type="Allelic variant" ID="601373.0005" DB="OMIM"/>
          <XRef Type="Allelic variant" ID="601373.0008" DB="OMIM"/>
          <XRef Type="Allelic variant" ID="601373.0009" DB="OMIM"/>
          <XRef Type="Allelic variant" ID="603029.0002" DB="OMIM"/>
          <XRef ID="609423" DB="OMIM"/>
        </Name>
        <XRef ID="C1836230" DB="MedGen"/>
        <XRef Type="MIM" ID="609423" DB="OMIM"/>
      </Trait>
    </TraitSet>
  </ReferenceClinVarAssertion>
  <ClinVarAssertion ID="25921">
    <ClinVarSubmissionID localKey="604672.0001_HUMAN IMMUNODEFICIENCY VIRUS TYPE 1, SUSCEPTIBILITY TO" submitter="OMIM" submitterDate="2012-03-09" title="CD209, -336A-G_HUMAN IMMUNODEFICIENCY VIRUS TYPE 1, SUSCEPTIBILITY TO"/>
    <ClinVarAccession Acc="SCV000025921" OrgType="primary" OrganizationCategory="resource" Version="1" Type="SCV" OrgID="3" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2006-02-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>risk factor</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ExternalID DB="OMIM" ID="604672.0001" Type="Allelic variant"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species>human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="Description">Martin et al. (2004) found that European Americans at risk for parenteral HIV infection (see 609423) were more likely to carry the -336C SNP than the -336T SNP in the promoter of DCSIGN. This association was not observed in those at risk for mucosally acquired infection. Although the -336C SNP was common in African Americans, no significant association with risk of infection was observed in this group.</Attribute>
        <Citation>
          <ID Source="PubMed">15564514</ID>
        </Citation>
        <XRef DB="OMIM" ID="609423" Type="MIM"/>
      </ObservedData>
      <ObservedData>
        <Attribute Type="Description">Sakuntabhai et al. (2005) reported strong association between the -336A-G polymorphism in the promoter of CD209, which they called DCSIGN1-336, and risk of dengue fever (614371). The G allele of the variant was associated with strong protection against dengue fever in 3 independent cohorts from Thailand, with a carrier frequency of 4.7% in individuals with dengue fever compared with 22.4% in individuals with dengue hemorrhagic fever (odds ratio for risk of dengue hemorrhagic fever vs dengue fever = 5.84) and 19.5% in controls (odds ratio for protection = 4.90). This variant affects an Sp1-like binding site and transcriptional activity in vitro. Carrington (2006) confirmed that the -336T-C SNP reported by Martin et al. (2004) and the -336A-G SNP reported by Sakuntabhai et al. (2005) are the same variant.</Attribute>
        <Citation>
          <ID Source="PubMed">15838506</ID>
        </Citation>
        <Citation>
          <CitationText>Carrington, M. Personal Communication. 2006. Baltimore, Md.</CitationText>
        </Citation>
        <Citation>
          <ID Source="PubMed">15564514</ID>
        </Citation>
        <XRef DB="OMIM" ID="614371" Type="MIM"/>
      </ObservedData>
      <ObservedData>
        <Attribute Type="Description">Barreiro et al. (2006) found an association between susceptibility to tuberculosis (607948) and -336G in a South African Coloured population.</Attribute>
        <Citation>
          <ID Source="PubMed">16379498</ID>
        </Citation>
        <XRef DB="OMIM" ID="607948" Type="MIM"/>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant">
      <Measure Type="Variation">
        <Name>
          <ElementValue Type="Preferred">CD209, -336A-G</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="NonHGVS">-336A-G</Attribute>
        </AttributeSet>
        <MeasureRelationship Type="variant in gene">
          <Symbol>
            <ElementValue Type="Preferred">CD209</ElementValue>
          </Symbol>
        </MeasureRelationship>
        <XRef DB="OMIM" ID="604672.0001" Type="Allelic variant"/>
      </Measure>
    </MeasureSet>
    <TraitSet Type="Disease">
      <Trait Type="Disease">
        <Name>
          <ElementValue Type="Preferred">HUMAN IMMUNODEFICIENCY VIRUS TYPE 1, SUSCEPTIBILITY TO</ElementValue>
        </Name>
      </Trait>
    </TraitSet>
  </ClinVarAssertion>
</ClinVarSet>

<ClinVarSet ID="18635586">
  <RecordStatus>current</RecordStatus>
  <Title>TLR2, IVS2, GT(n) REPEAT POLYMORPHISM AND Colorectal cancer, susceptibility to</Title>
  <ReferenceClinVarAssertion DateCreated="2012-08-13" DateLastUpdated="2017-04-07" ID="64549">
    <ClinVarAccession Acc="RCV000007046" Version="2" Type="RCV" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2006-08-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>risk factor</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData ID="17808678">
        <Attribute Type="Description">Boraska Jelavic et al. (2006) studied genotype and allele frequencies of the GT microsatellite repeat polymorphism in intron 2 of the TLR2 gene in 89 Croatian patients with sporadic colorectal cancer (see 114500) and 88 Croatian sex- and age-matched controls. The frequency of TLR2 alleles with 20 and 21 GT repeats was decreased (p = 0.0044 and p = 0.001, respectively) and the frequency of the allele with 31 GT repeats was increased (p = 0.0147) in patients versus controls.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">16879199</ID>
        </Citation>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant" ID="6664">
      <Measure Type="Variation" ID="21703">
        <Name>
          <ElementValue Type="Preferred">TLR2, IVS2, GT(n) REPEAT POLYMORPHISM</ElementValue>
        </Name>
        <CytogeneticLocation>4q32</CytogeneticLocation>
        <MeasureRelationship Type="asserted, but not computed">
          <Name>
            <ElementValue Type="Preferred">toll like receptor 2</ElementValue>
          </Name>
          <Symbol>
            <ElementValue Type="Preferred">TLR2</ElementValue>
          </Symbol>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="4" Accession="NC_000004.12" start="153684080" stop="153710643" display_start="153684080" display_stop="153710643" Strand="+"/>
          <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="4" Accession="NC_000004.11" start="154605440" stop="154627242" display_start="154605440" display_stop="154627242" variantLength="21803" Strand="+"/>
          <XRef ID="7097" DB="Gene"/>
          <XRef Type="MIM" ID="603028" DB="OMIM"/>
          <XRef ID="HGNC:11848" DB="HGNC"/>
        </MeasureRelationship>
        <XRef Type="Allelic variant" ID="603028.0002" DB="OMIM"/>
      </Measure>
      <Name>
        <ElementValue Type="Preferred">TLR2, IVS2, GT(n) REPEAT POLYMORPHISM</ElementValue>
      </Name>
    </MeasureSet>
    <TraitSet Type="Disease" ID="1570">
      <Trait ID="10180" Type="Disease">
        <Name>
          <ElementValue Type="Preferred">Colorectal cancer, susceptibility to</ElementValue>
        </Name>
        <XRef ID="C1858438" DB="MedGen"/>
      </Trait>
    </TraitSet>
  </ReferenceClinVarAssertion>
  <ClinVarAssertion ID="27242">
    <ClinVarSubmissionID localKey="603028.0002_COLORECTAL CANCER, SUSCEPTIBILITY TO" submitter="OMIM" submitterDate="2013-03-18" title="TLR2, IVS2, GT(n) REPEAT POLYMORPHISM_COLORECTAL CANCER, SUSCEPTIBILITY TO"/>
    <ClinVarAccession Acc="SCV000027242" OrgType="primary" OrganizationCategory="resource" Version="1" Type="SCV" OrgID="3" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2006-08-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>risk factor</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ExternalID DB="OMIM" ID="603028.0002" Type="Allelic variant"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species>human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="Description">Boraska Jelavic et al. (2006) studied genotype and allele frequencies of the GT microsatellite repeat polymorphism in intron 2 of the TLR2 gene in 89 Croatian patients with sporadic colorectal cancer (see 114500) and 88 Croatian sex- and age-matched controls. The frequency of TLR2 alleles with 20 and 21 GT repeats was decreased (p = 0.0044 and p = 0.001, respectively) and the frequency of the allele with 31 GT repeats was increased (p = 0.0147) in patients versus controls.</Attribute>
        <Citation>
          <ID Source="PubMed">16879199</ID>
        </Citation>
        <XRef DB="OMIM" ID="114500" Type="MIM"/>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant">
      <Measure Type="Variation">
        <Name>
          <ElementValue Type="Preferred">TLR2, IVS2, GT(n) REPEAT POLYMORPHISM</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="NonHGVS">IVS2, GT(n) REPEAT POLYMORPHISM</Attribute>
        </AttributeSet>
        <MeasureRelationship Type="variant in gene">
          <Symbol>
            <ElementValue Type="Preferred">TLR2</ElementValue>
          </Symbol>
        </MeasureRelationship>
        <XRef DB="OMIM" ID="603028.0002" Type="Allelic variant"/>
      </Measure>
    </MeasureSet>
    <TraitSet Type="Disease">
      <Trait Type="Disease">
        <Name>
          <ElementValue Type="Preferred">COLORECTAL CANCER, SUSCEPTIBILITY TO</ElementValue>
        </Name>
      </Trait>
    </TraitSet>
  </ClinVarAssertion>
</ClinVarSet>

<ClinVarSet ID="18635618">
  <RecordStatus>current</RecordStatus>
  <Title>CUBN, IVS6, C-G AND Megaloblastic anemia 1, Finnish type</Title>
  <ReferenceClinVarAssertion DateCreated="2012-08-13" DateLastUpdated="2017-04-07" ID="64581">
    <ClinVarAccession Acc="RCV000007078" Version="2" Type="RCV" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="1999-03-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData ID="17812690">
        <Attribute Type="Description">Aminoff et al. (1999) found that in 1 Finnish family with MGA1 (261100), the proband was homozygous for an intronic mutation which was found in none of the 302 control Finnish chromosomes. An apparent in-frame insertion had occurred due to a point mutation in the intron interrupting domain 6 of the CUBN gene. The change was a C-to-G transversion.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">10080186</ID>
        </Citation>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant" ID="6690">
      <Measure Type="single nucleotide variant" ID="21729">
        <Name>
          <ElementValue Type="Preferred">CUBN, IVS6, C-G</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="nucleotide change">IVS6, C-G</Attribute>
          <XRef Type="Allelic variant" ID="602997.0002" DB="OMIM"/>
        </AttributeSet>
        <CytogeneticLocation>10p12.1</CytogeneticLocation>
        <MeasureRelationship Type="asserted, but not computed">
          <Name>
            <ElementValue Type="Preferred">cubilin</ElementValue>
          </Name>
          <Symbol>
            <ElementValue Type="Preferred">CUBN</ElementValue>
          </Symbol>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="10" Accession="NC_000010.11" start="16823966" stop="17130492" display_start="16823966" display_stop="17130492" Strand="-"/>
          <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="10" Accession="NC_000010.10" start="16865964" stop="17171815" display_start="16865964" display_stop="17171815" variantLength="305852" Strand="-"/>
          <XRef ID="8029" DB="Gene"/>
          <XRef Type="MIM" ID="602997" DB="OMIM"/>
          <XRef ID="HGNC:2548" DB="HGNC"/>
        </MeasureRelationship>
        <XRef Type="Allelic variant" ID="602997.0002" DB="OMIM"/>
      </Measure>
      <Name>
        <ElementValue Type="Preferred">CUBN, IVS6, C-G</ElementValue>
      </Name>
    </MeasureSet>
    <TraitSet Type="Disease" ID="1853">
      <Trait ID="10262" Type="Disease">
        <Name>
          <ElementValue Type="Preferred">Megaloblastic anemia 1, Finnish type</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="public definition">Imerslund-Gräsbeck syndrome is a condition caused by low levels of vitamin B12 (also known as cobalamin). The primary feature of this condition is a blood disorder called megaloblastic anemia. In this form of anemia, which is a disorder characterized by the shortage of red blood cells, the red cells that are present are abnormally large. About half of people with Imerslund-Gräsbeck syndrome also have high levels of protein in their urine (proteinuria). Although proteinuria can be an indication of kidney problems, people with Imerslund-Gräsbeck syndrome appear to have normal kidney function.Imerslund-Gräsbeck syndrome typically begins in infancy or early childhood. The blood abnormality leads to many of the signs and symptoms of the condition, including an inability to grow and gain weight at the expected rate (failure to thrive), pale skin (pallor), excessive tiredness (fatigue), and recurring gastrointestinal or respiratory infections. Other features of Imerslund-Gräsbeck syndrome include mild neurological problems, such as weak muscle tone (hypotonia), numbness or tingling in the hands or feet, movement problems, delayed development, or confusion. Rarely, affected individuals have abnormalities of organs or tissues that make up the urinary tract, such as the bladder or the tubes that carry fluid from the kidneys to the bladder (the ureters).</Attribute>
          <XRef ID="imerslund-grasbeck-syndrome" DB="Genetics Home Reference"/>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="Genetics Home Reference (GHR) links">Imerslund-Gräsbeck syndrome</Attribute>
          <XRef ID="imerslund-grasbeck-syndrome" DB="Genetics Home Reference"/>
        </AttributeSet>
        <XRef ID="C4016819" DB="MedGen"/>
      </Trait>
    </TraitSet>
  </ReferenceClinVarAssertion>
  <ClinVarAssertion ID="27274">
    <ClinVarSubmissionID localKey="602997.0002_MEGALOBLASTIC ANEMIA 1, FINNISH TYPE" submitter="OMIM" submitterDate="2012-08-17" title="CUBN, IVS6, C-G _MEGALOBLASTIC ANEMIA 1, FINNISH TYPE"/>
    <ClinVarAccession Acc="SCV000027274" OrgType="primary" OrganizationCategory="resource" Version="1" Type="SCV" OrgID="3" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="1999-03-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ExternalID DB="OMIM" ID="602997.0002" Type="Allelic variant"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species>human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="Description">Aminoff et al. (1999) found that in 1 Finnish family with MGA1 (261100), the proband was homozygous for an intronic mutation which was found in none of the 302 control Finnish chromosomes. An apparent in-frame insertion had occurred due to a point mutation in the intron interrupting domain 6 of the CUBN gene. The change was a C-to-G transversion.</Attribute>
        <Citation>
          <ID Source="PubMed">10080186</ID>
        </Citation>
        <XRef DB="OMIM" ID="261100" Type="MIM"/>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant">
      <Measure Type="Variation">
        <Name>
          <ElementValue Type="Preferred">CUBN, IVS6, C-G</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="NonHGVS">IVS6, C-G</Attribute>
        </AttributeSet>
        <MeasureRelationship Type="variant in gene">
          <Symbol>
            <ElementValue Type="Preferred">CUBN</ElementValue>
          </Symbol>
        </MeasureRelationship>
        <XRef DB="OMIM" ID="602997.0002" Type="Allelic variant"/>
      </Measure>
    </MeasureSet>
    <TraitSet Type="Disease">
      <Trait Type="Disease">
        <Name>
          <ElementValue Type="Preferred">MEGALOBLASTIC ANEMIA 1, FINNISH TYPE</ElementValue>
        </Name>
      </Trait>
    </TraitSet>
  </ClinVarAssertion>
</ClinVarSet>

<ClinVarSet ID="18635882">
  <RecordStatus>current</RecordStatus>
  <Title>PITX3, 17-BP DUP, NT657 AND ANTERIOR SEGMENT DYSGENESIS 1, MULTIPLE SUBTYPES</Title>
  <ReferenceClinVarAssertion DateCreated="2012-08-13" DateLastUpdated="2017-04-07" ID="64852">
    <ClinVarAccession Acc="RCV000007349" Version="4" Type="RCV" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2008-01-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData ID="17813146">
        <Attribute Type="Description">Anterior Segment Dysgenesis 1, Multiple Subtypes</Attribute>
      </ObservedData>
      <ObservedData ID="17813146">
        <Attribute Type="Description">In 6 affected members of a 6-generation family with autosomal dominant anterior segment mesenchymal dysgenesis (ASGD1; 107250) and cortical cataract, previously described by Hittner et al. (1982), Semina et al. (1998) identified a 17-bp insertion in exon 4 of the PITX3 gene, resulting in a frameshift and altering 82 C-terminal amino acids that collectively represent more than one-quarter of the total protein length of 302 amino acids. The region of insertion lies outside the homeodomain but includes the 14-amino acid motif that is conserved among all of the PITX proteins and some other paired-like homeoproteins. The mutation segregated with disease and was not found in 300 control chromosomes. There was marked variability in the phenotype, which was characterized by corneal and lens opacities of variable degree, with optic nerve abnormalities noted in 3 patients.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">6801987</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">9620774</ID>
        </Citation>
      </ObservedData>
      <ObservedData ID="17813146">
        <Attribute Type="Description">In all clinically affected members of a large Australian kindred segregating anterior segment abnormalities, including Peters anomaly with corneal clouding, iridolenticular corneal adhesions, displaced Schwalbe line, and cataract, previously reported by Withers et al. (1999), Summers et al. (2008) identified heterozygosity for the 17-bp duplication in the PITX3 gene. Noting that there was no difference in the size of the duplication between severely affected and more mildly affected individuals, the authors suggested the existence of modifier loci.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">10361984</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">18989383</ID>
        </Citation>
      </ObservedData>
      <ObservedData ID="17813146">
        <Attribute Type="Description">Cataract 11, Posterior Polar</Attribute>
      </ObservedData>
      <ObservedData ID="17813146">
        <Attribute Type="Description">In affected members of 4 large unrelated families with autosomal dominant posterior polar cataract (CTRCT11; 610623), 3 of English descent and 1 of Chinese descent, Berry et al. (2004) identified heterozygosity for a 17-bp duplication at nucleotide 657 of the PITX3 gene. In one 4-generation English family, 1 of the 10 affected members also had ASMD, but her affected daughter, who had the same 17-bp duplication, had only cataract. In another 4-generation English family, 4 of 11 affected members also had ASMD, but in the remaining 6-generation English family and 4-generation Chinese family, none of those affected had any other abnormalities. Berry et al. (2004) suggested that cataract, rather than ASMD, may be the major feature of PITX3 mutations, and that there may be another gene causing ASMD. Berry et al. (2004) noted that sequence analysis indicated that this mutation, originally reported as an insertion, is actually a duplication; the mutation was not found in 100 healthy individuals.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">15286169</ID>
        </Citation>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant" ID="6937">
      <Measure Type="Duplication" ID="21976">
        <Name>
          <ElementValue Type="Preferred">PITX3, 17-BP DUP, NT657</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="nucleotide change">17-BP DUP, NT657</Attribute>
          <XRef Type="Allelic variant" ID="602669.0001" DB="OMIM"/>
        </AttributeSet>
        <CytogeneticLocation>10q25</CytogeneticLocation>
        <MeasureRelationship Type="asserted, but not computed">
          <Name>
            <ElementValue Type="Preferred">paired like homeodomain 3</ElementValue>
          </Name>
          <Symbol>
            <ElementValue Type="Preferred">PITX3</ElementValue>
          </Symbol>
          <AttributeSet>
            <Attribute dateValue="2013-11-06" Type="Haploinsufficiency">No evidence available</Attribute>
            <Citation>
              <URL>https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=PITX3</URL>
            </Citation>
          </AttributeSet>
          <AttributeSet>
            <Attribute dateValue="2013-11-06" Type="Triplosensitivity">No evidence available</Attribute>
            <Citation>
              <URL>https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=PITX3</URL>
            </Citation>
          </AttributeSet>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="10" Accession="NC_000010.11" start="102230189" stop="102241474" display_start="102230189" display_stop="102241474" Strand="-"/>
          <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="10" Accession="NC_000010.10" start="103989945" stop="104001230" display_start="103989945" display_stop="104001230" variantLength="11286" Strand="-"/>
          <XRef ID="5309" DB="Gene"/>
          <XRef Type="MIM" ID="602669" DB="OMIM"/>
          <XRef ID="HGNC:9006" DB="HGNC"/>
        </MeasureRelationship>
        <XRef Type="Allelic variant" ID="602669.0001" DB="OMIM"/>
      </Measure>
      <Name>
        <ElementValue Type="Preferred">PITX3, 17-BP DUP, NT657</ElementValue>
      </Name>
    </MeasureSet>
    <TraitSet Type="Disease" ID="34915">
      <Trait ID="36836" Type="Disease">
        <Name>
          <ElementValue Type="Preferred">ANTERIOR SEGMENT DYSGENESIS 1, MULTIPLE SUBTYPES</ElementValue>
          <XRef Type="Allelic variant" ID="602669.0001" DB="OMIM"/>
        </Name>
      </Trait>
    </TraitSet>
  </ReferenceClinVarAssertion>
  <ClinVarAssertion ID="27547">
    <ClinVarSubmissionID localKey="602669.0001_ANTERIOR SEGMENT DYSGENESIS 1, MULTIPLE SUBTYPES" submitter="OMIM" submitterDate="2017-01-26" title="PITX3, 17-BP DUP, NT657_ANTERIOR SEGMENT DYSGENESIS 1, MULTIPLE SUBTYPES"/>
    <ClinVarAccession Acc="SCV000027547" OrgType="primary" OrganizationCategory="resource" Version="3" Type="SCV" OrgID="3" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2008-01-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ExternalID DB="OMIM" ID="602669.0001" Type="Allelic variant"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species>human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="Description">Anterior Segment Dysgenesis 1, Multiple Subtypes</Attribute>
      </ObservedData>
      <ObservedData>
        <Attribute Type="Description">In 6 affected members of a 6-generation family with autosomal dominant anterior segment mesenchymal dysgenesis (ASGD1; 107250) and cortical cataract, previously described by Hittner et al. (1982), Semina et al. (1998) identified a 17-bp insertion in exon 4 of the PITX3 gene, resulting in a frameshift and altering 82 C-terminal amino acids that collectively represent more than one-quarter of the total protein length of 302 amino acids. The region of insertion lies outside the homeodomain but includes the 14-amino acid motif that is conserved among all of the PITX proteins and some other paired-like homeoproteins. The mutation segregated with disease and was not found in 300 control chromosomes. There was marked variability in the phenotype, which was characterized by corneal and lens opacities of variable degree, with optic nerve abnormalities noted in 3 patients.</Attribute>
        <Citation>
          <ID Source="PubMed">6801987</ID>
        </Citation>
        <Citation>
          <ID Source="PubMed">9620774</ID>
        </Citation>
        <XRef DB="OMIM" ID="107250" Type="MIM"/>
      </ObservedData>
      <ObservedData>
        <Attribute Type="Description">In all clinically affected members of a large Australian kindred segregating anterior segment abnormalities, including Peters anomaly with corneal clouding, iridolenticular corneal adhesions, displaced Schwalbe line, and cataract, previously reported by Withers et al. (1999), Summers et al. (2008) identified heterozygosity for the 17-bp duplication in the PITX3 gene. Noting that there was no difference in the size of the duplication between severely affected and more mildly affected individuals, the authors suggested the existence of modifier loci.</Attribute>
        <Citation>
          <ID Source="PubMed">10361984</ID>
        </Citation>
        <Citation>
          <ID Source="PubMed">18989383</ID>
        </Citation>
      </ObservedData>
      <ObservedData>
        <Attribute Type="Description">Cataract 11, Posterior Polar</Attribute>
      </ObservedData>
      <ObservedData>
        <Attribute Type="Description">In affected members of 4 large unrelated families with autosomal dominant posterior polar cataract (CTRCT11; 610623), 3 of English descent and 1 of Chinese descent, Berry et al. (2004) identified heterozygosity for a 17-bp duplication at nucleotide 657 of the PITX3 gene. In one 4-generation English family, 1 of the 10 affected members also had ASMD, but her affected daughter, who had the same 17-bp duplication, had only cataract. In another 4-generation English family, 4 of 11 affected members also had ASMD, but in the remaining 6-generation English family and 4-generation Chinese family, none of those affected had any other abnormalities. Berry et al. (2004) suggested that cataract, rather than ASMD, may be the major feature of PITX3 mutations, and that there may be another gene causing ASMD. Berry et al. (2004) noted that sequence analysis indicated that this mutation, originally reported as an insertion, is actually a duplication; the mutation was not found in 100 healthy individuals.</Attribute>
        <Citation>
          <ID Source="PubMed">15286169</ID>
        </Citation>
        <XRef DB="OMIM" ID="610623" Type="MIM"/>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant">
      <Measure Type="Variation">
        <Name>
          <ElementValue Type="Preferred">PITX3, 17-BP DUP, NT657</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="NonHGVS">17-BP DUP, NT657</Attribute>
        </AttributeSet>
        <MeasureRelationship Type="variant in gene">
          <Symbol>
            <ElementValue Type="Preferred">PITX3</ElementValue>
          </Symbol>
        </MeasureRelationship>
        <XRef DB="OMIM" ID="602669.0001" Type="Allelic variant"/>
      </Measure>
    </MeasureSet>
    <TraitSet Type="Disease">
      <Trait Type="Disease">
        <Name>
          <ElementValue Type="Preferred">ANTERIOR SEGMENT DYSGENESIS 1, MULTIPLE SUBTYPES</ElementValue>
        </Name>
      </Trait>
    </TraitSet>
  </ClinVarAssertion>
</ClinVarSet>

<ClinVarSet ID="18635963">
  <RecordStatus>current</RecordStatus>
  <Title>TECTA, 1-BP INS, 649C AND Deafness, neurosensory autosomal recessive 21</Title>
  <ReferenceClinVarAssertion DateCreated="2012-08-13" DateLastUpdated="2017-04-07" ID="64936">
    <ClinVarAccession Acc="RCV000007433" Version="2" Type="RCV" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2003-05-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData ID="17812914">
        <Attribute Type="Description">In affected members of a consanguineous Iranian family with hearing loss (603629), Naz et al. (2003) identified homozygosity for a 1-bp insertion, 649insC, in exon 5 of the TECTA gene, resulting in a frameshift. Affected subjects exhibited a severe hearing loss that was more pronounced in the 1,000-2,000 Hz frequency range, resulting in a flat to shallow U-shaped audiogram. The heterozygous carriers of the frameshift mutation had normal hearing thresholds. Naz et al. (2003) concluded that the distinctive audiometric profile provided a useful clinical marker to facilitate genetic diagnosis.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">12746400</ID>
        </Citation>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant" ID="7018">
      <Measure Type="Insertion" ID="22057">
        <Name>
          <ElementValue Type="Preferred">TECTA, 1-BP INS, 649C</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="nucleotide change">1-BP INS, 649C</Attribute>
          <XRef Type="Allelic variant" ID="602574.0006" DB="OMIM"/>
        </AttributeSet>
        <CytogeneticLocation>11q22-q24</CytogeneticLocation>
        <MeasureRelationship Type="asserted, but not computed">
          <Name>
            <ElementValue Type="Preferred">tectorin alpha</ElementValue>
          </Name>
          <Symbol>
            <ElementValue Type="Preferred">TECTA</ElementValue>
          </Symbol>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="11" Accession="NC_000011.10" start="121102666" stop="121190806" display_start="121102666" display_stop="121190806" Strand="+"/>
          <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="11" Accession="NC_000011.9" start="120973374" stop="121061514" display_start="120973374" display_stop="121061514" variantLength="88141" Strand="+"/>
          <XRef ID="7007" DB="Gene"/>
          <XRef Type="MIM" ID="602574" DB="OMIM"/>
          <XRef ID="HGNC:11720" DB="HGNC"/>
        </MeasureRelationship>
        <XRef Type="Allelic variant" ID="602574.0006" DB="OMIM"/>
      </Measure>
      <Name>
        <ElementValue Type="Preferred">TECTA, 1-BP INS, 649C</ElementValue>
      </Name>
    </MeasureSet>
    <TraitSet Type="Disease" ID="1937">
      <Trait ID="10291" Type="Disease">
        <Name>
          <ElementValue Type="Preferred">Deafness, neurosensory autosomal recessive 21</ElementValue>
        </Name>
        <XRef ID="C4016799" DB="MedGen"/>
      </Trait>
    </TraitSet>
  </ReferenceClinVarAssertion>
  <ClinVarAssertion ID="27633">
    <ClinVarSubmissionID localKey="602574.0006_DEAFNESS, NEUROSENSORY AUTOSOMAL RECESSIVE 21" submitter="OMIM" submitterDate="2011-07-27" title="TECTA, 1-BP INS, 649C_DEAFNESS, NEUROSENSORY AUTOSOMAL RECESSIVE 21"/>
    <ClinVarAccession Acc="SCV000027633" OrgType="primary" OrganizationCategory="resource" Version="1" Type="SCV" OrgID="3" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2003-05-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ExternalID DB="OMIM" ID="602574.0006" Type="Allelic variant"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species>human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="Description">In affected members of a consanguineous Iranian family with hearing loss (603629), Naz et al. (2003) identified homozygosity for a 1-bp insertion, 649insC, in exon 5 of the TECTA gene, resulting in a frameshift. Affected subjects exhibited a severe hearing loss that was more pronounced in the 1,000-2,000 Hz frequency range, resulting in a flat to shallow U-shaped audiogram. The heterozygous carriers of the frameshift mutation had normal hearing thresholds. Naz et al. (2003) concluded that the distinctive audiometric profile provided a useful clinical marker to facilitate genetic diagnosis.</Attribute>
        <Citation>
          <ID Source="PubMed">12746400</ID>
        </Citation>
        <XRef DB="OMIM" ID="603629" Type="MIM"/>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant">
      <Measure Type="Variation">
        <Name>
          <ElementValue Type="Preferred">TECTA, 1-BP INS, 649C</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="NonHGVS">1-BP INS, 649C</Attribute>
        </AttributeSet>
        <MeasureRelationship Type="variant in gene">
          <Symbol>
            <ElementValue Type="Preferred">TECTA</ElementValue>
          </Symbol>
        </MeasureRelationship>
        <XRef DB="OMIM" ID="602574.0006" Type="Allelic variant"/>
      </Measure>
    </MeasureSet>
    <TraitSet Type="Disease">
      <Trait Type="Disease">
        <Name>
          <ElementValue Type="Preferred">DEAFNESS, NEUROSENSORY AUTOSOMAL RECESSIVE 21</ElementValue>
        </Name>
      </Trait>
    </TraitSet>
  </ClinVarAssertion>
</ClinVarSet>

<ClinVarSet ID="18635964">
  <RecordStatus>current</RecordStatus>
  <Title>TECTA, 1-BP DEL, 6037G AND Deafness, neurosensory autosomal recessive 21</Title>
  <ReferenceClinVarAssertion DateCreated="2012-08-13" DateLastUpdated="2017-04-07" ID="64937">
    <ClinVarAccession Acc="RCV000007434" Version="2" Type="RCV" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2003-05-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData ID="17812915">
        <Attribute Type="Description">In affected members of a consanguineous Pakistani family with hearing loss (603629), Naz et al. (2003) identified homozygosity for a 1-bp deletion, 6037delG, in exon 20 of the TECTA gene, resulting in a frameshift. Testing demonstrated a flat to shallow U-shaped audiogram. The hearing loss was prelingual, bilateral, and moderate to severe. By history, the hearing impairment was nonprogressive. The heterozygous carriers of the frameshift mutation had normal hearing thresholds.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">12746400</ID>
        </Citation>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant" ID="7019">
      <Measure Type="Deletion" ID="22058">
        <Name>
          <ElementValue Type="Preferred">TECTA, 1-BP DEL, 6037G</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="nucleotide change">1-BP DEL, 6037G</Attribute>
          <XRef Type="Allelic variant" ID="602574.0007" DB="OMIM"/>
        </AttributeSet>
        <CytogeneticLocation>11q22-q24</CytogeneticLocation>
        <MeasureRelationship Type="asserted, but not computed">
          <Name>
            <ElementValue Type="Preferred">tectorin alpha</ElementValue>
          </Name>
          <Symbol>
            <ElementValue Type="Preferred">TECTA</ElementValue>
          </Symbol>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="11" Accession="NC_000011.10" start="121102666" stop="121190806" display_start="121102666" display_stop="121190806" Strand="+"/>
          <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="11" Accession="NC_000011.9" start="120973374" stop="121061514" display_start="120973374" display_stop="121061514" variantLength="88141" Strand="+"/>
          <XRef ID="7007" DB="Gene"/>
          <XRef Type="MIM" ID="602574" DB="OMIM"/>
          <XRef ID="HGNC:11720" DB="HGNC"/>
        </MeasureRelationship>
        <XRef Type="Allelic variant" ID="602574.0007" DB="OMIM"/>
      </Measure>
      <Name>
        <ElementValue Type="Preferred">TECTA, 1-BP DEL, 6037G</ElementValue>
      </Name>
    </MeasureSet>
    <TraitSet Type="Disease" ID="1937">
      <Trait ID="10291" Type="Disease">
        <Name>
          <ElementValue Type="Preferred">Deafness, neurosensory autosomal recessive 21</ElementValue>
        </Name>
        <XRef ID="C4016799" DB="MedGen"/>
      </Trait>
    </TraitSet>
  </ReferenceClinVarAssertion>
  <ClinVarAssertion ID="27634">
    <ClinVarSubmissionID localKey="602574.0007_DEAFNESS, NEUROSENSORY AUTOSOMAL RECESSIVE 21" submitter="OMIM" submitterDate="2011-07-27" title="TECTA, 1-BP DEL, 6037G_DEAFNESS, NEUROSENSORY AUTOSOMAL RECESSIVE 21"/>
    <ClinVarAccession Acc="SCV000027634" OrgType="primary" OrganizationCategory="resource" Version="1" Type="SCV" OrgID="3" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2003-05-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ExternalID DB="OMIM" ID="602574.0007" Type="Allelic variant"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species>human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="Description">In affected members of a consanguineous Pakistani family with hearing loss (603629), Naz et al. (2003) identified homozygosity for a 1-bp deletion, 6037delG, in exon 20 of the TECTA gene, resulting in a frameshift. Testing demonstrated a flat to shallow U-shaped audiogram. The hearing loss was prelingual, bilateral, and moderate to severe. By history, the hearing impairment was nonprogressive. The heterozygous carriers of the frameshift mutation had normal hearing thresholds.</Attribute>
        <Citation>
          <ID Source="PubMed">12746400</ID>
        </Citation>
        <XRef DB="OMIM" ID="603629" Type="MIM"/>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant">
      <Measure Type="Variation">
        <Name>
          <ElementValue Type="Preferred">TECTA, 1-BP DEL, 6037G</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="NonHGVS">1-BP DEL, 6037G</Attribute>
        </AttributeSet>
        <MeasureRelationship Type="variant in gene">
          <Symbol>
            <ElementValue Type="Preferred">TECTA</ElementValue>
          </Symbol>
        </MeasureRelationship>
        <XRef DB="OMIM" ID="602574.0007" Type="Allelic variant"/>
      </Measure>
    </MeasureSet>
    <TraitSet Type="Disease">
      <Trait Type="Disease">
        <Name>
          <ElementValue Type="Preferred">DEAFNESS, NEUROSENSORY AUTOSOMAL RECESSIVE 21</ElementValue>
        </Name>
      </Trait>
    </TraitSet>
  </ClinVarAssertion>
</ClinVarSet>

<ClinVarSet ID="18636226">
  <RecordStatus>current</RecordStatus>
  <Title>DNM2, LYS558 DEL AND Charcot-Marie-Tooth disease, dominant intermediate b, with neutropenia</Title>
  <ReferenceClinVarAssertion DateCreated="2012-08-13" DateLastUpdated="2017-04-07" ID="65204">
    <ClinVarAccession Acc="RCV000007701" Version="2" Type="RCV" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2009-07-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData ID="17813582">
        <Attribute Type="Description">In a Belgian family with dominant intermediate Charcot-Marie-Tooth disease and associated neutropenia (606482), Zuchner et al. (2005) identified a deletion of nucleotides 1672 through 1674 (1672_1674delAAG) in the DNM2 gene, resulting in deletion of a single amino acid, lys558. That an abnormality of lys558 was found in 2 families (see also 602378.0002) in which neutropenia, not a general feature of dominant intermediate Charcot-Marie-Tooth disease, cosegregated with the neuropathy implied that this residue has a function in maturation or survival of peripheral blood cells. Congenital neutropenia (202700) is caused by mutations in the gene elastase-2 gene (ELA2; 130130), which maps to 19p13.3. In the Belgian family, Zuchner et al. (2005) excluded mutations in ELA2 as the cause of neutropenia by sequence analysis of all coding exons.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">15731758</ID>
        </Citation>
      </ObservedData>
      <ObservedData ID="17813582">
        <Attribute Type="Description">In a follow-up of the Belgian family reported by Zuchner et al. (2005), Claeys et al. (2009) found that 1 mutation carrier had neutropenia and cataracts without signs of a neuropathy. In addition, 5 members of this family had early-onset cataracts in their teenage years.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">15731758</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">19502294</ID>
        </Citation>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant" ID="7278">
      <Measure Type="Deletion" ID="22317">
        <Name>
          <ElementValue Type="Preferred">DNM2, LYS558 DEL</ElementValue>
        </Name>
        <Name>
          <ElementValue Type="Alternate">DNM2, LYS558 DEL</ElementValue>
          <XRef Type="Allelic variant" ID="602378.0003" DB="OMIM"/>
        </Name>
        <CytogeneticLocation>19p13.2</CytogeneticLocation>
        <MeasureRelationship Type="asserted, but not computed">
          <Name>
            <ElementValue Type="Preferred">dynamin 2</ElementValue>
          </Name>
          <Symbol>
            <ElementValue Type="Preferred">DNM2</ElementValue>
          </Symbol>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="19" Accession="NC_000019.10" start="10718053" stop="10831910" display_start="10718053" display_stop="10831910" Strand="+"/>
          <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="19" Accession="NC_000019.9" start="10828728" stop="10942585" display_start="10828728" display_stop="10942585" variantLength="113858" Strand="+"/>
          <XRef ID="1785" DB="Gene"/>
          <XRef Type="MIM" ID="602378" DB="OMIM"/>
          <XRef ID="HGNC:2974" DB="HGNC"/>
        </MeasureRelationship>
        <XRef Type="Allelic variant" ID="602378.0003" DB="OMIM"/>
      </Measure>
      <Name>
        <ElementValue Type="Preferred">DNM2, LYS558 DEL</ElementValue>
      </Name>
    </MeasureSet>
    <TraitSet Type="Disease" ID="1978">
      <Trait ID="9177" Type="Disease">
        <Name>
          <ElementValue Type="Preferred">Charcot-Marie-Tooth disease, dominant intermediate b, with neutropenia</ElementValue>
        </Name>
        <XRef ID="C2751367" DB="MedGen"/>
      </Trait>
    </TraitSet>
  </ReferenceClinVarAssertion>
  <ClinVarAssertion ID="27902">
    <ClinVarSubmissionID localKey="602378.0003_CHARCOT-MARIE-TOOTH DISEASE, DOMINANT INTERMEDIATE B, WITH NEUTROPENIA" submitter="OMIM" submitterDate="2011-12-29" title="DNM2, LYS558 DEL_CHARCOT-MARIE-TOOTH DISEASE, DOMINANT INTERMEDIATE B, WITH NEUTROPENIA"/>
    <ClinVarAccession Acc="SCV000027902" OrgType="primary" OrganizationCategory="resource" Version="1" Type="SCV" OrgID="3" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2009-07-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ExternalID DB="OMIM" ID="602378.0003" Type="Allelic variant"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species>human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="Description">In a Belgian family with dominant intermediate Charcot-Marie-Tooth disease and associated neutropenia (606482), Zuchner et al. (2005) identified a deletion of nucleotides 1672 through 1674 (1672_1674delAAG) in the DNM2 gene, resulting in deletion of a single amino acid, lys558. That an abnormality of lys558 was found in 2 families (see also 602378.0002) in which neutropenia, not a general feature of dominant intermediate Charcot-Marie-Tooth disease, cosegregated with the neuropathy implied that this residue has a function in maturation or survival of peripheral blood cells. Congenital neutropenia (202700) is caused by mutations in the gene elastase-2 gene (ELA2; 130130), which maps to 19p13.3. In the Belgian family, Zuchner et al. (2005) excluded mutations in ELA2 as the cause of neutropenia by sequence analysis of all coding exons.</Attribute>
        <Citation>
          <ID Source="PubMed">15731758</ID>
        </Citation>
        <XRef DB="OMIM" ID="606482" Type="MIM"/>
        <XRef DB="OMIM" ID="202700" Type="MIM"/>
        <XRef DB="OMIM" ID="130130" Type="MIM"/>
      </ObservedData>
      <ObservedData>
        <Attribute Type="Description">In a follow-up of the Belgian family reported by Zuchner et al. (2005), Claeys et al. (2009) found that 1 mutation carrier had neutropenia and cataracts without signs of a neuropathy. In addition, 5 members of this family had early-onset cataracts in their teenage years.</Attribute>
        <Citation>
          <ID Source="PubMed">15731758</ID>
        </Citation>
        <Citation>
          <ID Source="PubMed">19502294</ID>
        </Citation>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant">
      <Measure Type="Variation">
        <Name>
          <ElementValue Type="Preferred">DNM2, LYS558 DEL</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="NonHGVS">LYS558 DEL</Attribute>
        </AttributeSet>
        <MeasureRelationship Type="variant in gene">
          <Symbol>
            <ElementValue Type="Preferred">DNM2</ElementValue>
          </Symbol>
        </MeasureRelationship>
        <XRef DB="OMIM" ID="602378.0003" Type="Allelic variant"/>
      </Measure>
    </MeasureSet>
    <TraitSet Type="Disease">
      <Trait Type="Disease">
        <Name>
          <ElementValue Type="Preferred">CHARCOT-MARIE-TOOTH DISEASE, DOMINANT INTERMEDIATE B, WITH NEUTROPENIA</ElementValue>
        </Name>
      </Trait>
    </TraitSet>
  </ClinVarAssertion>
</ClinVarSet>

<ClinVarSet ID="18636518">
  <RecordStatus>current</RecordStatus>
  <Title>TBX1, 1-BP DEL, 1223C AND Conotruncal anomaly face syndrome/velocardiofacial syndrome</Title>
  <ReferenceClinVarAssertion DateCreated="2012-08-13" DateLastUpdated="2017-04-07" ID="65504">
    <ClinVarAccession Acc="RCV000008001" Version="3" Type="RCV" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2005-04-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData ID="17810006">
        <Attribute Type="Description">In a mother and her son and daughter with conotruncal anomaly face syndrome (217095)/velocardiofacial syndrome (192430) and normal intelligence, Yagi et al. (2003) identified a heterozygous 1-bp deletion, 1223delC, in the TBX1 gene. The deletion occurred at codon 408 and caused a frameshift leading to a stop codon after 51 codons. This truncated TBX1 protein remained as the DNA binding motif but did not have the C-terminal region, including the putative activator and repressor domains.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">14585638</ID>
        </Citation>
      </ObservedData>
      <ObservedData ID="17810006">
        <Attribute Type="Description">Stoller and Epstein (2005) identified a previously unrecognized nuclear localization signal (NLS) at the C terminus of Tbx1 that is deleted by the 1223delC mutation, thus explaining the mechanism of disease in DiGeorge syndrome patients with this mutation. The NLS is conserved across species among T-box family members,  including T (601397) and TBX10 (604648).</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">15703190</ID>
        </Citation>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant" ID="7565">
      <Measure Type="Deletion" ID="22604">
        <Name>
          <ElementValue Type="Preferred">TBX1, 1-BP DEL, 1223C</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="nucleotide change">1-BP DEL, 1223C</Attribute>
          <XRef Type="Allelic variant" ID="602054.0003" DB="OMIM"/>
        </AttributeSet>
        <CytogeneticLocation>22q11.2</CytogeneticLocation>
        <MeasureRelationship Type="asserted, but not computed">
          <Name>
            <ElementValue Type="Preferred">T-box 1</ElementValue>
          </Name>
          <Symbol>
            <ElementValue Type="Preferred">TBX1</ElementValue>
          </Symbol>
          <AttributeSet>
            <Attribute dateValue="2012-03-22" Type="Haploinsufficiency">Some evidence for dosage pathogenicity</Attribute>
            <Citation>
              <URL>https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=TBX1</URL>
            </Citation>
          </AttributeSet>
          <AttributeSet>
            <Attribute dateValue="2012-03-22" Type="Triplosensitivity">No evidence available</Attribute>
            <Citation>
              <URL>https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=TBX1</URL>
            </Citation>
          </AttributeSet>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="22" Accession="NC_000022.11" start="19756703" stop="19783593" display_start="19756703" display_stop="19783593" Strand="+"/>
          <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="22" Accession="NC_000022.10" start="19744225" stop="19771115" display_start="19744225" display_stop="19771115" variantLength="26891" Strand="+"/>
          <XRef ID="6899" DB="Gene"/>
          <XRef Type="MIM" ID="602054" DB="OMIM"/>
          <XRef ID="HGNC:11592" DB="HGNC"/>
        </MeasureRelationship>
        <XRef Type="Allelic variant" ID="602054.0003" DB="OMIM"/>
      </Measure>
      <Name>
        <ElementValue Type="Preferred">TBX1, 1-BP DEL, 1223C</ElementValue>
      </Name>
    </MeasureSet>
    <TraitSet Type="Disease" ID="2058">
      <Trait ID="10335" Type="Disease">
        <Name>
          <ElementValue Type="Preferred">Conotruncal anomaly face syndrome/velocardiofacial syndrome</ElementValue>
        </Name>
        <XRef ID="C4016770" DB="MedGen"/>
      </Trait>
    </TraitSet>
  </ReferenceClinVarAssertion>
  <ClinVarAssertion ID="28206">
    <ClinVarSubmissionID localKey="602054.0003_CONOTRUNCAL ANOMALY FACE SYNDROME/VELOCARDIOFACIAL SYNDROME" submitter="OMIM" submitterDate="2012-09-24" title="TBX1, 1-BP DEL, 1223C _CONOTRUNCAL ANOMALY FACE SYNDROME/VELOCARDIOFACIAL SYNDROME"/>
    <ClinVarAccession Acc="SCV000028206" OrgType="primary" OrganizationCategory="resource" Version="1" Type="SCV" OrgID="3" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2005-04-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ExternalID DB="OMIM" ID="602054.0003" Type="Allelic variant"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species>human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="Description">In a mother and her son and daughter with conotruncal anomaly face syndrome (217095)/velocardiofacial syndrome (192430) and normal intelligence, Yagi et al. (2003) identified a heterozygous 1-bp deletion, 1223delC, in the TBX1 gene. The deletion occurred at codon 408 and caused a frameshift leading to a stop codon after 51 codons. This truncated TBX1 protein remained as the DNA binding motif but did not have the C-terminal region, including the putative activator and repressor domains.</Attribute>
        <Citation>
          <ID Source="PubMed">14585638</ID>
        </Citation>
        <XRef DB="OMIM" ID="217095" Type="MIM"/>
        <XRef DB="OMIM" ID="192430" Type="MIM"/>
      </ObservedData>
      <ObservedData>
        <Attribute Type="Description">Stoller and Epstein (2005) identified a previously unrecognized nuclear localization signal (NLS) at the C terminus of Tbx1 that is deleted by the 1223delC mutation, thus explaining the mechanism of disease in DiGeorge syndrome patients with this mutation. The NLS is conserved across species among T-box family members, including T (601397) and TBX10 (604648).</Attribute>
        <Citation>
          <ID Source="PubMed">15703190</ID>
        </Citation>
        <XRef DB="OMIM" ID="601397" Type="MIM"/>
        <XRef DB="OMIM" ID="604648" Type="MIM"/>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant">
      <Measure Type="Variation">
        <Name>
          <ElementValue Type="Preferred">TBX1, 1-BP DEL, 1223C</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="NonHGVS">1-BP DEL, 1223C</Attribute>
        </AttributeSet>
        <MeasureRelationship Type="variant in gene">
          <Symbol>
            <ElementValue Type="Preferred">TBX1</ElementValue>
          </Symbol>
        </MeasureRelationship>
        <XRef DB="OMIM" ID="602054.0003" Type="Allelic variant"/>
      </Measure>
    </MeasureSet>
    <TraitSet Type="Disease">
      <Trait Type="Disease">
        <Name>
          <ElementValue Type="Preferred">CONOTRUNCAL ANOMALY FACE SYNDROME/VELOCARDIOFACIAL SYNDROME</ElementValue>
        </Name>
      </Trait>
    </TraitSet>
  </ClinVarAssertion>
</ClinVarSet>

<ClinVarSet ID="18636532">
  <RecordStatus>current</RecordStatus>
  <Title>UCP3, IVS6, G-A, +1 AND UCP3 POLYMORPHISM, EXON 6 SPLICE DONOR JUNCTION</Title>
  <ReferenceClinVarAssertion DateCreated="2012-08-13" DateLastUpdated="2017-04-07" ID="65518">
    <ClinVarAccession Acc="RCV000008015" Version="2" Type="RCV" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="1998-10-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Benign</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData ID="17810011">
        <Attribute Type="Description">In a 16-year-old female with morbid obesity (601665), Argyropoulos et al. (1998) found compound heterozygosity for a polymorphism at the exon 6 splice donor junction (Ggt-Gat) and the R143X mutation (602004.0002). The rare R143X mutation was inherited in the maternal line; the splice site polymorphism was presumably transmitted from the father. The g-to-a transition at the splice donor site of exon 6 resulted in loss of the splice junction and truncation of the protein product at the first tga stop codon of the adjacent intron.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">9769326</ID>
        </Citation>
      </ObservedData>
      <ObservedData ID="17810011">
        <Attribute Type="Description">Among unrelated individuals, Argyropoulos et al. (1998) found that heterozygotes for the exon 6 splice donor polymorphism had a 50% reduction in fat oxidation adjusted for lean body mass and a marked elevation in the nonprotein respiratory quotient, compared with wildtype subjects. No significant differences were found between heterozygotes and wildtype individuals for BMI, percentage of body fat, and resting energy expenditure adjusted for lean body mass. The same analyses performed for the V102I polymorphism (602044.0001) showed no significant differences between heterozygotes and wildtype individuals for any of the aforementioned quantitative traits. Nonetheless, the African American population studied had a high prevalence of obesity; therefore, the possibility that this could mask a potential effect of UCP3 mutations on BMI was also examined. Indeed, Argyropoulos et al. (1998) found that the frequency of the g/a heterozygous genotype was nearly twice as high (P = 0.04) in obese (30%) compared with lean (16%) individuals.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">9769326</ID>
        </Citation>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant" ID="7578">
      <Measure Type="single nucleotide variant" ID="22617">
        <Name>
          <ElementValue Type="Preferred">UCP3, IVS6, G-A, +1</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="nucleotide change">IVS6, G-A, +1</Attribute>
          <XRef Type="Allelic variant" ID="602044.0003" DB="OMIM"/>
        </AttributeSet>
        <CytogeneticLocation>11q13</CytogeneticLocation>
        <MeasureRelationship Type="asserted, but not computed">
          <Name>
            <ElementValue Type="Preferred">uncoupling protein 3</ElementValue>
          </Name>
          <Symbol>
            <ElementValue Type="Preferred">UCP3</ElementValue>
          </Symbol>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="11" Accession="NC_000011.10" start="74000281" stop="74009237" display_start="74000281" display_stop="74009237" Strand="-"/>
          <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="11" Accession="NC_000011.9" start="73711325" stop="73720281" display_start="73711325" display_stop="73720281" variantLength="8957" Strand="-"/>
          <XRef ID="7352" DB="Gene"/>
          <XRef Type="MIM" ID="602044" DB="OMIM"/>
          <XRef ID="HGNC:12519" DB="HGNC"/>
        </MeasureRelationship>
        <XRef Type="Allelic variant" ID="602044.0003" DB="OMIM"/>
      </Measure>
      <Name>
        <ElementValue Type="Preferred">UCP3, IVS6, G-A, +1</ElementValue>
      </Name>
    </MeasureSet>
    <TraitSet Type="Disease" ID="2064">
      <Trait ID="10338" Type="Disease">
        <Name>
          <ElementValue Type="Preferred">UCP3 POLYMORPHISM, EXON 6 SPLICE DONOR JUNCTION</ElementValue>
          <XRef Type="Allelic variant" ID="602044.0003" DB="OMIM"/>
        </Name>
      </Trait>
    </TraitSet>
  </ReferenceClinVarAssertion>
  <ClinVarAssertion ID="28220">
    <ClinVarSubmissionID localKey="602044.0003_UCP3 POLYMORPHISM, EXON 6 SPLICE DONOR JUNCTION" submitter="OMIM" submitterDate="2008-09-02" title="UCP3, IVS6, G-A, +1_UCP3 POLYMORPHISM, EXON 6 SPLICE DONOR JUNCTION"/>
    <ClinVarAccession Acc="SCV000028220" OrgType="primary" OrganizationCategory="resource" Version="1" Type="SCV" OrgID="3" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="1998-10-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Benign</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ExternalID DB="OMIM" ID="602044.0003" Type="Allelic variant"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species>human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="Description">In a 16-year-old female with morbid obesity (601665), Argyropoulos et al. (1998) found compound heterozygosity for a polymorphism at the exon 6 splice donor junction (Ggt-Gat) and the R143X mutation (602004.0002). The rare R143X mutation was inherited in the maternal line; the splice site polymorphism was presumably transmitted from the father. The g-to-a transition at the splice donor site of exon 6 resulted in loss of the splice junction and truncation of the protein product at the first tga stop codon of the adjacent intron.</Attribute>
        <Citation>
          <ID Source="PubMed">9769326</ID>
        </Citation>
        <XRef DB="OMIM" ID="601665" Type="MIM"/>
      </ObservedData>
      <ObservedData>
        <Attribute Type="Description">Among unrelated individuals, Argyropoulos et al. (1998) found that heterozygotes for the exon 6 splice donor polymorphism had a 50% reduction in fat oxidation adjusted for lean body mass and a marked elevation in the nonprotein respiratory quotient, compared with wildtype subjects. No significant differences were found between heterozygotes and wildtype individuals for BMI, percentage of body fat, and resting energy expenditure adjusted for lean body mass. The same analyses performed for the V102I polymorphism (602044.0001) showed no significant differences between heterozygotes and wildtype individuals for any of the aforementioned quantitative traits. Nonetheless, the African American population studied had a high prevalence of obesity; therefore, the possibility that this could mask a potential effect of UCP3 mutations on BMI was also examined. Indeed, Argyropoulos et al. (1998) found that the frequency of the g/a heterozygous genotype was nearly twice as high (P = 0.04) in obese (30%) compared with lean (16%) individuals.</Attribute>
        <Citation>
          <ID Source="PubMed">9769326</ID>
        </Citation>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant">
      <Measure Type="Variation">
        <Name>
          <ElementValue Type="Preferred">UCP3, IVS6, G-A, +1</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="NonHGVS">IVS6, G-A, +1</Attribute>
        </AttributeSet>
        <MeasureRelationship Type="variant in gene">
          <Symbol>
            <ElementValue Type="Preferred">UCP3</ElementValue>
          </Symbol>
        </MeasureRelationship>
        <XRef DB="OMIM" ID="602044.0003" Type="Allelic variant"/>
      </Measure>
    </MeasureSet>
    <TraitSet Type="Disease">
      <Trait Type="Disease">
        <Name>
          <ElementValue Type="Preferred">UCP3 POLYMORPHISM, EXON 6 SPLICE DONOR JUNCTION</ElementValue>
        </Name>
      </Trait>
    </TraitSet>
  </ClinVarAssertion>
</ClinVarSet>

<ClinVarSet ID="18636553">
  <RecordStatus>current</RecordStatus>
  <Title>CLCNKB, DEL AND BARTTER SYNDROME, TYPE 4B, WITH SENSORINEURAL DEAFNESS</Title>
  <ReferenceClinVarAssertion DateCreated="2012-08-13" DateLastUpdated="2017-04-07" ID="65539">
    <ClinVarAccession Acc="RCV000008036" Version="3" Type="RCV" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2004-03-25">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData ID="17810016">
        <Attribute Type="Description">In a child with renal salt wasting and deafness (BARTS4B; 613090) who had no mutation in the BSND gene (606412), Schlingmann et al. (2004) identified both a homozygous deletion of the CLCNKB gene and a homozygous cys80-to-trp (C80W) mutation in the CLCNKA gene (C80W; 602024.0001). The patient was born prematurely to consanguineous parents, and the pregnancy was complicated by severe maternal polyhydramnios during the last 6 weeks of gestation.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">15044642</ID>
        </Citation>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant" ID="7598">
      <Measure Type="Deletion" ID="22637">
        <Name>
          <ElementValue Type="Preferred">CLCNKB, DEL</ElementValue>
        </Name>
        <Name>
          <ElementValue Type="Alternate">CLCNKB, DEL</ElementValue>
          <XRef Type="Allelic variant" ID="602023.0008" DB="OMIM"/>
        </Name>
        <AttributeSet>
          <Attribute Type="nucleotide change">DEL</Attribute>
          <XRef Type="Allelic variant" ID="602023.0008" DB="OMIM"/>
        </AttributeSet>
        <CytogeneticLocation>1p36</CytogeneticLocation>
        <MeasureRelationship Type="asserted, but not computed">
          <Name>
            <ElementValue Type="Preferred">chloride voltage-gated channel Kb</ElementValue>
          </Name>
          <Symbol>
            <ElementValue Type="Preferred">CLCNKB</ElementValue>
          </Symbol>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="1" Accession="NC_000001.11" start="16043736" stop="16057326" display_start="16043736" display_stop="16057326" Strand="+"/>
          <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="1" Accession="NC_000001.10" start="16370230" stop="16383820" display_start="16370230" display_stop="16383820" variantLength="13591" Strand="+"/>
          <XRef ID="1188" DB="Gene"/>
          <XRef Type="MIM" ID="602023" DB="OMIM"/>
          <XRef ID="HGNC:2027" DB="HGNC"/>
        </MeasureRelationship>
        <XRef Type="Allelic variant" ID="602023.0008" DB="OMIM"/>
      </Measure>
      <Name>
        <ElementValue Type="Preferred">CLCNKB, DEL</ElementValue>
      </Name>
    </MeasureSet>
    <TraitSet Type="Disease" ID="26762">
      <Trait ID="35353" Type="Disease">
        <Name>
          <ElementValue Type="Preferred">BARTTER SYNDROME, TYPE 4B, WITH SENSORINEURAL DEAFNESS</ElementValue>
          <XRef Type="Allelic variant" ID="602023.0008" DB="OMIM"/>
          <XRef Type="Allelic variant" ID="602023.0011" DB="OMIM"/>
        </Name>
      </Trait>
    </TraitSet>
  </ReferenceClinVarAssertion>
  <ClinVarAssertion ID="28241">
    <ClinVarSubmissionID localKey="602023.0008_BARTTER SYNDROME, TYPE 4B, WITH SENSORINEURAL DEAFNESS" submitter="OMIM" submitterDate="2016-05-12" title="CLCNKB, DEL _BARTTER SYNDROME, TYPE 4B, WITH SENSORINEURAL DEAFNESS"/>
    <ClinVarAccession Acc="SCV000028241" OrgType="primary" OrganizationCategory="resource" Version="2" Type="SCV" OrgID="3" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2004-03-25">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ExternalID DB="OMIM" ID="602023.0008" Type="Allelic variant"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species>human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="Description">In a child with renal salt wasting and deafness (BARTS4B; 613090) who had no mutation in the BSND gene (606412), Schlingmann et al. (2004) identified both a homozygous deletion of the CLCNKB gene and a homozygous cys80-to-trp (C80W) mutation in the CLCNKA gene (C80W; 602024.0001). The patient was born prematurely to consanguineous parents, and the pregnancy was complicated by severe maternal polyhydramnios during the last 6 weeks of gestation.</Attribute>
        <Citation>
          <ID Source="PubMed">15044642</ID>
        </Citation>
        <XRef DB="OMIM" ID="613090" Type="MIM"/>
        <XRef DB="OMIM" ID="606412" Type="MIM"/>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant">
      <Measure Type="Variation">
        <Name>
          <ElementValue Type="Preferred">CLCNKB, DEL</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="NonHGVS">DEL</Attribute>
        </AttributeSet>
        <MeasureRelationship Type="variant in gene">
          <Symbol>
            <ElementValue Type="Preferred">CLCNKB</ElementValue>
          </Symbol>
        </MeasureRelationship>
        <XRef DB="OMIM" ID="602023.0008" Type="Allelic variant"/>
      </Measure>
    </MeasureSet>
    <TraitSet Type="Disease">
      <Trait Type="Disease">
        <Name>
          <ElementValue Type="Preferred">BARTTER SYNDROME, TYPE 4B, WITH SENSORINEURAL DEAFNESS</ElementValue>
        </Name>
      </Trait>
    </TraitSet>
  </ClinVarAssertion>
</ClinVarSet>

<ClinVarSet ID="18636556">
  <RecordStatus>current</RecordStatus>
  <Title>CLCNKB, IVS17DS, G-A, +1 AND BARTTER SYNDROME, TYPE 4B, WITH SENSORINEURAL DEAFNESS</Title>
  <ReferenceClinVarAssertion DateCreated="2012-08-13" DateLastUpdated="2017-04-07" ID="65542">
    <ClinVarAccession Acc="RCV000008039" Version="3" Type="RCV" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2008-03-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData ID="17810017">
        <Attribute Type="Description">In a 2-year-old Japanese girl with a severe form of Bartter syndrome with sensorineural deafness (BARTS4B; 613090), Nozu et al. (2008) identified a heterozygous G-to-A transition in intron 7 of the CLCNKB gene, resulting in a splice site mutation, and a heterozygous mutation in the CLCNKA gene (Q260X; 602024.0002), both inherited from the father. The maternal allele had a 12-kb deletion including portions of both CLCNKA and CLCNKB. Neither parent was clinically affected. The findings indicated clear digenic inheritance in this patient and confirmed that loss of function of all 4 alleles of the CLCNKA and CLCNKB genes can result in Bartter syndrome type 4B.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">18310267</ID>
        </Citation>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant" ID="7601">
      <Measure Type="single nucleotide variant" ID="22640">
        <Name>
          <ElementValue Type="Preferred">CLCNKB, IVS17DS, G-A, +1</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="nucleotide change">IVS17DS, G-A, +1</Attribute>
          <XRef Type="Allelic variant" ID="602023.0011" DB="OMIM"/>
        </AttributeSet>
        <CytogeneticLocation>1p36</CytogeneticLocation>
        <MeasureRelationship Type="asserted, but not computed">
          <Name>
            <ElementValue Type="Preferred">chloride voltage-gated channel Kb</ElementValue>
          </Name>
          <Symbol>
            <ElementValue Type="Preferred">CLCNKB</ElementValue>
          </Symbol>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="1" Accession="NC_000001.11" start="16043736" stop="16057326" display_start="16043736" display_stop="16057326" Strand="+"/>
          <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="1" Accession="NC_000001.10" start="16370230" stop="16383820" display_start="16370230" display_stop="16383820" variantLength="13591" Strand="+"/>
          <XRef ID="1188" DB="Gene"/>
          <XRef Type="MIM" ID="602023" DB="OMIM"/>
          <XRef ID="HGNC:2027" DB="HGNC"/>
        </MeasureRelationship>
        <XRef Type="Allelic variant" ID="602023.0011" DB="OMIM"/>
      </Measure>
      <Name>
        <ElementValue Type="Preferred">CLCNKB, IVS17DS, G-A, +1</ElementValue>
      </Name>
    </MeasureSet>
    <TraitSet Type="Disease" ID="26762">
      <Trait ID="35353" Type="Disease">
        <Name>
          <ElementValue Type="Preferred">BARTTER SYNDROME, TYPE 4B, WITH SENSORINEURAL DEAFNESS</ElementValue>
          <XRef Type="Allelic variant" ID="602023.0008" DB="OMIM"/>
          <XRef Type="Allelic variant" ID="602023.0011" DB="OMIM"/>
        </Name>
      </Trait>
    </TraitSet>
  </ReferenceClinVarAssertion>
  <ClinVarAssertion ID="28244">
    <ClinVarSubmissionID localKey="602023.0011_BARTTER SYNDROME, TYPE 4B, WITH SENSORINEURAL DEAFNESS" submitter="OMIM" submitterDate="2016-05-12" title="CLCNKB, IVS17DS, G-A, +1 _BARTTER SYNDROME, TYPE 4B, WITH SENSORINEURAL DEAFNESS"/>
    <ClinVarAccession Acc="SCV000028244" OrgType="primary" OrganizationCategory="resource" Version="2" Type="SCV" OrgID="3" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2008-03-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ExternalID DB="OMIM" ID="602023.0011" Type="Allelic variant"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species>human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="Description">In a 2-year-old Japanese girl with a severe form of Bartter syndrome with sensorineural deafness (BARTS4B; 613090), Nozu et al. (2008) identified a heterozygous G-to-A transition in intron 7 of the CLCNKB gene, resulting in a splice site mutation, and a heterozygous mutation in the CLCNKA gene (Q260X; 602024.0002), both inherited from the father. The maternal allele had a 12-kb deletion including portions of both CLCNKA and CLCNKB. Neither parent was clinically affected. The findings indicated clear digenic inheritance in this patient and confirmed that loss of function of all 4 alleles of the CLCNKA and CLCNKB genes can result in Bartter syndrome type 4B.</Attribute>
        <Citation>
          <ID Source="PubMed">18310267</ID>
        </Citation>
        <XRef DB="OMIM" ID="613090" Type="MIM"/>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant">
      <Measure Type="Variation">
        <Name>
          <ElementValue Type="Preferred">CLCNKB, IVS17DS, G-A, +1</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="NonHGVS">IVS17DS, G-A, +1</Attribute>
        </AttributeSet>
        <MeasureRelationship Type="variant in gene">
          <Symbol>
            <ElementValue Type="Preferred">CLCNKB</ElementValue>
          </Symbol>
        </MeasureRelationship>
        <XRef DB="OMIM" ID="602023.0011" Type="Allelic variant"/>
      </Measure>
    </MeasureSet>
    <TraitSet Type="Disease">
      <Trait Type="Disease">
        <Name>
          <ElementValue Type="Preferred">BARTTER SYNDROME, TYPE 4B, WITH SENSORINEURAL DEAFNESS</ElementValue>
        </Name>
      </Trait>
    </TraitSet>
  </ClinVarAssertion>
</ClinVarSet>

<ClinVarSet ID="18645254">
  <RecordStatus>current</RecordStatus>
  <Title>PLP1, IVS3, 19-BP DEL, +28 AND Pelizaeus-Merzbacher disease, atypical</Title>
  <ReferenceClinVarAssertion DateCreated="2012-08-13" DateLastUpdated="2017-04-07" ID="69349">
    <ClinVarAccession Acc="RCV000011846" Version="3" Type="RCV" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2008-12-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData ID="17817837">
        <Attribute Type="Description">In a male patient with relatively late onset of nystagmus and rapidly progressive ataxia, Hobson et al. (2000) identified a 19-bp deletion in intron 3 near the splice donor site. The authors suggested that the deletion may define a highly conserved intron enhancer sequence that governs the alternative splicing of PLP and DM20. Three female family members were carriers of the mutation. Hobson et al. (2002) characterized the clinical phenotype of the previously reported male patient who at age 6 years had onset of difficulty in walking, rendering him wheelchair-bound by age 11 years with spastic paraparesis, cerebellar findings, optic atrophy, nystagmus, dysarthria, and cognitive decline. Sequential MRI studies showed delay in myelin formation and diffuse abnormal white matter signals, while MRS studies showed findings consistent with increased turnover of myelin and neuronal and axonal loss. Studies of the deletion in cultured oligodendrocytes showed that it contains a sequence that is critical for efficient PLP-specific splicing. Hobson et al. (2002) concluded that deletion of this region in PLP intron 3 causes a reduction in PLP message and protein, which affects myelin stability and axonal integrity.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">11071483</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">18835559</ID>
        </Citation>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant" ID="11097">
      <Measure Type="Deletion" ID="26136">
        <Name>
          <ElementValue Type="Preferred">PLP1, IVS3, 19-BP DEL, +28</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="nucleotide change">IVS3, 19-BP DEL, +28</Attribute>
          <XRef Type="Allelic variant" ID="300401.0025" DB="OMIM"/>
        </AttributeSet>
        <CytogeneticLocation>Xq22</CytogeneticLocation>
        <MeasureRelationship Type="asserted, but not computed">
          <Name>
            <ElementValue Type="Preferred">proteolipid protein 1</ElementValue>
          </Name>
          <Symbol>
            <ElementValue Type="Preferred">PLP1</ElementValue>
          </Symbol>
          <AttributeSet>
            <Attribute dateValue="2012-05-17" Type="Haploinsufficiency">Sufficient evidence for dosage pathogenicity</Attribute>
            <Citation>
              <URL>https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=PLP1</URL>
            </Citation>
          </AttributeSet>
          <AttributeSet>
            <Attribute dateValue="2012-05-17" Type="Triplosensitivity">Sufficient evidence for dosage pathogenicity</Attribute>
            <Citation>
              <URL>https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=PLP1</URL>
            </Citation>
          </AttributeSet>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="X" Accession="NC_000023.11" start="103776506" stop="103792619" display_start="103776506" display_stop="103792619" Strand="+"/>
          <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="X" Accession="NC_000023.10" start="103031438" stop="103047547" display_start="103031438" display_stop="103047547" variantLength="16110" Strand="+"/>
          <XRef ID="5354" DB="Gene"/>
          <XRef Type="MIM" ID="300401" DB="OMIM"/>
          <XRef ID="HGNC:9086" DB="HGNC"/>
        </MeasureRelationship>
        <XRef Type="Allelic variant" ID="300401.0025" DB="OMIM"/>
      </Measure>
      <Name>
        <ElementValue Type="Preferred">PLP1, IVS3, 19-BP DEL, +28</ElementValue>
      </Name>
    </MeasureSet>
    <TraitSet Type="Disease" ID="3070">
      <Trait ID="10869" Type="Disease">
        <Name>
          <ElementValue Type="Preferred">Pelizaeus-Merzbacher disease, atypical</ElementValue>
        </Name>
        <XRef ID="C0751915" DB="MedGen"/>
      </Trait>
    </TraitSet>
  </ReferenceClinVarAssertion>
  <ClinVarAssertion ID="32079">
    <ClinVarSubmissionID localKey="300401.0025_PELIZAEUS-MERZBACHER DISEASE, ATYPICAL" submitter="OMIM" submitterDate="2016-12-02" title="PLP1, IVS3, 19-BP DEL, +28_PELIZAEUS-MERZBACHER DISEASE, ATYPICAL"/>
    <ClinVarAccession Acc="SCV000032079" OrgType="primary" OrganizationCategory="resource" Version="2" Type="SCV" OrgID="3" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2008-12-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ExternalID DB="OMIM" ID="300401.0025" Type="Allelic variant"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species>human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="Description">In a male patient with relatively late onset of nystagmus and rapidly progressive ataxia, Hobson et al. (2000) identified a 19-bp deletion in intron 3 near the splice donor site. The authors suggested that the deletion may define a highly conserved intron enhancer sequence that governs the alternative splicing of PLP and DM20. Three female family members were carriers of the mutation. Hobson et al. (2002) characterized the clinical phenotype of the previously reported male patient who at age 6 years had onset of difficulty in walking, rendering him wheelchair-bound by age 11 years with spastic paraparesis, cerebellar findings, optic atrophy, nystagmus, dysarthria, and cognitive decline. Sequential MRI studies showed delay in myelin formation and diffuse abnormal white matter signals, while MRS studies showed findings consistent with increased turnover of myelin and neuronal and axonal loss. Studies of the deletion in cultured oligodendrocytes showed that it contains a sequence that is critical for efficient PLP-specific splicing. Hobson et al. (2002) concluded that deletion of this region in PLP intron 3 causes a reduction in PLP message and protein, which affects myelin stability and axonal integrity.</Attribute>
        <Citation>
          <ID Source="PubMed">11071483</ID>
        </Citation>
        <Citation>
          <ID Source="PubMed">18835559</ID>
        </Citation>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant">
      <Measure Type="Variation">
        <Name>
          <ElementValue Type="Preferred">PLP1, IVS3, 19-BP DEL, +28</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="NonHGVS">IVS3, 19-BP DEL, +28</Attribute>
        </AttributeSet>
        <MeasureRelationship Type="variant in gene">
          <Symbol>
            <ElementValue Type="Preferred">PLP1</ElementValue>
          </Symbol>
        </MeasureRelationship>
        <XRef DB="OMIM" ID="300401.0025" Type="Allelic variant"/>
      </Measure>
    </MeasureSet>
    <TraitSet Type="Disease">
      <Trait Type="Disease">
        <Name>
          <ElementValue Type="Preferred">PELIZAEUS-MERZBACHER DISEASE, ATYPICAL</ElementValue>
        </Name>
      </Trait>
    </TraitSet>
  </ClinVarAssertion>
</ClinVarSet>

<ClinVarSet ID="18636733">
  <RecordStatus>current</RecordStatus>
  <Title>PEX12, 2-BP DEL, 26CA AND Peroxisomal biogenesis disorder 3b</Title>
  <ReferenceClinVarAssertion DateCreated="2012-08-13" DateLastUpdated="2017-04-07" ID="65721">
    <ClinVarAccession Acc="RCV000008218" Version="5" Type="RCV" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="1998-11-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData ID="17814077">
        <Attribute Type="Description">In a patient (PBD099) with a mild form of peroxisome biogenesis disorder of complementation group 3 (PBD3B; 266510), Chang and Gould (1998) identified compound heterozygosity for 2 mutations in the PEX12 gene: a 2-bp deletion (26delCA) early in the coding region and a splice site mutation (601758.0008). PEX12 mRNA present in the patient's cells was derived from only the allele with the 2-bp deletion. The deduced protein product of this mRNA would contain only the first 8 amino acids of the protein, but functional expression studies showed that the mutant PEX12 protein retained significant residual activity, approximately one-seventh that of the wildtype protein. Further analysis showed that the 2-bp mutation resulted in the synthesis of a 29-kD PEX12 protein in vitro, consistent with translation initiation at a downstream internal AUG codon. The authors noted that translation initiation at internal AUG codons may modulate disease phenotypes and should be considered when unexpectedly mild phenotypes result from predicated 'severe' mutations early in the coding region.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">9792857</ID>
        </Citation>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant" ID="7776">
      <Measure Type="Deletion" ID="22815">
        <Name>
          <ElementValue Type="Preferred">PEX12, 2-BP DEL, 26CA</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="nucleotide change">2-BP DEL, 26CA</Attribute>
          <XRef Type="Allelic variant" ID="601758.0007" DB="OMIM"/>
        </AttributeSet>
        <CytogeneticLocation>17</CytogeneticLocation>
        <MeasureRelationship Type="asserted, but not computed">
          <Name>
            <ElementValue Type="Preferred">peroxisomal biogenesis factor 12</ElementValue>
          </Name>
          <Symbol>
            <ElementValue Type="Preferred">PEX12</ElementValue>
          </Symbol>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="17" Accession="NC_000017.11" start="35574795" stop="35578637" display_start="35574795" display_stop="35578637" Strand="-"/>
          <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="17" Accession="NC_000017.10" start="33901813" stop="33905655" display_start="33901813" display_stop="33905655" variantLength="3843" Strand="-"/>
          <XRef ID="5193" DB="Gene"/>
          <XRef Type="MIM" ID="601758" DB="OMIM"/>
          <XRef ID="HGNC:8854" DB="HGNC"/>
        </MeasureRelationship>
        <XRef Type="Allelic variant" ID="601758.0007" DB="OMIM"/>
      </Measure>
      <Name>
        <ElementValue Type="Preferred">PEX12, 2-BP DEL, 26CA</ElementValue>
      </Name>
    </MeasureSet>
    <TraitSet Type="Disease" ID="9247">
      <Trait ID="17602" Type="Disease">
        <Name>
          <ElementValue Type="Preferred">Peroxisomal biogenesis disorder 3b</ElementValue>
        </Name>
        <XRef ID="C3551381" DB="MedGen"/>
      </Trait>
    </TraitSet>
  </ReferenceClinVarAssertion>
  <ClinVarAssertion ID="28425">
    <ClinVarSubmissionID localKey="601758.0007_PEROXISOMAL BIOGENESIS DISORDER 3B" submitter="OMIM" submitterDate="2017-01-31" title="PEX12, 2-BP DEL, 26CA_PEROXISOMAL BIOGENESIS DISORDER 3B"/>
    <ClinVarAccession Acc="SCV000028425" OrgType="primary" OrganizationCategory="resource" Version="3" Type="SCV" OrgID="3" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="1998-11-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ExternalID DB="OMIM" ID="601758.0007" Type="Allelic variant"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species>human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="Description">In a patient (PBD099) with a mild form of peroxisome biogenesis disorder of complementation group 3 (PBD3B; 266510), Chang and Gould (1998) identified compound heterozygosity for 2 mutations in the PEX12 gene: a 2-bp deletion (26delCA) early in the coding region and a splice site mutation (601758.0008). PEX12 mRNA present in the patient's cells was derived from only the allele with the 2-bp deletion. The deduced protein product of this mRNA would contain only the first 8 amino acids of the protein, but functional expression studies showed that the mutant PEX12 protein retained significant residual activity, approximately one-seventh that of the wildtype protein. Further analysis showed that the 2-bp mutation resulted in the synthesis of a 29-kD PEX12 protein in vitro, consistent with translation initiation at a downstream internal AUG codon. The authors noted that translation initiation at internal AUG codons may modulate disease phenotypes and should be considered when unexpectedly mild phenotypes result from predicated 'severe' mutations early in the coding region.</Attribute>
        <Citation>
          <ID Source="PubMed">9792857</ID>
        </Citation>
        <XRef DB="OMIM" ID="266510" Type="MIM"/>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant">
      <Measure Type="Variation">
        <Name>
          <ElementValue Type="Preferred">PEX12, 2-BP DEL, 26CA</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="NonHGVS">2-BP DEL, 26CA</Attribute>
        </AttributeSet>
        <MeasureRelationship Type="variant in gene">
          <Symbol>
            <ElementValue Type="Preferred">PEX12</ElementValue>
          </Symbol>
        </MeasureRelationship>
        <XRef DB="OMIM" ID="601758.0007" Type="Allelic variant"/>
      </Measure>
    </MeasureSet>
    <TraitSet Type="Disease">
      <Trait Type="Disease">
        <Name>
          <ElementValue Type="Preferred">PEROXISOMAL BIOGENESIS DISORDER 3B</ElementValue>
        </Name>
      </Trait>
    </TraitSet>
  </ClinVarAssertion>
</ClinVarSet>

<ClinVarSet ID="18636734">
  <RecordStatus>current</RecordStatus>
  <Title>PEX12, IVS1DS, G-T, +1 AND Peroxisomal biogenesis disorder 3b</Title>
  <ReferenceClinVarAssertion DateCreated="2012-08-13" DateLastUpdated="2017-04-07" ID="65722">
    <ClinVarAccession Acc="RCV000008219" Version="5" Type="RCV" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="1998-11-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData ID="17810149">
        <Attribute Type="Description">For discussion of the splice site mutation in the PEX12 gene that was found in compound heterozygous state in a patient (PBD099) with a mild form of peroxisome biogenesis disorder of complementation group 3 (PBD3B; 266510) by Chang and Gould (1998), see 601758.0007.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">9792857</ID>
        </Citation>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant" ID="7777">
      <Measure Type="single nucleotide variant" ID="22816">
        <Name>
          <ElementValue Type="Preferred">PEX12, IVS1DS, G-T, +1</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="nucleotide change">IVS1DS, G-T, +1</Attribute>
          <XRef Type="Allelic variant" ID="601758.0008" DB="OMIM"/>
        </AttributeSet>
        <CytogeneticLocation>17</CytogeneticLocation>
        <MeasureRelationship Type="asserted, but not computed">
          <Name>
            <ElementValue Type="Preferred">peroxisomal biogenesis factor 12</ElementValue>
          </Name>
          <Symbol>
            <ElementValue Type="Preferred">PEX12</ElementValue>
          </Symbol>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="17" Accession="NC_000017.11" start="35574795" stop="35578637" display_start="35574795" display_stop="35578637" Strand="-"/>
          <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="17" Accession="NC_000017.10" start="33901813" stop="33905655" display_start="33901813" display_stop="33905655" variantLength="3843" Strand="-"/>
          <XRef ID="5193" DB="Gene"/>
          <XRef Type="MIM" ID="601758" DB="OMIM"/>
          <XRef ID="HGNC:8854" DB="HGNC"/>
        </MeasureRelationship>
        <XRef Type="Allelic variant" ID="601758.0008" DB="OMIM"/>
      </Measure>
      <Name>
        <ElementValue Type="Preferred">PEX12, IVS1DS, G-T, +1</ElementValue>
      </Name>
    </MeasureSet>
    <TraitSet Type="Disease" ID="9247">
      <Trait ID="17602" Type="Disease">
        <Name>
          <ElementValue Type="Preferred">Peroxisomal biogenesis disorder 3b</ElementValue>
        </Name>
        <XRef ID="C3551381" DB="MedGen"/>
      </Trait>
    </TraitSet>
  </ReferenceClinVarAssertion>
  <ClinVarAssertion ID="28426">
    <ClinVarSubmissionID localKey="601758.0008_PEROXISOMAL BIOGENESIS DISORDER 3B" submitter="OMIM" submitterDate="2017-01-31" title="PEX12, IVS1DS, G-T, +1_PEROXISOMAL BIOGENESIS DISORDER 3B"/>
    <ClinVarAccession Acc="SCV000028426" OrgType="primary" OrganizationCategory="resource" Version="4" Type="SCV" OrgID="3" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="1998-11-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ExternalID DB="OMIM" ID="601758.0008" Type="Allelic variant"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species>human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="Description">For discussion of the splice site mutation in the PEX12 gene that was found in compound heterozygous state in a patient (PBD099) with a mild form of peroxisome biogenesis disorder of complementation group 3 (PBD3B; 266510) by Chang and Gould (1998), see 601758.0007.</Attribute>
        <Citation>
          <ID Source="PubMed">9792857</ID>
        </Citation>
        <XRef DB="OMIM" ID="266510" Type="MIM"/>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant">
      <Measure Type="Variation">
        <Name>
          <ElementValue Type="Preferred">PEX12, IVS1DS, G-T, +1</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="NonHGVS">IVS1DS, G-T, +1</Attribute>
        </AttributeSet>
        <MeasureRelationship Type="variant in gene">
          <Symbol>
            <ElementValue Type="Preferred">PEX12</ElementValue>
          </Symbol>
        </MeasureRelationship>
        <XRef DB="OMIM" ID="601758.0008" Type="Allelic variant"/>
      </Measure>
    </MeasureSet>
    <TraitSet Type="Disease">
      <Trait Type="Disease">
        <Name>
          <ElementValue Type="Preferred">PEROXISOMAL BIOGENESIS DISORDER 3B</ElementValue>
        </Name>
      </Trait>
    </TraitSet>
  </ClinVarAssertion>
</ClinVarSet>

<ClinVarSet ID="18637644">
  <RecordStatus>current</RecordStatus>
  <Title>AMHR2, IVS2DS, G-T, +1 AND Persistent mullerian duct syndrome, type II</Title>
  <ReferenceClinVarAssertion DateCreated="2012-08-13" DateLastUpdated="2017-04-07" ID="66661">
    <ClinVarAccession Acc="RCV000009158" Version="2" Type="RCV" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="1995-12-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData ID="17810797">
        <Attribute Type="Description">Imbeaud et al. (1995) demonstrated a G-to-A transition at position +1 of the splice donor site of intron 2 of the AMHR gene in a 3-month-old boy, born to allegedly unrelated Pakistani parents, who came to medical attention because of right cryptorchidism associated with a left inguinal hernia. At surgery, both testes were found in the left scrotum and inguinal canal, associated with a uterus and 2 fallopian tubes (see 261550). Biopsy showed normal seminiferous tubules containing germ cells. Normal regression of fetal rat mullerian ducts was elicited by coculture with a small testicular fragment, thus indicating that AMH was produced. Indeed, the AMH gene was sequenced and found to be normal in this patient. The G-to-A transition they found destroyed an HphI restriction site, allowing the determination of the genotype in the patient and his parents. The mutation was homozygous in the patient and both parents were heterozygotes. The mutation resulted in alternative splicing with production of 2 types of mRNA were produced: the shorter mRNA moiety showed skipping of the second exon with conservation of the reading frame; the longer one contained a 12-bp portion of intron 2, generated by the use of a cryptic donor sequence, GTATA, downstream of the splicing mutation. The result was a gly78-to-asp change of 1 amino acid followed by the insertion of 4 new residues, EWQR, at the end of exon 2.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">7493017</ID>
        </Citation>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant" ID="8626">
      <Measure Type="single nucleotide variant" ID="23665">
        <Name>
          <ElementValue Type="Preferred">AMHR2, IVS2DS, G-T, +1</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="nucleotide change">IVS2DS, G-T, +1</Attribute>
          <XRef Type="Allelic variant" ID="600956.0001" DB="OMIM"/>
        </AttributeSet>
        <CytogeneticLocation>12q13</CytogeneticLocation>
        <MeasureRelationship Type="asserted, but not computed">
          <Name>
            <ElementValue Type="Preferred">anti-Mullerian hormone receptor type 2</ElementValue>
          </Name>
          <Symbol>
            <ElementValue Type="Preferred">AMHR2</ElementValue>
          </Symbol>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="12" Accession="NC_000012.12" start="53423855" stop="53431672" display_start="53423855" display_stop="53431672" Strand="+"/>
          <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="12" Accession="NC_000012.11" start="53817638" stop="53825317" display_start="53817638" display_stop="53825317" variantLength="7680" Strand="+"/>
          <XRef ID="269" DB="Gene"/>
          <XRef Type="MIM" ID="600956" DB="OMIM"/>
          <XRef ID="HGNC:465" DB="HGNC"/>
        </MeasureRelationship>
        <XRef Type="Allelic variant" ID="600956.0001" DB="OMIM"/>
      </Measure>
      <Name>
        <ElementValue Type="Preferred">AMHR2, IVS2DS, G-T, +1</ElementValue>
      </Name>
    </MeasureSet>
    <TraitSet Type="Disease" ID="2370">
      <Trait ID="10460" Type="Disease">
        <Name>
          <ElementValue Type="Preferred">Persistent mullerian duct syndrome, type II</ElementValue>
        </Name>
        <XRef ID="C3897940" DB="MedGen"/>
      </Trait>
    </TraitSet>
  </ReferenceClinVarAssertion>
  <ClinVarAssertion ID="29375">
    <ClinVarSubmissionID localKey="600956.0001_PERSISTENT MULLERIAN DUCT SYNDROME, TYPE II" submitter="OMIM" submitterDate="2010-07-16" title="AMHR2, IVS2DS, G-T, +1_PERSISTENT MULLERIAN DUCT SYNDROME, TYPE II"/>
    <ClinVarAccession Acc="SCV000029375" OrgType="primary" OrganizationCategory="resource" Version="1" Type="SCV" OrgID="3" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="1995-12-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ExternalID DB="OMIM" ID="600956.0001" Type="Allelic variant"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species>human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="Description">Imbeaud et al. (1995) demonstrated a G-to-A transition at position +1 of the splice donor site of intron 2 of the AMHR gene in a 3-month-old boy, born to allegedly unrelated Pakistani parents, who came to medical attention because of right cryptorchidism associated with a left inguinal hernia. At surgery, both testes were found in the left scrotum and inguinal canal, associated with a uterus and 2 fallopian tubes (see 261550). Biopsy showed normal seminiferous tubules containing germ cells. Normal regression of fetal rat mullerian ducts was elicited by coculture with a small testicular fragment, thus indicating that AMH was produced. Indeed, the AMH gene was sequenced and found to be normal in this patient. The G-to-A transition they found destroyed an HphI restriction site, allowing the determination of the genotype in the patient and his parents. The mutation was homozygous in the patient and both parents were heterozygotes. The mutation resulted in alternative splicing with production of 2 types of mRNA were produced: the shorter mRNA moiety showed skipping of the second exon with conservation of the reading frame; the longer one contained a 12-bp portion of intron 2, generated by the use of a cryptic donor sequence, GTATA, downstream of the splicing mutation. The result was a gly78-to-asp change of 1 amino acid followed by the insertion of 4 new residues, EWQR, at the end of exon 2.</Attribute>
        <Citation>
          <ID Source="PubMed">7493017</ID>
        </Citation>
        <XRef DB="OMIM" ID="261550" Type="MIM"/>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant">
      <Measure Type="Variation">
        <Name>
          <ElementValue Type="Preferred">AMHR2, IVS2DS, G-T, +1</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="NonHGVS">IVS2DS, G-T, +1</Attribute>
        </AttributeSet>
        <MeasureRelationship Type="variant in gene">
          <Symbol>
            <ElementValue Type="Preferred">AMHR2</ElementValue>
          </Symbol>
        </MeasureRelationship>
        <XRef DB="OMIM" ID="600956.0001" Type="Allelic variant"/>
      </Measure>
    </MeasureSet>
    <TraitSet Type="Disease">
      <Trait Type="Disease">
        <Name>
          <ElementValue Type="Preferred">PERSISTENT MULLERIAN DUCT SYNDROME, TYPE II</ElementValue>
        </Name>
      </Trait>
    </TraitSet>
  </ClinVarAssertion>
</ClinVarSet>

<ClinVarSet ID="18637645">
  <RecordStatus>current</RecordStatus>
  <Title>AMHR2, 27-BP DEL, NT6331 AND Persistent mullerian duct syndrome, type II</Title>
  <ReferenceClinVarAssertion DateCreated="2012-08-13" DateLastUpdated="2017-04-07" ID="66662">
    <ClinVarAccession Acc="RCV000009159" Version="2" Type="RCV" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2009-08-15">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData ID="17815196">
        <Attribute Type="Description">Imbeaud et al. (1996) detected a 27-bp deletion (6331_6357del) in exon 10 of the AMHR gene, on at least 1 allele in 10 of 16 patients studied with AMHR mutations. The deletion was homozygous in 4 patients and was coupled with missense mutations in 6 patients.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">8872466</ID>
        </Citation>
      </ObservedData>
      <ObservedData ID="17815196">
        <Attribute Type="Description">Belville et al. (2009) noted that the 6331_6357del is missing residues 444 to 452, which are located at the top of the C-lobe in the X region of the kinase domain. Molecular modeling predicted that the deletion should lead to a substantial conformational change in the AMHR2 fold, since the residues constitute part of the alpha-G helix and the loop that precedes it.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">19457927</ID>
        </Citation>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant" ID="8627">
      <Measure Type="Deletion" ID="23666">
        <Name>
          <ElementValue Type="Preferred">AMHR2, 27-BP DEL, NT6331</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="nucleotide change">27-BP DEL, NT6331</Attribute>
          <XRef Type="Allelic variant" ID="600956.0002" DB="OMIM"/>
        </AttributeSet>
        <CytogeneticLocation>12q13</CytogeneticLocation>
        <MeasureRelationship Type="asserted, but not computed">
          <Name>
            <ElementValue Type="Preferred">anti-Mullerian hormone receptor type 2</ElementValue>
          </Name>
          <Symbol>
            <ElementValue Type="Preferred">AMHR2</ElementValue>
          </Symbol>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="12" Accession="NC_000012.12" start="53423855" stop="53431672" display_start="53423855" display_stop="53431672" Strand="+"/>
          <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="12" Accession="NC_000012.11" start="53817638" stop="53825317" display_start="53817638" display_stop="53825317" variantLength="7680" Strand="+"/>
          <XRef ID="269" DB="Gene"/>
          <XRef Type="MIM" ID="600956" DB="OMIM"/>
          <XRef ID="HGNC:465" DB="HGNC"/>
        </MeasureRelationship>
        <XRef Type="Allelic variant" ID="600956.0002" DB="OMIM"/>
      </Measure>
      <Name>
        <ElementValue Type="Preferred">AMHR2, 27-BP DEL, NT6331</ElementValue>
      </Name>
    </MeasureSet>
    <TraitSet Type="Disease" ID="2370">
      <Trait ID="10460" Type="Disease">
        <Name>
          <ElementValue Type="Preferred">Persistent mullerian duct syndrome, type II</ElementValue>
        </Name>
        <XRef ID="C3897940" DB="MedGen"/>
      </Trait>
    </TraitSet>
  </ReferenceClinVarAssertion>
  <ClinVarAssertion ID="29376">
    <ClinVarSubmissionID localKey="600956.0002_PERSISTENT MULLERIAN DUCT SYNDROME, TYPE II" submitter="OMIM" submitterDate="2010-07-16" title="AMHR2, 27-BP DEL, NT6331 _PERSISTENT MULLERIAN DUCT SYNDROME, TYPE II"/>
    <ClinVarAccession Acc="SCV000029376" OrgType="primary" OrganizationCategory="resource" Version="1" Type="SCV" OrgID="3" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2009-08-15">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ExternalID DB="OMIM" ID="600956.0002" Type="Allelic variant"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species>human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="Description">Imbeaud et al. (1996) detected a 27-bp deletion (6331_6357del) in exon 10 of the AMHR gene, on at least 1 allele in 10 of 16 patients studied with AMHR mutations. The deletion was homozygous in 4 patients and was coupled with missense mutations in 6 patients.</Attribute>
        <Citation>
          <ID Source="PubMed">8872466</ID>
        </Citation>
      </ObservedData>
      <ObservedData>
        <Attribute Type="Description">Belville et al. (2009) noted that the 6331_6357del is missing residues 444 to 452, which are located at the top of the C-lobe in the X region of the kinase domain. Molecular modeling predicted that the deletion should lead to a substantial conformational change in the AMHR2 fold, since the residues constitute part of the alpha-G helix and the loop that precedes it.</Attribute>
        <Citation>
          <ID Source="PubMed">19457927</ID>
        </Citation>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant">
      <Measure Type="Variation">
        <Name>
          <ElementValue Type="Preferred">AMHR2, 27-BP DEL, NT6331</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="NonHGVS">27-BP DEL, NT6331</Attribute>
        </AttributeSet>
        <MeasureRelationship Type="variant in gene">
          <Symbol>
            <ElementValue Type="Preferred">AMHR2</ElementValue>
          </Symbol>
        </MeasureRelationship>
        <XRef DB="OMIM" ID="600956.0002" Type="Allelic variant"/>
      </Measure>
    </MeasureSet>
    <TraitSet Type="Disease">
      <Trait Type="Disease">
        <Name>
          <ElementValue Type="Preferred">PERSISTENT MULLERIAN DUCT SYNDROME, TYPE II</ElementValue>
        </Name>
      </Trait>
    </TraitSet>
  </ClinVarAssertion>
</ClinVarSet>

<ClinVarSet ID="18628106">
  <RecordStatus>current</RecordStatus>
  <Title>HAMP, 4-BP DEL, ATGG AND Hemochromatosis, juvenile, digenic</Title>
  <ReferenceClinVarAssertion DateCreated="2012-08-13" DateLastUpdated="2017-04-07" ID="62009">
    <ClinVarAccession Acc="RCV000004506" Version="2" Type="RCV" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2003-09-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData ID="17809004">
        <Attribute Type="Description">Merryweather-Clarke et al. (2003) reported an individual with a juvenile hemochromatosis (613313) phenotype who was heterozygous for the C282Y mutation in the HFE gene (613609.0001) as well as a 4-bp HAMP frameshift mutation. The mutation deleted the last codon of exon 2 (met50) as well as the first base of the splice donor site of intron 2 (IVS+1(-G)). The mutation was predicted to result in retention of the splice consensus site, but altered the reading frame, extending it beyond the end of the normal transcript. The proband's unaffected mother was also heterozygous for the HAMP frameshift mutation, but lacked the HFE C282Y mutation and was heterozygous for the HFE H63D mutation (613609.0002).</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">12915468</ID>
        </Citation>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant" ID="4285">
      <Measure Type="Deletion" ID="19324">
        <Name>
          <ElementValue Type="Preferred">HAMP, 4-BP DEL, ATGG</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="nucleotide change">4-BP DEL, ATGG</Attribute>
          <XRef Type="Allelic variant" ID="606464.0003" DB="OMIM"/>
        </AttributeSet>
        <CytogeneticLocation>19q13</CytogeneticLocation>
        <MeasureRelationship Type="asserted, but not computed">
          <Name>
            <ElementValue Type="Preferred">hepcidin antimicrobial peptide</ElementValue>
          </Name>
          <Symbol>
            <ElementValue Type="Preferred">HAMP</ElementValue>
          </Symbol>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="19" Accession="NC_000019.10" start="35282346" stop="35285143" display_start="35282346" display_stop="35285143" Strand="+"/>
          <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="19" Accession="NC_000019.9" start="35773409" stop="35776045" display_start="35773409" display_stop="35776045" variantLength="2637" Strand="+"/>
          <XRef ID="57817" DB="Gene"/>
          <XRef Type="MIM" ID="606464" DB="OMIM"/>
          <XRef ID="HGNC:15598" DB="HGNC"/>
        </MeasureRelationship>
        <XRef Type="Allelic variant" ID="606464.0003" DB="OMIM"/>
      </Measure>
      <Name>
        <ElementValue Type="Preferred">HAMP, 4-BP DEL, ATGG</ElementValue>
      </Name>
    </MeasureSet>
    <TraitSet Type="Disease" ID="10">
      <Trait ID="9585" Type="Disease">
        <Name>
          <ElementValue Type="Preferred">Hemochromatosis, juvenile, digenic</ElementValue>
        </Name>
        <XRef ID="C3150862" DB="MedGen"/>
      </Trait>
    </TraitSet>
  </ReferenceClinVarAssertion>
  <ClinVarAssertion ID="24680">
    <ClinVarSubmissionID localKey="606464.0003_HEMOCHROMATOSIS, JUVENILE, DIGENIC" submitter="OMIM" submitterDate="2012-11-28" title="HAMP, 4-BP DEL, ATGG_HEMOCHROMATOSIS, JUVENILE, DIGENIC"/>
    <ClinVarAccession Acc="SCV000024680" OrgType="primary" OrganizationCategory="resource" Version="1" Type="SCV" OrgID="3" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2003-09-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ExternalID DB="OMIM" ID="606464.0003" Type="Allelic variant"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species>human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="Description">Merryweather-Clarke et al. (2003) reported an individual with a juvenile hemochromatosis (613313) phenotype who was heterozygous for the C282Y mutation in the HFE gene (613609.0001) as well as a 4-bp HAMP frameshift mutation. The mutation deleted the last codon of exon 2 (met50) as well as the first base of the splice donor site of intron 2 (IVS+1(-G)). The mutation was predicted to result in retention of the splice consensus site, but altered the reading frame, extending it beyond the end of the normal transcript. The proband's unaffected mother was also heterozygous for the HAMP frameshift mutation, but lacked the HFE C282Y mutation and was heterozygous for the HFE H63D mutation (613609.0002).</Attribute>
        <Citation>
          <ID Source="PubMed">12915468</ID>
        </Citation>
        <XRef DB="OMIM" ID="613313" Type="MIM"/>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant">
      <Measure Type="Variation">
        <Name>
          <ElementValue Type="Preferred">HAMP, 4-BP DEL, ATGG</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="NonHGVS">4-BP DEL, ATGG</Attribute>
        </AttributeSet>
        <MeasureRelationship Type="variant in gene">
          <Symbol>
            <ElementValue Type="Preferred">HAMP</ElementValue>
          </Symbol>
        </MeasureRelationship>
        <XRef DB="OMIM" ID="606464.0003" Type="Allelic variant"/>
      </Measure>
    </MeasureSet>
    <TraitSet Type="Disease">
      <Trait Type="Disease">
        <Name>
          <ElementValue Type="Preferred">HEMOCHROMATOSIS, JUVENILE, DIGENIC</ElementValue>
        </Name>
      </Trait>
    </TraitSet>
  </ClinVarAssertion>
</ClinVarSet>

<ClinVarSet ID="18646290">
  <RecordStatus>current</RecordStatus>
  <Title>C2, SER189PHE AND C2 deficiency, type II</Title>
  <ReferenceClinVarAssertion DateCreated="2012-08-13" DateLastUpdated="2017-04-07" ID="70414">
    <ClinVarAccession Acc="RCV000012911" Version="2" Type="RCV" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="1996-03-08">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData ID="17814703">
        <Attribute Type="Description">C2 deficiency type II (217000) is characterized by a selective block in C2 secretion. The type II C2 null allele (C2Q0) is linked to 2 major histocompatibility haplotypes that differ from the MHC of the common type I C2 deficiency. To determine the molecular basis of type II deficiency, Wetsel et al. (1996) isolated 2 type II C2Q0 genes and transfected them separately into L-cells. Different missense mutations at highly conserved residues in each of the C2Q0 alleles were found. One was a 566C-T transition in exon 5 resulting in a ser189-to-phe (S189F) substitution. The other was a 1930G-A transition in exon 11 resulting in a gly444-to-arg (G444R) substitution (613927.0003). Each was on a different MHC haplotype and each mutant C2 gene product was retained early in the secretory pathway.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">8621452</ID>
        </Citation>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant" ID="12128">
      <Measure Type="single nucleotide variant" ID="27167">
        <Name>
          <ElementValue Type="Preferred">C2, SER189PHE</ElementValue>
        </Name>
        <Name>
          <ElementValue Type="Alternate">C2, SER189PHE</ElementValue>
          <XRef Type="Allelic variant" ID="613927.0002" DB="OMIM"/>
        </Name>
        <AttributeSet>
          <Attribute Type="ProteinChange1LetterCode">S189F</Attribute>
          <XRef Type="Allelic variant" ID="613927.0002" DB="OMIM"/>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="ProteinChange3LetterCode">SER189PHE</Attribute>
          <XRef Type="Allelic variant" ID="613927.0002" DB="OMIM"/>
        </AttributeSet>
        <CytogeneticLocation>6p21.3</CytogeneticLocation>
        <MeasureRelationship Type="asserted, but not computed">
          <Name>
            <ElementValue Type="Preferred">complement C2</ElementValue>
          </Name>
          <Symbol>
            <ElementValue Type="Preferred">C2</ElementValue>
          </Symbol>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="6" Accession="NC_000006.12" start="31897785" stop="31945674" display_start="31897785" display_stop="31945674" Strand="+"/>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="6" Accession="NT_113891.3" start="3375210" stop="3423101" display_start="3375210" display_stop="3423101" Strand="+"/>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="6" Accession="NT_167245.2" start="3145559" stop="3193454" display_start="3145559" display_stop="3193454" Strand="+"/>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="6" Accession="NT_167246.2" start="3232692" stop="3250651" display_start="3232692" display_stop="3250651" Strand="+"/>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="6" Accession="NT_167247.2" start="3239857" stop="3287710" display_start="3239857" display_stop="3287710" Strand="+"/>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="6" Accession="NT_167248.2" start="3153757" stop="3201649" display_start="3153757" display_stop="3201649" Strand="+"/>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="6" Accession="NT_167249.2" start="3228716" stop="3246863" display_start="3228716" display_stop="3246863" Strand="+"/>
          <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="6" Accession="NC_000006.11" start="31865561" stop="31913448" display_start="31865561" display_stop="31913448" variantLength="47888" Strand="+"/>
          <XRef ID="717" DB="Gene"/>
          <XRef Type="MIM" ID="613927" DB="OMIM"/>
          <XRef ID="HGNC:1248" DB="HGNC"/>
        </MeasureRelationship>
        <XRef Type="Allelic variant" ID="613927.0002" DB="OMIM"/>
      </Measure>
      <Name>
        <ElementValue Type="Preferred">C2, SER189PHE</ElementValue>
      </Name>
    </MeasureSet>
    <TraitSet Type="Disease" ID="3285">
      <Trait ID="10954" Type="Disease">
        <Name>
          <ElementValue Type="Preferred">C2 deficiency, type II</ElementValue>
        </Name>
        <XRef ID="C4017352" DB="MedGen"/>
      </Trait>
    </TraitSet>
  </ReferenceClinVarAssertion>
  <ClinVarAssertion ID="33152">
    <ClinVarSubmissionID localKey="613927.0002_C2 DEFICIENCY, TYPE II" submitter="OMIM" submitterDate="2012-06-07" title="C2, SER189PHE_C2 DEFICIENCY, TYPE II"/>
    <ClinVarAccession Acc="SCV000033152" OrgType="primary" OrganizationCategory="resource" Version="1" Type="SCV" OrgID="3" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="1996-03-08">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ExternalID DB="OMIM" ID="613927.0002" Type="Allelic variant"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species>human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="Description">C2 deficiency type II (217000) is characterized by a selective block in C2 secretion. The type II C2 null allele (C2Q0) is linked to 2 major histocompatibility haplotypes that differ from the MHC of the common type I C2 deficiency. To determine the molecular basis of type II deficiency, Wetsel et al. (1996) isolated 2 type II C2Q0 genes and transfected them separately into L-cells. Different missense mutations at highly conserved residues in each of the C2Q0 alleles were found. One was a 566C-T transition in exon 5 resulting in a ser189-to-phe (S189F) substitution. The other was a 1930G-A transition in exon 11 resulting in a gly444-to-arg (G444R) substitution (613927.0003). Each was on a different MHC haplotype and each mutant C2 gene product was retained early in the secretory pathway.</Attribute>
        <Citation>
          <ID Source="PubMed">8621452</ID>
        </Citation>
        <XRef DB="OMIM" ID="217000" Type="MIM"/>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant">
      <Measure Type="Variation">
        <Name>
          <ElementValue Type="Preferred">C2, SER189PHE</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="NonHGVS">SER189PHE</Attribute>
        </AttributeSet>
        <MeasureRelationship Type="variant in gene">
          <Symbol>
            <ElementValue Type="Preferred">C2</ElementValue>
          </Symbol>
        </MeasureRelationship>
        <XRef DB="OMIM" ID="613927.0002" Type="Allelic variant"/>
      </Measure>
    </MeasureSet>
    <TraitSet Type="Disease">
      <Trait Type="Disease">
        <Name>
          <ElementValue Type="Preferred">C2 DEFICIENCY, TYPE II</ElementValue>
        </Name>
      </Trait>
    </TraitSet>
  </ClinVarAssertion>
</ClinVarSet>

<ClinVarSet ID="18646291">
  <RecordStatus>current</RecordStatus>
  <Title>C2, GLY444ARG AND C2 deficiency, type II</Title>
  <ReferenceClinVarAssertion DateCreated="2012-08-13" DateLastUpdated="2017-04-07" ID="70415">
    <ClinVarAccession Acc="RCV000012912" Version="2" Type="RCV" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="1996-03-08">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData ID="17819324">
        <Attribute Type="Description">See 613927.0002 and Wetsel et al. (1996).</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">8621452</ID>
        </Citation>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant" ID="12129">
      <Measure Type="Variation" ID="27168">
        <Name>
          <ElementValue Type="Preferred">C2, GLY444ARG</ElementValue>
        </Name>
        <Name>
          <ElementValue Type="Alternate">C2, GLY444ARG</ElementValue>
          <XRef Type="Allelic variant" ID="613927.0003" DB="OMIM"/>
        </Name>
        <AttributeSet>
          <Attribute Type="ProteinChange1LetterCode">G444R</Attribute>
          <XRef Type="Allelic variant" ID="613927.0003" DB="OMIM"/>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="ProteinChange3LetterCode">GLY444ARG</Attribute>
          <XRef Type="Allelic variant" ID="613927.0003" DB="OMIM"/>
        </AttributeSet>
        <CytogeneticLocation>6p21.3</CytogeneticLocation>
        <MeasureRelationship Type="asserted, but not computed">
          <Name>
            <ElementValue Type="Preferred">complement C2</ElementValue>
          </Name>
          <Symbol>
            <ElementValue Type="Preferred">C2</ElementValue>
          </Symbol>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="6" Accession="NC_000006.12" start="31897785" stop="31945674" display_start="31897785" display_stop="31945674" Strand="+"/>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="6" Accession="NT_113891.3" start="3375210" stop="3423101" display_start="3375210" display_stop="3423101" Strand="+"/>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="6" Accession="NT_167245.2" start="3145559" stop="3193454" display_start="3145559" display_stop="3193454" Strand="+"/>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="6" Accession="NT_167246.2" start="3232692" stop="3250651" display_start="3232692" display_stop="3250651" Strand="+"/>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="6" Accession="NT_167247.2" start="3239857" stop="3287710" display_start="3239857" display_stop="3287710" Strand="+"/>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="6" Accession="NT_167248.2" start="3153757" stop="3201649" display_start="3153757" display_stop="3201649" Strand="+"/>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="6" Accession="NT_167249.2" start="3228716" stop="3246863" display_start="3228716" display_stop="3246863" Strand="+"/>
          <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="6" Accession="NC_000006.11" start="31865561" stop="31913448" display_start="31865561" display_stop="31913448" variantLength="47888" Strand="+"/>
          <XRef ID="717" DB="Gene"/>
          <XRef Type="MIM" ID="613927" DB="OMIM"/>
          <XRef ID="HGNC:1248" DB="HGNC"/>
        </MeasureRelationship>
        <XRef Type="Allelic variant" ID="613927.0003" DB="OMIM"/>
      </Measure>
      <Name>
        <ElementValue Type="Preferred">C2, GLY444ARG</ElementValue>
      </Name>
    </MeasureSet>
    <TraitSet Type="Disease" ID="3285">
      <Trait ID="10954" Type="Disease">
        <Name>
          <ElementValue Type="Preferred">C2 deficiency, type II</ElementValue>
        </Name>
        <XRef ID="C4017352" DB="MedGen"/>
      </Trait>
    </TraitSet>
  </ReferenceClinVarAssertion>
  <ClinVarAssertion ID="33153">
    <ClinVarSubmissionID localKey="613927.0003_C2 DEFICIENCY, TYPE II" submitter="OMIM" submitterDate="2012-06-07" title="C2, GLY444ARG_C2 DEFICIENCY, TYPE II"/>
    <ClinVarAccession Acc="SCV000033153" OrgType="primary" OrganizationCategory="resource" Version="1" Type="SCV" OrgID="3" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="1996-03-08">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ExternalID DB="OMIM" ID="613927.0003" Type="Allelic variant"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species>human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="Description">See 613927.0002 and Wetsel et al. (1996).</Attribute>
        <Citation>
          <ID Source="PubMed">8621452</ID>
        </Citation>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant">
      <Measure Type="Variation">
        <Name>
          <ElementValue Type="Preferred">C2, GLY444ARG</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="NonHGVS">GLY444ARG</Attribute>
        </AttributeSet>
        <MeasureRelationship Type="variant in gene">
          <Symbol>
            <ElementValue Type="Preferred">C2</ElementValue>
          </Symbol>
        </MeasureRelationship>
        <XRef DB="OMIM" ID="613927.0003" Type="Allelic variant"/>
      </Measure>
    </MeasureSet>
    <TraitSet Type="Disease">
      <Trait Type="Disease">
        <Name>
          <ElementValue Type="Preferred">C2 DEFICIENCY, TYPE II</ElementValue>
        </Name>
      </Trait>
    </TraitSet>
  </ClinVarAssertion>
</ClinVarSet>

<ClinVarSet ID="18637682">
  <RecordStatus>current</RecordStatus>
  <Title>SERPINH1, -656C-T AND Preterm premature rupture of membranes</Title>
  <ReferenceClinVarAssertion DateCreated="2012-08-13" DateLastUpdated="2017-04-07" ID="66699">
    <ClinVarAccession Acc="RCV000009196" Version="2" Type="RCV" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2006-09-05">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData ID="17810807">
        <Attribute Type="Description">In a study of ethnic/racial distribution and a -656C-T SNP in the promoter of the SERPINH1 gene, Wang et al. (2006) found that the -656T allele had a greater frequency in African and African American populations than in European Americans (12.4% versus 4.1%). The -656T allele displayed significantly reduced promoter activity compared to the wildtype -656C allele in amnion fibroblasts. Two independent case-control studies of African American neonates from pregnancies complicated by preterm premature rupture of the membranes (PPROM; 610504) revealed a significant association between the -656T allele and PPROM (p less than 0.0009 and 0.0076, respectively); combining the 2 studies (244 cases and 358 controls) resulted in a highly significant association between the -656T allele and PPROM (p less than 0.0000045). Wang et al. (2006) stated that this was the first example of an ancestry-informative marker associated with preterm birth in African Americans.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">16938879</ID>
        </Citation>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant" ID="8664">
      <Measure Type="single nucleotide variant" ID="23703">
        <Name>
          <ElementValue Type="Preferred">SERPINH1, -656C-T</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="nucleotide change">-656C-T</Attribute>
          <XRef Type="Allelic variant" ID="600943.0001" DB="OMIM"/>
        </AttributeSet>
        <CytogeneticLocation>11q13.5</CytogeneticLocation>
        <MeasureRelationship Type="asserted, but not computed">
          <Name>
            <ElementValue Type="Preferred">serpin family H member 1</ElementValue>
          </Name>
          <Symbol>
            <ElementValue Type="Preferred">SERPINH1</ElementValue>
          </Symbol>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="11" Accession="NC_000011.10" start="75562056" stop="75572804" display_start="75562056" display_stop="75572804" Strand="+"/>
          <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="11" Accession="NC_000011.9" start="75273100" stop="75283848" display_start="75273100" display_stop="75283848" variantLength="10749" Strand="+"/>
          <XRef ID="871" DB="Gene"/>
          <XRef Type="MIM" ID="600943" DB="OMIM"/>
          <XRef ID="HGNC:1546" DB="HGNC"/>
        </MeasureRelationship>
        <XRef Type="Allelic variant" ID="600943.0001" DB="OMIM"/>
      </Measure>
      <Name>
        <ElementValue Type="Preferred">SERPINH1, -656C-T</ElementValue>
      </Name>
    </MeasureSet>
    <TraitSet Type="Disease" ID="2377">
      <Trait ID="5799" Type="Disease">
        <Name>
          <ElementValue Type="Preferred">Preterm premature rupture of membranes</ElementValue>
          <XRef ID="Preterm+premature+rupture+of+the+membranes/9154" DB="Genetic Alliance"/>
          <XRef ID="312974005" DB="SNOMED CT"/>
        </Name>
        <Name>
          <ElementValue Type="Alternate">Preterm premature rupture of the membranes</ElementValue>
        </Name>
        <Symbol>
          <ElementValue Type="Preferred">PPROM</ElementValue>
          <XRef Type="MIM" ID="610504" DB="OMIM"/>
        </Symbol>
        <XRef ID="C0729264" DB="MedGen"/>
        <XRef Type="MIM" ID="610504" DB="OMIM"/>
      </Trait>
    </TraitSet>
  </ReferenceClinVarAssertion>
  <ClinVarAssertion ID="29413">
    <ClinVarSubmissionID localKey="600943.0001_PRETERM PREMATURE RUPTURE OF THE MEMBRANES" submitter="OMIM" submitterDate="2013-01-30" title="SERPINH1, -656C-T_PRETERM PREMATURE RUPTURE OF THE MEMBRANES"/>
    <ClinVarAccession Acc="SCV000029413" OrgType="primary" OrganizationCategory="resource" Version="1" Type="SCV" OrgID="3" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2006-09-05">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ExternalID DB="OMIM" ID="600943.0001" Type="Allelic variant"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species>human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="Description">In a study of ethnic/racial distribution and a -656C-T SNP in the promoter of the SERPINH1 gene, Wang et al. (2006) found that the -656T allele had a greater frequency in African and African American populations than in European Americans (12.4% versus 4.1%). The -656T allele displayed significantly reduced promoter activity compared to the wildtype -656C allele in amnion fibroblasts. Two independent case-control studies of African American neonates from pregnancies complicated by preterm premature rupture of the membranes (PPROM; 610504) revealed a significant association between the -656T allele and PPROM (p less than 0.0009 and 0.0076, respectively); combining the 2 studies (244 cases and 358 controls) resulted in a highly significant association between the -656T allele and PPROM (p less than 0.0000045). Wang et al. (2006) stated that this was the first example of an ancestry-informative marker associated with preterm birth in African Americans.</Attribute>
        <Citation>
          <ID Source="PubMed">16938879</ID>
        </Citation>
        <XRef DB="OMIM" ID="610504" Type="MIM"/>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant">
      <Measure Type="Variation">
        <Name>
          <ElementValue Type="Preferred">SERPINH1, -656C-T</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="NonHGVS">-656C-T</Attribute>
        </AttributeSet>
        <MeasureRelationship Type="variant in gene">
          <Symbol>
            <ElementValue Type="Preferred">SERPINH1</ElementValue>
          </Symbol>
        </MeasureRelationship>
        <XRef DB="OMIM" ID="600943.0001" Type="Allelic variant"/>
      </Measure>
    </MeasureSet>
    <TraitSet Type="Disease">
      <Trait Type="Disease">
        <Name>
          <ElementValue Type="Preferred">PRETERM PREMATURE RUPTURE OF THE MEMBRANES</ElementValue>
        </Name>
      </Trait>
    </TraitSet>
  </ClinVarAssertion>
</ClinVarSet>

<ClinVarSet ID="18637729">
  <RecordStatus>current</RecordStatus>
  <Title>PPP1R3A, 2-BP DEL, 1985AG AND Insulin resistance, severe, digenic</Title>
  <ReferenceClinVarAssertion DateCreated="2012-08-13" DateLastUpdated="2017-04-07" ID="66747">
    <ClinVarAccession Acc="RCV000009244" Version="2" Type="RCV" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2002-08-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData ID="17810822">
        <Attribute Type="Description">In a 'Europid family' with digenic inheritance of severe insulin resistance and type II diabetes mellitus (125853), the heterozygous PPP1R3 mutation found by Savage et al. (2002) was deletion of AG at 2 bp following 1984C, leading to a frameshift in codon 662 and a premature stop at codon 668. The grandmother and 3 of her children and 2 grandchildren with severe insulin resistance had this mutation. In the 5 individuals with severe insulin resistance, this mutation was combined with heterozygosity at the PPARG locus (601487.0011).</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">12118251</ID>
        </Citation>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant" ID="8707">
      <Measure Type="Deletion" ID="23746">
        <Name>
          <ElementValue Type="Preferred">PPP1R3A, 2-BP DEL, 1985AG</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="nucleotide change">2-BP DEL, 1985AG</Attribute>
          <XRef Type="Allelic variant" ID="600917.0003" DB="OMIM"/>
        </AttributeSet>
        <CytogeneticLocation>7q11.23-q21.11</CytogeneticLocation>
        <MeasureRelationship Type="asserted, but not computed">
          <Name>
            <ElementValue Type="Preferred">protein phosphatase 1 regulatory subunit 3A</ElementValue>
          </Name>
          <Symbol>
            <ElementValue Type="Preferred">PPP1R3A</ElementValue>
          </Symbol>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="7" Accession="NC_000007.14" start="113876827" stop="113919094" display_start="113876827" display_stop="113919094" Strand="-"/>
          <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="7" Accession="NC_000007.13" start="113516881" stop="113559081" display_start="113516881" display_stop="113559081" variantLength="42201" Strand="-"/>
          <XRef ID="5506" DB="Gene"/>
          <XRef Type="MIM" ID="600917" DB="OMIM"/>
          <XRef ID="HGNC:9291" DB="HGNC"/>
        </MeasureRelationship>
        <XRef Type="Allelic variant" ID="600917.0003" DB="OMIM"/>
      </Measure>
      <Name>
        <ElementValue Type="Preferred">PPP1R3A, 2-BP DEL, 1985AG</ElementValue>
      </Name>
    </MeasureSet>
    <TraitSet Type="Disease" ID="2391">
      <Trait ID="10469" Type="Disease">
        <Name>
          <ElementValue Type="Preferred">Insulin resistance, severe, digenic</ElementValue>
        </Name>
        <XRef ID="C4016701" DB="MedGen"/>
      </Trait>
    </TraitSet>
  </ReferenceClinVarAssertion>
  <ClinVarAssertion ID="29462">
    <ClinVarSubmissionID localKey="600917.0003_INSULIN RESISTANCE, SEVERE, DIGENIC" submitter="OMIM" submitterDate="2009-10-01" title="PPP1R3A, 2-BP DEL, 1985AG_INSULIN RESISTANCE, SEVERE, DIGENIC"/>
    <ClinVarAccession Acc="SCV000029462" OrgType="primary" OrganizationCategory="resource" Version="1" Type="SCV" OrgID="3" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2002-08-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ExternalID DB="OMIM" ID="600917.0003" Type="Allelic variant"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species>human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="Description">In a 'Europid family' with digenic inheritance of severe insulin resistance and type II diabetes mellitus (125853), the heterozygous PPP1R3 mutation found by Savage et al. (2002) was deletion of AG at 2 bp following 1984C, leading to a frameshift in codon 662 and a premature stop at codon 668. The grandmother and 3 of her children and 2 grandchildren with severe insulin resistance had this mutation. In the 5 individuals with severe insulin resistance, this mutation was combined with heterozygosity at the PPARG locus (601487.0011).</Attribute>
        <Citation>
          <ID Source="PubMed">12118251</ID>
        </Citation>
        <XRef DB="OMIM" ID="125853" Type="MIM"/>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant">
      <Measure Type="Variation">
        <Name>
          <ElementValue Type="Preferred">PPP1R3A, 2-BP DEL, 1985AG</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="NonHGVS">2-BP DEL, 1985AG</Attribute>
        </AttributeSet>
        <MeasureRelationship Type="variant in gene">
          <Symbol>
            <ElementValue Type="Preferred">PPP1R3A</ElementValue>
          </Symbol>
        </MeasureRelationship>
        <XRef DB="OMIM" ID="600917.0003" Type="Allelic variant"/>
      </Measure>
    </MeasureSet>
    <TraitSet Type="Disease">
      <Trait Type="Disease">
        <Name>
          <ElementValue Type="Preferred">INSULIN RESISTANCE, SEVERE, DIGENIC</ElementValue>
        </Name>
      </Trait>
    </TraitSet>
  </ClinVarAssertion>
</ClinVarSet>

<ClinVarSet ID="18637730">
  <RecordStatus>current</RecordStatus>
  <Title>PPP1R3A, 2-BP DEL, 1985AG AND Diabetes mellitus, type II, digenic</Title>
  <ReferenceClinVarAssertion DateCreated="2012-08-13" DateLastUpdated="2017-04-07" ID="66748">
    <ClinVarAccession Acc="RCV000009245" Version="2" Type="RCV" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2002-08-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData ID="17815122">
        <Attribute Type="Description">In a 'Europid family' with digenic inheritance of severe insulin resistance and type II diabetes mellitus (125853), the heterozygous PPP1R3 mutation found by Savage et al. (2002) was deletion of AG at 2 bp following 1984C, leading to a frameshift in codon 662 and a premature stop at codon 668. The grandmother and 3 of her children and 2 grandchildren with severe insulin resistance had this mutation. In the 5 individuals with severe insulin resistance, this mutation was combined with heterozygosity at the PPARG locus (601487.0011).</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">12118251</ID>
        </Citation>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant" ID="8707">
      <Measure Type="Deletion" ID="23746">
        <Name>
          <ElementValue Type="Preferred">PPP1R3A, 2-BP DEL, 1985AG</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="nucleotide change">2-BP DEL, 1985AG</Attribute>
          <XRef Type="Allelic variant" ID="600917.0003" DB="OMIM"/>
        </AttributeSet>
        <CytogeneticLocation>7q11.23-q21.11</CytogeneticLocation>
        <MeasureRelationship Type="asserted, but not computed">
          <Name>
            <ElementValue Type="Preferred">protein phosphatase 1 regulatory subunit 3A</ElementValue>
          </Name>
          <Symbol>
            <ElementValue Type="Preferred">PPP1R3A</ElementValue>
          </Symbol>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="7" Accession="NC_000007.14" start="113876827" stop="113919094" display_start="113876827" display_stop="113919094" Strand="-"/>
          <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="7" Accession="NC_000007.13" start="113516881" stop="113559081" display_start="113516881" display_stop="113559081" variantLength="42201" Strand="-"/>
          <XRef ID="5506" DB="Gene"/>
          <XRef Type="MIM" ID="600917" DB="OMIM"/>
          <XRef ID="HGNC:9291" DB="HGNC"/>
        </MeasureRelationship>
        <XRef Type="Allelic variant" ID="600917.0003" DB="OMIM"/>
      </Measure>
      <Name>
        <ElementValue Type="Preferred">PPP1R3A, 2-BP DEL, 1985AG</ElementValue>
      </Name>
    </MeasureSet>
    <TraitSet Type="Disease" ID="2224">
      <Trait ID="10401" Type="Disease">
        <Name>
          <ElementValue Type="Preferred">Diabetes mellitus, type II, digenic</ElementValue>
        </Name>
        <XRef ID="C4017629" DB="MedGen"/>
      </Trait>
    </TraitSet>
  </ReferenceClinVarAssertion>
  <ClinVarAssertion ID="29463">
    <ClinVarSubmissionID localKey="600917.0003_DIABETES MELLITUS, TYPE II, DIGENIC" submitter="OMIM" submitterDate="2009-10-01" title="PPP1R3A, 2-BP DEL, 1985AG_DIABETES MELLITUS, TYPE II, DIGENIC"/>
    <ClinVarAccession Acc="SCV000029463" OrgType="primary" OrganizationCategory="resource" Version="1" Type="SCV" OrgID="3" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2002-08-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to included disease"/>
    <ExternalID DB="OMIM" ID="600917.0003" Type="Allelic variant"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species>human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="Description">In a 'Europid family' with digenic inheritance of severe insulin resistance and type II diabetes mellitus (125853), the heterozygous PPP1R3 mutation found by Savage et al. (2002) was deletion of AG at 2 bp following 1984C, leading to a frameshift in codon 662 and a premature stop at codon 668. The grandmother and 3 of her children and 2 grandchildren with severe insulin resistance had this mutation. In the 5 individuals with severe insulin resistance, this mutation was combined with heterozygosity at the PPARG locus (601487.0011).</Attribute>
        <Citation>
          <ID Source="PubMed">12118251</ID>
        </Citation>
        <XRef DB="OMIM" ID="125853" Type="MIM"/>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant">
      <Measure Type="Variation">
        <Name>
          <ElementValue Type="Preferred">PPP1R3A, 2-BP DEL, 1985AG</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="NonHGVS">2-BP DEL, 1985AG</Attribute>
        </AttributeSet>
        <MeasureRelationship Type="variant in gene">
          <Symbol>
            <ElementValue Type="Preferred">PPP1R3A</ElementValue>
          </Symbol>
        </MeasureRelationship>
        <XRef DB="OMIM" ID="600917.0003" Type="Allelic variant"/>
      </Measure>
    </MeasureSet>
    <TraitSet Type="Disease">
      <Trait Type="Disease">
        <Name>
          <ElementValue Type="included">DIABETES MELLITUS, TYPE II, DIGENIC</ElementValue>
        </Name>
      </Trait>
    </TraitSet>
  </ClinVarAssertion>
</ClinVarSet>

<ClinVarSet ID="18638037">
  <RecordStatus>current</RecordStatus>
  <Title>KLF1, 1-BP DEL, 569C AND BLOOD GROUP--LUTHERAN INHIBITOR</Title>
  <ReferenceClinVarAssertion DateCreated="2012-08-13" DateLastUpdated="2017-04-07" ID="67066">
    <ClinVarAccession Acc="RCV000009563" Version="3" Type="RCV" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2008-09-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData ID="17815518">
        <Attribute Type="Description">In 6 individuals of Spanish descent with the dominant In(Lu) blood phenotype (INLU; 111150), Singleton et al. (2008) identified a heterozygous 1-bp deletion (569delC) in exon 2 of the KLF1 gene, resulting in a frameshift and premature termination. The substitution was predicted to render the transcription factor nonfunctional. The individuals had no reported pathology, indicating that 1 functional KLF1 allele is sufficient to sustain human erythropoiesis.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">18487511</ID>
        </Citation>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant" ID="9000">
      <Measure Type="Deletion" ID="24039">
        <Name>
          <ElementValue Type="Preferred">KLF1, 1-BP DEL, 569C</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="nucleotide change">1-BP DEL, 569C</Attribute>
          <XRef Type="Allelic variant" ID="600599.0002" DB="OMIM"/>
        </AttributeSet>
        <CytogeneticLocation>19p13.13-p13.12</CytogeneticLocation>
        <MeasureRelationship Type="asserted, but not computed">
          <Name>
            <ElementValue Type="Preferred">Kruppel like factor 1</ElementValue>
          </Name>
          <Symbol>
            <ElementValue Type="Preferred">KLF1</ElementValue>
          </Symbol>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="19" Accession="NC_000019.10" start="12884422" stop="12887203" display_start="12884422" display_stop="12887203" Strand="-"/>
          <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="19" Accession="NC_000019.9" start="12995235" stop="12998016" display_start="12995235" display_stop="12998016" variantLength="2782" Strand="-"/>
          <XRef ID="10661" DB="Gene"/>
          <XRef Type="MIM" ID="600599" DB="OMIM"/>
          <XRef ID="HGNC:6345" DB="HGNC"/>
        </MeasureRelationship>
        <XRef Type="Allelic variant" ID="600599.0002" DB="OMIM"/>
      </Measure>
      <Name>
        <ElementValue Type="Preferred">KLF1, 1-BP DEL, 569C</ElementValue>
      </Name>
    </MeasureSet>
    <TraitSet Type="Disease" ID="2478">
      <Trait ID="1034" Type="BloodGroup">
        <Name>
          <ElementValue Type="Preferred">BLOOD GROUP--LUTHERAN INHIBITOR</ElementValue>
          <XRef ID="BLOOD+GROUP--LUTHERAN+INHIBITOR/7839" DB="Genetic Alliance"/>
          <XRef Type="MIM" ID="111150" DB="OMIM"/>
          <XRef Type="Allelic variant" ID="600599.0001" DB="OMIM"/>
          <XRef Type="Allelic variant" ID="600599.0002" DB="OMIM"/>
          <XRef Type="Allelic variant" ID="600599.0003" DB="OMIM"/>
          <XRef Type="Allelic variant" ID="600599.0004" DB="OMIM"/>
          <XRef Type="Allelic variant" ID="600599.0007" DB="OMIM"/>
          <XRef Type="Allelic variant" ID="600599.0008" DB="OMIM"/>
          <XRef Type="Allelic variant" ID="600599.0009" DB="OMIM"/>
        </Name>
        <Name>
          <ElementValue Type="Alternate">DOMINANT LU (a-b-) PHENOTYPE</ElementValue>
          <XRef Type="MIM" ID="111150" DB="OMIM"/>
        </Name>
        <Symbol>
          <ElementValue Type="Preferred">INLU</ElementValue>
          <XRef Type="MIM" ID="111150" DB="OMIM"/>
        </Symbol>
        <XRef ID="C1292231" DB="MedGen"/>
        <XRef Type="MIM" ID="111150" DB="OMIM"/>
      </Trait>
    </TraitSet>
  </ReferenceClinVarAssertion>
  <ClinVarAssertion ID="29781">
    <ClinVarSubmissionID localKey="600599.0002_BLOOD GROUP--LUTHERAN INHIBITOR" submitter="OMIM" submitterDate="2013-09-05" title="KLF1, 1-BP DEL, 569C _BLOOD GROUP--LUTHERAN INHIBITOR"/>
    <ClinVarAccession Acc="SCV000029781" OrgType="primary" OrganizationCategory="resource" Version="2" Type="SCV" OrgID="3" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2008-09-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ExternalID DB="OMIM" ID="600599.0002" Type="Allelic variant"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species>human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="Description">In 6 individuals of Spanish descent with the dominant In(Lu) blood phenotype (INLU; 111150), Singleton et al. (2008) identified a heterozygous 1-bp deletion (569delC) in exon 2 of the KLF1 gene, resulting in a frameshift and premature termination. The substitution was predicted to render the transcription factor nonfunctional. The individuals had no reported pathology, indicating that 1 functional KLF1 allele is sufficient to sustain human erythropoiesis.</Attribute>
        <Citation>
          <ID Source="PubMed">18487511</ID>
        </Citation>
        <XRef DB="OMIM" ID="111150" Type="MIM"/>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant">
      <Measure Type="Variation">
        <Name>
          <ElementValue Type="Preferred">KLF1, 1-BP DEL, 569C</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="NonHGVS">1-BP DEL, 569C</Attribute>
        </AttributeSet>
        <MeasureRelationship Type="variant in gene">
          <Symbol>
            <ElementValue Type="Preferred">KLF1</ElementValue>
          </Symbol>
        </MeasureRelationship>
        <XRef DB="OMIM" ID="600599.0002" Type="Allelic variant"/>
      </Measure>
    </MeasureSet>
    <TraitSet Type="Disease">
      <Trait Type="Disease">
        <Name>
          <ElementValue Type="Preferred">BLOOD GROUP--LUTHERAN INHIBITOR</ElementValue>
        </Name>
      </Trait>
    </TraitSet>
  </ClinVarAssertion>
</ClinVarSet>

<ClinVarSet ID="18633815">
  <RecordStatus>current</RecordStatus>
  <Title>PCDH15, 3-BP DEL, 5601AAC AND USHER SYNDROME, TYPE ID/F, DIGENIC</Title>
  <ReferenceClinVarAssertion DateCreated="2012-08-13" DateLastUpdated="2017-04-07" ID="62723">
    <ClinVarAccession Acc="RCV000005220" Version="2" Type="RCV" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2005-03-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData ID="17810246">
        <Attribute Type="Description">In a patient from the U.S. with Usher syndrome type IF (602083),  Ouyang et al. (2005) identified heterozygosity for a 3-bp deletion (5601-5603delAAC) in exon 33 of the PCDH15 gene, resulting in deletion of threonine-1867. The 3-bp deletion was also identified in compound heterozygosity with a PCDH15 missense mutation in another patient with USH1F. The mutation accounted for 2 (33%) of 6 mutant alleles identified by Ouyang et al. (2005) at the PCDH15 locus.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">15660226</ID>
        </Citation>
      </ObservedData>
      <ObservedData ID="17810246">
        <Attribute Type="Description">Zheng et al. (2005) identified 2 patients with a diagnosis of Usher syndrome type I (see 601067) who carried this deletion in heterozygosity, in combination with an additional mutation in the CDH23 gene: a single-basepair deletion (193delC; 605516.0011) and a missense mutation (T1209A; 605516.0013), respectively. The T1209A mutation in the CDH23 gene was later reclassified as a variant of unknown function.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">15537665</ID>
        </Citation>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant" ID="4934">
      <Measure Type="Deletion" ID="19973">
        <Name>
          <ElementValue Type="Preferred">PCDH15, 3-BP DEL, 5601AAC</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="nucleotide change">3-BP DEL, 5601AAC</Attribute>
          <XRef Type="Allelic variant" ID="605514.0005" DB="OMIM"/>
        </AttributeSet>
        <CytogeneticLocation>10q21-q22</CytogeneticLocation>
        <MeasureRelationship Type="asserted, but not computed">
          <Name>
            <ElementValue Type="Preferred">protocadherin related 15</ElementValue>
          </Name>
          <Symbol>
            <ElementValue Type="Preferred">PCDH15</ElementValue>
          </Symbol>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="10" Accession="NC_000010.11" start="53802771" stop="55629182" display_start="53802771" display_stop="55629182" Strand="-"/>
          <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="10" Accession="NC_000010.10" start="55562530" stop="56561050" display_start="55562530" display_stop="56561050" variantLength="998521" Strand="-"/>
          <XRef ID="65217" DB="Gene"/>
          <XRef Type="MIM" ID="605514" DB="OMIM"/>
          <XRef ID="HGNC:14674" DB="HGNC"/>
        </MeasureRelationship>
        <XRef Type="Allelic variant" ID="605514.0005" DB="OMIM"/>
      </Measure>
      <Name>
        <ElementValue Type="Preferred">PCDH15, 3-BP DEL, 5601AAC</ElementValue>
      </Name>
    </MeasureSet>
    <TraitSet Type="Disease" ID="1355">
      <Trait ID="10114" Type="Disease">
        <Name>
          <ElementValue Type="Preferred">USHER SYNDROME, TYPE ID/F, DIGENIC</ElementValue>
          <XRef Type="Allelic variant" ID="605514.0005" DB="OMIM"/>
          <XRef Type="Allelic variant" ID="605514.0008" DB="OMIM"/>
          <XRef Type="Allelic variant" ID="605516.0011" DB="OMIM"/>
          <XRef Type="Allelic variant" ID="605516.0012" DB="OMIM"/>
        </Name>
        <XRef ID="C3276419" DB="MedGen"/>
      </Trait>
    </TraitSet>
  </ReferenceClinVarAssertion>
  <ClinVarAssertion ID="25398">
    <ClinVarSubmissionID localKey="605514.0005_USHER SYNDROME, TYPE ID/F, DIGENIC" submitter="OMIM" submitterDate="2013-02-13" title="PCDH15, 3-BP DEL, 5601AAC_USHER SYNDROME, TYPE ID/F, DIGENIC"/>
    <ClinVarAccession Acc="SCV000025398" OrgType="primary" OrganizationCategory="resource" Version="1" Type="SCV" OrgID="3" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2005-03-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to included disease"/>
    <ExternalID DB="OMIM" ID="605514.0005" Type="Allelic variant"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species>human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="Description">In a patient from the U.S. with Usher syndrome type IF (602083), Ouyang et al. (2005) identified heterozygosity for a 3-bp deletion (5601-5603delAAC) in exon 33 of the PCDH15 gene, resulting in deletion of threonine-1867. The 3-bp deletion was also identified in compound heterozygosity with a PCDH15 missense mutation in another patient with USH1F. The mutation accounted for 2 (33%) of 6 mutant alleles identified by Ouyang et al. (2005) at the PCDH15 locus.</Attribute>
        <Citation>
          <ID Source="PubMed">15660226</ID>
        </Citation>
        <XRef DB="OMIM" ID="602083" Type="MIM"/>
      </ObservedData>
      <ObservedData>
        <Attribute Type="Description">Zheng et al. (2005) identified 2 patients with a diagnosis of Usher syndrome type I (see 601067) who carried this deletion in heterozygosity, in combination with an additional mutation in the CDH23 gene: a single-basepair deletion (193delC; 605516.0011) and a missense mutation (T1209A; 605516.0013), respectively. The T1209A mutation in the CDH23 gene was later reclassified as a variant of unknown function.</Attribute>
        <Citation>
          <ID Source="PubMed">15537665</ID>
        </Citation>
        <XRef DB="OMIM" ID="601067" Type="MIM"/>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant">
      <Measure Type="Variation">
        <Name>
          <ElementValue Type="Preferred">PCDH15, 3-BP DEL, 5601AAC</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="NonHGVS">3-BP DEL, 5601AAC</Attribute>
        </AttributeSet>
        <MeasureRelationship Type="variant in gene">
          <Symbol>
            <ElementValue Type="Preferred">PCDH15</ElementValue>
          </Symbol>
        </MeasureRelationship>
        <XRef DB="OMIM" ID="605514.0005" Type="Allelic variant"/>
      </Measure>
    </MeasureSet>
    <TraitSet Type="Disease">
      <Trait Type="Disease">
        <Name>
          <ElementValue Type="included">USHER SYNDROME, TYPE ID/F, DIGENIC</ElementValue>
        </Name>
      </Trait>
    </TraitSet>
  </ClinVarAssertion>
</ClinVarSet>

<ClinVarSet ID="18646558">
  <RecordStatus>current</RecordStatus>
  <Title>TNF, -308G-A AND Human immunodeficiency virus dementia, susceptibility to</Title>
  <ReferenceClinVarAssertion DateCreated="2012-08-13" DateLastUpdated="2017-04-07" ID="70694">
    <ClinVarAccession Acc="RCV000013191" Version="3" Type="RCV" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2006-03-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>risk factor</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData ID="17819846">
        <Attribute Type="Description">Mira et al. (1999) referred to the TNFA promoter polymorphisms at position -308 as TNF1 for guanine and TNF2 for adenine. In a multicenter study involving 7 institutions, they found a significant association between the TNF2 allele and susceptibility to septic shock and death from septic shock. The septic shock group was defined by the following 6 criteria within a 12-hour period: (1) clinical evidence of infection; (2) hyperthermia or hypothermia; (3) tachycardia; (4) tachypnea; (5) necessity for vasopressor to maintain systolic blood pressure; and (6) evidence of inadequate organ function or perfusion.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">10450718</ID>
        </Citation>
      </ObservedData>
      <ObservedData ID="17819846">
        <Attribute Type="Description">Moraes et al. (2001) found that the TNF2 polymorphism is significantly associated with a stronger response (Mitsuda reaction) to lepromin in borderline tuberculoid leprosy patients. Epigenetic factors such as a history of BCG vaccination or a reversal reaction, but not both, were also associated with boosted Mitsuda reactions. Moraes et al. (2001) concluded that augmented TNF production may be associated with the TNF2 allele and an increased granulomatous response.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">11261930</ID>
        </Citation>
      </ObservedData>
      <ObservedData ID="17819846">
        <Attribute Type="Description">Ma et al. (1998) found a higher frequency of the rare T2 TNFA polymorphism (-308G-A) in 43 Japanese Guillain-Barre syndrome (139393) patients who had had antecedent infection with C. jejuni than in 85 community controls.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">9818939</ID>
        </Citation>
      </ObservedData>
      <ObservedData ID="17819846">
        <Attribute Type="Description">Witte et al. (2002) evaluated the relation between the -308G-A promoter polymorphism and risk of asthma (600807) in 236 cases and 275 nonasthmatic controls. Logistic regression analyses indicated that having 1 or 2 copies of the -308A allele increased the risk of asthma (odds ratio = 1.58), the magnitude of which was increased when restricting the cases to those with acute asthma (odds ratio = 1.86, P = 0.04) or further restricting the subjects to those with a family history of asthma and those of European American ancestry (odds ratio = 3.16, P = 0.04).</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">11896460</ID>
        </Citation>
      </ObservedData>
      <ObservedData ID="17819846">
        <Attribute Type="Description">Shin et al. (2004) genotyped 550 Korean asthmatics and 171 Korean controls at 5 SNPs in TNFA and 2 SNPs in TNFB. Six common haplotypes could be constructed in the TNF gene cluster. The -308G-A polymorphism showed a significant association with the risk of asthma (p = 0.0004). The frequency of the -308A allele-containing genotype in asthmatics (9.8%) was much lower than that in normal controls (22.9%). The protective effects of this polymorphism on asthma were also evident in separated subgroups by atopic status (p = 0.05 in nonatopic subjects and p = 0.003 in atopic subjects). The most common haplotype of the TNF gene cluster (TNF-ht1-GGTCCGG) was associated with total serum IgE levels (147050) in asthma patients, especially in nonatopic patients (p = 0.004). Shin et al. (2004) concluded that genetic variants of TNF may be involved in the development of asthma and total serum IgE level in bronchial asthma patients.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">14681301</ID>
        </Citation>
      </ObservedData>
      <ObservedData ID="17819846">
        <Attribute Type="Description">Aoki et al. (2006) did not find a significant association between the TNF -308G-A polymorphism and childhood atopic asthma in 2 independent Japanese populations; however, metaanalysis of a total of 2,477 asthma patients and 3,217 control individuals showed that the -308G-A polymorphism was significantly associated with asthma. The combined odds ratio was 1.46 for fixed or random effects (p = 0.0000001 and p = 0.00014, respectively).</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">16865291</ID>
        </Citation>
      </ObservedData>
      <ObservedData ID="17819846">
        <Attribute Type="Description">Quasney et al. (2001) stated that immunologic mechanisms resulting in macrophage infiltration and glial cell activation in the brain are thought to be involved in the pathophysiology of HIV dementia. Moreover, elevated levels of TNF-alpha have been found in the brains of patients with HIV dementia. In a study of 16 patients with HIV dementia, 45 HIV-infected patients without dementia, and 231 controls, they found an increased frequency of the -308A allele in patients with HIV dementia (0.28 vs 0.11 in controls and 0.07 in HIV patients without dementia). There were no individuals with the A/A genotype in either of the HIV-infected groups. Quasney et al. (2001) noted that the -308A allele is associated with higher TNF-alpha secretion in response to an inflammatory stimulus and that evidence has shown a role for TNF-alpha in neuronal damage, thus suggesting a genetic predisposition to the development of HIV dementia.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">11506397</ID>
        </Citation>
      </ObservedData>
      <ObservedData ID="17819846">
        <Attribute Type="Description">Cox et al. (1994) reported that the -308A allele has an increased frequency in type I diabetes mellitus (222100). Krikovszky et al. (2002) studied ambulatory blood pressure in 126 Hungarian adolescents with type I diabetes mellitus. They found that the prevalence of the -308A allele was higher in diabetic adolescents than in the Hungarian reference population. TNFA genotype was associated with both systolic and diastolic blood pressure values. The -308A allele carrier state appeared to be associated with lower systolic and diastolic blood pressure values.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">12485196</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">8056188</ID>
        </Citation>
      </ObservedData>
      <ObservedData ID="17819846">
        <Attribute Type="Description">Szalai et al. (2002) found an increased frequency of the C4B*Q0 allele (see 120820) in patients with severe coronary artery disease (CAD) who underwent bypass surgery compared to healthy controls (14.2% vs 9.9%). Investigation of specific allelic combinations revealed that C4B*Q0 in combination with the TNF-alpha -308A allele was significantly higher in CAD patients, particularly those with preoperative myocardial infarction.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">11826025</ID>
        </Citation>
      </ObservedData>
      <ObservedData ID="17819846">
        <Attribute Type="Description">In a study of 147 patients with psoriatic arthritis (607507) and 389 controls, Balding et al. (2003) found that the -308A allele was significantly associated with both the presence and progression of joint erosions in psoriatic arthritis, and that the AA genotype was associated with the lowest mean age at onset of psoriasis (p = 0.0081).</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">12746914</ID>
        </Citation>
      </ObservedData>
      <ObservedData ID="17819846">
        <Attribute Type="Description">In a group of 261 patients with migraine without aura (see, e.g., 157300), Rainero et al. (2004) found that the G/G genotype was associated with an increased risk of migraine (odds ratio of 3.30). Rainero et al. (2004) suggested that TNF-alpha may be involved in the pathogenesis of migraine, perhaps due to its effect on cerebral blood flow; alternatively, a closely linked locus may be involved.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">14718719</ID>
        </Citation>
      </ObservedData>
      <ObservedData ID="17819846">
        <Attribute Type="Description">In a metaanalysis of 19 studies, Lee et al. (2006) found an association between the -308A/A genotype and the -308A allele and systemic lupus erythematosus (SLE; 152700) in European-derived population (odds ratio of 4.0 for A/A and 2.1 for the A allele), but not in Asian-derived populations.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">16418737</ID>
        </Citation>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant" ID="12388">
      <Measure Type="single nucleotide variant" ID="27427">
        <Name>
          <ElementValue Type="Preferred">TNF, -308G-A</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="nucleotide change">-308G-A</Attribute>
          <XRef Type="Allelic variant" ID="191160.0004" DB="OMIM"/>
        </AttributeSet>
        <CytogeneticLocation>6p21.3</CytogeneticLocation>
        <MeasureRelationship Type="asserted, but not computed">
          <Name>
            <ElementValue Type="Preferred">tumor necrosis factor</ElementValue>
          </Name>
          <Symbol>
            <ElementValue Type="Preferred">TNF</ElementValue>
          </Symbol>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="6" Accession="NC_000006.12" start="31575567" stop="31578336" display_start="31575567" display_stop="31578336" Strand="+"/>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="6" Accession="NT_113891.3" start="3052854" stop="3055623" display_start="3052854" display_stop="3055623" Strand="+"/>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="6" Accession="NT_167244.2" start="2909108" stop="2910915" display_start="2909108" display_stop="2910915" Strand="+"/>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="6" Accession="NT_167245.2" start="2823300" stop="2826069" display_start="2823300" display_stop="2826069" Strand="+"/>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="6" Accession="NT_167246.2" start="2880608" stop="2883377" display_start="2880608" display_stop="2883377" Strand="+"/>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="6" Accession="NT_167247.2" start="2917465" stop="2920234" display_start="2917465" display_stop="2920234" Strand="+"/>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="6" Accession="NT_167248.2" start="2831386" stop="2834157" display_start="2831386" display_stop="2834157" Strand="+"/>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="6" Accession="NT_167249.2" start="2874847" stop="2877616" display_start="2874847" display_stop="2877616" Strand="+"/>
          <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="6" Accession="NC_000006.11" start="31543343" stop="31546112" display_start="31543343" display_stop="31546112" variantLength="2770" Strand="+"/>
          <XRef ID="7124" DB="Gene"/>
          <XRef Type="MIM" ID="191160" DB="OMIM"/>
          <XRef ID="HGNC:11892" DB="HGNC"/>
        </MeasureRelationship>
        <Citation Type="Position Statement" Abbrev="EGAPP, 2010">
          <ID Source="PubMed">21042222</ID>
        </Citation>
        <XRef Type="Allelic variant" ID="191160.0004" DB="OMIM"/>
      </Measure>
      <Name>
        <ElementValue Type="Preferred">TNF, -308G-A</ElementValue>
      </Name>
    </MeasureSet>
    <TraitSet Type="Disease" ID="3361">
      <Trait ID="11001" Type="Disease">
        <Name>
          <ElementValue Type="Preferred">Human immunodeficiency virus dementia, susceptibility to</ElementValue>
        </Name>
      </Trait>
    </TraitSet>
  </ReferenceClinVarAssertion>
  <ClinVarAssertion ID="33438">
    <ClinVarSubmissionID localKey="191160.0004_HUMAN IMMUNODEFICIENCY VIRUS DEMENTIA, SUSCEPTIBILITY TO" submitter="OMIM" submitterDate="2016-09-06" title="TNF, -308G-A_HUMAN IMMUNODEFICIENCY VIRUS DEMENTIA, SUSCEPTIBILITY TO"/>
    <ClinVarAccession Acc="SCV000033438" OrgType="primary" OrganizationCategory="resource" Version="2" Type="SCV" OrgID="3" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2006-03-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>risk factor</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to included disease"/>
    <ExternalID DB="OMIM" ID="191160.0004" Type="Allelic variant"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species>human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="Description">Mira et al. (1999) referred to the TNFA promoter polymorphisms at position -308 as TNF1 for guanine and TNF2 for adenine. In a multicenter study involving 7 institutions, they found a significant association between the TNF2 allele and susceptibility to septic shock and death from septic shock. The septic shock group was defined by the following 6 criteria within a 12-hour period: (1) clinical evidence of infection; (2) hyperthermia or hypothermia; (3) tachycardia; (4) tachypnea; (5) necessity for vasopressor to maintain systolic blood pressure; and (6) evidence of inadequate organ function or perfusion.</Attribute>
        <Citation>
          <ID Source="PubMed">10450718</ID>
        </Citation>
      </ObservedData>
      <ObservedData>
        <Attribute Type="Description">Moraes et al. (2001) found that the TNF2 polymorphism is significantly associated with a stronger response (Mitsuda reaction) to lepromin in borderline tuberculoid leprosy patients. Epigenetic factors such as a history of BCG vaccination or a reversal reaction, but not both, were also associated with boosted Mitsuda reactions. Moraes et al. (2001) concluded that augmented TNF production may be associated with the TNF2 allele and an increased granulomatous response.</Attribute>
        <Citation>
          <ID Source="PubMed">11261930</ID>
        </Citation>
      </ObservedData>
      <ObservedData>
        <Attribute Type="Description">Ma et al. (1998) found a higher frequency of the rare T2 TNFA polymorphism (-308G-A) in 43 Japanese Guillain-Barre syndrome (139393) patients who had had antecedent infection with C. jejuni than in 85 community controls.</Attribute>
        <Citation>
          <ID Source="PubMed">9818939</ID>
        </Citation>
        <XRef DB="OMIM" ID="139393" Type="MIM"/>
      </ObservedData>
      <ObservedData>
        <Attribute Type="Description">Witte et al. (2002) evaluated the relation between the -308G-A promoter polymorphism and risk of asthma (600807) in 236 cases and 275 nonasthmatic controls. Logistic regression analyses indicated that having 1 or 2 copies of the -308A allele increased the risk of asthma (odds ratio = 1.58), the magnitude of which was increased when restricting the cases to those with acute asthma (odds ratio = 1.86, P = 0.04) or further restricting the subjects to those with a family history of asthma and those of European American ancestry (odds ratio = 3.16, P = 0.04).</Attribute>
        <Citation>
          <ID Source="PubMed">11896460</ID>
        </Citation>
        <XRef DB="OMIM" ID="600807" Type="MIM"/>
      </ObservedData>
      <ObservedData>
        <Attribute Type="Description">Shin et al. (2004) genotyped 550 Korean asthmatics and 171 Korean controls at 5 SNPs in TNFA and 2 SNPs in TNFB. Six common haplotypes could be constructed in the TNF gene cluster. The -308G-A polymorphism showed a significant association with the risk of asthma (p = 0.0004). The frequency of the -308A allele-containing genotype in asthmatics (9.8%) was much lower than that in normal controls (22.9%). The protective effects of this polymorphism on asthma were also evident in separated subgroups by atopic status (p = 0.05 in nonatopic subjects and p = 0.003 in atopic subjects). The most common haplotype of the TNF gene cluster (TNF-ht1-GGTCCGG) was associated with total serum IgE levels (147050) in asthma patients, especially in nonatopic patients (p = 0.004). Shin et al. (2004) concluded that genetic variants of TNF may be involved in the development of asthma and total serum IgE level in bronchial asthma patients.</Attribute>
        <Citation>
          <ID Source="PubMed">14681301</ID>
        </Citation>
        <XRef DB="OMIM" ID="147050" Type="MIM"/>
      </ObservedData>
      <ObservedData>
        <Attribute Type="Description">Aoki et al. (2006) did not find a significant association between the TNF -308G-A polymorphism and childhood atopic asthma in 2 independent Japanese populations; however, metaanalysis of a total of 2,477 asthma patients and 3,217 control individuals showed that the -308G-A polymorphism was significantly associated with asthma. The combined odds ratio was 1.46 for fixed or random effects (p = 0.0000001 and p = 0.00014, respectively).</Attribute>
        <Citation>
          <ID Source="PubMed">16865291</ID>
        </Citation>
      </ObservedData>
      <ObservedData>
        <Attribute Type="Description">Quasney et al. (2001) stated that immunologic mechanisms resulting in macrophage infiltration and glial cell activation in the brain are thought to be involved in the pathophysiology of HIV dementia. Moreover, elevated levels of TNF-alpha have been found in the brains of patients with HIV dementia. In a study of 16 patients with HIV dementia, 45 HIV-infected patients without dementia, and 231 controls, they found an increased frequency of the -308A allele in patients with HIV dementia (0.28 vs 0.11 in controls and 0.07 in HIV patients without dementia). There were no individuals with the A/A genotype in either of the HIV-infected groups. Quasney et al. (2001) noted that the -308A allele is associated with higher TNF-alpha secretion in response to an inflammatory stimulus and that evidence has shown a role for TNF-alpha in neuronal damage, thus suggesting a genetic predisposition to the development of HIV dementia.</Attribute>
        <Citation>
          <ID Source="PubMed">11506397</ID>
        </Citation>
      </ObservedData>
      <ObservedData>
        <Attribute Type="Description">Cox et al. (1994) reported that the -308A allele has an increased frequency in type I diabetes mellitus (222100). Krikovszky et al. (2002) studied ambulatory blood pressure in 126 Hungarian adolescents with type I diabetes mellitus. They found that the prevalence of the -308A allele was higher in diabetic adolescents than in the Hungarian reference population. TNFA genotype was associated with both systolic and diastolic blood pressure values. The -308A allele carrier state appeared to be associated with lower systolic and diastolic blood pressure values.</Attribute>
        <Citation>
          <ID Source="PubMed">8056188</ID>
        </Citation>
        <Citation>
          <ID Source="PubMed">12485196</ID>
        </Citation>
        <XRef DB="OMIM" ID="222100" Type="MIM"/>
      </ObservedData>
      <ObservedData>
        <Attribute Type="Description">Szalai et al. (2002) found an increased frequency of the C4B*Q0 allele (see 120820) in patients with severe coronary artery disease (CAD) who underwent bypass surgery compared to healthy controls (14.2% vs 9.9%). Investigation of specific allelic combinations revealed that C4B*Q0 in combination with the TNF-alpha -308A allele was significantly higher in CAD patients, particularly those with preoperative myocardial infarction.</Attribute>
        <Citation>
          <ID Source="PubMed">11826025</ID>
        </Citation>
        <XRef DB="OMIM" ID="120820" Type="MIM"/>
      </ObservedData>
      <ObservedData>
        <Attribute Type="Description">In a study of 147 patients with psoriatic arthritis (607507) and 389 controls, Balding et al. (2003) found that the -308A allele was significantly associated with both the presence and progression of joint erosions in psoriatic arthritis, and that the AA genotype was associated with the lowest mean age at onset of psoriasis (p = 0.0081).</Attribute>
        <Citation>
          <ID Source="PubMed">12746914</ID>
        </Citation>
        <XRef DB="OMIM" ID="607507" Type="MIM"/>
      </ObservedData>
      <ObservedData>
        <Attribute Type="Description">In a group of 261 patients with migraine without aura (see, e.g., 157300), Rainero et al. (2004) found that the G/G genotype was associated with an increased risk of migraine (odds ratio of 3.30). Rainero et al. (2004) suggested that TNF-alpha may be involved in the pathogenesis of migraine, perhaps due to its effect on cerebral blood flow; alternatively, a closely linked locus may be involved.</Attribute>
        <Citation>
          <ID Source="PubMed">14718719</ID>
        </Citation>
        <XRef DB="OMIM" ID="157300" Type="MIM"/>
      </ObservedData>
      <ObservedData>
        <Attribute Type="Description">In a metaanalysis of 19 studies, Lee et al. (2006) found an association between the -308A/A genotype and the -308A allele and systemic lupus erythematosus (SLE; 152700) in European-derived population (odds ratio of 4.0 for A/A and 2.1 for the A allele), but not in Asian-derived populations.</Attribute>
        <Citation>
          <ID Source="PubMed">16418737</ID>
        </Citation>
        <XRef DB="OMIM" ID="152700" Type="MIM"/>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant">
      <Measure Type="Variation">
        <Name>
          <ElementValue Type="Preferred">TNF, -308G-A</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="NonHGVS">-308G-A</Attribute>
        </AttributeSet>
        <MeasureRelationship Type="variant in gene">
          <Symbol>
            <ElementValue Type="Preferred">TNF</ElementValue>
          </Symbol>
        </MeasureRelationship>
        <XRef DB="OMIM" ID="191160.0004" Type="Allelic variant"/>
      </Measure>
    </MeasureSet>
    <TraitSet Type="Disease">
      <Trait Type="Disease">
        <Name>
          <ElementValue Type="included">HUMAN IMMUNODEFICIENCY VIRUS DEMENTIA, SUSCEPTIBILITY TO</ElementValue>
        </Name>
      </Trait>
    </TraitSet>
  </ClinVarAssertion>
</ClinVarSet>

<ClinVarSet ID="18646559">
  <RecordStatus>current</RecordStatus>
  <Title>TNF, -308G-A AND Migraine without aura, susceptibility to</Title>
  <ReferenceClinVarAssertion DateCreated="2012-08-13" DateLastUpdated="2017-04-07" ID="70695">
    <ClinVarAccession Acc="RCV000013192" Version="3" Type="RCV" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2006-03-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>risk factor</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData ID="17819924">
        <Attribute Type="Description">Mira et al. (1999) referred to the TNFA promoter polymorphisms at position -308 as TNF1 for guanine and TNF2 for adenine. In a multicenter study involving 7 institutions, they found a significant association between the TNF2 allele and susceptibility to septic shock and death from septic shock. The septic shock group was defined by the following 6 criteria within a 12-hour period: (1) clinical evidence of infection; (2) hyperthermia or hypothermia; (3) tachycardia; (4) tachypnea; (5) necessity for vasopressor to maintain systolic blood pressure; and (6) evidence of inadequate organ function or perfusion.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">10450718</ID>
        </Citation>
      </ObservedData>
      <ObservedData ID="17819924">
        <Attribute Type="Description">Moraes et al. (2001) found that the TNF2 polymorphism is significantly associated with a stronger response (Mitsuda reaction) to lepromin in borderline tuberculoid leprosy patients. Epigenetic factors such as a history of BCG vaccination or a reversal reaction, but not both, were also associated with boosted Mitsuda reactions. Moraes et al. (2001) concluded that augmented TNF production may be associated with the TNF2 allele and an increased granulomatous response.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">11261930</ID>
        </Citation>
      </ObservedData>
      <ObservedData ID="17819924">
        <Attribute Type="Description">Ma et al. (1998) found a higher frequency of the rare T2 TNFA polymorphism (-308G-A) in 43 Japanese Guillain-Barre syndrome (139393) patients who had had antecedent infection with C. jejuni than in 85 community controls.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">9818939</ID>
        </Citation>
      </ObservedData>
      <ObservedData ID="17819924">
        <Attribute Type="Description">Witte et al. (2002) evaluated the relation between the -308G-A promoter polymorphism and risk of asthma (600807) in 236 cases and 275 nonasthmatic controls. Logistic regression analyses indicated that having 1 or 2 copies of the -308A allele increased the risk of asthma (odds ratio = 1.58), the magnitude of which was increased when restricting the cases to those with acute asthma (odds ratio = 1.86, P = 0.04) or further restricting the subjects to those with a family history of asthma and those of European American ancestry (odds ratio = 3.16, P = 0.04).</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">11896460</ID>
        </Citation>
      </ObservedData>
      <ObservedData ID="17819924">
        <Attribute Type="Description">Shin et al. (2004) genotyped 550 Korean asthmatics and 171 Korean controls at 5 SNPs in TNFA and 2 SNPs in TNFB. Six common haplotypes could be constructed in the TNF gene cluster. The -308G-A polymorphism showed a significant association with the risk of asthma (p = 0.0004). The frequency of the -308A allele-containing genotype in asthmatics (9.8%) was much lower than that in normal controls (22.9%). The protective effects of this polymorphism on asthma were also evident in separated subgroups by atopic status (p = 0.05 in nonatopic subjects and p = 0.003 in atopic subjects). The most common haplotype of the TNF gene cluster (TNF-ht1-GGTCCGG) was associated with total serum IgE levels (147050) in asthma patients, especially in nonatopic patients (p = 0.004). Shin et al. (2004) concluded that genetic variants of TNF may be involved in the development of asthma and total serum IgE level in bronchial asthma patients.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">14681301</ID>
        </Citation>
      </ObservedData>
      <ObservedData ID="17819924">
        <Attribute Type="Description">Aoki et al. (2006) did not find a significant association between the TNF -308G-A polymorphism and childhood atopic asthma in 2 independent Japanese populations; however, metaanalysis of a total of 2,477 asthma patients and 3,217 control individuals showed that the -308G-A polymorphism was significantly associated with asthma. The combined odds ratio was 1.46 for fixed or random effects (p = 0.0000001 and p = 0.00014, respectively).</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">16865291</ID>
        </Citation>
      </ObservedData>
      <ObservedData ID="17819924">
        <Attribute Type="Description">Quasney et al. (2001) stated that immunologic mechanisms resulting in macrophage infiltration and glial cell activation in the brain are thought to be involved in the pathophysiology of HIV dementia. Moreover, elevated levels of TNF-alpha have been found in the brains of patients with HIV dementia. In a study of 16 patients with HIV dementia, 45 HIV-infected patients without dementia, and 231 controls, they found an increased frequency of the -308A allele in patients with HIV dementia (0.28 vs 0.11 in controls and 0.07 in HIV patients without dementia). There were no individuals with the A/A genotype in either of the HIV-infected groups. Quasney et al. (2001) noted that the -308A allele is associated with higher TNF-alpha secretion in response to an inflammatory stimulus and that evidence has shown a role for TNF-alpha in neuronal damage, thus suggesting a genetic predisposition to the development of HIV dementia.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">11506397</ID>
        </Citation>
      </ObservedData>
      <ObservedData ID="17819924">
        <Attribute Type="Description">Cox et al. (1994) reported that the -308A allele has an increased frequency in type I diabetes mellitus (222100). Krikovszky et al. (2002) studied ambulatory blood pressure in 126 Hungarian adolescents with type I diabetes mellitus. They found that the prevalence of the -308A allele was higher in diabetic adolescents than in the Hungarian reference population. TNFA genotype was associated with both systolic and diastolic blood pressure values. The -308A allele carrier state appeared to be associated with lower systolic and diastolic blood pressure values.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">12485196</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">8056188</ID>
        </Citation>
      </ObservedData>
      <ObservedData ID="17819924">
        <Attribute Type="Description">Szalai et al. (2002) found an increased frequency of the C4B*Q0 allele (see 120820) in patients with severe coronary artery disease (CAD) who underwent bypass surgery compared to healthy controls (14.2% vs 9.9%). Investigation of specific allelic combinations revealed that C4B*Q0 in combination with the TNF-alpha -308A allele was significantly higher in CAD patients, particularly those with preoperative myocardial infarction.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">11826025</ID>
        </Citation>
      </ObservedData>
      <ObservedData ID="17819924">
        <Attribute Type="Description">In a study of 147 patients with psoriatic arthritis (607507) and 389 controls, Balding et al. (2003) found that the -308A allele was significantly associated with both the presence and progression of joint erosions in psoriatic arthritis, and that the AA genotype was associated with the lowest mean age at onset of psoriasis (p = 0.0081).</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">12746914</ID>
        </Citation>
      </ObservedData>
      <ObservedData ID="17819924">
        <Attribute Type="Description">In a group of 261 patients with migraine without aura (see, e.g., 157300), Rainero et al. (2004) found that the G/G genotype was associated with an increased risk of migraine (odds ratio of 3.30). Rainero et al. (2004) suggested that TNF-alpha may be involved in the pathogenesis of migraine, perhaps due to its effect on cerebral blood flow; alternatively, a closely linked locus may be involved.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">14718719</ID>
        </Citation>
      </ObservedData>
      <ObservedData ID="17819924">
        <Attribute Type="Description">In a metaanalysis of 19 studies, Lee et al. (2006) found an association between the -308A/A genotype and the -308A allele and systemic lupus erythematosus (SLE; 152700) in European-derived population (odds ratio of 4.0 for A/A and 2.1 for the A allele), but not in Asian-derived populations.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">16418737</ID>
        </Citation>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant" ID="12388">
      <Measure Type="single nucleotide variant" ID="27427">
        <Name>
          <ElementValue Type="Preferred">TNF, -308G-A</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="nucleotide change">-308G-A</Attribute>
          <XRef Type="Allelic variant" ID="191160.0004" DB="OMIM"/>
        </AttributeSet>
        <CytogeneticLocation>6p21.3</CytogeneticLocation>
        <MeasureRelationship Type="asserted, but not computed">
          <Name>
            <ElementValue Type="Preferred">tumor necrosis factor</ElementValue>
          </Name>
          <Symbol>
            <ElementValue Type="Preferred">TNF</ElementValue>
          </Symbol>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="6" Accession="NC_000006.12" start="31575567" stop="31578336" display_start="31575567" display_stop="31578336" Strand="+"/>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="6" Accession="NT_113891.3" start="3052854" stop="3055623" display_start="3052854" display_stop="3055623" Strand="+"/>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="6" Accession="NT_167244.2" start="2909108" stop="2910915" display_start="2909108" display_stop="2910915" Strand="+"/>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="6" Accession="NT_167245.2" start="2823300" stop="2826069" display_start="2823300" display_stop="2826069" Strand="+"/>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="6" Accession="NT_167246.2" start="2880608" stop="2883377" display_start="2880608" display_stop="2883377" Strand="+"/>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="6" Accession="NT_167247.2" start="2917465" stop="2920234" display_start="2917465" display_stop="2920234" Strand="+"/>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="6" Accession="NT_167248.2" start="2831386" stop="2834157" display_start="2831386" display_stop="2834157" Strand="+"/>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="6" Accession="NT_167249.2" start="2874847" stop="2877616" display_start="2874847" display_stop="2877616" Strand="+"/>
          <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="6" Accession="NC_000006.11" start="31543343" stop="31546112" display_start="31543343" display_stop="31546112" variantLength="2770" Strand="+"/>
          <XRef ID="7124" DB="Gene"/>
          <XRef Type="MIM" ID="191160" DB="OMIM"/>
          <XRef ID="HGNC:11892" DB="HGNC"/>
        </MeasureRelationship>
        <Citation Type="Position Statement" Abbrev="EGAPP, 2010">
          <ID Source="PubMed">21042222</ID>
        </Citation>
        <XRef Type="Allelic variant" ID="191160.0004" DB="OMIM"/>
      </Measure>
      <Name>
        <ElementValue Type="Preferred">TNF, -308G-A</ElementValue>
      </Name>
    </MeasureSet>
    <TraitSet Type="Disease" ID="3362">
      <Trait ID="11002" Type="Disease">
        <Name>
          <ElementValue Type="Preferred">Migraine without aura, susceptibility to</ElementValue>
        </Name>
      </Trait>
    </TraitSet>
  </ReferenceClinVarAssertion>
  <ClinVarAssertion ID="33439">
    <ClinVarSubmissionID localKey="191160.0004_MIGRAINE WITHOUT AURA, SUSCEPTIBILITY TO" submitter="OMIM" submitterDate="2016-09-06" title="TNF, -308G-A_MIGRAINE WITHOUT AURA, SUSCEPTIBILITY TO"/>
    <ClinVarAccession Acc="SCV000033439" OrgType="primary" OrganizationCategory="resource" Version="2" Type="SCV" OrgID="3" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2006-03-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>risk factor</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to included disease"/>
    <ExternalID DB="OMIM" ID="191160.0004" Type="Allelic variant"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species>human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="Description">Mira et al. (1999) referred to the TNFA promoter polymorphisms at position -308 as TNF1 for guanine and TNF2 for adenine. In a multicenter study involving 7 institutions, they found a significant association between the TNF2 allele and susceptibility to septic shock and death from septic shock. The septic shock group was defined by the following 6 criteria within a 12-hour period: (1) clinical evidence of infection; (2) hyperthermia or hypothermia; (3) tachycardia; (4) tachypnea; (5) necessity for vasopressor to maintain systolic blood pressure; and (6) evidence of inadequate organ function or perfusion.</Attribute>
        <Citation>
          <ID Source="PubMed">10450718</ID>
        </Citation>
      </ObservedData>
      <ObservedData>
        <Attribute Type="Description">Moraes et al. (2001) found that the TNF2 polymorphism is significantly associated with a stronger response (Mitsuda reaction) to lepromin in borderline tuberculoid leprosy patients. Epigenetic factors such as a history of BCG vaccination or a reversal reaction, but not both, were also associated with boosted Mitsuda reactions. Moraes et al. (2001) concluded that augmented TNF production may be associated with the TNF2 allele and an increased granulomatous response.</Attribute>
        <Citation>
          <ID Source="PubMed">11261930</ID>
        </Citation>
      </ObservedData>
      <ObservedData>
        <Attribute Type="Description">Ma et al. (1998) found a higher frequency of the rare T2 TNFA polymorphism (-308G-A) in 43 Japanese Guillain-Barre syndrome (139393) patients who had had antecedent infection with C. jejuni than in 85 community controls.</Attribute>
        <Citation>
          <ID Source="PubMed">9818939</ID>
        </Citation>
        <XRef DB="OMIM" ID="139393" Type="MIM"/>
      </ObservedData>
      <ObservedData>
        <Attribute Type="Description">Witte et al. (2002) evaluated the relation between the -308G-A promoter polymorphism and risk of asthma (600807) in 236 cases and 275 nonasthmatic controls. Logistic regression analyses indicated that having 1 or 2 copies of the -308A allele increased the risk of asthma (odds ratio = 1.58), the magnitude of which was increased when restricting the cases to those with acute asthma (odds ratio = 1.86, P = 0.04) or further restricting the subjects to those with a family history of asthma and those of European American ancestry (odds ratio = 3.16, P = 0.04).</Attribute>
        <Citation>
          <ID Source="PubMed">11896460</ID>
        </Citation>
        <XRef DB="OMIM" ID="600807" Type="MIM"/>
      </ObservedData>
      <ObservedData>
        <Attribute Type="Description">Shin et al. (2004) genotyped 550 Korean asthmatics and 171 Korean controls at 5 SNPs in TNFA and 2 SNPs in TNFB. Six common haplotypes could be constructed in the TNF gene cluster. The -308G-A polymorphism showed a significant association with the risk of asthma (p = 0.0004). The frequency of the -308A allele-containing genotype in asthmatics (9.8%) was much lower than that in normal controls (22.9%). The protective effects of this polymorphism on asthma were also evident in separated subgroups by atopic status (p = 0.05 in nonatopic subjects and p = 0.003 in atopic subjects). The most common haplotype of the TNF gene cluster (TNF-ht1-GGTCCGG) was associated with total serum IgE levels (147050) in asthma patients, especially in nonatopic patients (p = 0.004). Shin et al. (2004) concluded that genetic variants of TNF may be involved in the development of asthma and total serum IgE level in bronchial asthma patients.</Attribute>
        <Citation>
          <ID Source="PubMed">14681301</ID>
        </Citation>
        <XRef DB="OMIM" ID="147050" Type="MIM"/>
      </ObservedData>
      <ObservedData>
        <Attribute Type="Description">Aoki et al. (2006) did not find a significant association between the TNF -308G-A polymorphism and childhood atopic asthma in 2 independent Japanese populations; however, metaanalysis of a total of 2,477 asthma patients and 3,217 control individuals showed that the -308G-A polymorphism was significantly associated with asthma. The combined odds ratio was 1.46 for fixed or random effects (p = 0.0000001 and p = 0.00014, respectively).</Attribute>
        <Citation>
          <ID Source="PubMed">16865291</ID>
        </Citation>
      </ObservedData>
      <ObservedData>
        <Attribute Type="Description">Quasney et al. (2001) stated that immunologic mechanisms resulting in macrophage infiltration and glial cell activation in the brain are thought to be involved in the pathophysiology of HIV dementia. Moreover, elevated levels of TNF-alpha have been found in the brains of patients with HIV dementia. In a study of 16 patients with HIV dementia, 45 HIV-infected patients without dementia, and 231 controls, they found an increased frequency of the -308A allele in patients with HIV dementia (0.28 vs 0.11 in controls and 0.07 in HIV patients without dementia). There were no individuals with the A/A genotype in either of the HIV-infected groups. Quasney et al. (2001) noted that the -308A allele is associated with higher TNF-alpha secretion in response to an inflammatory stimulus and that evidence has shown a role for TNF-alpha in neuronal damage, thus suggesting a genetic predisposition to the development of HIV dementia.</Attribute>
        <Citation>
          <ID Source="PubMed">11506397</ID>
        </Citation>
      </ObservedData>
      <ObservedData>
        <Attribute Type="Description">Cox et al. (1994) reported that the -308A allele has an increased frequency in type I diabetes mellitus (222100). Krikovszky et al. (2002) studied ambulatory blood pressure in 126 Hungarian adolescents with type I diabetes mellitus. They found that the prevalence of the -308A allele was higher in diabetic adolescents than in the Hungarian reference population. TNFA genotype was associated with both systolic and diastolic blood pressure values. The -308A allele carrier state appeared to be associated with lower systolic and diastolic blood pressure values.</Attribute>
        <Citation>
          <ID Source="PubMed">8056188</ID>
        </Citation>
        <Citation>
          <ID Source="PubMed">12485196</ID>
        </Citation>
        <XRef DB="OMIM" ID="222100" Type="MIM"/>
      </ObservedData>
      <ObservedData>
        <Attribute Type="Description">Szalai et al. (2002) found an increased frequency of the C4B*Q0 allele (see 120820) in patients with severe coronary artery disease (CAD) who underwent bypass surgery compared to healthy controls (14.2% vs 9.9%). Investigation of specific allelic combinations revealed that C4B*Q0 in combination with the TNF-alpha -308A allele was significantly higher in CAD patients, particularly those with preoperative myocardial infarction.</Attribute>
        <Citation>
          <ID Source="PubMed">11826025</ID>
        </Citation>
        <XRef DB="OMIM" ID="120820" Type="MIM"/>
      </ObservedData>
      <ObservedData>
        <Attribute Type="Description">In a study of 147 patients with psoriatic arthritis (607507) and 389 controls, Balding et al. (2003) found that the -308A allele was significantly associated with both the presence and progression of joint erosions in psoriatic arthritis, and that the AA genotype was associated with the lowest mean age at onset of psoriasis (p = 0.0081).</Attribute>
        <Citation>
          <ID Source="PubMed">12746914</ID>
        </Citation>
        <XRef DB="OMIM" ID="607507" Type="MIM"/>
      </ObservedData>
      <ObservedData>
        <Attribute Type="Description">In a group of 261 patients with migraine without aura (see, e.g., 157300), Rainero et al. (2004) found that the G/G genotype was associated with an increased risk of migraine (odds ratio of 3.30). Rainero et al. (2004) suggested that TNF-alpha may be involved in the pathogenesis of migraine, perhaps due to its effect on cerebral blood flow; alternatively, a closely linked locus may be involved.</Attribute>
        <Citation>
          <ID Source="PubMed">14718719</ID>
        </Citation>
        <XRef DB="OMIM" ID="157300" Type="MIM"/>
      </ObservedData>
      <ObservedData>
        <Attribute Type="Description">In a metaanalysis of 19 studies, Lee et al. (2006) found an association between the -308A/A genotype and the -308A allele and systemic lupus erythematosus (SLE; 152700) in European-derived population (odds ratio of 4.0 for A/A and 2.1 for the A allele), but not in Asian-derived populations.</Attribute>
        <Citation>
          <ID Source="PubMed">16418737</ID>
        </Citation>
        <XRef DB="OMIM" ID="152700" Type="MIM"/>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant">
      <Measure Type="Variation">
        <Name>
          <ElementValue Type="Preferred">TNF, -308G-A</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="NonHGVS">-308G-A</Attribute>
        </AttributeSet>
        <MeasureRelationship Type="variant in gene">
          <Symbol>
            <ElementValue Type="Preferred">TNF</ElementValue>
          </Symbol>
        </MeasureRelationship>
        <XRef DB="OMIM" ID="191160.0004" Type="Allelic variant"/>
      </Measure>
    </MeasureSet>
    <TraitSet Type="Disease">
      <Trait Type="Disease">
        <Name>
          <ElementValue Type="included">MIGRAINE WITHOUT AURA, SUSCEPTIBILITY TO</ElementValue>
        </Name>
      </Trait>
    </TraitSet>
  </ClinVarAssertion>
</ClinVarSet>

<ClinVarSet ID="18646561">
  <RecordStatus>current</RecordStatus>
  <Title>TNF, -308G-A AND Systemic lupus erythematosus, susceptibility to</Title>
  <ReferenceClinVarAssertion DateCreated="2012-08-13" DateLastUpdated="2017-04-07" ID="70697">
    <ClinVarAccession Acc="RCV000013194" Version="3" Type="RCV" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2006-03-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>risk factor</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData ID="17819721">
        <Attribute Type="Description">Mira et al. (1999) referred to the TNFA promoter polymorphisms at position -308 as TNF1 for guanine and TNF2 for adenine. In a multicenter study involving 7 institutions, they found a significant association between the TNF2 allele and susceptibility to septic shock and death from septic shock. The septic shock group was defined by the following 6 criteria within a 12-hour period: (1) clinical evidence of infection; (2) hyperthermia or hypothermia; (3) tachycardia; (4) tachypnea; (5) necessity for vasopressor to maintain systolic blood pressure; and (6) evidence of inadequate organ function or perfusion.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">10450718</ID>
        </Citation>
      </ObservedData>
      <ObservedData ID="17819721">
        <Attribute Type="Description">Moraes et al. (2001) found that the TNF2 polymorphism is significantly associated with a stronger response (Mitsuda reaction) to lepromin in borderline tuberculoid leprosy patients. Epigenetic factors such as a history of BCG vaccination or a reversal reaction, but not both, were also associated with boosted Mitsuda reactions. Moraes et al. (2001) concluded that augmented TNF production may be associated with the TNF2 allele and an increased granulomatous response.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">11261930</ID>
        </Citation>
      </ObservedData>
      <ObservedData ID="17819721">
        <Attribute Type="Description">Ma et al. (1998) found a higher frequency of the rare T2 TNFA polymorphism (-308G-A) in 43 Japanese Guillain-Barre syndrome (139393) patients who had had antecedent infection with C. jejuni than in 85 community controls.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">9818939</ID>
        </Citation>
      </ObservedData>
      <ObservedData ID="17819721">
        <Attribute Type="Description">Witte et al. (2002) evaluated the relation between the -308G-A promoter polymorphism and risk of asthma (600807) in 236 cases and 275 nonasthmatic controls. Logistic regression analyses indicated that having 1 or 2 copies of the -308A allele increased the risk of asthma (odds ratio = 1.58), the magnitude of which was increased when restricting the cases to those with acute asthma (odds ratio = 1.86, P = 0.04) or further restricting the subjects to those with a family history of asthma and those of European American ancestry (odds ratio = 3.16, P = 0.04).</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">11896460</ID>
        </Citation>
      </ObservedData>
      <ObservedData ID="17819721">
        <Attribute Type="Description">Shin et al. (2004) genotyped 550 Korean asthmatics and 171 Korean controls at 5 SNPs in TNFA and 2 SNPs in TNFB. Six common haplotypes could be constructed in the TNF gene cluster. The -308G-A polymorphism showed a significant association with the risk of asthma (p = 0.0004). The frequency of the -308A allele-containing genotype in asthmatics (9.8%) was much lower than that in normal controls (22.9%). The protective effects of this polymorphism on asthma were also evident in separated subgroups by atopic status (p = 0.05 in nonatopic subjects and p = 0.003 in atopic subjects). The most common haplotype of the TNF gene cluster (TNF-ht1-GGTCCGG) was associated with total serum IgE levels (147050) in asthma patients, especially in nonatopic patients (p = 0.004). Shin et al. (2004) concluded that genetic variants of TNF may be involved in the development of asthma and total serum IgE level in bronchial asthma patients.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">14681301</ID>
        </Citation>
      </ObservedData>
      <ObservedData ID="17819721">
        <Attribute Type="Description">Aoki et al. (2006) did not find a significant association between the TNF -308G-A polymorphism and childhood atopic asthma in 2 independent Japanese populations; however, metaanalysis of a total of 2,477 asthma patients and 3,217 control individuals showed that the -308G-A polymorphism was significantly associated with asthma. The combined odds ratio was 1.46 for fixed or random effects (p = 0.0000001 and p = 0.00014, respectively).</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">16865291</ID>
        </Citation>
      </ObservedData>
      <ObservedData ID="17819721">
        <Attribute Type="Description">Quasney et al. (2001) stated that immunologic mechanisms resulting in macrophage infiltration and glial cell activation in the brain are thought to be involved in the pathophysiology of HIV dementia. Moreover, elevated levels of TNF-alpha have been found in the brains of patients with HIV dementia. In a study of 16 patients with HIV dementia, 45 HIV-infected patients without dementia, and 231 controls, they found an increased frequency of the -308A allele in patients with HIV dementia (0.28 vs 0.11 in controls and 0.07 in HIV patients without dementia). There were no individuals with the A/A genotype in either of the HIV-infected groups. Quasney et al. (2001) noted that the -308A allele is associated with higher TNF-alpha secretion in response to an inflammatory stimulus and that evidence has shown a role for TNF-alpha in neuronal damage, thus suggesting a genetic predisposition to the development of HIV dementia.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">11506397</ID>
        </Citation>
      </ObservedData>
      <ObservedData ID="17819721">
        <Attribute Type="Description">Cox et al. (1994) reported that the -308A allele has an increased frequency in type I diabetes mellitus (222100). Krikovszky et al. (2002) studied ambulatory blood pressure in 126 Hungarian adolescents with type I diabetes mellitus. They found that the prevalence of the -308A allele was higher in diabetic adolescents than in the Hungarian reference population. TNFA genotype was associated with both systolic and diastolic blood pressure values. The -308A allele carrier state appeared to be associated with lower systolic and diastolic blood pressure values.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">12485196</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">8056188</ID>
        </Citation>
      </ObservedData>
      <ObservedData ID="17819721">
        <Attribute Type="Description">Szalai et al. (2002) found an increased frequency of the C4B*Q0 allele (see 120820) in patients with severe coronary artery disease (CAD) who underwent bypass surgery compared to healthy controls (14.2% vs 9.9%). Investigation of specific allelic combinations revealed that C4B*Q0 in combination with the TNF-alpha -308A allele was significantly higher in CAD patients, particularly those with preoperative myocardial infarction.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">11826025</ID>
        </Citation>
      </ObservedData>
      <ObservedData ID="17819721">
        <Attribute Type="Description">In a study of 147 patients with psoriatic arthritis (607507) and 389 controls, Balding et al. (2003) found that the -308A allele was significantly associated with both the presence and progression of joint erosions in psoriatic arthritis, and that the AA genotype was associated with the lowest mean age at onset of psoriasis (p = 0.0081).</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">12746914</ID>
        </Citation>
      </ObservedData>
      <ObservedData ID="17819721">
        <Attribute Type="Description">In a group of 261 patients with migraine without aura (see, e.g., 157300), Rainero et al. (2004) found that the G/G genotype was associated with an increased risk of migraine (odds ratio of 3.30). Rainero et al. (2004) suggested that TNF-alpha may be involved in the pathogenesis of migraine, perhaps due to its effect on cerebral blood flow; alternatively, a closely linked locus may be involved.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">14718719</ID>
        </Citation>
      </ObservedData>
      <ObservedData ID="17819721">
        <Attribute Type="Description">In a metaanalysis of 19 studies, Lee et al. (2006) found an association between the -308A/A genotype and the -308A allele and systemic lupus erythematosus (SLE; 152700) in European-derived population (odds ratio of 4.0 for A/A and 2.1 for the A allele), but not in Asian-derived populations.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">16418737</ID>
        </Citation>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant" ID="12388">
      <Measure Type="single nucleotide variant" ID="27427">
        <Name>
          <ElementValue Type="Preferred">TNF, -308G-A</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="nucleotide change">-308G-A</Attribute>
          <XRef Type="Allelic variant" ID="191160.0004" DB="OMIM"/>
        </AttributeSet>
        <CytogeneticLocation>6p21.3</CytogeneticLocation>
        <MeasureRelationship Type="asserted, but not computed">
          <Name>
            <ElementValue Type="Preferred">tumor necrosis factor</ElementValue>
          </Name>
          <Symbol>
            <ElementValue Type="Preferred">TNF</ElementValue>
          </Symbol>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="6" Accession="NC_000006.12" start="31575567" stop="31578336" display_start="31575567" display_stop="31578336" Strand="+"/>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="6" Accession="NT_113891.3" start="3052854" stop="3055623" display_start="3052854" display_stop="3055623" Strand="+"/>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="6" Accession="NT_167244.2" start="2909108" stop="2910915" display_start="2909108" display_stop="2910915" Strand="+"/>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="6" Accession="NT_167245.2" start="2823300" stop="2826069" display_start="2823300" display_stop="2826069" Strand="+"/>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="6" Accession="NT_167246.2" start="2880608" stop="2883377" display_start="2880608" display_stop="2883377" Strand="+"/>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="6" Accession="NT_167247.2" start="2917465" stop="2920234" display_start="2917465" display_stop="2920234" Strand="+"/>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="6" Accession="NT_167248.2" start="2831386" stop="2834157" display_start="2831386" display_stop="2834157" Strand="+"/>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="6" Accession="NT_167249.2" start="2874847" stop="2877616" display_start="2874847" display_stop="2877616" Strand="+"/>
          <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="6" Accession="NC_000006.11" start="31543343" stop="31546112" display_start="31543343" display_stop="31546112" variantLength="2770" Strand="+"/>
          <XRef ID="7124" DB="Gene"/>
          <XRef Type="MIM" ID="191160" DB="OMIM"/>
          <XRef ID="HGNC:11892" DB="HGNC"/>
        </MeasureRelationship>
        <Citation Type="Position Statement" Abbrev="EGAPP, 2010">
          <ID Source="PubMed">21042222</ID>
        </Citation>
        <XRef Type="Allelic variant" ID="191160.0004" DB="OMIM"/>
      </Measure>
      <Name>
        <ElementValue Type="Preferred">TNF, -308G-A</ElementValue>
      </Name>
    </MeasureSet>
    <TraitSet Type="Disease" ID="1149">
      <Trait ID="10051" Type="Disease">
        <Name>
          <ElementValue Type="Preferred">Systemic lupus erythematosus, susceptibility to</ElementValue>
        </Name>
      </Trait>
    </TraitSet>
  </ReferenceClinVarAssertion>
  <ClinVarAssertion ID="33441">
    <ClinVarSubmissionID localKey="191160.0004_SYSTEMIC LUPUS ERYTHEMATOSUS, SUSCEPTIBILITY TO" submitter="OMIM" submitterDate="2016-09-06" title="TNF, -308G-A_SYSTEMIC LUPUS ERYTHEMATOSUS, SUSCEPTIBILITY TO"/>
    <ClinVarAccession Acc="SCV000033441" OrgType="primary" OrganizationCategory="resource" Version="2" Type="SCV" OrgID="3" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2006-03-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>risk factor</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to included disease"/>
    <ExternalID DB="OMIM" ID="191160.0004" Type="Allelic variant"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species>human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="Description">Mira et al. (1999) referred to the TNFA promoter polymorphisms at position -308 as TNF1 for guanine and TNF2 for adenine. In a multicenter study involving 7 institutions, they found a significant association between the TNF2 allele and susceptibility to septic shock and death from septic shock. The septic shock group was defined by the following 6 criteria within a 12-hour period: (1) clinical evidence of infection; (2) hyperthermia or hypothermia; (3) tachycardia; (4) tachypnea; (5) necessity for vasopressor to maintain systolic blood pressure; and (6) evidence of inadequate organ function or perfusion.</Attribute>
        <Citation>
          <ID Source="PubMed">10450718</ID>
        </Citation>
      </ObservedData>
      <ObservedData>
        <Attribute Type="Description">Moraes et al. (2001) found that the TNF2 polymorphism is significantly associated with a stronger response (Mitsuda reaction) to lepromin in borderline tuberculoid leprosy patients. Epigenetic factors such as a history of BCG vaccination or a reversal reaction, but not both, were also associated with boosted Mitsuda reactions. Moraes et al. (2001) concluded that augmented TNF production may be associated with the TNF2 allele and an increased granulomatous response.</Attribute>
        <Citation>
          <ID Source="PubMed">11261930</ID>
        </Citation>
      </ObservedData>
      <ObservedData>
        <Attribute Type="Description">Ma et al. (1998) found a higher frequency of the rare T2 TNFA polymorphism (-308G-A) in 43 Japanese Guillain-Barre syndrome (139393) patients who had had antecedent infection with C. jejuni than in 85 community controls.</Attribute>
        <Citation>
          <ID Source="PubMed">9818939</ID>
        </Citation>
        <XRef DB="OMIM" ID="139393" Type="MIM"/>
      </ObservedData>
      <ObservedData>
        <Attribute Type="Description">Witte et al. (2002) evaluated the relation between the -308G-A promoter polymorphism and risk of asthma (600807) in 236 cases and 275 nonasthmatic controls. Logistic regression analyses indicated that having 1 or 2 copies of the -308A allele increased the risk of asthma (odds ratio = 1.58), the magnitude of which was increased when restricting the cases to those with acute asthma (odds ratio = 1.86, P = 0.04) or further restricting the subjects to those with a family history of asthma and those of European American ancestry (odds ratio = 3.16, P = 0.04).</Attribute>
        <Citation>
          <ID Source="PubMed">11896460</ID>
        </Citation>
        <XRef DB="OMIM" ID="600807" Type="MIM"/>
      </ObservedData>
      <ObservedData>
        <Attribute Type="Description">Shin et al. (2004) genotyped 550 Korean asthmatics and 171 Korean controls at 5 SNPs in TNFA and 2 SNPs in TNFB. Six common haplotypes could be constructed in the TNF gene cluster. The -308G-A polymorphism showed a significant association with the risk of asthma (p = 0.0004). The frequency of the -308A allele-containing genotype in asthmatics (9.8%) was much lower than that in normal controls (22.9%). The protective effects of this polymorphism on asthma were also evident in separated subgroups by atopic status (p = 0.05 in nonatopic subjects and p = 0.003 in atopic subjects). The most common haplotype of the TNF gene cluster (TNF-ht1-GGTCCGG) was associated with total serum IgE levels (147050) in asthma patients, especially in nonatopic patients (p = 0.004). Shin et al. (2004) concluded that genetic variants of TNF may be involved in the development of asthma and total serum IgE level in bronchial asthma patients.</Attribute>
        <Citation>
          <ID Source="PubMed">14681301</ID>
        </Citation>
        <XRef DB="OMIM" ID="147050" Type="MIM"/>
      </ObservedData>
      <ObservedData>
        <Attribute Type="Description">Aoki et al. (2006) did not find a significant association between the TNF -308G-A polymorphism and childhood atopic asthma in 2 independent Japanese populations; however, metaanalysis of a total of 2,477 asthma patients and 3,217 control individuals showed that the -308G-A polymorphism was significantly associated with asthma. The combined odds ratio was 1.46 for fixed or random effects (p = 0.0000001 and p = 0.00014, respectively).</Attribute>
        <Citation>
          <ID Source="PubMed">16865291</ID>
        </Citation>
      </ObservedData>
      <ObservedData>
        <Attribute Type="Description">Quasney et al. (2001) stated that immunologic mechanisms resulting in macrophage infiltration and glial cell activation in the brain are thought to be involved in the pathophysiology of HIV dementia. Moreover, elevated levels of TNF-alpha have been found in the brains of patients with HIV dementia. In a study of 16 patients with HIV dementia, 45 HIV-infected patients without dementia, and 231 controls, they found an increased frequency of the -308A allele in patients with HIV dementia (0.28 vs 0.11 in controls and 0.07 in HIV patients without dementia). There were no individuals with the A/A genotype in either of the HIV-infected groups. Quasney et al. (2001) noted that the -308A allele is associated with higher TNF-alpha secretion in response to an inflammatory stimulus and that evidence has shown a role for TNF-alpha in neuronal damage, thus suggesting a genetic predisposition to the development of HIV dementia.</Attribute>
        <Citation>
          <ID Source="PubMed">11506397</ID>
        </Citation>
      </ObservedData>
      <ObservedData>
        <Attribute Type="Description">Cox et al. (1994) reported that the -308A allele has an increased frequency in type I diabetes mellitus (222100). Krikovszky et al. (2002) studied ambulatory blood pressure in 126 Hungarian adolescents with type I diabetes mellitus. They found that the prevalence of the -308A allele was higher in diabetic adolescents than in the Hungarian reference population. TNFA genotype was associated with both systolic and diastolic blood pressure values. The -308A allele carrier state appeared to be associated with lower systolic and diastolic blood pressure values.</Attribute>
        <Citation>
          <ID Source="PubMed">8056188</ID>
        </Citation>
        <Citation>
          <ID Source="PubMed">12485196</ID>
        </Citation>
        <XRef DB="OMIM" ID="222100" Type="MIM"/>
      </ObservedData>
      <ObservedData>
        <Attribute Type="Description">Szalai et al. (2002) found an increased frequency of the C4B*Q0 allele (see 120820) in patients with severe coronary artery disease (CAD) who underwent bypass surgery compared to healthy controls (14.2% vs 9.9%). Investigation of specific allelic combinations revealed that C4B*Q0 in combination with the TNF-alpha -308A allele was significantly higher in CAD patients, particularly those with preoperative myocardial infarction.</Attribute>
        <Citation>
          <ID Source="PubMed">11826025</ID>
        </Citation>
        <XRef DB="OMIM" ID="120820" Type="MIM"/>
      </ObservedData>
      <ObservedData>
        <Attribute Type="Description">In a study of 147 patients with psoriatic arthritis (607507) and 389 controls, Balding et al. (2003) found that the -308A allele was significantly associated with both the presence and progression of joint erosions in psoriatic arthritis, and that the AA genotype was associated with the lowest mean age at onset of psoriasis (p = 0.0081).</Attribute>
        <Citation>
          <ID Source="PubMed">12746914</ID>
        </Citation>
        <XRef DB="OMIM" ID="607507" Type="MIM"/>
      </ObservedData>
      <ObservedData>
        <Attribute Type="Description">In a group of 261 patients with migraine without aura (see, e.g., 157300), Rainero et al. (2004) found that the G/G genotype was associated with an increased risk of migraine (odds ratio of 3.30). Rainero et al. (2004) suggested that TNF-alpha may be involved in the pathogenesis of migraine, perhaps due to its effect on cerebral blood flow; alternatively, a closely linked locus may be involved.</Attribute>
        <Citation>
          <ID Source="PubMed">14718719</ID>
        </Citation>
        <XRef DB="OMIM" ID="157300" Type="MIM"/>
      </ObservedData>
      <ObservedData>
        <Attribute Type="Description">In a metaanalysis of 19 studies, Lee et al. (2006) found an association between the -308A/A genotype and the -308A allele and systemic lupus erythematosus (SLE; 152700) in European-derived population (odds ratio of 4.0 for A/A and 2.1 for the A allele), but not in Asian-derived populations.</Attribute>
        <Citation>
          <ID Source="PubMed">16418737</ID>
        </Citation>
        <XRef DB="OMIM" ID="152700" Type="MIM"/>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant">
      <Measure Type="Variation">
        <Name>
          <ElementValue Type="Preferred">TNF, -308G-A</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="NonHGVS">-308G-A</Attribute>
        </AttributeSet>
        <MeasureRelationship Type="variant in gene">
          <Symbol>
            <ElementValue Type="Preferred">TNF</ElementValue>
          </Symbol>
        </MeasureRelationship>
        <XRef DB="OMIM" ID="191160.0004" Type="Allelic variant"/>
      </Measure>
    </MeasureSet>
    <TraitSet Type="Disease">
      <Trait Type="Disease">
        <Name>
          <ElementValue Type="included">SYSTEMIC LUPUS ERYTHEMATOSUS, SUSCEPTIBILITY TO</ElementValue>
        </Name>
      </Trait>
    </TraitSet>
  </ClinVarAssertion>
</ClinVarSet>

<ClinVarSet ID="18638083">
  <RecordStatus>current</RecordStatus>
  <Title>ITIH4, IVS17, +8, C-T AND Hypercholesterolemia, susceptibility to</Title>
  <ReferenceClinVarAssertion DateCreated="2012-08-13" DateLastUpdated="2017-04-07" ID="67112">
    <ClinVarAccession Acc="RCV000009609" Version="2" Type="RCV" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2004-01-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>risk factor</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData ID="17815634">
        <Attribute Type="Description">Fujita et al. (2004) reported an association between a C/T single nucleotide polymorphism (SNP) at position +8 in intron 17 of the ITIH4 gene and plasma total cholesterol levels in 351 adult individuals from an east-central area of Japan. Those who lacked the T allele had significantly higher plasma total cholesterol levels than the others who had the T allele. Of the 309 without the T allele, approximately 90% presented with hypercholesterolemia (see 143890), whereas only 10% were hypercholesterolemic among 42 individuals with the T allele. They interpreted the data as suggesting that genetic variation at the ITIH4 locus is a determinant of plasma cholesterol metabolism.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">14661079</ID>
        </Citation>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant" ID="9042">
      <Measure Type="single nucleotide variant" ID="24081">
        <Name>
          <ElementValue Type="Preferred">ITIH4, IVS17, +8, C-T</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="nucleotide change">IVS17, +8, C-T</Attribute>
          <XRef Type="Allelic variant" ID="600564.0001" DB="OMIM"/>
        </AttributeSet>
        <CytogeneticLocation>3p21.2-p14.1</CytogeneticLocation>
        <MeasureRelationship Type="asserted, but not computed">
          <Name>
            <ElementValue Type="Preferred">inter-alpha-trypsin inhibitor heavy chain family member 4</ElementValue>
          </Name>
          <Symbol>
            <ElementValue Type="Preferred">ITIH4</ElementValue>
          </Symbol>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="3" Accession="NC_000003.12" start="52812990" stop="52830701" display_start="52812990" display_stop="52830701" Strand="-"/>
          <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="3" Accession="NC_000003.11" start="52847005" stop="52864716" display_start="52847005" display_stop="52864716" variantLength="17712" Strand="-"/>
          <XRef ID="3700" DB="Gene"/>
          <XRef Type="MIM" ID="600564" DB="OMIM"/>
          <XRef ID="HGNC:6169" DB="HGNC"/>
        </MeasureRelationship>
        <XRef Type="Allelic variant" ID="600564.0001" DB="OMIM"/>
      </Measure>
      <Name>
        <ElementValue Type="Preferred">ITIH4, IVS17, +8, C-T</ElementValue>
      </Name>
    </MeasureSet>
    <TraitSet Type="Disease" ID="1627">
      <Trait ID="10193" Type="Disease">
        <Name>
          <ElementValue Type="Preferred">Hypercholesterolemia, susceptibility to</ElementValue>
        </Name>
      </Trait>
    </TraitSet>
  </ReferenceClinVarAssertion>
  <ClinVarAssertion ID="29827">
    <ClinVarSubmissionID localKey="600564.0001_HYPERCHOLESTEROLEMIA, SUSCEPTIBILITY TO" submitter="OMIM" submitterDate="2013-04-03" title="ITIH4, IVS17, +8, C-T _HYPERCHOLESTEROLEMIA, SUSCEPTIBILITY TO"/>
    <ClinVarAccession Acc="SCV000029827" OrgType="primary" OrganizationCategory="resource" Version="1" Type="SCV" OrgID="3" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2004-01-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>risk factor</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ExternalID DB="OMIM" ID="600564.0001" Type="Allelic variant"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species>human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="Description">Fujita et al. (2004) reported an association between a C/T single nucleotide polymorphism (SNP) at position +8 in intron 17 of the ITIH4 gene and plasma total cholesterol levels in 351 adult individuals from an east-central area of Japan. Those who lacked the T allele had significantly higher plasma total cholesterol levels than the others who had the T allele. Of the 309 without the T allele, approximately 90% presented with hypercholesterolemia (see 143890), whereas only 10% were hypercholesterolemic among 42 individuals with the T allele. They interpreted the data as suggesting that genetic variation at the ITIH4 locus is a determinant of plasma cholesterol metabolism.</Attribute>
        <Citation>
          <ID Source="PubMed">14661079</ID>
        </Citation>
        <XRef DB="OMIM" ID="143890" Type="MIM"/>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant">
      <Measure Type="Variation">
        <Name>
          <ElementValue Type="Preferred">ITIH4, IVS17, +8, C-T</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="NonHGVS">IVS17, +8, C-T</Attribute>
        </AttributeSet>
        <MeasureRelationship Type="variant in gene">
          <Symbol>
            <ElementValue Type="Preferred">ITIH4</ElementValue>
          </Symbol>
        </MeasureRelationship>
        <XRef DB="OMIM" ID="600564.0001" Type="Allelic variant"/>
      </Measure>
    </MeasureSet>
    <TraitSet Type="Disease">
      <Trait Type="Disease">
        <Name>
          <ElementValue Type="Preferred">HYPERCHOLESTEROLEMIA, SUSCEPTIBILITY TO</ElementValue>
        </Name>
      </Trait>
    </TraitSet>
  </ClinVarAssertion>
</ClinVarSet>

<ClinVarSet ID="18638174">
  <RecordStatus>current</RecordStatus>
  <Title>ECE1, -338C-A AND Hypertension, essential, susceptibility to</Title>
  <ReferenceClinVarAssertion DateCreated="2012-08-13" DateLastUpdated="2017-04-07" ID="67208">
    <ClinVarAccession Acc="RCV000009705" Version="3" Type="RCV" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2003-02-15">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>risk factor</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData ID="17811107">
        <Attribute Type="Description">Funke-Kaiser et al. (2003) identified a polymorphism in the 5-prime flanking region of the ECE1 gene, -338C-A, that was associated with ambulatory blood pressure values (see 145500). The polymorphism is located within a putative consensus site for E2F (see 189971) and GATA (see 601656) proteins. The -338A allele was associated with higher daytime and nighttime 24-hour systolic and diastolic blood pressure in nontreated hypertensive women. Transient transfection of the reporter constructs containing the -338A allele showed an increase in promoter activity compared with the wildtype promoter. Electrophoretic mobility shift assays revealed the specific binding of E2F2 (600426), a transcription factor, to both ECE1b promoter sequences, with the -338A allele being associated with an increased affinity to E2F2 compared with -338C.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">12566389</ID>
        </Citation>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant" ID="9134">
      <Measure Type="single nucleotide variant" ID="24173">
        <Name>
          <ElementValue Type="Preferred">ECE1, -338C-A</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="nucleotide change">-338C-A</Attribute>
          <XRef Type="Allelic variant" ID="600423.0002" DB="OMIM"/>
        </AttributeSet>
        <CytogeneticLocation>1p36.1</CytogeneticLocation>
        <MeasureRelationship Type="asserted, but not computed">
          <Name>
            <ElementValue Type="Preferred">endothelin converting enzyme 1</ElementValue>
          </Name>
          <Symbol>
            <ElementValue Type="Preferred">ECE1</ElementValue>
          </Symbol>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="1" Accession="NC_000001.11" start="21217247" stop="21345541" display_start="21217247" display_stop="21345541" Strand="-"/>
          <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="1" Accession="NC_000001.10" start="21543739" stop="21672033" display_start="21543739" display_stop="21672033" variantLength="128295" Strand="-"/>
          <XRef ID="1889" DB="Gene"/>
          <XRef Type="MIM" ID="600423" DB="OMIM"/>
          <XRef ID="HGNC:3146" DB="HGNC"/>
        </MeasureRelationship>
        <XRef Type="Allelic variant" ID="600423.0002" DB="OMIM"/>
      </Measure>
      <Name>
        <ElementValue Type="Preferred">ECE1, -338C-A</ElementValue>
      </Name>
    </MeasureSet>
    <TraitSet Type="Disease" ID="2511">
      <Trait ID="10513" Type="Disease">
        <Name>
          <ElementValue Type="Preferred">Hypertension, essential, susceptibility to</ElementValue>
        </Name>
      </Trait>
    </TraitSet>
  </ReferenceClinVarAssertion>
  <ClinVarAssertion ID="29923">
    <ClinVarSubmissionID localKey="600423.0002_HYPERTENSION, ESSENTIAL, SUSCEPTIBILITY TO" submitter="OMIM" submitterDate="2016-11-17" title="ECE1, -338C-A_HYPERTENSION, ESSENTIAL, SUSCEPTIBILITY TO"/>
    <ClinVarAccession Acc="SCV000029923" OrgType="primary" OrganizationCategory="resource" Version="2" Type="SCV" OrgID="3" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2003-02-15">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>risk factor</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ExternalID DB="OMIM" ID="600423.0002" Type="Allelic variant"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species>human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="Description">Funke-Kaiser et al. (2003) identified a polymorphism in the 5-prime flanking region of the ECE1 gene, -338C-A, that was associated with ambulatory blood pressure values (see 145500). The polymorphism is located within a putative consensus site for E2F (see 189971) and GATA (see 601656) proteins. The -338A allele was associated with higher daytime and nighttime 24-hour systolic and diastolic blood pressure in nontreated hypertensive women. Transient transfection of the reporter constructs containing the -338A allele showed an increase in promoter activity compared with the wildtype promoter. Electrophoretic mobility shift assays revealed the specific binding of E2F2 (600426), a transcription factor, to both ECE1b promoter sequences, with the -338A allele being associated with an increased affinity to E2F2 compared with -338C.</Attribute>
        <Citation>
          <ID Source="PubMed">12566389</ID>
        </Citation>
        <XRef DB="OMIM" ID="145500" Type="MIM"/>
        <XRef DB="OMIM" ID="189971" Type="MIM"/>
        <XRef DB="OMIM" ID="601656" Type="MIM"/>
        <XRef DB="OMIM" ID="600426" Type="MIM"/>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant">
      <Measure Type="Variation">
        <Name>
          <ElementValue Type="Preferred">ECE1, -338C-A</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="NonHGVS">-338C-A</Attribute>
        </AttributeSet>
        <MeasureRelationship Type="variant in gene">
          <Symbol>
            <ElementValue Type="Preferred">ECE1</ElementValue>
          </Symbol>
        </MeasureRelationship>
        <XRef DB="OMIM" ID="600423.0002" Type="Allelic variant"/>
      </Measure>
    </MeasureSet>
    <TraitSet Type="Disease">
      <Trait Type="Disease">
        <Name>
          <ElementValue Type="Preferred">HYPERTENSION, ESSENTIAL, SUSCEPTIBILITY TO</ElementValue>
        </Name>
      </Trait>
    </TraitSet>
  </ClinVarAssertion>
</ClinVarSet>

<ClinVarSet ID="18638175">
  <RecordStatus>current</RecordStatus>
  <Title>ECE1, -839T-G AND Hypertension, essential, susceptibility to</Title>
  <ReferenceClinVarAssertion DateCreated="2012-08-13" DateLastUpdated="2017-04-07" ID="67209">
    <ClinVarAccession Acc="RCV000009706" Version="3" Type="RCV" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2003-02-15">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>risk factor</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData ID="17815901">
        <Attribute Type="Description">Funke-Kaiser et al. (2003) identified a polymorphism in the 5-prime flanking region of the ECE1 gene, -839T-G, that was associated with ambulatory blood pressure values (see 145500).</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">12566389</ID>
        </Citation>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant" ID="9135">
      <Measure Type="single nucleotide variant" ID="24174">
        <Name>
          <ElementValue Type="Preferred">ECE1, -839T-G</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="nucleotide change">-839T-G</Attribute>
          <XRef Type="Allelic variant" ID="600423.0003" DB="OMIM"/>
        </AttributeSet>
        <CytogeneticLocation>1p36.1</CytogeneticLocation>
        <MeasureRelationship Type="asserted, but not computed">
          <Name>
            <ElementValue Type="Preferred">endothelin converting enzyme 1</ElementValue>
          </Name>
          <Symbol>
            <ElementValue Type="Preferred">ECE1</ElementValue>
          </Symbol>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="1" Accession="NC_000001.11" start="21217247" stop="21345541" display_start="21217247" display_stop="21345541" Strand="-"/>
          <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="1" Accession="NC_000001.10" start="21543739" stop="21672033" display_start="21543739" display_stop="21672033" variantLength="128295" Strand="-"/>
          <XRef ID="1889" DB="Gene"/>
          <XRef Type="MIM" ID="600423" DB="OMIM"/>
          <XRef ID="HGNC:3146" DB="HGNC"/>
        </MeasureRelationship>
        <XRef Type="Allelic variant" ID="600423.0003" DB="OMIM"/>
      </Measure>
      <Name>
        <ElementValue Type="Preferred">ECE1, -839T-G</ElementValue>
      </Name>
    </MeasureSet>
    <TraitSet Type="Disease" ID="2511">
      <Trait ID="10513" Type="Disease">
        <Name>
          <ElementValue Type="Preferred">Hypertension, essential, susceptibility to</ElementValue>
        </Name>
      </Trait>
    </TraitSet>
  </ReferenceClinVarAssertion>
  <ClinVarAssertion ID="29924">
    <ClinVarSubmissionID localKey="600423.0003_HYPERTENSION, ESSENTIAL, SUSCEPTIBILITY TO" submitter="OMIM" submitterDate="2016-11-17" title="ECE1, -839T-G_HYPERTENSION, ESSENTIAL, SUSCEPTIBILITY TO"/>
    <ClinVarAccession Acc="SCV000029924" OrgType="primary" OrganizationCategory="resource" Version="2" Type="SCV" OrgID="3" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2003-02-15">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>risk factor</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ExternalID DB="OMIM" ID="600423.0003" Type="Allelic variant"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species>human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="Description">Funke-Kaiser et al. (2003) identified a polymorphism in the 5-prime flanking region of the ECE1 gene, -839T-G, that was associated with ambulatory blood pressure values (see 145500).</Attribute>
        <Citation>
          <ID Source="PubMed">12566389</ID>
        </Citation>
        <XRef DB="OMIM" ID="145500" Type="MIM"/>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant">
      <Measure Type="Variation">
        <Name>
          <ElementValue Type="Preferred">ECE1, -839T-G</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="NonHGVS">-839T-G</Attribute>
        </AttributeSet>
        <MeasureRelationship Type="variant in gene">
          <Symbol>
            <ElementValue Type="Preferred">ECE1</ElementValue>
          </Symbol>
        </MeasureRelationship>
        <XRef DB="OMIM" ID="600423.0003" Type="Allelic variant"/>
      </Measure>
    </MeasureSet>
    <TraitSet Type="Disease">
      <Trait Type="Disease">
        <Name>
          <ElementValue Type="Preferred">HYPERTENSION, ESSENTIAL, SUSCEPTIBILITY TO</ElementValue>
        </Name>
      </Trait>
    </TraitSet>
  </ClinVarAssertion>
</ClinVarSet>

<ClinVarSet ID="18638281">
  <RecordStatus>current</RecordStatus>
  <Title>SLC11A1, 274C-T AND Mycobacterium tuberculosis, susceptibility to infection by</Title>
  <ReferenceClinVarAssertion DateCreated="2012-08-13" DateLastUpdated="2017-04-07" ID="67316">
    <ClinVarAccession Acc="RCV000009813" Version="4" Type="RCV" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2005-08-23">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>risk factor</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData ID="17815927">
        <Attribute Type="Description">Using a family-based control design to study 184 ethnically diverse families from the Houston, Texas, area with at least 1 child affected with pediatric tuberculosis disease (see 607948), Malik et al. (2005) identified 4 NRAMP1 allelic variants associated with pediatric tuberculosis disease. The most significant association was found with the common C allele of the N02 SNP (274C-T in exon 3). The association between the N02 C allele and pediatric tuberculosis disease was stronger in males from simplex rather than multiplex families, suggesting an interplay between genetic control and the intensity of exposure to M. tuberculosis. Malik et al. (2005) concluded that the N02 C allele promotes rapid progression from infection to disease.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">16103355</ID>
        </Citation>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant" ID="9232">
      <Measure Type="single nucleotide variant" ID="24271">
        <Name>
          <ElementValue Type="Preferred">SLC11A1, 274C-T</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="nucleotide change">274C-T</Attribute>
          <XRef Type="Allelic variant" ID="600266.0001" DB="OMIM"/>
        </AttributeSet>
        <CytogeneticLocation>2q35</CytogeneticLocation>
        <MeasureRelationship Type="asserted, but not computed">
          <Name>
            <ElementValue Type="Preferred">solute carrier family 11 member 1</ElementValue>
          </Name>
          <Symbol>
            <ElementValue Type="Preferred">SLC11A1</ElementValue>
          </Symbol>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="2" Accession="NC_000002.12" start="218381766" stop="218396894" display_start="218381766" display_stop="218396894" Strand="+"/>
          <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="2" Accession="NC_000002.11" start="219246751" stop="219261616" display_start="219246751" display_stop="219261616" variantLength="14866" Strand="+"/>
          <XRef ID="6556" DB="Gene"/>
          <XRef Type="MIM" ID="600266" DB="OMIM"/>
          <XRef ID="HGNC:10907" DB="HGNC"/>
        </MeasureRelationship>
        <XRef Type="Allelic variant" ID="600266.0001" DB="OMIM"/>
      </Measure>
      <Name>
        <ElementValue Type="Preferred">SLC11A1, 274C-T</ElementValue>
      </Name>
    </MeasureSet>
    <TraitSet Type="Disease" ID="2184">
      <Trait ID="10380" Type="Disease">
        <Name>
          <ElementValue Type="Preferred">Mycobacterium tuberculosis, susceptibility to infection by</ElementValue>
          <XRef ID="2456" DB="Office of Rare Diseases"/>
        </Name>
        <XRef ID="C2936833" DB="MedGen"/>
      </Trait>
    </TraitSet>
  </ReferenceClinVarAssertion>
  <ClinVarAssertion ID="30034">
    <ClinVarSubmissionID localKey="600266.0001_MYCOBACTERIUM TUBERCULOSIS, SUSCEPTIBILITY TO INFECTION BY" submitter="OMIM" submitterDate="2017-01-30" title="SLC11A1, 274C-T_MYCOBACTERIUM TUBERCULOSIS, SUSCEPTIBILITY TO INFECTION BY"/>
    <ClinVarAccession Acc="SCV000030034" OrgType="primary" OrganizationCategory="resource" Version="3" Type="SCV" OrgID="3" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2005-08-23">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>risk factor</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ExternalID DB="OMIM" ID="600266.0001" Type="Allelic variant"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species>human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="Description">Using a family-based control design to study 184 ethnically diverse families from the Houston, Texas, area with at least 1 child affected with pediatric tuberculosis disease (see 607948), Malik et al. (2005) identified 4 NRAMP1 allelic variants associated with pediatric tuberculosis disease. The most significant association was found with the common C allele of the N02 SNP (274C-T in exon 3). The association between the N02 C allele and pediatric tuberculosis disease was stronger in males from simplex rather than multiplex families, suggesting an interplay between genetic control and the intensity of exposure to M. tuberculosis. Malik et al. (2005) concluded that the N02 C allele promotes rapid progression from infection to disease.</Attribute>
        <Citation>
          <ID Source="PubMed">16103355</ID>
        </Citation>
        <XRef DB="OMIM" ID="607948" Type="MIM"/>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant">
      <Measure Type="Variation">
        <Name>
          <ElementValue Type="Preferred">SLC11A1, 274C-T</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="NonHGVS">274C-T</Attribute>
        </AttributeSet>
        <MeasureRelationship Type="variant in gene">
          <Symbol>
            <ElementValue Type="Preferred">SLC11A1</ElementValue>
          </Symbol>
        </MeasureRelationship>
        <XRef DB="OMIM" ID="600266.0001" Type="Allelic variant"/>
      </Measure>
    </MeasureSet>
    <TraitSet Type="Disease">
      <Trait Type="Disease">
        <Name>
          <ElementValue Type="Preferred">MYCOBACTERIUM TUBERCULOSIS, SUSCEPTIBILITY TO INFECTION BY</ElementValue>
        </Name>
      </Trait>
    </TraitSet>
  </ClinVarAssertion>
</ClinVarSet>

<ClinVarSet ID="18647124">
  <RecordStatus>current</RecordStatus>
  <Title>HTR2A, -1438G-A AND Obsessive-compulsive disorder, susceptibility to</Title>
  <ReferenceClinVarAssertion DateCreated="2012-08-13" DateLastUpdated="2017-04-07" ID="71303">
    <ClinVarAccession Acc="RCV000013800" Version="2" Type="RCV" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2004-09-15">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>risk factor</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData ID="17820420">
        <Attribute Type="Description">Enoch et al. (1998) demonstrated an association between the A allele of an A-to-G polymorphism at position -1438 in the HTR2A promoter and obsessive-compulsive disorder (OCD; 164230). Walitza et al. (2002) confirmed this finding in an association analysis of the -1438G-A promoter polymorphism in 55 children and adolescents with OCD and in 223 controls consisting of unrelated students. Statistically significant differences in genotype (p less than 0.05) and allele frequencies (p less than 0.05) were observed that suggested an association of the -1438A allele with OCD.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">12476319</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">9635956</ID>
        </Citation>
      </ObservedData>
      <ObservedData ID="17820420">
        <Attribute Type="Description">The -1438G-A SNP lies upstream of 2 alternative promoters for the HTR2A gene. To investigate possible functional effects of this polymorphism on either promoter, Parsons et al. (2004) used 2 different reporter gene assays in 3 cell lines. In the presence of the SV40 enhancer, promoter activity was significantly greater with the A allele relative to the G allele, but only in cell lines expressing endogenous HTR2A, suggesting that transcriptional factors and the presence of both promoters might be necessary to elicit this effect.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">15364038</ID>
        </Citation>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant" ID="12937">
      <Measure Type="single nucleotide variant" ID="27976">
        <Name>
          <ElementValue Type="Preferred">HTR2A, -1438G-A</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="nucleotide change">-1438G-A</Attribute>
          <XRef Type="Allelic variant" ID="182135.0002" DB="OMIM"/>
        </AttributeSet>
        <CytogeneticLocation>13q14-q21</CytogeneticLocation>
        <MeasureRelationship Type="asserted, but not computed">
          <Name>
            <ElementValue Type="Preferred">5-hydroxytryptamine receptor 2A</ElementValue>
          </Name>
          <Symbol>
            <ElementValue Type="Preferred">HTR2A</ElementValue>
          </Symbol>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="13" Accession="NC_000013.11" start="46831542" stop="46897076" display_start="46831542" display_stop="46897076" Strand="-"/>
          <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="13" Accession="NC_000013.10" start="47405676" stop="47471210" display_start="47405676" display_stop="47471210" variantLength="65535" Strand="-"/>
          <XRef ID="3356" DB="Gene"/>
          <XRef Type="MIM" ID="182135" DB="OMIM"/>
          <XRef ID="HGNC:5293" DB="HGNC"/>
        </MeasureRelationship>
        <XRef Type="Allelic variant" ID="182135.0002" DB="OMIM"/>
      </Measure>
      <Name>
        <ElementValue Type="Preferred">HTR2A, -1438G-A</ElementValue>
      </Name>
    </MeasureSet>
    <TraitSet Type="Disease" ID="3525">
      <Trait ID="11088" Type="Disease">
        <Name>
          <ElementValue Type="Preferred">Obsessive-compulsive disorder, susceptibility to</ElementValue>
        </Name>
      </Trait>
    </TraitSet>
  </ReferenceClinVarAssertion>
  <ClinVarAssertion ID="34047">
    <ClinVarSubmissionID localKey="182135.0002_OBSESSIVE-COMPULSIVE DISORDER, SUSCEPTIBILITY TO" submitter="OMIM" submitterDate="2012-04-12" title="HTR2A, -1438G-A _OBSESSIVE-COMPULSIVE DISORDER, SUSCEPTIBILITY TO"/>
    <ClinVarAccession Acc="SCV000034047" OrgType="primary" OrganizationCategory="resource" Version="1" Type="SCV" OrgID="3" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2004-09-15">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>risk factor</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ExternalID DB="OMIM" ID="182135.0002" Type="Allelic variant"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species>human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="Description">Enoch et al. (1998) demonstrated an association between the A allele of an A-to-G polymorphism at position -1438 in the HTR2A promoter and obsessive-compulsive disorder (OCD; 164230). Walitza et al. (2002) confirmed this finding in an association analysis of the -1438G-A promoter polymorphism in 55 children and adolescents with OCD and in 223 controls consisting of unrelated students. Statistically significant differences in genotype (p less than 0.05) and allele frequencies (p less than 0.05) were observed that suggested an association of the -1438A allele with OCD.</Attribute>
        <Citation>
          <ID Source="PubMed">9635956</ID>
        </Citation>
        <Citation>
          <ID Source="PubMed">12476319</ID>
        </Citation>
        <XRef DB="OMIM" ID="164230" Type="MIM"/>
      </ObservedData>
      <ObservedData>
        <Attribute Type="Description">The -1438G-A SNP lies upstream of 2 alternative promoters for the HTR2A gene. To investigate possible functional effects of this polymorphism on either promoter, Parsons et al. (2004) used 2 different reporter gene assays in 3 cell lines. In the presence of the SV40 enhancer, promoter activity was significantly greater with the A allele relative to the G allele, but only in cell lines expressing endogenous HTR2A, suggesting that transcriptional factors and the presence of both promoters might be necessary to elicit this effect.</Attribute>
        <Citation>
          <ID Source="PubMed">15364038</ID>
        </Citation>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant">
      <Measure Type="Variation">
        <Name>
          <ElementValue Type="Preferred">HTR2A, -1438G-A</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="NonHGVS">-1438G-A</Attribute>
        </AttributeSet>
        <MeasureRelationship Type="variant in gene">
          <Symbol>
            <ElementValue Type="Preferred">HTR2A</ElementValue>
          </Symbol>
        </MeasureRelationship>
        <XRef DB="OMIM" ID="182135.0002" Type="Allelic variant"/>
      </Measure>
    </MeasureSet>
    <TraitSet Type="Disease">
      <Trait Type="Disease">
        <Name>
          <ElementValue Type="Preferred">OBSESSIVE-COMPULSIVE DISORDER, SUSCEPTIBILITY TO</ElementValue>
        </Name>
      </Trait>
    </TraitSet>
  </ClinVarAssertion>
</ClinVarSet>

<ClinVarSet ID="18647136">
  <RecordStatus>current</RecordStatus>
  <Title>FUT2, DEL AND Bombay phenotype, classic</Title>
  <ReferenceClinVarAssertion DateCreated="2012-08-13" DateLastUpdated="2017-04-07" ID="71315">
    <ClinVarAccession Acc="RCV000013812" Version="24" Type="RCV" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2000-01-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData ID="17820326">
        <Attribute Type="Description">In 3 unrelated individuals with the Bombay phenotype, Koda et al. (1997) found that a 725T-G transversion in FUT1 (211100.0004), which results in an amino acid change, leu242 to arg, and complete deletion of FUT2 were responsible for the classic Bombay phenotype. The individuals lacked the H antigen not only on blood cells but also in saliva, which prompted Koda et al. (1997) to investigate the FUT2 gene in these persons. The mutations in both genes were homozygous. The results of analyses of FUT1 and FUT2 by Koda et al. (1997) suggested that the homozygosity for these 2 unusual and linked genetic mutations is common in individuals with the classic Bombay phenotype.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">9299444</ID>
        </Citation>
      </ObservedData>
      <ObservedData ID="17820326">
        <Attribute Type="Description">Koda et al. (2000) isolated the junction region of the deletion of FUT2 and found evidence that the deletion was generated by Alu-Alu recombination.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">10982186</ID>
        </Citation>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant" ID="12947">
      <Measure Type="Deletion" ID="27986">
        <Name>
          <ElementValue Type="Preferred">FUT2, DEL</ElementValue>
        </Name>
        <Name>
          <ElementValue Type="Alternate">FUT2, DEL</ElementValue>
          <XRef Type="Allelic variant" ID="182100.0003" DB="OMIM"/>
        </Name>
        <AttributeSet>
          <Attribute Type="nucleotide change">DEL</Attribute>
          <XRef Type="Allelic variant" ID="182100.0003" DB="OMIM"/>
        </AttributeSet>
        <CytogeneticLocation>19q13.3</CytogeneticLocation>
        <MeasureRelationship Type="asserted, but not computed">
          <Name>
            <ElementValue Type="Preferred">fucosyltransferase 2</ElementValue>
          </Name>
          <Symbol>
            <ElementValue Type="Preferred">FUT2</ElementValue>
          </Symbol>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="19" Accession="NC_000019.10" start="48695971" stop="48705934" display_start="48695971" display_stop="48705934" Strand="+"/>
          <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="19" Accession="NC_000019.9" start="49199227" stop="49209190" display_start="49199227" display_stop="49209190" variantLength="9964" Strand="+"/>
          <XRef ID="2524" DB="Gene"/>
          <XRef Type="MIM" ID="182100" DB="OMIM"/>
          <XRef ID="HGNC:4013" DB="HGNC"/>
        </MeasureRelationship>
        <XRef Type="Allelic variant" ID="182100.0003" DB="OMIM"/>
      </Measure>
      <Name>
        <ElementValue Type="Preferred">FUT2, DEL</ElementValue>
      </Name>
    </MeasureSet>
    <TraitSet Type="Disease" ID="3532">
      <Trait ID="11093" Type="Disease">
        <Name>
          <ElementValue Type="Preferred">Bombay phenotype, classic</ElementValue>
        </Name>
      </Trait>
    </TraitSet>
  </ReferenceClinVarAssertion>
  <ClinVarAssertion ID="34059">
    <ClinVarSubmissionID localKey="182100.0003_BOMBAY PHENOTYPE, CLASSIC" submitter="OMIM" submitterDate="2016-08-31" title="FUT2, DEL_BOMBAY PHENOTYPE, CLASSIC"/>
    <ClinVarAccession Acc="SCV000034059" OrgType="primary" OrganizationCategory="resource" Version="3" Type="SCV" OrgID="3" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2000-01-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ExternalID DB="OMIM" ID="182100.0003" Type="Allelic variant"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species>human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="Description">In 3 unrelated individuals with the Bombay phenotype, Koda et al. (1997) found that a 725T-G transversion in FUT1 (211100.0004), which results in an amino acid change, leu242 to arg, and complete deletion of FUT2 were responsible for the classic Bombay phenotype. The individuals lacked the H antigen not only on blood cells but also in saliva, which prompted Koda et al. (1997) to investigate the FUT2 gene in these persons. The mutations in both genes were homozygous. The results of analyses of FUT1 and FUT2 by Koda et al. (1997) suggested that the homozygosity for these 2 unusual and linked genetic mutations is common in individuals with the classic Bombay phenotype.</Attribute>
        <Citation>
          <ID Source="PubMed">9299444</ID>
        </Citation>
      </ObservedData>
      <ObservedData>
        <Attribute Type="Description">Koda et al. (2000) isolated the junction region of the deletion of FUT2 and found evidence that the deletion was generated by Alu-Alu recombination.</Attribute>
        <Citation>
          <ID Source="PubMed">10982186</ID>
        </Citation>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant">
      <Measure Type="Variation">
        <Name>
          <ElementValue Type="Preferred">FUT2, DEL</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="NonHGVS">DEL</Attribute>
        </AttributeSet>
        <MeasureRelationship Type="variant in gene">
          <Symbol>
            <ElementValue Type="Preferred">FUT2</ElementValue>
          </Symbol>
        </MeasureRelationship>
        <XRef DB="OMIM" ID="182100.0003" Type="Allelic variant"/>
      </Measure>
    </MeasureSet>
    <TraitSet Type="Disease">
      <Trait Type="Disease">
        <Name>
          <ElementValue Type="Preferred">BOMBAY PHENOTYPE, CLASSIC</ElementValue>
        </Name>
      </Trait>
    </TraitSet>
  </ClinVarAssertion>
</ClinVarSet>

<ClinVarSet ID="18638424">
  <RecordStatus>current</RecordStatus>
  <Title>AQP3, IVS5, G-A, +1 AND GIL BLOOD GROUP</Title>
  <ReferenceClinVarAssertion DateCreated="2012-08-13" DateLastUpdated="2017-04-07" ID="67464">
    <ClinVarAccession Acc="RCV000009961" Version="3" Type="RCV" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2002-11-29">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Affects</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData ID="17816219">
        <Attribute Type="Description">In 2 unrelated women who developed alloantibodies to the high frequency antigen GIL (607457) (Daniels et al., 1998), Roudier et al. (2002) found a homozygous mutation in the AQP3 gene affecting the 5-prime donor splice site of intron 5: IVS5DS+1G-A. The mutation resulted in skipping of exon 5, frameshift, and premature termination of translation. One proband was a white French woman who had had 10 pregnancies before 1979, when an antibody against the GIL antigen reacting with all red blood cells (RBCs) except her own was identified following a hemolytic reaction that occurred during orthopedic surgery. Proband 2 was a white American woman who had no history of blood transfusion. Red blood cells from her first child had a weakly positive direct antiglobulin test and her serum contained an anti-GIL antibody.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">12239222</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">15377196</ID>
        </Citation>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant" ID="9367">
      <Measure Type="single nucleotide variant" ID="24406">
        <Name>
          <ElementValue Type="Preferred">AQP3, IVS5, G-A, +1</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="nucleotide change">IVS5, G-A, +1</Attribute>
          <XRef Type="Allelic variant" ID="600170.0001" DB="OMIM"/>
        </AttributeSet>
        <CytogeneticLocation>9p13</CytogeneticLocation>
        <MeasureRelationship Type="asserted, but not computed">
          <Name>
            <ElementValue Type="Preferred">aquaporin 3 (Gill blood group)</ElementValue>
          </Name>
          <Symbol>
            <ElementValue Type="Preferred">AQP3</ElementValue>
          </Symbol>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.33" AssemblyStatus="current" Chr="9" Accession="NC_000009.12" start="33441154" stop="33447633" display_start="33441154" display_stop="33447633" Strand="-"/>
          <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="9" Accession="NC_000009.11" start="33441151" stop="33447630" display_start="33441151" display_stop="33447630" variantLength="6480" Strand="-"/>
          <XRef ID="360" DB="Gene"/>
          <XRef Type="MIM" ID="600170" DB="OMIM"/>
          <XRef ID="HGNC:636" DB="HGNC"/>
        </MeasureRelationship>
        <XRef Type="Allelic variant" ID="600170.0001" DB="OMIM"/>
      </Measure>
      <Name>
        <ElementValue Type="Preferred">AQP3, IVS5, G-A, +1</ElementValue>
      </Name>
    </MeasureSet>
    <TraitSet Type="Disease" ID="2571">
      <Trait ID="2217" Type="BloodGroup">
        <Name>
          <ElementValue Type="Preferred">GIL BLOOD GROUP</ElementValue>
          <XRef ID="GIL+BLOOD+GROUP/8463" DB="Genetic Alliance"/>
          <XRef Type="MIM" ID="607457" DB="OMIM"/>
          <XRef Type="Allelic variant" ID="600170.0001" DB="OMIM"/>
        </Name>
        <XRef ID="C1843889" DB="MedGen"/>
        <XRef Type="MIM" ID="607457" DB="OMIM"/>
      </Trait>
    </TraitSet>
  </ReferenceClinVarAssertion>
  <ClinVarAssertion ID="30182">
    <ClinVarSubmissionID localKey="600170.0001_GIL BLOOD GROUP" submitter="OMIM" submitterDate="2010-01-07" title="AQP3, IVS5, G-A, +1_GIL BLOOD GROUP"/>
    <ClinVarAccession Acc="SCV000030182" OrgType="primary" OrganizationCategory="resource" Version="1" Type="SCV" OrgID="3" DateUpdated="2017-04-07"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2002-11-29">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Affects</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ExternalID DB="OMIM" ID="600170.0001" Type="Allelic variant"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species>human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="Description">In 2 unrelated women who developed alloantibodies to the high frequency antigen GIL (607457) (Daniels et al., 1998), Roudier et al. (2002) found a homozygous mutation in the AQP3 gene affecting the 5-prime donor splice site of intron 5: IVS5DS+1G-A. The mutation resulted in skipping of exon 5, frameshift, and premature termination of translation. One proband was a white French woman who had had 10 pregnancies before 1979, when an antibody against the GIL antigen reacting with all red blood cells (RBCs) except her own was identified following a hemolytic reaction that occurred during orthopedic surgery. Proband 2 was a white American woman who had no history of blood transfusion. Red blood cells from her first child had a weakly positive direct antiglobulin test and her serum contained an anti-GIL antibody.</Attribute>
        <Citation>
          <ID Source="PubMed">15377196</ID>
        </Citation>
        <Citation>
          <ID Source="PubMed">12239222</ID>
        </Citation>
        <XRef DB="OMIM" ID="607457" Type="MIM"/>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant">
      <Measure Type="Variation">
        <Name>
          <ElementValue Type="Preferred">AQP3, IVS5, G-A, +1</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="NonHGVS">IVS5, G-A, +1</Attribute>
        </AttributeSet>
        <MeasureRelationship Type="variant in gene">
          <Symbol>
            <ElementValue Type="Preferred">AQP3</ElementValue>
          </Symbol>
        </MeasureRelationship>
        <XRef DB="OMIM" ID="600170.0001" Type="Allelic variant"/>
      </Measure>
    </MeasureSet>
    <TraitSet Type="Disease">
      <Trait Type="Disease">
        <Name>
          <ElementValue Type="Preferred">GIL BLOOD GROUP</ElementValue>
        </Name>
      </Trait>
    </TraitSet>
  </ClinVarAssertion>
</ClinVarSet>

</ReleaseSet>
